---
document_datetime: 2023-09-21 18:04:23
document_pages: 146
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-2830-ii-0023-g-epar-assessment-report-variation_en.pdf
document_name: keytruda-h-c-2830-ii-0023-g-epar-assessment-report-variation_en.pdf
version: success
processing_time: 261.0545518
conversion_datetime: 2025-12-15 06:30:12.747877
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

20 July 2017 EMA/512404/2017 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Keytruda

International non-proprietary name: pembrolizumab

Procedure No. EMEA/H/C/003820/II/0023/G

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                 | 6                                                                                                         |
|--------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II group of variations ....................................................................................6   |                                                                                                           |
| 1.2. Steps taken for the assessment of the product                                                                       | ........................................................7                                                 |
| 2. Scientific discussion................................................................................                 | 8                                                                                                         |
| 2.1. Introduction                                                                                                        | ........................................................................................................8 |
| 2.2. Non-clinical aspects..............................................................................................9 |                                                                                                           |
| 2.2.1. Ecotoxicity/environmental risk assessment...........................................................9             |                                                                                                           |
| 2.3. Clinical aspects                                                                                                    | .................................................................................................. 10     |
| 2.3.1. Introduction....................................................................................................  | 10                                                                                                        |
| 2.3.2. Pharmacokinetics                                                                                                  | ............................................................................................ 11           |
| 2.3.3. Pharmacodynamics..........................................................................................        | 20                                                                                                        |
| 2.3.4. PK/PD modelling                                                                                                   | ............................................................................................. 22          |
| 2.3.5. Discussion on clinical pharmacology...................................................................            | 29                                                                                                        |
| 2.3.6. Conclusions on clinical pharmacology.................................................................             | 31                                                                                                        |
| 2.4. Clinical efficacy                                                                                                   | .................................................................................................. 31     |
| 2.4.1. Dose response study(ies)                                                                                          | ................................................................................. 32                      |
| 2.4.2. Main study(ies)                                                                                                   | ............................................................................................... 33        |
| 2.4.3. Discussion on clinical efficacy............................................................................       | 97                                                                                                        |
| 2.4.4. Conclusions on the clinical efficacy ..................................................................           | 103                                                                                                       |
| 2.5. Clinical safety                                                                                                     | .................................................................................................. 103    |
| 2.5.1. Discussion on clinical safety............................................................................         | 127                                                                                                       |
| 2.5.2. Conclusions on clinical safety..........................................................................          | 128                                                                                                       |
| 2.5.3. PSUR cycle                                                                                                        | ................................................................................................... 129   |
| 2.6. Risk management plan                                                                                                | ..................................................................................... 129                 |
| 2.7. Update of the Product information......................................................................             | 135                                                                                                       |
| 2.7.1. User consultation                                                                                                 | .......................................................................................... 135            |
| 3. Benefit-Risk Balance...........................................................................                       | 136                                                                                                       |
| 3.1. Therapeutic Context .........................................................................................       | 136                                                                                                       |
| 3.1.1. Disease or condition                                                                                              | ...................................................................................... 136                |
| 3.1.2. Available therapies and unmet medical need.....................................................                   | 136                                                                                                       |
| 3.1.3. Main clinical studies.......................................................................................      | 136                                                                                                       |
| 3.2. Favourable effects............................................................................................      | 136                                                                                                       |
| 3.3. Uncertainties and limitations about favourable effects...........................................                   | 137                                                                                                       |
| 3.4. Unfavourable effects.........................................................................................       | 138                                                                                                       |
| 3.5. Uncertainties and limitations about unfavourable effects                                                            | ....................................... 138                                                               |
| 3.6. Effects Table....................................................................................................   | 139                                                                                                       |
| 3.7. Benefit-risk assessment and discussion...............................................................               | 141                                                                                                       |
| 3.7.1. Importance of favourable and unfavourable effects............................................                     | 141                                                                                                       |
| 3.7.2. Balance of benefits and risks ..........................................................................          | 141                                                                                                       |
| 3.7.3. Additional considerations on the benefit-risk balance                                                             | ......................................... 141                                                             |
| 3.8. Conclusions.....................................................................................................    | 141                                                                                                       |

<div style=\"page-break-after: always\"></div>

## 4. Recommendations  ............................................................................... 142 APPENDIX 1 ............................................................................................ 144

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| AE        | Adverse Event                                           |
|-----------|---------------------------------------------------------|
| AEOSI     | Adverse Event of Special Interest                       |
| ALB       | Albumin                                                 |
| ADA       | Anti-drug antibody                                      |
| APT       | All Patients Treated                                    |
| ASaT/APat | All Subject as Treated/ All Patient as Treated          |
| AUC       | Area under the concentration-time curve                 |
| AUCss     | Area under the concentration-time curve at steady state |
| CI        | Confidence interval                                     |
| CV        | Coefficient of variation                                |
| CL        | Clearance                                               |
| CMAX      | Peak serum concentration                                |
| Cmin      | Trough serum concentration                              |
| CONC      | Concentration                                           |
| CR        | Complete Response                                       |
| CWRES     | Conditional weighted residuals                          |
| ECI       | Event of Clinical Interest                              |
| ECOG      | Eastern Cooperative Oncology Group                      |
| eDMC      | external Data Monitoring Committee                      |
| DOR       | Duration of Response                                    |
| eGFR      | Estimated glomerular filtration rate                    |
| ePROs     | electronically collected Patient-Reported Outcomes      |
| FAS       | Full Analysis Set                                       |
| FWER      | family-wise type I error rate                           |
| HR        | Hazard Ratio                                            |
| HL        | Hodgkin lymphoma                                        |
| HNSCC     | Head and neck squamous cell carcinoma                   |
| IA2       | Second Interim Analysis                                 |
| IPRED     | Individual predicted concentration                      |
| irAE      | Immune-related Adverse Event                            |
| ITT       | Intention To Treat                                      |
| IIV       | Interindividual variability                             |
| IV        | Intravenous                                             |
| IWRES     | Individual weighted residual                            |
| LS        | least squares                                           |
| mAb       | Monoclonal antibody                                     |
| MedDRA    | Medical Dictionary for Regulatory Activities            |
| MSI-H     | microsatellite instability-high                         |
| Nab       | Neutralizing antibody                                   |
| NONMEM    | Nonlinear mixed-effects modeling software               |
| NSCLC     | Non Small Cell Lung Cancer                              |
| OFV       | Objective function value                                |
| ORR       | Objective Response Rate                                 |
| OS        | Overall Survival                                        |
| PFS       | Progression Free Survival                               |

<div style=\"page-break-after: always\"></div>

| PK         | Pharmacokinetic                                                                   |
|------------|-----------------------------------------------------------------------------------|
| Pop PK     | Population Pharmacokinetic                                                        |
| PRED       | Population predicted concentration                                                |
| PS         | Performance Status                                                                |
| PR         | Partial Response                                                                  |
| PRO        | Patien-Reported Outcome                                                           |
| Q          | Inter-compartmental flow rate                                                     |
| Q3W        | every 3 weeks                                                                     |
| QoL        | Quality of Life                                                                   |
| RECIST 1.1 | Response Evaluation Criteria on Solid Tumors Version 1.1                          |
| mRECIST    | modified Response Evaluation Criteria on Solid Tumors Version                     |
| RSE        | Percent relative standard error = [standard error/population mean estimate] x 100 |
| SAE        | Serious Adverse Event                                                             |
| SD         | Standard Deviation                                                                |
| SOC        | Standard of Care                                                                  |
| t1/2       | Terminal elimination half-life                                                    |
| ULN        | Upper limit of normal                                                             |
| WRES       | Weighted residuals                                                                |
| WT         | Body weight                                                                       |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II group of variations

Pursuant to Article 7.2 of Commission Regulation (EC) No 1234/2008, Merck Sharp &amp; Dohme Limited submitted to the European Medicines Agency on 1 February 2017 an application for a group of variations.

The following variations were requested in the group:

| Variations requested   | Variations requested                                                                                                           | Type    | Annexes affected   |
|------------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a                | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |
| C.I.6.a                | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of Indication to add treatment of urothelial carcinoma in patients previously treated with chemotherapy based on the results from study KEYNOTE-045; a phase 3, randomized, active-controlled, multi-site, open-label trial evaluating pembrolizumab administered at 200 mg Q3W versus investigators' choice of paclitaxel, docetaxel, or vinflunine in patients previously treated with chemotherapy.

Extension of Indication to add treatment of urothelial carcinoma in patients ineligible for cisplatin (not previously treated) based on the results from study KEYNOTE-52; a phase 2, single-arm, multisite, openlabel trial of pembrolizumab at 200 mg Q3W in the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.

As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC have been updated and the Package Leaflet has been updated accordingly.

Further, the MAH is proposing a change to section 4.3 of the SmPC to add that only patients with severe hypersensitivity should be excluded from therapy, and a change to section 4.4 of the SmPC adding possible hypersensitivity and anaphylaxis as part of infusion reactions.

The application included an updated RMP version 7.0.

The group of variations proposed amendments to the Summary of Product Characteristics and Package Leaflet and the Risk Management Plan.

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0059/2014 on the agreement of a paediatric investigation plan (PIP).

At  the  time  of  submission  of  the  application,  the  PIP  P/0059/2014  was  not  yet  completed  as  some measures were deferred.

<div style=\"page-break-after: always\"></div>

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The applicant did not seek Scientific Advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

| Rapporteur: Daniela Melchiorri                           | Co-Rapporteur:                                           | Jan Mueller-Berghaus   |
|----------------------------------------------------------|----------------------------------------------------------|------------------------|
| Timetable                                                |                                                          | Actual dates           |
| Submission date                                          |                                                          | 1 February 2017        |
| Start of procedure                                       |                                                          | 18 February 2017       |
| CHMP Rapporteur Assessment Report                        |                                                          | 17 April 2017          |
| CHMP Co-Rapporteur Assessment Report                     |                                                          | 12 April 2017          |
| PRAC Rapporteur Assessment Report                        |                                                          | 19 April 2017          |
| PRAC members comments                                    |                                                          | n/a                    |
| PRAC Outcome                                             |                                                          | 5 May 2017             |
| CHMP members comments                                    |                                                          | 11 May 2017            |
| Updated CHMP Rapporteur(s) (Joint) Assessment            | Report                                                   | 12 May 2017            |
| Request for supplementary information (RSI)              |                                                          | 18 May 2017            |
| CHMP Rapporteur joint response Assessment Report         |                                                          | 4 July 2017            |
| CHMP members comments                                    |                                                          | 12 July 2017           |
| Updated CHMP Rapporteur joint response Assessment Report | Updated CHMP Rapporteur joint response Assessment Report | 14 July 2017           |
| Opinion                                                  | Opinion                                                  | 20 July 2017           |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

Keytruda (pembrolizumab, MK-3475) is a humanised monoclonal antibody acting as immune checkpoint inhibitor through the block of the interaction between the programmed death-1 (PD-1) receptor and its ligands PD-L1 and PDL2, with a consequent impediment of inhibitory signal in T cells.

Urothelial cancer (UC) is an aggressive malignancy associated with a 5 years survival of about 5% in the metastatic  setting.  More  than  90%  of  urothelial  tract  tumours  pertain  to  bladder,  8%  originate  in  the renal  pelvis  and  the  remaining  2%  arise  from  ureter  and  urethra.  In  the  large  majority  of  cases,  the histological  subtype is transitional cell  carcinoma. The other types, including lymphoepithelioma-like or sarcomatoid  carcinoma,  micropapillary  or  nested  variants  and  primary  squamous  cell  carcinoma  and adenocarcinoma, are relatively uncommon.

Approximately  4%  of  patients  have  metastatic  disease  at  the  time  of  diagnosis.  Cisplatin-containing combination  chemotherapy  has  been  the  standard of  care  in  the  treatment  of  advanced  or  metastatic urothelial  cancer  since  the  late  1980s.  A  median  OS  of  about  14  months  has  been  observed  with  the combination  of  cisplatin/gemcitabine  or  MVAC  (methotrexate,  vinblastine,  adriamycin  and  cisplatin)  in advanced surgically unresectable and metastatic urothelial cancer patients (von der Maase H, J Clin Oncol 2005). No improvement in survival has been achieved with newer triplets, novel four-drug regimens or dose-dense chemotherapy (Bellmunt J, J Clin Oncol 2012; Milowsky MI, J Clin Oncol 2009).

More than 50% of patients are unfit for cisplatin due to poor performance status, impaired renal function, or  specific  comorbidities.  For  these  patients,  NCCN  Guidelines  (version  2.2017)  and  ESMO  Practice Guideline (Bellmunt J, Annals of Oncology 2014) recommend carboplatin-based regimens or single agent taxane or gemcitabine. A median OS of 9 months has been reported with the carboplatin/gemcitabine combination (De Santis M, J Clin Oncol 2012). In case of patients with PS ≥2 and poor renal function, the participation in clinical trials or BSC is recommended by ESMO guidelines.

Failing first-line platinum-based chemotherapy, the prognosis is compromised with a median OS reduced to 5 to 7 months (Bellmunt J, J Clin Oncol 2009). In this setting there is no globally recognised standard of  care,  and  vinflunine  is  the  only  drug  approved  in  EU  for  the  treatment  of  advanced  or  metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen.

The role of immunotherapy in UC was first established in the 1970s with the use of BCG for non-muscle invasive bladder cancer. Urothelial carcinoma appears to be immunogenic, with high expression level of PD-L1 (Boorjian SA, Clin Cancer Res 2008; Faraj SF, Urology 2015).

In  EU,  Keytruda  received  a  MA  on  17  July  2015  as  monotherapy  for  the  treatment  of  advanced (unresectable or metastatic) melanoma in adults, and was approved as monotherapy on 29 July 2016 for the treatment of previously treated PD-L1 TPS ≥1% locally advanced or metastatic NSCLC patients and on 27 January 2017 for the first-line treatment of metastatic PD-L1 TPS ≥50% NSCLC.

The current application is a type II variation to extend the indication in treatment of locally advanced or metastatic urothelial carcinoma both in patients previously treated with chemotherapy, based on results from the study KEYNOTE-045 (' A Phase III Randomized Clinical Trial of Pembrolizumab versus Paclitaxel, Docetaxel or Vinflunine  in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer '), and in those not eligible for cisplatin-containing chemotherapy, based on results from the study KEYNOTE-052 (' A  Phase  II  Clinical  Trial  of  Pembrolizumab  in  Subjects  with  Advanced/Unresectable  or  Metastatic Urothelial Cancer ').

<div style=\"page-break-after: always\"></div>

The MAH applied for the following change of indication:

KEYTRUDA as monotherapy is indicated  for  the  treatment  of  locally  advanced  or  metastatic  urothelial carcinoma in adults who have received prior chemotherapy.

KEYTRUDA as monotherapy is indicated  for  the  treatment  of  locally  advanced  or  metastatic  urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy.

An overview of the current pembrolizumab development plan in urothelial carcinoma is reported in the following Table:

Table: Ongoing and planned pembrolizumab studies in Urothelial Carcinoma

<!-- image -->

| Study/Status         | Design                                                                                                     | StudyPopulation                                                                                                                                                                                                                                                 | Dosage Regimen                                                                                                                                                                                        | Primary Efficacy Point(s)                                                                               |
|----------------------|------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| KEYNOTE- 012 Ongoing | Multicenter, nonrandomized, multicohort trial ofMK-3475in subjects with PD-L1 positive advanced solid srom | 33subjectsenrolledinCohort C (enrollment complete); all subjects with PD-Ll expressing tumors andrecurent or metastaticuinarytactcancer                                                                                                                         | Pembrolizumab 10 mgkgIV Q2W OR Pembrolizumab 200mgIVQ3W                                                                                                                                               | Safety; ORR in PD-L1+                                                                                   |
| KEYNOTE. 045 Ongoing | Randomized, controlled, open label Phase 3 study                                                           | 542subjectsrandomized (enrollment complete);all subjectswith2L+urothelial cancer,controlisphysician's choicechemotherapy (docetaxel, paclitaxel, vinflunine)                                                                                                    | Pembrolizumab 200mgIVQ3W                                                                                                                                                                              | PFSandOSin all comers, CPS≥1%,CPS ≥10%                                                                  |
| KEYNOTE- 052 Ongoing | Multicenter, open label, nonrandomized, Phase 2 study                                                      | 374 subjects enrolled; all subjects have urothelial cancer andarecisplatin-ineligible;100 subjects constituted a training setfortheCPSstronglypositive cutpoint detenmination                                                                                   | Pembrolizumab 200mgIVQ3W                                                                                                                                                                              | ORR in all comers,CPS ≥1%,CPS 10%                                                                       |
| KEYNOTE- 057 Ongoing | Single arm, open label Phase2study                                                                         | Upto260subjectswithhigh risk non-muscle-invasive bladder cancer (NMIBC) umresponsivetoBacillus CalmetteGuerin                                                                                                                                                   | Pembrolizumab 200mgIVQ3W                                                                                                                                                                              | Anti-tumor activity of pembrolizumab, with regards to absence of high risk NMIBC or progressive disease |
| KEYNOTE- 361 Ongoing | Randomized, controlled, open label, Phase 3 study                                                          | Up to990subjectswith advancedormetastatic urothelial cancer willbe treated; 3 treatment regimens in a first- line setting will be evaluated: (1)pembrolizumab monotherapy;(2) pembrolizumab plus combination chemotherapy; or (3) combination chemotherapy only | Regimen (l) (Monotherapy): Pembrolizumab 200mgIVQ3W Regimen (2) (Combination): Pembrolizumab+ cisplatin/carbopla tin+gemcitabine Regimen (3) (Chemotherapy only): cisplatin/ carboplatin+ gemcitabine | PFS and OS in allcomers,CPS ≥1%                                                                         |

## 2.2. Non-clinical aspects

No new clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

The rationale for not submitting an environmental risk assessment was provided.

According to the 'Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use' (EMEA/CHMP/SWP/4447/00), pembrolizumab is exempt from preparation of an Environmental Risk Assessment as the product and excipients do not pose a significant risk to the environment.

<div style=\"page-break-after: always\"></div>

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

<!-- image -->

|                                        | Phase                                  | Phase                               | Country             | Country                                                                                                         | Trial Title                                                                                                     | Trial Title                                                                                                          | Trial design                                                                                                         | Trial design                                | Dosing reginen                                                                                                      | Dosing reginen                                                                                                                                                    | Trial population                                                                                                                                                  | Subject exposure                                            |
|----------------------------------------|----------------------------------------|-------------------------------------|---------------------|-----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|
| MK-3475- 1b [Rqf. 5.3.5.2 :P012V021    | MK-3475- 1b [Rqf. 5.3.5.2 :P012V021    | MK-3475- 1b [Rqf. 5.3.5.2 :P012V021 | Worlhwide Irael USA | Worlhwide Irael USA                                                                                             | A PhaseIb Multi-Cohort ShuryqfMK-3475inSubjccts with AcwancedThmors                                             | A PhaseIb Multi-Cohort ShuryqfMK-3475inSubjccts with AcwancedThmors                                                  | Multi-centernormndomized opnlabel 24months                                                                           | Multi-centernormndomized opnlabel 24months  | 10mg/kgqfMK-3475IV ry 2 weoks (Cohort C)                                                                            | 10mg/kgqfMK-3475IV ry 2 weoks (Cohort C)                                                                                                                          | Malesfemales Age:218 Urinoy tract coicer patients (Cohort C)                                                                                                      | 10mgkgQ2: 33 subjects (Cohort C)                            |
| Trial ID                               | Trial ID                               | Phase                               | Phase               | Counmy                                                                                                          | Counmy                                                                                                          | Trial Tile                                                                                                           | Trial Tile                                                                                                           | Trial design                                | Dosing regimen                                                                                                      | Trialpopulation                                                                                                                                                   | Trialpopulation                                                                                                                                                   | Snbjectaposure                                              |
| 3475-052 [Rqf 5.3.5.2: P052 VOIMK3475] | 3475-052 [Rqf 5.3.5.2: P052 VOIMK3475] |                                     |                     | Aushralia Canada Domok Guatemala Hmgay bulamd Irael Repulic of Korca Malqysia Netherlands Puorto Rico Singqpore | Aushralia Canada Domok Guatemala Hmgay bulamd Irael Repulic of Korca Malqysia Netherlands Puorto Rico Singqpore | APhase ClinicalThial qfPambrolizumab(MK- Achanced/Uhresectable or 3475) in Subjects with MetastaticUrotholial Camcor | APhase ClinicalThial qfPambrolizumab(MK- Achanced/Uhresectable or 3475) in Subjects with MetastaticUrotholial Camcor | Non-ramdomized. open-label, multi-site tial | Ponbrolizumab 200 mg Q3W                                                                                            | Males/fomales Age: ≥18years with achvanced/uwesectacble (inoporable) or metastatic wothelialcmicerwhohmve chemotherapy cmd who ar not oligible toreceiv cisplatin | Males/fomales Age: ≥18years with achvanced/uwesectacble (inoporable) or metastatic wothelialcmicerwhohmve chemotherapy cmd who ar not oligible toreceiv cisplatin | Pembrolizumab 200 mg Q3F: 370                               |
| Trial D                                | Phase                                  |                                     |                     | Trial Tile                                                                                                      | Trial Tile                                                                                                      |                                                                                                                      |                                                                                                                      | Trial design                                | Dosing reginen                                                                                                      | Dosing reginen                                                                                                                                                    | Trial population                                                                                                                                                  | Subject                                                     |
| 3475-045                               | IⅢ                                     |                                     |                     | APhaseIllRandomized                                                                                             | APhaseIllRandomized                                                                                             | Clinical Trialf Pembrolizumab active-conbolledtrial (MK-3475)ww55                                                    | Clinical Trialf Pembrolizumab active-conbolledtrial (MK-3475)ww55                                                    | Redomizedopn-label                          | Pembrolizumab200mg IV Q3F                                                                                           | Pembrolizumab200mg IV Q3F                                                                                                                                         | Male ad fomale subjects≥18yes qfage on the dyqf consent with metastatic or locally achvanced/wwresecta blewrothelial cmicer that has recured or progressed        | exposure 52lsubjects Dreated  pambrolizumab: 84:docetaxlel: |
| [Ref. 5.3.5.1 : P045V01]               |                                        |                                     |                     | PaclitaxclDoceteelor Vinflunine in Subjects with Recurent orProgressie MotastaticUrotholialCancer               | PaclitaxclDoceteelor Vinflunine in Subjects with Recurent orProgressie MotastaticUrotholialCancer               |                                                                                                                      |                                                                                                                      |                                             | Or, investigator's choice qf Pacliteel 175mg/mcwory 3 wecks: Docctel 75 mg/mcvwry 3 Wwoks OR Cow yau ote oue 3weeks | Or, investigator's choice qf Pacliteel 175mg/mcwory 3 wecks: Docctel 75 mg/mcvwry 3 Wwoks OR Cow yau ote oue 3weeks                                               | following platinum- basedchemotherapy                                                                                                                             | 266: pacliteol: 84:viflumine: 87)                           |

<div style=\"page-break-after: always\"></div>

## 2.3.2. Pharmacokinetics

Clinical pharmacology data related to Urothelial Carcinoma (UC) indication are available from two clinical studies KEYNOTE-052 and KEYNOTE-045 and are further informed by results obtained in other indications previously  approved  with  pembrolizumab.  In  addition,  results  from  KEYNOTE-012  C  are  included  as supportive information.

The updated clinical pharmacology results in this submission include:

-  Pharmacokinetic (PK) data from KEYNOTE-052 at 200 mg every three weeks (Q3W) in patients with locally advanced or metastatic urothelial carcinoma (UC) who are not eligible for cisplatincontaining chemotherapy.
-  Pharmacokinetic (PK) data from KEYNOTE-045 at 200 mg every three weeks (Q3W) in patients with locally advanced or metastatic urothelial carcinoma (UC) who have disease progression on or after  platinum-containing  chemotherapy  or  within  12  months  of  neoadjuvant  or  adjuvant treatment with platinum-containing chemotherapy.
-  Pharmacokinetic (PK) data from KEYNOTE-012 cohort C at 10 mg/Kg every two weeks (Q2W) in subjects with UC as supportive information.
-  The available data supporting the appropriateness of the 200 mg Q3W dose of pembrolizumab for UC.
-  An  updated  program-wide  evaluation  of  incidence  of  immunogenicity  including  data  from KEYNOTE-052, KEYNOTE-045 and KEYNOTE-012 in UC.

## Pharmacokinetics using human biomaterials

## PD-L1 assessment in Merck Urothelial cancer Trials of Pembrolizumab

A cut-off point for the PD-L1 biomarker using the Combined Positive Score (CPS) of 1% and 10% was established for the urothelial carcinoma program and was used in evaluation of samples from KN052 and KN045.  The  CPS  1%  cut-point  was  developed  based  on  data  from  KN012  and  studies  in  indications outside of the urothelial carcinoma program, and the CPS 10% was developed based on a 100 patient training set of KN052 (biomarker discovery population). The CPS 10% cut-off point was validated in the remaining population for KN052 (approximately 250 subjects - validation population).

Formaline-fixed paraffin-embedded (FFPE) samples from the Merck urothelial cancer clinical studies will be assessed for PD-L1 expression using the CPS method, following staining using the PD-L1 IHC 22C3 pharmDx assay.

CPS is defined as the percentage of tumour cells and mononuclear inflammatory cells (MIC) within the tumour nests and the adjacent supporting stroma expressing PD-L1 at any intensity. The denominator (all  tumour  cells)  includes  count  of  all  tumour  cells  within  the  section  determined  using  adjacent haematoxylin/eosin staining, independent of PD-L1 staining. The maximum of Combined Positive Score is defined as 100% and is represented by the equation below.

Samples were considered PD-L1 positive if CPS ≥ 1% and strongly positive if CPS ≥ 10%). Samples were considered PD-L1 negative if CPS &lt;1% (or &lt;10)%.

Details of the PD-L1 IHC 22C3 pharmDx assay have also been submitted for NSCLC.

<div style=\"page-break-after: always\"></div>

Analytical  validation  related  to  analytical  sensitivity  and  precision  around  the  CPS ≥ 1%  cut-off  in urothelial  carcinoma  specimens  was  conducted  at  Quintiles  Laboratories  (PD-L1  testing  lab  for  the urothelial carcinoma clinical studies) and the report was submitted as well as analytical validation related to precision around the CPS ≥ 10% cut-off in urothelial carcinoma specimens.

## Pharmacokinetic data in UC subjects

Sparse samples for pharmacokinetic analysis were collected in KEYNOTE-012 cohort C (10 mg/kg Q2W), KEYNOTE-052 (200 mg Q3W) and KEYNOTE-045 (200 mg Q3W).

PK sample schedule in KN012 : Pre-dose pembrolizumab serum concentrations (Ctrough) were obtained within 24 hours prior to dosing at Cycles 1, 2, 5, 9 and every 4 cycles (8 weeks) thereafter up to Cycle 37. Post-dose serum concentrations (Cmax) were drawn within approximately 30 minutes after the end of the infusion in Cycle 1 and Cycle 2. One additional PK sample is drawn between 24 and 96 hours (1-4 days) after Cycle 1 dosing.

Summary statistics of the observed pembrolizumab trough (pre-dose) and post-dose concentrations in UC subjects from KN012 are presented in the table below:

Summary Statistics of Pembrolizumab Predose (Ctrough), Postdose (Cmax), Post Cycle 1 Serum Concentration Values Following Administration of Multiple 10 mg/kg I.V. Doses with a 2 Week Dosing Interval in KN012 Urothelial Cancer Cohort

<!-- image -->

Data Source: [04JQV8: p012pkdmbld04]

The individual and arithmetic mean observed pembrolizumab trough concentrations from these same subjects are presented in the figure below:

<div style=\"page-break-after: always\"></div>

Individual and Arithmetic Mean (SE) Pembrolizumab Ctrough -Time Profiles Following Multiple I.V. Doses of 10 mg/kg Q2W in Study KN012 Urothelial CancerCohort;(a)Linearscale,(b) Logscale

<!-- image -->

Note:Greylinesrepresentindividual concentration observations.Blackdashedlinesrepresent arithmeticmeanconcentrations and errorbars are associated+/-SE(StandardError)

Data Source:[04JQV8: p012pkdmbld04]

## PK comparison across indication (Study KN012 cohort C)

Comparison of PK parameters among KN001 Melanoma, KN001 NSCLC, and KN012 urothelial cancer (UC) subjects were presented in the following table and figure:

<div style=\"page-break-after: always\"></div>

## Geometric Mean (GMCV %) Serum Concentration Values of Pembrolizumab Following Administration of Multiple I.V.10 mg/kg Q2W in KN012 Urothelial Cancer Cohort and Multiple 10 mg/kg Q2W I.V. Doses Q2W in KN001 Melanoma and NSCLC

| NOMTAFD (day)   | Cycle              | Relative Time     | N   | KN001 Melanoma GM(CV%) (g/mL)   | N   | KN001 NSCLC GM(CV%) (g/mL)   | N   | KN012 UC GM(CV%) (g/mL)   |
|-----------------|--------------------|-------------------|-----|---------------------------------|-----|------------------------------|-----|---------------------------|
| 0.02            | Cycle 1 (Week 0)   | Postdose          | 168 | 223 (25)                        | 197 | 227 (27)                     | 29  | 236 (20)                  |
| 2               |                    | 24-72HRS postdose |     |                                 | 169 | 155 (29)                     | 31  | 147 (32)                  |
| 14              | Cycle 2 (Week 2)   | Predose           | 5   | 63.7 (14)                       | 188 | 54.6 (33)                    | 28  | 55.5 (33)                 |
| 14.02           |                    | Postdose          | 3   | 304 (8)                         |     |                              | 29  | 271 (23)                  |
| 28              | Cycle3 (Week 4)    | Predose           | 150 | 94.0 (47)                       | 173 | 89.3 (39)                    |     |                           |
| 28.02           |                    | Postdose          | 147 | 316 (30)                        |     |                              |     |                           |
| 56              | Cycle 5 (Week 8)   | Predose           |     |                                 |     |                              | 16  | 172 (34)                  |
| 70              | Cycle 6 (Week 10)  | Predose           |     |                                 | 116 | 148 (42)                     |     |                           |
| 70.02           |                    | Postdose          |     |                                 | 107 | 385 (34)                     |     |                           |
| 84              | Cycle 7 (Week 12)  | Predose           | 111 | 174 (50)                        | 5   | 159 (19)                     |     |                           |
| 98              | Cycle 8 (Week 14)  | Predose           |     |                                 | 91  | 179 (42)                     |     |                           |
| 112             | Cycle 9 (Week 16)  | Predose           |     |                                 | 11  | 157 (52)                     | 8   | 228 (38)                  |
| 112.02          |                    | Postdose          |     |                                 | 10  | 339 (25)                     |     |                           |
| 154             | Cycle 12 (Week 22) | Predose           |     |                                 | 75  | 206 (43)                     |     |                           |
| 168             | Cycle 13 (Week 24) | Predose           | 87  | 233 (44)                        |     |                              | 8   | 292 (44)                  |
| 210             | Cycle 16 (Week 30) | Predose           |     |                                 | 33  | 205 (46)                     |     |                           |
| 224             | Cycle 17 (Week 32) | Predose           |     |                                 |     |                              | 8   | 283 (71)                  |
| 238             | Cycle 18 (Week 34) | Predose           |     |                                 | 28  | 218 (37)                     |     |                           |
| 252             | Cycle 19 (Week 36) | Predose           | 60  | 254 (38)                        |     |                              |     |                           |
| 280             | Cycle 21 (Week 40) | Predose           |     |                                 |     |                              | 6   | 387 (15)                  |
|                 | Cycle 22 (Week 42) | Predose           |     |                                 | 3   | 209 (18)                     |     |                           |
| 322             | Cycle 24 (Week 46) | Predose           |     |                                 | 36  | 229 (38)                     |     |                           |
| 336             | Cycle 25 (Week 48) | Predose           | 17  | 234 (27)                        |     |                              | 5   | 341 (32)                  |
| 392             | Cycle 29 (Week 56) | Predose           |     |                                 |     |                              | 4   | 378 (22)                  |
| 420             | Cycle 31 (Week 60) | Predose           | 4   | 184 (29)                        |     |                              |     |                           |
| 448             | Cycle 33 (Week 64) | Predose           |     |                                 |     |                              | 4   | 353 (40)                  |
| 490             | Cycle 36 (Week 70) | Predose           |     |                                 | 9   | 229 (35)                     |     |                           |
| 504             | Cycle 37 (Week 72) | Predose           | 14  | 242 (40)                        |     |                              | 3   | 287 (38)                  |
| 672             | Cycle 49 (Week 96) | Predose           | 10  | 289 (53)                        |     |                              |     |                           |

GM = Geometric Mean;

NOMTAFD=Nominal time after first pembrolizumab administration

CV%: Geometric Coefficient of Variation;

Postdose samples are drawn within 30 min after infusion;

<div style=\"page-break-after: always\"></div>

Arithmetic Mean Ctrough-Time Profiles of Pembrolizumab Following Administration of Multiple I.V. 10 mg/kg Q2W in KN012 Urothelial Cancer Cohort and Multiple 10 mg/kg I.V. Doses Q2W in KN001 Melanoma and NSCLC (Log-Linear scale)

<!-- image -->

PK sample schedule in KN052 : Pre-dose pembrolizumab serum concentrations (Ctrough) were obtained within 24 hours prior to dosing at Cycles 1, 2, 4, 8 and every 4 cycles (12 weeks) thereafter. Post-dose serum concentrations (Cmax) were drawn within approximately 30 minutes after the end of the infusion in Cycle 1 and Cycle 8. Additional PK samples are drawn between 72 and 168 hours (3-7 days) and Day 15 after Cycle 1 dosing.

Summary statistics of the observed pembrolizumab trough (pre-dose) and post-dose concentrations in UC subjects from KN052 are presented in the table below:

PostCycle1SerumConcentrationValuesFollowingAdministrationof Multiple 200 mg I.V. Doses with a 3 Week Dosing Interval in KN052

| Cycle                                                 | NOMTAFD                                               | N                                                     | GM (%CV)                                              | AM (SD)                                               | Min                                                   | Median                                                | Max                                                   |
|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                                       | (day)                                                 | (\"g/mL)                                               | (\"g/mL)                                               | (\"g/mL)                                               | (\"g/mL)                                               | (\"g/mL)                                               | (\"g/mL)                                               |
| Predose (Ctrough)                                     |                                                       |                                                       |                                                       |                                                       |                                                       |                                                       |                                                       |
| Cycle 2 (Week 3)                                      | 21                                                    | 286                                                   | 11.1 (42)                                             | 11.9 (4)                                              | 2.07                                                  | 11.5                                                  | 26.2                                                  |
| Cycle 4 (Week 9)                                      | 63                                                    | 170                                                   | 20.6 (51)                                             | 22.8 (9)                                              | 4.41                                                  | 22.4                                                  | 56.1                                                  |
| Cycle 8 (Week 21)                                     | 147                                                   | 59                                                    | 28.0 (38)                                             | 29.9 (10)                                             | 8.15                                                  | 27.9                                                  | 59.8                                                  |
| Cycle 12 (Week 33)                                    | 231                                                   | 22                                                    | 29.4 (53)                                             | 32.5 (14)                                             | 6.60                                                  | 29.5                                                  | 61.4                                                  |
| Cycle 16 (Week 45)                                    | 315                                                   | 10                                                    | 33.4 (38)                                             | 35.4 (12)                                             | 18.6                                                  | 36.2                                                  | 54.7                                                  |
| Postdose (vithin 30min post end of infusion)          | Postdose (vithin 30min post end of infusion)          |                                                       |                                                       |                                                       |                                                       |                                                       |                                                       |
| Cycle 1 (Week 0)                                      | 0                                                     | 298                                                   | 58.0 (28)                                             | 60.2 (17)                                             | 22.8                                                  | 57.4                                                  | 148                                                   |
| Cycle 8 (Week 21)                                     | 147                                                   | 53                                                    | 83.1 (29)                                             | 86.4 (24)                                             | 37.2                                                  | 81.1                                                  | 149                                                   |
| Post C1(additional samples drawn after Cycle1 dosing) | Post C1(additional samples drawn after Cycle1 dosing) | Post C1(additional samples drawn after Cycle1 dosing) | Post C1(additional samples drawn after Cycle1 dosing) | Post C1(additional samples drawn after Cycle1 dosing) | Post C1(additional samples drawn after Cycle1 dosing) | Post C1(additional samples drawn after Cycle1 dosing) | Post C1(additional samples drawn after Cycle1 dosing) |
| Cycle 1 (72-168 hr)                                   | 5                                                     | 299                                                   | 23.4 (31)                                             | 24.5 (8)                                              | 8.52                                                  | 23.5                                                  | 61.3                                                  |
| Cycle 1 (336 hr)                                      | 14                                                    | 287                                                   | 14.4 (36)                                             | 15.2 (5)                                              | 4.39                                                  | 14.7                                                  | 35.5                                                  |

NOMTAFD=Nominal time afterfirst dose;

GM=GeometricMean:

o%CV=GeometricCoefficient ofVariation:

SD=Standard Deviation:

AM=ArithmeticMean:

Results for time points with N &gt;3.

Data Source:[04JR0J: p052pkdm05]

<div style=\"page-break-after: always\"></div>

The individual and arithmetic mean observed pembrolizumab trough concentrations from these same subjects are presented in the figure below:

Individual and Arithmetic Mean (SE) Pembrolizumab Ctrough -Time Profiles Following Multiple I.V. Doses of 200 mg Q3W in Study KN052 (a) Linear' scale, (b) Log scale

<!-- image -->

Note: Greylines represent individual concentration observations.Black dashed lines represent arithmetic mean concentrations and error bars are associated +/- SE (Standard Error). Data Source: [04JR0J: p052pkdm05]

## PK comparison across indication (study KN052)

Comparison of PK parameters among KN001 Melanoma, KN001 NSCLC, and KN052 urothelial cancer (UC) subjects were presented in the following table and boxplots:

PembrolizumabFollowingAdministrationof MultipleI.V.200mgQ3W Fixed Doses inKN052UCand Multiple 2mg/kgQ3WI.V.Doses inKN001 MelanomaandNSCLC

<!-- image -->

|                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 | KN001MIEL 2mg/kg                                                                                                                                                                                                | KN001MIEL 2mg/kg                                                                                                                                                                                                | KN001 NSCLC 2mg/kg                                                                                                                                                                                              | KN001 NSCLC 2mg/kg                                                                                                                                                                                              | KN052UC 200 mg                                                                                                                                                                                                  | KN052UC 200 mg                                                                                                                                                                                                  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| NONITAFD (day)                                                                                                                                                                                                  | Cycle                                                                                                                                                                                                           | Relative time                                                                                                                                                                                                   | N                                                                                                                                                                                                               | GAI(CT%) (g/mL)                                                                                                                                                                                                 | N                                                                                                                                                                                                               | GII(CT%) (g/mL)                                                                                                                                                                                                 | N                                                                                                                                                                                                               | (g/mL)                                                                                                                                                                                                          |
| 0.02                                                                                                                                                                                                            | Cycle 1 (Week 0)                                                                                                                                                                                                | Postdose                                                                                                                                                                                                        | 151                                                                                                                                                                                                             | 46.0 (37)                                                                                                                                                                                                       | 53                                                                                                                                                                                                              | 42.4 (32)                                                                                                                                                                                                       | 298                                                                                                                                                                                                             | 58.0 (28)                                                                                                                                                                                                       |
| 21                                                                                                                                                                                                              | Cycle 2 (Week 3)                                                                                                                                                                                                | Predose                                                                                                                                                                                                         | 141                                                                                                                                                                                                             | 9.12 (51)                                                                                                                                                                                                       | 43                                                                                                                                                                                                              | 8.09 (39)                                                                                                                                                                                                       | 286                                                                                                                                                                                                             | 11.1 (42)                                                                                                                                                                                                       |
| 21.02                                                                                                                                                                                                           |                                                                                                                                                                                                                 | Postdose                                                                                                                                                                                                        | 89                                                                                                                                                                                                              | 52.6 (49)                                                                                                                                                                                                       |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |
| 42                                                                                                                                                                                                              | Cycle 3 (Week 6)                                                                                                                                                                                                | Predose                                                                                                                                                                                                         | 47                                                                                                                                                                                                              | 16.6 (57)                                                                                                                                                                                                       | 38                                                                                                                                                                                                              | 11.5 (63)                                                                                                                                                                                                       |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |
| 63                                                                                                                                                                                                              | Cycle 4 (Week 9)                                                                                                                                                                                                | Predose                                                                                                                                                                                                         |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 | 170                                                                                                                                                                                                             | 20.6 (51)                                                                                                                                                                                                       |
| 84                                                                                                                                                                                                              | Cycle 5 (Week 12)                                                                                                                                                                                               | Predose                                                                                                                                                                                                         | 62                                                                                                                                                                                                              | 19.6 (57)                                                                                                                                                                                                       |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |
| 105                                                                                                                                                                                                             | Cycle 6 (Week 15)                                                                                                                                                                                               | Predose                                                                                                                                                                                                         | 32                                                                                                                                                                                                              | 24.6 (34)                                                                                                                                                                                                       | 27                                                                                                                                                                                                              | 18.7 (42)                                                                                                                                                                                                       |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |
| 105.02                                                                                                                                                                                                          |                                                                                                                                                                                                                 | Postdose                                                                                                                                                                                                        | 30                                                                                                                                                                                                              | 65.6 (24)                                                                                                                                                                                                       | 26                                                                                                                                                                                                              | 58.9 (43)                                                                                                                                                                                                       |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |
| 147                                                                                                                                                                                                             | Cycle 8 (Week 21)                                                                                                                                                                                               | Predose                                                                                                                                                                                                         | 31                                                                                                                                                                                                              | 23.5 (50)                                                                                                                                                                                                       | 21                                                                                                                                                                                                              | 18.9 (55)                                                                                                                                                                                                       | 59                                                                                                                                                                                                              | 28.0 (38)                                                                                                                                                                                                       |
| 147.02                                                                                                                                                                                                          |                                                                                                                                                                                                                 | Postdose                                                                                                                                                                                                        |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 | 53                                                                                                                                                                                                              | 83.1 (29)                                                                                                                                                                                                       |
| 168                                                                                                                                                                                                             | Cycle 9 (Week 24)                                                                                                                                                                                               | Predose                                                                                                                                                                                                         | 46                                                                                                                                                                                                              | 25.3 (59)                                                                                                                                                                                                       |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |
| 231                                                                                                                                                                                                             | Cycle 12 (Week 33)                                                                                                                                                                                              | Predose                                                                                                                                                                                                         | 23                                                                                                                                                                                                              | 29.6 (35)                                                                                                                                                                                                       | 7                                                                                                                                                                                                               | 22.3 (64)                                                                                                                                                                                                       | 22                                                                                                                                                                                                              | 29.4 (53)                                                                                                                                                                                                       |
| 757                                                                                                                                                                                                             | Cycle 13 (Week 36)                                                                                                                                                                                              | Predose                                                                                                                                                                                                         | 47                                                                                                                                                                                                              | 27.1 (50)                                                                                                                                                                                                       |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |
| 315                                                                                                                                                                                                             | Cycle 16 (Week 45)                                                                                                                                                                                              | Predose                                                                                                                                                                                                         | 18                                                                                                                                                                                                              | 33.8 (67)                                                                                                                                                                                                       |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 | 10                                                                                                                                                                                                              | 33.4 (38)                                                                                                                                                                                                       |
| 336                                                                                                                                                                                                             | Cycle 17 (Week48)                                                                                                                                                                                               | Predose                                                                                                                                                                                                         | 39                                                                                                                                                                                                              | 32.2 (45)                                                                                                                                                                                                       |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |
| 483                                                                                                                                                                                                             | Cycle 24 (Week 69)                                                                                                                                                                                              | Predose                                                                                                                                                                                                         | 8                                                                                                                                                                                                               | 30.3 (40)                                                                                                                                                                                                       |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |
| 504                                                                                                                                                                                                             | Cycle 25 (Week 72)                                                                                                                                                                                              | Predose                                                                                                                                                                                                         | 11                                                                                                                                                                                                              | 28.1 (37)                                                                                                                                                                                                       |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |
| NOMTAFD-Nominal timeaferfirst pembrolizumab administration; GM=GeometricMean, %CV=GeometricCoefficientofVariation; Postdose samples are drawn within 30 min after infusion; Results for time points with N > 3. | NOMTAFD-Nominal timeaferfirst pembrolizumab administration; GM=GeometricMean, %CV=GeometricCoefficientofVariation; Postdose samples are drawn within 30 min after infusion; Results for time points with N > 3. | NOMTAFD-Nominal timeaferfirst pembrolizumab administration; GM=GeometricMean, %CV=GeometricCoefficientofVariation; Postdose samples are drawn within 30 min after infusion; Results for time points with N > 3. | NOMTAFD-Nominal timeaferfirst pembrolizumab administration; GM=GeometricMean, %CV=GeometricCoefficientofVariation; Postdose samples are drawn within 30 min after infusion; Results for time points with N > 3. | NOMTAFD-Nominal timeaferfirst pembrolizumab administration; GM=GeometricMean, %CV=GeometricCoefficientofVariation; Postdose samples are drawn within 30 min after infusion; Results for time points with N > 3. | NOMTAFD-Nominal timeaferfirst pembrolizumab administration; GM=GeometricMean, %CV=GeometricCoefficientofVariation; Postdose samples are drawn within 30 min after infusion; Results for time points with N > 3. | NOMTAFD-Nominal timeaferfirst pembrolizumab administration; GM=GeometricMean, %CV=GeometricCoefficientofVariation; Postdose samples are drawn within 30 min after infusion; Results for time points with N > 3. | NOMTAFD-Nominal timeaferfirst pembrolizumab administration; GM=GeometricMean, %CV=GeometricCoefficientofVariation; Postdose samples are drawn within 30 min after infusion; Results for time points with N > 3. | NOMTAFD-Nominal timeaferfirst pembrolizumab administration; GM=GeometricMean, %CV=GeometricCoefficientofVariation; Postdose samples are drawn within 30 min after infusion; Results for time points with N > 3. |

DataSource:[04JR0J:plp52poolpk2q3w200f01]

<div style=\"page-break-after: always\"></div>

Boxplots with Serum Pembrolizumab Concentration Values from KN052 UC 200 mg Q3W Regimen Compared with KN001 Melanoma and NSCLC 2 mg/kg Q3W Regimen

<!-- image -->

PK sample schedule in KN045 : Pre-dose pembrolizumab serum concentrations (Ctrough) were obtained within 24 hours prior to dosing at Cycles 1, 2, 4, 8 and every 4 cycles (12 weeks) thereafter. Post-dose serum concentrations (Cmax) were drawn within approximately 30 minutes after the end of the infusion in Cycle 1 and Cycle 8. One additional PK sample is drawn between 72 and 168 hours (3-7 days) after Cycle 1 dosing.

Summary statistics of the observed pembrolizumab trough (pre-dose) and post-dose concentrations in UC subjects from KN045 are presented in the table below:

Summary Statistics of Pembrolizumab Predose (Ctrough), Postdose (Cmax), Post Cycle 1 Serum Concentration Values Following Administration of Multiple 200 mg I.V. Doses with a 3 Week Dosing Interval in KN045

<!-- image -->

| Cycle                                                | NOMTAFD                                              | N                                                    | GM (%CV)                                             | AM (SD)                                              | Min                                                  | Median                                               | Max                                                  |
|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                                      | day                                                  |                                                      |                                                      | (g/mL)                                               |                                                      |                                                      |                                                      |
| Predose (Ctrough)                                    |                                                      |                                                      |                                                      |                                                      |                                                      |                                                      |                                                      |
| Cycle 2 (Week 3)                                     | 21                                                   | 233                                                  | 13.1 (47)                                            | 14.2 (5)                                             | 0.475                                                | 13.9                                                 | 29.3                                                 |
| Cycle 4 (Week 9)                                     | 63                                                   | 169                                                  | 25.3 (52)                                            | 27.7 (11)                                            | 0.677                                                | 26.6                                                 | 62.1                                                 |
| Cycle 8 (Week 21)                                    | 147                                                  | 104                                                  | 33.4 (64)                                            | 37.8 (17)                                            | 1.13                                                 | 37.5                                                 | 95.6                                                 |
| Cycle 12 (Week 33)                                   | 231                                                  | 73                                                   | 39.2 (40)                                            | 42.0 (15)                                            | 14.5                                                 | 39.4                                                 | 83.1                                                 |
| Cycle 16 (Week 45)                                   | 315                                                  | 44                                                   | 39.0 (39)                                            | 41.7 (15)                                            | 12.2                                                 | 42.2                                                 | 90.9                                                 |
| Cycle 20 (Week 57)                                   | 399                                                  | 22                                                   | 38.7 (36)                                            | 41.0 (15)                                            | 19.3                                                 | 37.3                                                 | 82.8                                                 |
| Cycle 24 (Week 69)                                   | 483                                                  | 8                                                    | 36.7 (33)                                            | 38.5 (12)                                            | 25.3                                                 | 37.8                                                 | 54.5                                                 |
| Postdose (Cmax) (within 30 min post end of infusion) | Postdose (Cmax) (within 30 min post end of infusion) | Postdose (Cmax) (within 30 min post end of infusion) | Postdose (Cmax) (within 30 min post end of infusion) | Postdose (Cmax) (within 30 min post end of infusion) | Postdose (Cmax) (within 30 min post end of infusion) | Postdose (Cmax) (within 30 min post end of infusion) | Postdose (Cmax) (within 30 min post end of infusion) |
| Cycle 1 (Week 0)                                     | 0                                                    | 247                                                  | 65.7 (26)                                            | 67.9 (18)                                            | 33.9                                                 | 65.9                                                 | 144                                                  |
| Cycle 8 (Week 21)                                    | 147                                                  | 97                                                   | 103 (31)                                             | 107 (32)                                             | 44.8                                                 | 103                                                  | 219                                                  |
| Post Cycle 1 (72-168 hours post cycle 1)             | Post Cycle 1 (72-168 hours post cycle 1)             | Post Cycle 1 (72-168 hours post cycle 1)             | Post Cycle 1 (72-168 hours post cycle 1)             | Post Cycle 1 (72-168 hours post cycle 1)             | Post Cycle 1 (72-168 hours post cycle 1)             | Post Cycle 1 (72-168 hours post cycle 1)             | Post Cycle 1 (72-168 hours post cycle 1)             |
| Cycle 1 (Week 0)                                     | 5                                                    | 245                                                  | 29.0 (29)                                            | 30.2 (9)                                             | 15.2                                                 | 29.2                                                 | 57.5                                                 |

GM = Geometric Mean;

CV% = Geometric Coefficient of Variation;

AM = Arithmetic Mean;

SD = Standard Deviation;

Results reported for time points with N &gt; 3.

Data Source: [04JT5G: p045pkdm09]

<div style=\"page-break-after: always\"></div>

The individual and arithmetic mean observed pembrolizumab trough concentrations from these same subjects are presented in the figure below:

Individual and Arithmetic Mean (SE) Pembrolizumab Ctrough -Time Profiles Following Multiple I.V. Doses of 200 mg Q3W in Study KN045 (a) Linear scale, (b) Log scale

<!-- image -->

Note: Grey lines represent individual concentration observations. Black dashed lines represent arithmetic mean concentrationsanderrorbars areassociated+/-SE(StandardError).

Data Source: [04JT5G: p045pkdm09]

## PK comparison across indication (study KN045)

Comparison of PK parameters among KN001 Melanoma, KN001 NSCLC, and KN045 urothelial cancer (UC) subjects were presented in the following table and boxplots:

GeometricMean(GMCY%o)SerumConcentrationValuesof PembrolizumabFollowing Administration of Multiple I.V. 200mgQ3W in KN045UC and Multiple 2mg/kg I.V.Doses Q3WinKN001 Melanoma and NSCLC

<!-- image -->

| Cycle                                                                                                                                                                  | NONITAFD (day)                                                                                                                                                         | Relative Time                                                                                                                                                          | N                                                                                                                                                                      | KN001 Melanoma GMI(CI%) (1g/mL)                                                                                                                                        | N                                                                                                                                                                      | KN001 NSCLC GII(CT%) (g/mL)                                                                                                                                            | N                                                                                                                                                                      | KN045 UC GM(CY%) (g/mL)                                                                                                                                                |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Cycle 1 (Week 0)                                                                                                                                                       | 0                                                                                                                                                                      | Postdose                                                                                                                                                               | 151                                                                                                                                                                    | 46.0 (37)                                                                                                                                                              | 53                                                                                                                                                                     | 42.4 (32)                                                                                                                                                              | 247                                                                                                                                                                    | 65.7 (26)                                                                                                                                                              |
| Cycle 2 (Week 3)                                                                                                                                                       | 21                                                                                                                                                                     | Predose                                                                                                                                                                | 141                                                                                                                                                                    | 9.12 (51)                                                                                                                                                              | 43                                                                                                                                                                     | 8.09 (39)                                                                                                                                                              | 233                                                                                                                                                                    | 13.1 (47)                                                                                                                                                              |
| Cycle2 (Week 3)                                                                                                                                                        | 21                                                                                                                                                                     | Postdose                                                                                                                                                               | 89                                                                                                                                                                     | 52.6 (49)                                                                                                                                                              |                                                                                                                                                                        |                                                                                                                                                                        |                                                                                                                                                                        |                                                                                                                                                                        |
| Cycle3 (Week 6)                                                                                                                                                        | 42                                                                                                                                                                     | Predose                                                                                                                                                                | 47                                                                                                                                                                     | 16.6 (57)                                                                                                                                                              | 38                                                                                                                                                                     | 11.5 (63)                                                                                                                                                              |                                                                                                                                                                        |                                                                                                                                                                        |
| Cycle 4 (Week 9)                                                                                                                                                       | 63                                                                                                                                                                     | Predose                                                                                                                                                                |                                                                                                                                                                        |                                                                                                                                                                        |                                                                                                                                                                        |                                                                                                                                                                        | 169                                                                                                                                                                    | 25.3 (52)                                                                                                                                                              |
| Cycle5 (Week12)                                                                                                                                                        | 84                                                                                                                                                                     | Predose                                                                                                                                                                | 62                                                                                                                                                                     | 19.6 (57)                                                                                                                                                              |                                                                                                                                                                        |                                                                                                                                                                        |                                                                                                                                                                        |                                                                                                                                                                        |
| Cycle 6 (Week 15)                                                                                                                                                      | 105                                                                                                                                                                    | Predose                                                                                                                                                                | 32                                                                                                                                                                     | 24.6 (34)                                                                                                                                                              | 27                                                                                                                                                                     | 18.7 (42)                                                                                                                                                              |                                                                                                                                                                        |                                                                                                                                                                        |
| Cycle 6 (Week 15)                                                                                                                                                      | 105                                                                                                                                                                    | Postdose                                                                                                                                                               | 30                                                                                                                                                                     | 65.6 (24)                                                                                                                                                              | 26                                                                                                                                                                     | 58.9 (43)                                                                                                                                                              |                                                                                                                                                                        |                                                                                                                                                                        |
| Cycle 8 (Week 21)                                                                                                                                                      | 147                                                                                                                                                                    | Predose                                                                                                                                                                | 31                                                                                                                                                                     | 23.5 (50)                                                                                                                                                              | 21                                                                                                                                                                     | 18.9 (55)                                                                                                                                                              | 104                                                                                                                                                                    | 33.4 (64)                                                                                                                                                              |
| Cycle 8 (Week 21)                                                                                                                                                      | 147                                                                                                                                                                    | Postdose                                                                                                                                                               |                                                                                                                                                                        |                                                                                                                                                                        |                                                                                                                                                                        |                                                                                                                                                                        | 97                                                                                                                                                                     | 103 (31)                                                                                                                                                               |
| Cycle 9 (Week 24)                                                                                                                                                      | 168                                                                                                                                                                    | Predose                                                                                                                                                                | 46                                                                                                                                                                     | 25.3 (59)                                                                                                                                                              |                                                                                                                                                                        |                                                                                                                                                                        |                                                                                                                                                                        |                                                                                                                                                                        |
| Cycle 12 (Week 33)                                                                                                                                                     | 231                                                                                                                                                                    | Predose                                                                                                                                                                | 23                                                                                                                                                                     | 29.6 (35)                                                                                                                                                              | 7                                                                                                                                                                      | 22.3 (64)                                                                                                                                                              | 73                                                                                                                                                                     | 39.2 (40)                                                                                                                                                              |
| Cycle 13 (Week 36)                                                                                                                                                     | 252                                                                                                                                                                    | Predose                                                                                                                                                                | 47                                                                                                                                                                     | 27.1 (50)                                                                                                                                                              |                                                                                                                                                                        |                                                                                                                                                                        |                                                                                                                                                                        |                                                                                                                                                                        |
| Cycle 16 (Week 45)                                                                                                                                                     | 315                                                                                                                                                                    | Predose                                                                                                                                                                | 18                                                                                                                                                                     | 33.8 (67)                                                                                                                                                              |                                                                                                                                                                        |                                                                                                                                                                        | 44                                                                                                                                                                     | 39.0 (39)                                                                                                                                                              |
| Cycle 17 (Week 48)                                                                                                                                                     | 336                                                                                                                                                                    | Predose                                                                                                                                                                | 39                                                                                                                                                                     | 32.2 (45)                                                                                                                                                              |                                                                                                                                                                        |                                                                                                                                                                        |                                                                                                                                                                        |                                                                                                                                                                        |
| Cycle 20 (Week 57)                                                                                                                                                     | 399                                                                                                                                                                    | Predose                                                                                                                                                                |                                                                                                                                                                        |                                                                                                                                                                        |                                                                                                                                                                        |                                                                                                                                                                        | 22                                                                                                                                                                     | 38.7 (36)                                                                                                                                                              |
| Cycle 24 (Week 69)                                                                                                                                                     | 483                                                                                                                                                                    | Predose                                                                                                                                                                | 8                                                                                                                                                                      | 30.3 (40)                                                                                                                                                              |                                                                                                                                                                        |                                                                                                                                                                        | 8                                                                                                                                                                      | 36.7 (33)                                                                                                                                                              |
| Cycle 25 (Week 72)                                                                                                                                                     | 504                                                                                                                                                                    | Predose                                                                                                                                                                | 11                                                                                                                                                                     | 28.1 (37)                                                                                                                                                              |                                                                                                                                                                        |                                                                                                                                                                        |                                                                                                                                                                        |                                                                                                                                                                        |
| Cycle 33 (Week 96)                                                                                                                                                     | 672                                                                                                                                                                    | Predose                                                                                                                                                                | 3                                                                                                                                                                      | 38.7 (15)                                                                                                                                                              |                                                                                                                                                                        |                                                                                                                                                                        |                                                                                                                                                                        |                                                                                                                                                                        |
| NOMTAFD=Nominaltimeafterfirstpembrolizumabadministration; GM=Geometric Mean; CV%: Geometric Coefficient of Variation; Postdosesamplesaredrawnwithin30minafterinfusion. | NOMTAFD=Nominaltimeafterfirstpembrolizumabadministration; GM=Geometric Mean; CV%: Geometric Coefficient of Variation; Postdosesamplesaredrawnwithin30minafterinfusion. | NOMTAFD=Nominaltimeafterfirstpembrolizumabadministration; GM=Geometric Mean; CV%: Geometric Coefficient of Variation; Postdosesamplesaredrawnwithin30minafterinfusion. | NOMTAFD=Nominaltimeafterfirstpembrolizumabadministration; GM=Geometric Mean; CV%: Geometric Coefficient of Variation; Postdosesamplesaredrawnwithin30minafterinfusion. | NOMTAFD=Nominaltimeafterfirstpembrolizumabadministration; GM=Geometric Mean; CV%: Geometric Coefficient of Variation; Postdosesamplesaredrawnwithin30minafterinfusion. | NOMTAFD=Nominaltimeafterfirstpembrolizumabadministration; GM=Geometric Mean; CV%: Geometric Coefficient of Variation; Postdosesamplesaredrawnwithin30minafterinfusion. | NOMTAFD=Nominaltimeafterfirstpembrolizumabadministration; GM=Geometric Mean; CV%: Geometric Coefficient of Variation; Postdosesamplesaredrawnwithin30minafterinfusion. | NOMTAFD=Nominaltimeafterfirstpembrolizumabadministration; GM=Geometric Mean; CV%: Geometric Coefficient of Variation; Postdosesamplesaredrawnwithin30minafterinfusion. | NOMTAFD=Nominaltimeafterfirstpembrolizumabadministration; GM=Geometric Mean; CV%: Geometric Coefficient of Variation; Postdosesamplesaredrawnwithin30minafterinfusion. |

Data Source:[04JT5G:plp45poolpk2q3w200f01]

<div style=\"page-break-after: always\"></div>

Boxplots with Serum Pembrolizumab Concentration Values from KN045 UC 200 mg Q3W Regimen Compared with KN001 Melanoma and NSCLC 2 mg/kg Q3W Regimen

<!-- image -->

Data Source: [04JT5G: p1p45poolpk2q3w200f01]

## Absorption

Pembrolizumab is dosed via the intravenous route and therefore is immediately and completely bioavailable.

## Distribution

Consistent with a limited extravascular distribution, the volume of distribution of pembrolizumab at steady state is small (~7.5 L; CV: 20%). As expected for an antibody, pembrolizumab does not bind to plasma proteins in a specific manner.

## Elimination

The systemic clearance of pembrolizumab is ~0.2 L/day (CV: 37%) and the terminal half-life (t½) is ~25 days (CV: 38%).

## Special populations

The effects of various covariates on the pharmacokinetics of pembrolizumab were assessed in population pharmacokinetic analyses. The following factors had no clinically important effect on the clearance of pembrolizumab: age (range 15-94 years), gender, race, mild or moderate renal impairment, mild hepatic impairment and tumour burden. The relationship between body weight and clearance supports the use of either fixed dose or body weight-based dosing to provide adequate and similar control of exposure.

## Renal impairment

The effect of renal impairment on the clearance of pembrolizumab was evaluated by population pharmacokinetic analyses in patients with mild or moderate renal impairment compared to patients with normal renal function. No clinically important differences in the clearance of pembrolizumab were found between patients with mild or moderate renal impairment and patients with normal renal function. Pembrolizumab has not been studied in patients with severe renal impairment.

<div style=\"page-break-after: always\"></div>

## Hepatic impairment

The effect of hepatic impairment on the clearance of pembrolizumab was evaluated by population pharmacokinetic analyses in patients with mild hepatic impairment (as defined using the US National Cancer Institute criteria of hepatic dysfunction) compared to patients with normal hepatic function. No clinically important differences in the clearance of pembrolizumab were found between patients with mild hepatic impairment and normal hepatic function. Pembrolizumab has not been studied in patients with moderate or severe hepatic impairment (see section 4.2 of the SmPC).

## 2.3.3. Pharmacodynamics

## Mechanism of action

KEYTRUDA is an antibody that binds to the programmed death-1 (PD-1) receptor and blocks its interaction with ligands PD-L1 and PD-L2. The PD-1 receptor is a negative regulator of T-cell activity that has been shown to be involved in the control of T-cell immune responses. KEYTRUDA potentiates T-cell responses, including anti-tumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2, which are expressed in antigen presenting cells and may be expressed by tumours or other cells in the tumour microenvironment.

## Primary and secondary pharmacology

## Immunogenicity

The samples were assayed for anti-pembrolizumab antibodies presence using a validated electrochemiluminescence (ECL) immunoassay on the MesoScale Discovery (MSD) platform. Bioanalysis of pembrolizumab ADA was carried out using the standard 3-tiered assay approach that consisted of screening (Tier 1), confirmation (Tier 2) and antibody titer assessment (Tier 3).

Only Tier 2 confirmed ADA positive samples were moved to Tier 3 and reported with a titer value and a NAb result.

The initial neutralising assay, as used at Intertek, was a validated ligand binding ECL assay and consisted of two tiers: a screening tier and a confirmatory tier.

The first tier used a cut point aiming for 5% false positives while in the second, confirmatory, tier the cut point allowed for 1% false positives. In the confirmatory tier, Protein G depletion was used to confirm the presence of pembrolizumab neutralising antibodies. The neutralising assay was subsequently redesigned at a second CRO (PPD). The assay was a validated ligand binding ECL assay in which the approach was adjusted to a single tier approach. The assay cut point was aiming for 1% false positives instead of 5%, supporting the elimination of a second tier.

An integrated immunogenicity evaluation has been performed using data across studies keynote-001, 002, -006, -012, -013, -024, -045, -052, -055, -087 and -164. A total of 3727 subjects were included in the immunogenicity assessment across indications (1535 melanoma, 1238 NSCLC, 101 HNSCC, 45 MSIH, 220 HL and 579 UC) and across doses (at 2 mg/kg Q3W, 10 mg/kg Q3W/Q2W and 200 mg Q3W).

Out of the 3727 subjects included in the immunogenicity assessment, 2034 subjects were evaluable.

The observed incidence of treatment emergent ADA in evaluable subjects based on the pooled analysis is 1.8% (36 out of 2034). Of the 36 treatment emergent positive subjects, 9 (1 melanoma, 5 NSCLC, 1 HL

<div style=\"page-break-after: always\"></div>

and 2 UC) tested positive in the neutralizing assay. The 9 subjects positive in the neutralising assay accounted for a total incidence rate of treatment neutralizing positive subjects of 0.4% (9 out of 2034) in the overall population.

A summary of subject immunogenicity results is reported below:

Summary of Subject Immunogenicity Results (pooled analysis)

| Stratified by treatment          | Stratified by treatment          | Stratified by treatment   | Stratified by treatment   | Stratified by treatment   | Stratified by treatment   | Stratified by treatment   | Stratified by treatment   |
|----------------------------------|----------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
|                                  |                                  | All                       | All                       | Treatment                 | Treatment                 | Treatment                 | Treatment                 |
| Immunogenicitystatus treatments  | Immunogenicitystatus treatments  |                           |                           | 2 mg/kg                   | 2 mg/kg                   | 10 mg/kg 200 mg           | 10 mg/kg 200 mg           |
| Assessable subjectsa             | Assessable subjectsa             | 3727                      | 3727                      | 706 2038                  | 706 2038                  | 983                       | 983                       |
| Inconclusive subjectsb           | Inconclusive subjectsb           | 1693                      | 1693                      | 136 1489                  | 136 1489                  | 68                        | 68                        |
| Evaluable subjects               | Evaluable subjects               | 2034                      | 2034                      | 570 549                   | 570 549                   | 915                       | 915                       |
| Negatived                        | Negatived                        | 1977 (97.2%)              | 1977 (97.2%)              | 555 (97.4%) 533 (97.1%)   | 555 (97.4%) 533 (97.1%)   | 889 (97.2%)               | 889 (97.2%)               |
| Non-Treatment emergent positived | Non-Treatment emergent positived | 21 (1.0%)                 | 21 (1.0%)                 | 7 (1.2%) 4 (0.7%)         | 7 (1.2%) 4 (0.7%)         | 10 (1.1%)                 | 10 (1.1%)                 |
| Neutralizing negative            | Neutralizing negative            | 19 (0.9%)                 | 19 (0.9%)                 | 5 (%) 4 (0.7%)            | 5 (%) 4 (0.7%)            | 10 (1.1%)                 | 10 (1.1%)                 |
| Neutralizing positive            | Neutralizing positive            | 2 (0.1%)                  | 2 (0.1%)                  | 2 (%) 0                   | 2 (%) 0                   | 0                         | 0                         |
| Treatment emergent positived     | Treatment emergent positived     | 36 (1.8%)t 3              | 36 (1.8%)t 3              | 8 (1.4%) 12 (2.2%)        | 8 (1.4%) 12 (2.2%)        | 16 (1.7%)f                | 16 (1.7%)f                |
| Neutralizing negative            | Neutralizing negative            | 27 (1.3%) 3               | 27 (1.3%) 3               | 6 (1.1%) 11 (2.0%)        | 6 (1.1%) 11 (2.0%)        | 10 (1.1%)                 | 10 (1.1%)                 |
| Neutralizing positive            | Neutralizing positive            | 9 (0.4%)                  | 9 (0.4%)                  | 2 (0.4%) 1 (0.2%)         | 2 (0.4%) 1 (0.2%)         | 6 (0.7%)                  | 6 (0.7%)                  |
| Stratified byIndication          | Stratified byIndication          | Stratified byIndication   | Stratified byIndication   | Stratified byIndication   | Stratified byIndication   | Stratified byIndication   | Stratified byIndication   |
| Immunogenicity status            | Melanoma                         | Melanoma                  | NSCLC                     | HNSCC                     | MSI-H HL                  | MSI-H HL                  | UC                        |
| Assessable subjects              | 1535                             | 1535                      | 1238                      | 101 54                    | 220                       | 220                       | 579                       |
| Inconclusive subjects            | 1101                             | 1101                      | 445                       | 39 0                      | 38                        | 38                        | 70                        |
| Evaluable subjects               | 434                              | 434                       | 793                       | 62 54                     | 182                       | 182                       | 509                       |
| Negatived                        | 427 (98.4%)                      | 427 (98.4%)               | 764 (96.3%)               | 59 51 (95.2%) (94.4%)     | 179 (98.4%)               | 179 (98.4%)               | 497 (97.6%)               |
| Non-Treatment emergent positived | 4 (0.9%)                         | 4 (0.9%)                  | 6 (0.7%)                  | 2 (3.2%) 2 (3.7%)         | 2 (1.1%)                  | 2 (1.1%)                  | 5 (1.0%)                  |
| Neutralizing negative            | 3 (0.7%)                         | 3 (0.7%)                  | 5 (0.6%)                  | 2 (3.2%) 2 (3.7%)         | 2 (1.1%)                  | 2 (1.1%)                  | 5 (1.0%)                  |
| Neutralizing positive            | 1 (0.2%)                         | 1 (0.2%)                  | 1 (0.1%)                  | 0 0                       | 0                         | 0                         | 0                         |
| Treatment emergent Positived     | 3 (0.7%)                         | 3 (0.7%)                  | 23 =g(%6'z)               | 1 (1.6%) 1 (1.9%)         | 1 (0.6%)                  | 1 (0.6%)                  | 7 (1.4%)                  |
| Neutralizing negative            | 2 (0.5%)                         | 2 (0.5%)                  | 18 (2.3%)f ±              | 1 (1.6%) 1 (1.9%)         | 0                         | 0                         | 5 (1.0%)                  |
| Neutralizing positive            | 1 (0.2%)                         | 1 (0.2%)                  | 5 (0.6%)                  | 0 0                       | 1 (0.6%)                  | 1 (0.6%)                  | 2 (0.4%)                  |

a: Included are subjects with at least one ADA sample available after treatment with pembrolizumab

- b: Inconclusive subjects are the number of subjects with no positive ADA samples present and the drug concentration in the last sample above the DTL.
- c: Evaluable subjects are the total number of negative and positive subjects (non-treatment emergent and treatmentemergent.
- d: Denominator was total number of evaluable subjects.
- e: Including three subjects with pre and post dose sample ADA positive, and no increase in titer
- f: Including one subject with pre and post dose sample ADA positive, and increase in titer
- h: Including one subject with pre and post dose sample ADA positive, and no increase in titer.
- g: Including one subject with post dose sample ADA positive and pre dose sample missing.
- i: Including two subject with pre and post dose sample ADA positive, and no increase in titer.
- NSCLC: Non Small Cell Lung Carcinoma; HNSCC: Head and Neck Squamous Cell Carcinoma;

MSI-H: Microsatellite Instability-High; HL: Hodgkin Lymphoma; UC: Urothelial Cancer

Data source [Appendix 9]

Pembrolizumab exposure for these treatment emergent (ADA and neutralizing) subjects was within the same range of exposure observed for other non-positive subjects treated with the same regimen.

## Evaluation of drug tolerance level

At the recommended dosing regimen of 200 mg, the pembrolizumab concentration in the last post-dose sample was below the drug tolerance level (&lt;DTL) for about 92.9% of the subjects, indicating that the DLT for the ADA assay is adequate  for 200 mg.

<div style=\"page-break-after: always\"></div>

Overviewof SubjectswithPembrolizumabConcentrationsRelative to the DrugToleranceLeveloftheADAAssayintheLastPostdoseSample

<!-- image -->

|                                                   | Treatment      | Treatment    | Treatment     | Treatment    |
|---------------------------------------------------|----------------|--------------|---------------|--------------|
|                                                   | All Treatments | 2 mg/kg      | 10 mg/kg      | 200 mg       |
| Assessable Subjectsa                              | 3727           | 706          | 2038          | 983          |
| Lastpostdosesample: Pembrolizumabconc.≥DTL        | 1444 (38.8%)b  | 117 (16.6%)b | 1327 (65.1%)b | 0            |
| Last postdose sample: Pembrolizumab conc. unknown | 259 (6.9%)b    | 20 (2.8%)b   | 169 (8.3%)b   | 70 (7.1%)b   |
| Lastpostdose sample: Pembrolizumab conc.<DTL      | 2024 (54.3%)b  | 569 (80.6%)b | 542 (26.6%)b  | 913 (92.9%)b |

DTL: DrugTolerance Levelof theADA assay.

a: Assessable subjects are subjects treated with pembrolizumab and with at least 1 postdose sample available.

b:Denominatorwas thenumber of assessablesubjects.

Data source [Appendix 9]

## 2.3.4. PK/PD modelling

Previously, a pooled population PK analysis (report 04DDV3) using KN001, KN002 and KN006 studies was performed to characterise serum concentrations over time based on a dataset including 2188 subjects across the melanoma and NSCLC indications. This analysis is considered the definitive population PK analysis to characterize pembrolizumab PK and inform the label for pembrolizumab.

The structure of the definitive population PK model for pembrolizumab has a two-compartment model structure with a linear clearance from the central compartment, parameterized in terms of clearance (CL), inter-compartmental clearance (Q), central compartment volume of distribution (Vc), and peripheral compartment volume of distribution (Vp). All PK parameters were allometrically scaled based on body weight with separate exponents estimated for the clearance (CL, Q) and volume (Vc, Vp) parameters, as follows:

<!-- image -->

where θx is a typical value of a pharmacokinetic parameter P*, and θy is the fixed-effect parameter to be estimated. WT is the individual body weight, and Median

WT is the median body weight across the analysis population.

In addition to body weight, the existing population PK model contained several more covariate relationships, which were established through a stepwise covariate search. The covariate relationships used the following generic form for continuous covariates, similar to the relationships for body weight.

The following function was used to describe the effects of categorical covariates:

<!-- image -->

Where θx is a typical value of a pharmacokinetic parameter P*, and θy is the fixed-effect parameter to be estimated, and Cov is the (continuous) covariate value and Q is the indicator variable denoting the category of the (categorical) covariate.

Specifically, the following covariates were included in the model:

<div style=\"page-break-after: always\"></div>

| Covariate             | Type of covariate   | Parameter   |
|-----------------------|---------------------|-------------|
| Gender                | Categorical         | CL and Vc   |
| Bilirubin             | Continuous          | CL          |
| eGFR                  | Continuous          | CL          |
| Albumin               | Continuous          | CL and Vc   |
| Tumor burden          | Continuous          | CL          |
| ECOGperformancestatus | Categorical         | CL          |
| Cancer type           | Categorical         | CL          |
| PriorIPItreatment     | Categorical         | CL and Vc   |

In this model, the impact of these covariates on pembrolizumab exposure was limited (generally less than 20%) and therefore was not considered to be of clinical relevance.

Nevertheless, these covariates have been maintained in the model and re-estimated on the extended dataset. Of note, in establishing the final model on the new dataset, the covariate cancer type was reassessed. The covariate cancer type was redefined in the model in order to have a single category represent the existing (melanoma and NSCLC) dataset to allow comparison of the newly added UC indication.

Upon reassessment of the impact of cancer type (categorised as UC or Melanoma+NSCLC+other), a statistically significant effect of the covariate was observed on clearance, representing an increased clearance (by 14.6%) in UC patients relative to the non- UC patients.

Inter-individual variability (IIV) of the PK parameters (CL, Volume of distributions (Vc and Vp) and intercompartmental clearance Q) was included using a log-normal random effects model.

Residual variability (RV), a composite measure of assay error, dose/sample time collection errors, model misspecification, and any other unexplained variability within a subject, was modelled using a logtransformed additive error model (for the Assessment of the population PK analysis, please refer to the variation II/11 of Keytruda).

No additional model development was performed in the current analysis, and the definitive population PK was used as is. For this updated PK evaluation, the data from UC patients from studies KN012, KN052 and KN045 were added to the dataset. Therefore, the consistency of pembrolizumab PK in patients with UC from studies KN012, KN052 and KN045 with the established definitive population PK analysis was analysed. The model was used to predict pembrolizumab levels in UC patients after 200 mg Q3W and 10 mg/kg Q2W and the predictions were compared with observed levels determined in studies KN012, KN052 and KN045.

The final analysis dataset from studies KN001, KN002, KN006, KN052, KN012 cohort C and KN045 used for the population PK comprised of a total of 14976 pembrolizumab concentrations from 2794 patients, of which 2743 PK observations were from 606 UC patients. The number of subjects and PK observations by dose in the pooled analysis dataset are provided in the following table:

## Number's of Subjects and Observations byDose and Dosing Regimen in the Pooled Analysis Dataset (KN001, KN002, KN006, KN012,KN045, KN052)

| Doses                |   Nofsubjects |   %of subjects |   NofPKobservations |   %ofPKobservations |
|----------------------|---------------|----------------|---------------------|---------------------|
| 1 mg/kg Q2W (non-UC) |             4 |          0.143 |                  43 |              0.287  |
| 1 mg/kgQ3W (non-UC)  |             6 |          0.215 |                  10 |              0.0668 |
| 2 mg/kg Q3W (non-UC) |           435 |         15.6   |                2114 |             14.1    |
| 3 mg/kg Q2W (non-UC) |             3 |          0.107 |                  55 |              0.367  |
| 10mg/kgQ2W(non-UC)   |           660 |         23.6   |                4117 |             27.5    |
| 10mg/kgQ3W(non-UC)   |          1080 |         38.7   |                5894 |             39.4    |
| 10 mg/kgQ2W (UC)     |            33 |          1.18  |                 169 |              1.13   |
| 200 mg Q3W (UC)      |           573 |         20.5   |                2574 |             17.2    |

Note:somesubjectsreceivedmorethanonedoselevelsunderdoseescalationcohorts ReviewedperSOP-QP2-005

<div style=\"page-break-after: always\"></div>

## Goodness of fit plots

Goodness of fit plots of the final model using the integrated dataset, i.e. KN001, KN002, KN006, KN012, KN045 and KN052, are reported below:

## Goodness-of-fit Assessment for the Final Model

Black dots are UC individual data,Grey dots are individual datafor other indications,solid lines are smooth lines.In the two plots of the first row,bold dashed lines are lines of identity, whilst in the two plots of the second row dashed lines represent zero line.

<!-- image -->

Black dots areUC individual data;Grey dots are individual dataforotherindications; dashes lines are zeroline whilst solidlines arethe smoothlines.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Pharmacokinetic in target population

In support of this specific submission, a focused PK analysis was conducted primarily to show the similarity of observed concentrations in subjects with UC in KN012 (10 mg/kg Q2W), KN052 and KN045 (200 mg Q3W) with the predictions from the definitive population PK analysis.

## Comparison UC vs Other Indications

The existing population PK model for pembrolizumab was used to re-estimate the PK-parameters for the complete updated dataset (including data from UC patients from studies KN012, KN052 and KN045).

Following finalisation of the population PK model on the pooled dataset, the final model was used to enable comparisons of the pharmacokinetics of pembrolizumab between UC subjects and those from other indications.

Comparison of parameter estimates of the final model using the integrated dataset (i.e. KN001, KN002, KN006, KN012, KN045 and KN052) and the dataset used in previous pop PK model (Pooled Protocol KN001, KN002 and KN006 Dataset) is shown in the table below:

<div style=\"page-break-after: always\"></div>

## Comparisonof PopulationPharmacokineticParametersof Pembrolizumab (MK-3475) from the Previous Model with Non-UC vs.

## Updated Model Including UC Subjects

|                                            | The Previous Model N=2188 [Ref.5.3.5.3:04DDV3]                                                                       | The Previous Model N=2188 [Ref.5.3.5.3:04DDV3]                                                                       | The Previous Model N=2188 [Ref.5.3.5.3:04DDV3]                                                                       | Update Model N=2794 (606 UC out of 2794)                                                                                                                                              | Update Model N=2794 (606 UC out of 2794)                                                                                                                                              | Update Model N=2794 (606 UC out of 2794)                                                                                                                                              |
|--------------------------------------------|----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Parts and Studies included in the analysis | Melanoma/NSCLC;A,A1,A2,B1, B2, B3,C,D,F1,F2 and F3 from KN001,KN002, KN006                                           | Melanoma/NSCLC;A,A1,A2,B1, B2, B3,C,D,F1,F2 and F3 from KN001,KN002, KN006                                           | Melanoma/NSCLC;A,A1,A2,B1, B2, B3,C,D,F1,F2 and F3 from KN001,KN002, KN006                                           | Melanoma/NSCLC; A, A1, A2,B1,B2,B3,C,DandF1, F2, and F3 from KN001, KN002, KN006 UC; KN012, KN045 KN055                                                                               | Melanoma/NSCLC; A, A1, A2,B1,B2,B3,C,DandF1, F2, and F3 from KN001, KN002, KN006 UC; KN012, KN045 KN055                                                                               | Melanoma/NSCLC; A, A1, A2,B1,B2,B3,C,DandF1, F2, and F3 from KN001, KN002, KN006 UC; KN012, KN045 KN055                                                                               |
| Data cut-off date                          | KN001V0l; 26-July-2013 KN001V02; 18-April-2014 KN001V04; 23-Jamuary-2015 KN002V01; 12-May-2014 KN006V02:3-March-2015 | KN001V0l; 26-July-2013 KN001V02; 18-April-2014 KN001V04; 23-Jamuary-2015 KN002V01; 12-May-2014 KN006V02:3-March-2015 | KN001V0l; 26-July-2013 KN001V02; 18-April-2014 KN001V04; 23-Jamuary-2015 KN002V01; 12-May-2014 KN006V02:3-March-2015 | KN001V0l; 26-July-2013 KN001V02; 18-April-2014 KN001V04; 23-Jamuary-2015 KN002V01;12-May-2014 KN006V02;3-March-2015 KN012V02; 01-Sep-2015 KN045V0l; 07-Sep-2016 KN052V01; 01-Sep-2016 | KN001V0l; 26-July-2013 KN001V02; 18-April-2014 KN001V04; 23-Jamuary-2015 KN002V01;12-May-2014 KN006V02;3-March-2015 KN012V02; 01-Sep-2015 KN045V0l; 07-Sep-2016 KN052V01; 01-Sep-2016 | KN001V0l; 26-July-2013 KN001V02; 18-April-2014 KN001V04; 23-Jamuary-2015 KN002V01;12-May-2014 KN006V02;3-March-2015 KN012V02; 01-Sep-2015 KN045V0l; 07-Sep-2016 KN052V01; 01-Sep-2016 |
| Parameter                                  | Value                                                                                                                | 96RSE                                                                                                                | %CT                                                                                                                  | Value                                                                                                                                                                                 | %6RSE                                                                                                                                                                                 | :10%                                                                                                                                                                                  |
| CL (L/day)                                 | 0.22                                                                                                                 | 2.14                                                                                                                 | 37.9                                                                                                                 | 0.235                                                                                                                                                                                 | 1.65                                                                                                                                                                                  | 37.8                                                                                                                                                                                  |
| Ve (L)                                     | 3.48                                                                                                                 | 0.892                                                                                                                | 20.6                                                                                                                 | 3.47                                                                                                                                                                                  | 0.749                                                                                                                                                                                 | 20.3                                                                                                                                                                                  |
| Q (L/day)                                  | 0.795                                                                                                                | 4.02                                                                                                                 | 37.9                                                                                                                 | 0.731                                                                                                                                                                                 | 2.74                                                                                                                                                                                  | 37.8                                                                                                                                                                                  |
| Vp (L)                                     | 4.06                                                                                                                 | 2.01                                                                                                                 | 20.6                                                                                                                 | 3.94                                                                                                                                                                                  | 1.61                                                                                                                                                                                  | 20.3                                                                                                                                                                                  |
| a for CL and Q                             | 0.595                                                                                                                | 7.95                                                                                                                 |                                                                                                                      | 0.557                                                                                                                                                                                 | 7.21                                                                                                                                                                                  |                                                                                                                                                                                       |
| α for Ve and Vpc                           | 0.489                                                                                                                | 6.06                                                                                                                 |                                                                                                                      | 0.505                                                                                                                                                                                 | 4.99                                                                                                                                                                                  |                                                                                                                                                                                       |
| Albumin on CL                              | -0.907                                                                                                               | 8.39                                                                                                                 |                                                                                                                      | -0.671                                                                                                                                                                                | 18.7                                                                                                                                                                                  |                                                                                                                                                                                       |
| eGFR on CL                                 | 0.135                                                                                                                | 23.2                                                                                                                 |                                                                                                                      | 0.121                                                                                                                                                                                 | 21.4                                                                                                                                                                                  |                                                                                                                                                                                       |
| GENDER on CL                               | -0.152                                                                                                               | 11.7                                                                                                                 |                                                                                                                      | -0.158                                                                                                                                                                                | 10.0                                                                                                                                                                                  |                                                                                                                                                                                       |
| Cancer Type (NSCLC vs Mel+other) on CL     | 0.145                                                                                                                | 17.1                                                                                                                 |                                                                                                                      | NA                                                                                                                                                                                    | NA                                                                                                                                                                                    |                                                                                                                                                                                       |
| Cancer Type (UC vs Mel+NSCLC+other)on CL   | NA.                                                                                                                  | NA.                                                                                                                  |                                                                                                                      | 0.146                                                                                                                                                                                 | 16.8                                                                                                                                                                                  |                                                                                                                                                                                       |
| Baseline ECOG on CL                        | -0.0739                                                                                                              | 22.7                                                                                                                 |                                                                                                                      | -0.108                                                                                                                                                                                | 14.6                                                                                                                                                                                  |                                                                                                                                                                                       |
| Baseline tumor size on CL                  | 0.0872                                                                                                               | 12.2                                                                                                                 |                                                                                                                      | 0.100                                                                                                                                                                                 | 10.4                                                                                                                                                                                  |                                                                                                                                                                                       |
| IPI prior treatment status on CL           | 0.139                                                                                                                | 18.4                                                                                                                 |                                                                                                                      | 0.085                                                                                                                                                                                 | 24.7                                                                                                                                                                                  |                                                                                                                                                                                       |
| Albumin on Vc                              | -0.208                                                                                                               | 22.7                                                                                                                 |                                                                                                                      | -0.157                                                                                                                                                                                | 27.2                                                                                                                                                                                  |                                                                                                                                                                                       |
| GENDER Vc                                  | -0.134                                                                                                               | 9.31                                                                                                                 |                                                                                                                      | -0.134                                                                                                                                                                                | 8.35                                                                                                                                                                                  |                                                                                                                                                                                       |
| IPI prior treatment status on Vc           | 0.0735                                                                                                               | 23.5                                                                                                                 |                                                                                                                      | 0.0717                                                                                                                                                                                | 23.5                                                                                                                                                                                  |                                                                                                                                                                                       |
| Residualerror                              | 0.272                                                                                                                | 1.87                                                                                                                 |                                                                                                                      | 0.259                                                                                                                                                                                 | 1.86                                                                                                                                                                                  |                                                                                                                                                                                       |

b UC not included in update model.

* %CV of residual enor is related to estimate of between-subject variability on this parameter

Presented population parameter estimates exclude effects of covariates; therefore apply to a hypothetical typical patient with average characteristics. CL: clearance; Ve: central volume of dishibution; Q: intercompautmental clearance; Vp: peripheral volume of dishibution; %RSE: relative standard error (%); 95% CI: 95% confidence interval of parameter estimate based on bootshrap results; %CV: coefficient of vaniation of between-subject dishibutions of parameters; NA: not applicable.

Reviewed per SOP-QP2-005

Distributions of individual post-hoc parameter estimates for clearance and central volume of distribution by indication UC and non-UC (melanoma, NSCLC, other) is presented below:

## Comparison of CLandVdUsing theIndividualEmpiricalBayes Parameter'sbyIndication

<!-- image -->

<div style=\"page-break-after: always\"></div>

A tabular summary of descriptive statistics for post-hoc estimates and derived parameters for the 200 mg Q3W regimen in the UC population is provided below:

Descriptive Statistics of Individual PK Parameters (CL, Vc) and Derived Parameters (Cmax, AUCs, t1/2, Cmin,ss) at 200 mg Q3W in UC Patients

|                          |   N |     Mean |   Median |   Standard deviation |
|--------------------------|-----|----------|----------|----------------------|
| CL (L/day)               | 573 |    0.249 |    0.227 |                0.113 |
| Vc (L)                   | 573 |    3.31  |    3.28  |                0.699 |
| Cmax* (μg/mL)            | 516 |   62.7   |   60.6   |               13.3   |
| C min b (μg/mL)          | 150 |   33.5   |   32.4   |               13.2   |
| Half life (days)         | 573 |   24.2   |   23.9   |                7.17  |
| AUCs (μg.d/mL)           | 573 | 1850     | 1760     |              707     |
| Vd,(L)                   | 573 |    7.16  |    7.07  |                1.4   |
| Timetosteadystate (days) | 573 |  121     |  119     |               35.9   |

² Cmax is concentration at time of peak sample in Cycle 1 b Cmin is trough concentration Cycle 8 through 12 ReviewedperSOP-QP2-005

Additionally, the observed exposures for UC subjects receiving the 200 mg Q3W regimen were compared to prior data at 2 mg/kg Q3W and 10 mg/kg Q2W in melanoma and NSCLC subjects:

<!-- image -->

When assessed specifically for line of therapy (first line / second line) the exposures at 200 mg Q3W in UC subjects are similar to those from other indications at the same regimen.

<div style=\"page-break-after: always\"></div>

The following figure shows a comparison of exposure (AUC) across indications at clinically tested doses (log Scale) for the first- and second line UC patients, separately.

## Pembrolizumab (MK-3475) Exposure (AUC) Across Indications at Clinically Tested Doses (Log Scale)

## First line (KN052)

<!-- image -->

Note:Individual AUCss.6weeks estimates based on post-hoc clearance estimates.

Source:[Ref.5.3.5.3:04JR0J:Figure 6]

## Second line (KN045)

<!-- image -->

Note:Individual AUCss.6weeks estimates based onpost-hoc clearance estimates.

Source:[Ref.5.3.5.3:04JT5G:Figure 6]

The figures below report the Pembrolizumab serum concentrations for the UC subjects treated with 10 mg/kg Q2W or 200 mg Q3W, together with a predicted concentration range (median and 90% prediction interval) from the definitive population PK model, based on the data from patients with melanoma or NSCLC.

<div style=\"page-break-after: always\"></div>

Consistency of Observed Concentrations in UC Subjects with Predictions Based on Definitive Population PK Model: Pembrolizumab (MK-3475) Concentration-Time Profiles during the First Dose (left panel) and at Steady State (right panel) of Repeated Dosing at 10 mg/kg Q2W

<!-- image -->

10

Observed after 22 weeks

Median predicted

15

20

Time since last dose (day)

Left panel: after first dose; right panel: at steady state (after 22 weeks). Dots are individual data from UC patients; Solid line is median prediction from the model for a regimen of 10 mg/kg Q2W and the shaded area represents the 90% prediction interval. Reviewed per SOP-QP2-005

Consistency of Observed Concentrations in UC Subjects with Predictions Based on Definitive Population PK Model: Pembrolizumab (MK-3475) Concentration-Time Profiles during the First Dose (left panel) and at Steady State (right panel) of Repeated Dosing at 200 mg Q3W

100200

<!-- image -->

10

15

Median predicted

20

Time since first dose (day)

Left panel: after first dose; right panel: at steady state (after 21 weeks). Dots are individual data from UC patients; Dashed line is median prediction from the model for a regimen of 200 mg Q3W and the shaded area represents the 90% prediction interval. ReviewedperSOP-QP2-005

The MAH provided additional comparison of the observed PK data (trough and peak concentrations at each cycle) with those obtained with the 200 mg Q3W flat dose for UC and non-UC patients (1L NSCLC and HL) by means of tabular summaries of descriptive statistics and boxplots.  Exposure reached in patients with UC is consistent with other indications at the same dose level.

## 2.3.5. Discussion on clinical pharmacology

The starting point for the population PK analysis submitted in this variation application was the previous population  PK  analysis  04DDV3  based  on  dataset  including  2188  subjects  across  the  melanoma  and NSCLC  indications  (KN001,  KN002  and  KN006  studies).  This  analysis  is  considered  the  definitive population  PK  model  to  inform  the  label  for  pembrolizumab  and  no  further  model  development  was performed in the current analysis which incorporates data from UC patients recruited in studies KN012 (Cohort C), KN045 (second line) and  KN052 (first line cisplatin ineligible).

Thus, the final dataset consists of a total of 14976 determinations of pembrolizumab concentrations from 2794 patients (606 UC out of 2794).

Serum MK3475 concentration (μg/mL)

100

20

10

Observed

5

<div style=\"page-break-after: always\"></div>

The approach taken was to utilise the definitve population PK model to predict pembrolizumab levels in UC patients after 200 mg Q3W and 10 mg/kg Q2W. The predictions were compared with observed levels determined in studies KN012 (Cohort C), KN045 and  KN052.

Overall, the model proved adequate to capture pembrolizumab concentration indicating that the definitive population PK model provides an adequate representation of the pembrolizumab pharmacokinetics in UC, in addition to melanoma and NSCLC.

Observed plasma concentration in UC subjects both during the first dose (10 mg/kg or 200 mg Q3W) and at  steady  state  after  repeated  doses  (10  mg/kg  or  200  mg  Q3W)  fall  within  the  range  of  predicted concentration showing consistency in exposure between UC and other indications.

The PK report and the evaluation of studies KN012, KN045 and KN052 include descriptive statistics of serum concentration values of pembrolizumab following administration of multiple I.V 200 mg Q3W in UC patients and multiple 2 mg/kg I.V doses Q3W in KN001 melanoma and NSCLC patients.

Comparisons of peak and trough concentrations between indications showed that Pembrolizumab serum concentrations in cycle 1, 2 and 8 observed at 200 mg Q3W in UC patients are slightly higher compared to the range of concentrations at dose levels of 2 mg/kg Q3W observed in MEL and NSCLC patients.

The  data  presented  showed  that  this  difference  in  pembrolizumab  concentration  (higher  value  in  UC patients after 200 mg Q3W compared to MEL and NSCLC after 2 mg/kg Q3W) is mainly evident in study KN045 (second line).

Generally, considering the flat relationship between dose and exposure, it is considerate unlikely that this difference could lead to a significant clinical effect.

However,  all comparisons were  made  with  other  indications approved  with the  weight  based  dose regimen  of 2  mg/kg,  thus  excluding indications approved  with  the flat dose of  200mg  Q3W such  us  1L NSCLC  and  HL.  Similarly,  the  Boxplot  reporting  pembrolizumab exposure  across  indications  did  not consider the 200 mg Q3W dosing in 1L NSCLC (study KN024) and HL (study KN087).

Additional comparison of the observed PK data were provided (trough and peak concentrations at each cycle) with those obtained with the 200 mg Q3W flat dose for UC and non-UC patients (1L NSCLC and HL) by means of tabular summaries of descriptive statistics and boxplots.

The  available  concentrations  after  administration  of  the  fixed  dose  of  200  mg  Q3W  for  UC  patients (KEYNOTE-052 and -45) were compared with those observed for 1L NSCLC patients  (KN024), and cHL patients (KN087) for each cycle by time point. Exposure reached in patients with UC is consistent with other indications at the same dose level.

Moreover, a difference was observed in the PK profile of Pembrolizumab in UC patients when considering 1L and 2L studies separately, with lower exposure (AUC\\_ss) achieved in the first-line study KN052. To better address the comparability among UC patients and among other indications, Pembrolizumab (MK3475) Exposure (AUC) Across Indications at Clinically Tested Doses in linear scale was provided.

As requested, the applicant elaborated on the comparison of PK in UC vs non-UC and among both UC patient groups (1L, 2L). PK differences that have been detected are deemed to be minor.

An integrated immunogenicity evaluation has been performed using data across studies keynote-001, 002, -006, -012, -013, -024, -045, -052, -055, -087 and -164. A total of 3727 subjects were included in the immunogenicity assessment across indications (1535 melanoma, 1238 NSCLC, 101 HNSCC, 45 MSIH, 220 HL and 579 UC) and across doses (at 2 mg/kg Q3W, 10 mg/kg Q3W/Q2W and 200 mg Q3W). Out of  the  3727  subjects  included  in  the  immunogenicity  assessment,  2034  subjects  were  evaluable.  The observed incidence  of  treatment  emergent  ADA  in  evaluable  subjects  based  on  the  pooled  analysis  is 1.8% (36 out of 2034). Of the 36 treatment emergent positive subjects, 9 (1 melanoma, 5 NSCLC, 1 HL

<div style=\"page-break-after: always\"></div>

and  2  UC)  tested  positive  in  the  neutralizing  assay.  The  9  subjects  positive  in  the  neutralizing  assay accounted for a total incidence rate of treatment neutralizing positive subjects of 0.4% (9 out of 2034) in the overall population.

The incidence of treatment emergent ADA in subjects with UC is comparable to the overall incidence and consistent with other indications. No impact of binding or neutralizing ADA on pembrolizumab exposure was observed.

## 2.3.6. Conclusions on clinical pharmacology

The pharmacology data submitted are considered appropriate and supportive for this application.

## 2.4. Clinical efficacy

To  support  the  Keytruda  extension  of  indication  in  the  treatment  of  locally  advanced  or  metastatic urothelial carcinoma both for patients who have received prior chemotherapy and for those who are not eligible for cisplatin-containing chemotherapy, two single pivotal studies, each including patients in the two specific settings, have been submitted:

1. Study  KEYNOTE-045,  in  a  second-line  setting  for  patients  who  progressed  following  treatment with platinum-containing chemotherapy, and
2. Study  KEYNOTE-052  in  patients  previously  untreated  and  not  eligible  to  cisplatin-containing chemotherapy.

| Study ID/ centres/ locations                                                                                                                                                                                                                                                                                                                                                                                                                                               | Study design                                                                                                                                                                                                                                                                         | Treatment                                                                                                                                   | No of pts planned/ random/ treated                                   | Demographics                                                                                              | Primary endpoint            | Secondary efficacy endpoints                                                                                                    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------|---------------------------------------------------------------------------------------------------------------------------------|
| KEYNOTE-045 120 enrolling centers in 29 countries: Australia (3), Austria (4), Belgium (2), Canada (2), Chile (2), Denmark (4), France (5), Germany (4), Hungary (5), Ireland (1), Israel (7), Italy (6), Japan (20), Netherland (3), New Zealand (2), Norway (2), Peru (1), Poland (1), Portugal (2), Puerto Rico (1), Romania (2), Singapore (1), Spain (6), South Korea (3), Singapore (1), Sweden (1), Turkey (4), United Kingdom (2), United States (19), Taiwan (5). | Randomized (1:1), multicenter, open-label, active-controlled trial of pembrolizumab monotherapy vs investigator'choice in subjects with metastatic or locally advanced/unresectable urothelial carcinoma that had recurred or progressed following platinum-containing chemotherapy. | pembrolizumab 200 mg IV Q3W Investigator's choice paclitaxel 175 mg/m 2 IV Q3W or docetaxel 75mg/m 2 IV Q3W or vinflunine 320 mg/m 2 IV Q3W | 235/270/266 235/272/255 84 pts treated 84 pts treated 87 pts treated | Sex: 200M/70F Median age (min/max): 67 years (29-88) Sex: 202M/70F Median age (min/max): 65 years (26-84) | PFS (RECIST 1.1) by BICR OS | ORR (RECIST and mRECIST 1.1) by BICR DOR (RECIST 1.1) by BICR PFS (mRECIST 1.1) by BICR PFS At 6 and 12 mo (RECIST 1.1) by BICR |

<div style=\"page-break-after: always\"></div>

| KEYNOTE-052 77 enrolling centers in 17 countries: Australia (1), Canada (8), Denmark (2), Guatemala (2), Hungary (4), Ireland (1), Israel (5), Italy (3), Malaysia (1) Netherland (1), Puerto Rico (1), Singapore (2), Spain (9), Republic of Korea (3), United Kingdom (4), United States (28), Taiwan (2).   | Non-randomized, multicenter, open-label trial, in subjects with metastatic or locally advanced/unresectable or metastatic urothelial carcinoma who have not received prior systemic chemotherapy, and who are not eligible to receive cisplatin.   | pembrolizumab 200 mg IV Q3W   | 350/370/370   | ORR (RECIST 1.1) by BICR in ●all patients ●PD-L1 + (CPS≥1%) ●PD-L1 strongly +   | DOR (RECIST 1.1) by BICR PFS (RECIST 1.1) by BICR OS   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|---------------|---------------------------------------------------------------------------------|--------------------------------------------------------|

## 2.4.1. Dose response study(ies)

A fixed-dose regimen of pembrolizumab 200 mg Q3W is administered in both pivotal studies for the treatment of urothelial carcinoma (UC). Thirty-three patients with heavily pre-treated urinary tract cancer received pembrolizumab 10 mg/kg Q2W in the phase Ib multi-cohort study KEYNOTE-012. Among the overall 27 patients PD-L1 ≥1% assessable for activity, an overall response rate of 26%, including 11% of complete responses (by independent central review per RECIST 1.1), was achieved. Overall, the median duration of response was 10 months, with 2 CR still ongoing after 13 months of median follow up (Plimack E R, et al Lancet Oncol 2017; 18:212-220).

An integrated body of evidence suggests that 200 mg Q3W of pembrolizumab provides similar response to 2 mg/kg Q3W, 10 mg/kg Q3W, and 10 mg/kg Q2W.

Overall, the clinical data in urothelial carcinoma subjects, demonstrating efficacy at 200 mg Q3W and similarity of clinical response over a wide dose range (200 mg flat dose to 10 mg/kg), in conjunction with an integrated body of evidence in melanoma and NSCLC patients, support the use of pembrolizumab 200 mg Q3W fixed-dose as the appropriate dosing for urothelial carcinoma (see Section 2.3.4).

<div style=\"page-break-after: always\"></div>

## 2.4.2. Main study(ies)

Study Keynote-045: A Phase III Randomized Clinical Trial of Pembrolizumab versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer

Figure: Trial design

<!-- image -->

Note: The overall proportion of subjects receiving vinflunine in the control arm was initially planned to be capped at approximately 35%, however, the cap was never implemented. Vinflunine was only a comparator option in countries where vinflunine is approved for the treatment of metastatic urothelial cancer. Docetaxel was only a comparator option for subjects with a total bilirubin ≤1 x ULN, and an AST ≤ 1.5 x ULN if alkaline phosphatase is also &gt;2.5 x ULN.

## Methods

## Study participants

## Main inclusion criteria

- Histologically or cytologically confirmed diagnosis of urothelial cancer of the renal pelvis, ureter, bladder, or urethra. Both transitional cell and mixed transitional/nontransitional cell histologies were allowed, but transitional cell carcinoma had to be the predominant histology.
- Age ≥18 years
- Progression or recurrence of urothelial cancer following receipt of a 1 st line platinum-containing regimen (eg, cisplatin or carboplatin) that was received:
- a. in the metastatic setting or for inoperable locally advanced disease;

or

<div style=\"page-break-after: always\"></div>

b. as adjuvant therapy following cystectomy for localized muscle-invasive urothelial cancer, with recurrence/progression ≤ 12 months following completion of therapy;

or c. as neoadjuvant therapy prior to cystectomy for localized muscle-invasive urothelial cancer, with recurrence ≤ 12 months following completion of therapy.

Notes: Primary chemo-radiation given for subjects who were not considered surgical candidates was not considered a line of therapy for the purpose of this study.  Subjects with locally advanced unresectable disease who subsequently became eligible for surgery after platinum-containing therapy were not eligible for this study, unless they subsequently had disease recurrence in the metastatic setting.

- No more than 2 prior lines of systemic chemotherapy for metastatic urothelial cancer. Subjects for whom the most recent therapy was a non-platinum-based regimen following progression/recurrence on platinum-based therapy (ie, third-line subjects) were eligible if they had progressed/recurred on their most recent therapy.

Note: primary chemo-radiation for unresectable muscle-invasive bladder cancer with the aim of bladder preservation was not considered a prior line of systemic therapy for the purposes of determining study eligibility.

- Provided tissue for biomarker analysis from an archival tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated. A newly-obtained biopsy was strongly preferred but not required if archival tissue was adequate for analysis. Adequacy of the archived or freshly-obtained biopsy specimen had to be confirmed by the central laboratory during the screening period prior to enrollment.
- Measureable disease based on RECIST 1.1 as assessed by the Investigator/site radiologist. Tumor lesions situated in a previously irradiated area were considered measureable if progression had been demonstrated in such lesions.
- ECOG Performance Status of 0, 1, or 2, as assessed within 10 days prior to treatment initiation. Subjects with an ECOG-PS of 2 had to have a hemoglobin ≥ 10 g/dL, could not have liver metastases, and must have received the last dose of their last prior chemotherapy regimen ≥ 3 months (90 days) prior to enrollment.

## Main exclusion criteria

- Disease suitable for local therapy administered with curative intent.
- Current or previous participation in a study of an investigational agent, with study therapy received or investigation device used within 4 weeks of the first dose of treatment.
- Diagnosis of immunodeficiency or ongoing systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. The use of physiologic doses of corticosteroids could have been approved after consultation with the Sponsor.

<div style=\"page-break-after: always\"></div>

- Prior anticancer monoclonal antibody within 4 weeks prior to study Day 1 or not recovered (ie, ≤ Grade 1 or at baseline) from AEs due to agents administered more than 4 weeks earlier.
- Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who had not recovered (ie, ≤ Grade 1 or at baseline) from AEs due to a previously administered agent.

Notes: Subjects with ≤ Grade 2 neuropathy or ≤ Grade 2 alopecia are an exception to this criterion and could qualify for the study.  If a subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.

- Known additional malignancy progressing or requiring active treatment. Exceptions included basal cell carcinoma of the skin, squamous cell carcinoma of the skin that had undergone potentially curative therapy, or in situ cervical cancer. A history of prostate cancer identified incidentally following cysto-prostatectomy for bladder cancer was acceptable, provided that Stage was T2N0M0 or lower, Gleason score ≤ 6, and prostate-specific antigen undetectable.
- History of severe hypersensitivity reaction (eg, generalized rash/erythema, hypotension, bronchospasm, angioedema, or anaphylaxis) to paclitaxel or to other drugs formulated with polyoxyethylated castor oil, to docetaxel or other drugs formulated with polysorbate 80, or to vinflunine or other vinca alkaloids.
- History or current evidence of any condition, therapy, or laboratory abnormality that could confound the results of the trial, interfere with the subject ' s participation for the full duration of the trial, or not in the best interest of the subject to participate, in the opinion of the treating Investigator.
- Prior therapy with an anti-PD-1, anti-PD-L1 agent, or with an agent directed to another coinhibitory T-cell receptor (e.g. CTLA-4,OX-40, CD137).
- Known active central nervous system metastases and/or carcinomatous meningitis. Subjects with previously-treated brain metastases could participate provided they are stable (without evidence of progression by imaging for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms had returned to baseline), had no evidence of new or enlarging brain metastases, and were not using steroids for at least 7 days prior to trial treatment. This exception did not include carcinomatous meningitis, which was excluded regardless of clinical stability.
- Active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that required systemic or immunosuppressive agents. Subjects with vitiligo, Type I diabetes, or resolved childhood asthma/atopy could be an exception to this rule. Subjects who required intermittent use of bronchodilators, inhaled steroids, or local steroid injections were not excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjögren ' s syndrome were not excluded from the study.
- Required ongoing therapy with a medication that was a strong inhibitor or inducer of the CYP3A4 enzymes.
- Administration of live vaccine within 30 days prior to the first administration of study medication.

<div style=\"page-break-after: always\"></div>

## Treatments

- Pembrolizumab 200 mg administered as a 30 minute (-5 min/+10 min) IV infusion Q3W.
- Investigator's choice:
- o paclitaxel 175 mg/m 2  administered over 1 hours IV infusion Q3W
- o docetaxel 75 mg/m 2  administered over 1 hour IV infusion Q3W
- o vinflunine 320 mg/m 2  administered as a 20 minute IV infusion Q3W

The  appropriate  premedication  regimen  prior  to  paclitaxel  and  docetaxel  administration  may  be determined by the investigator.

In case of mild hepatic impairment (total bilirubin ≥ 1.25 × ULN), paclitaxel was to be started at a dose of 135 mg/m 2 .

Docetaxel was a comparator option only for subjects with a total bilirubin ≤ 1 × ULN, and an AST and/or ALT ≤ 1.5 × ULN if alkaline phosphatase was also &gt; 2.5 × ULN.

Vinflunine was only a comparator option in countries where vinflunine was approved for the treatment of metastatic urothelial cancer. Vinflunine starting dose was to be modified in the following cases:

| ECOG-PS≥ 1 or ECOG-PS 0 and prior pelvic irradiation                                                                                                  | 280 mg/m² Q3W In the absence of any hematological toxicity during the first cycle causing treatment delay or dose reduction, the dose was to be increased to 320 mg/m 2 Q3W for the subsequent cycles   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Renal impairment moderate (40 ml/min≤CrCl≤60 ml/min) severe (30 ml/min≤CrCl<40 ml/min)                                                                | 280 mg/m² Q3W 250 mg/m² Q3W                                                                                                                                                                             |
| Liver impairment Child-Pugh grade A or Prothrombin time ≥ 60% NV and 1.5xULN < Bilirubin ≤ xULN and presenting transaminases > ULN and/or GGT > 5xULN | 250 mg/m²Q3W                                                                                                                                                                                            |
| Age ≥75 years ≥75 years <80 ≥80 years                                                                                                                 | 280 mg/m² Q3W 250 mg/m²Q3W                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

Subjects continued with the assigned treatment until RECIST 1.1-defined progression confirmed by the investigator/site radiologist, unacceptable toxicity, intercurrent illness that prevented further administration of treatment, Investigator's decision to withdraw the subject, subject withdrew consent, confirmed positive pregnancy test, non-compliance with trial treatment or procedure requirements, the subject had received 24 months of pembrolizumab treatment or administrative reasons.

Despite  RECIST  1.1  defined  progression,  pembrolizumab  could  have  been  continued  while  awaiting radiologic  confirmation  of  PD.    If  repeat  imaging  still  meets  the  threshold  for  PD  ( ≥ 20%  increase  in tumor burden compared to nadir) but shows a reduction in tumor burden compared to the previous time point, treatment may be continued as per treatment calendar after consultation with Sponsor.

Patients  who  stopped  pembrolizumab  after  receiving  24  months  of  treatment  for  reasons  other  than disease progression or intolerability, or after a complete response having received at least 24 weeks of pembrolizumab and at least 2 treatments beyond the date of initial CR declared, may have been eligible, at discretion of the investigator, for up to one year of retreatment upon experiencing disease progression (Second Course Phase).

Patients in the experimental arm were allowed to stay on treatment after PD based on RECIST 1.1 to account for pseudo-progressions and delayed responses. Overall, 98 patients were treated beyond first radiographic progression, and treatment was continued in 40% of them, including 17 patients who were not confirmed to be in progression and 22 patients with confirmed radiographic progression.

## Objectives

The study primary objective was to demonstrate the superiority of pembrolizumab versus Investigator's choice (paclitaxel, docetaxel or vinflunine) in terms of Progression Free Survival (PFS) per RECIST 1.1 by blinded independent central review (BICR), and of Overall Survival (OS) in all subjects with recurrent/progressive after platinum-based chemotherapy metastatic urothelial cancer, as well as in those with PD-L1 positive (CPS≥1%) and PD-L1 strongly positive (CPS≥10%) tumors.

The trial was considered to have met its primary objective if the pembrolizumab arm was superior to paclitaxel, docetaxel, or vinflunine in any of the following:

- H1: PFS in all subjects (regardless of PD-L1 expression)
- H2: OS in all subjects (regardless of PD-L1 expression)
- H3: PFS in subjects with PD-L1 positive expression (CPS≥1%)
- H4: OS in subjects with PD-L1 positive expression (CPS≥1%)
- H5: PFS in subjects with PD-L1 strongly positive expression (CPS≥10%)
- H6: OS in subjects with PD-L1 strongly positive expression (CPS≥10%)

As secondary objectives, Objective Response Rate (ORR) and response duration per RECIST 1.1 by BICR, ORR per modified RECIST (mRECIST) by BICR, PFS per mRECIST by BICR and per RECIST 1.1 from randomization to specific timepoints (6 months, 12 months), and safety and tolerability profile of pembrolizumab compared to Investigator's choice were evaluated in all subjects, as well as in those with PD-L1 positive (CPS≥1%) and PD-L1 strongly positive (CPS≥10%) recurrent/progressive metastatic urothelial cancer.

Other exploratory objectives were to evaluate changes in health-related quality of life assessment from baseline (eEORTC QLQ-C30), to characterize utilities (eEQ-5D), to investigate the relationship between

<div style=\"page-break-after: always\"></div>

PD-L1 expression and response to pembrolizumab treatment, as well as between pembrolizumab treatment and biomarkers predicting response (eg, immunohistochemistry, proteomic signatures, genetic variation, and gene expression signatures) utilizing newly obtained or archival formalin-fixed, paraffinembedded (FFPE) tumor tissue, and to evaluate PFS per RECIST 1.1 by Investigator review in the next line of therapy in patients treated with pembrolizumab in comparison to those who received paclitaxel, docetaxel or vinflunine.

## Outcomes/endpoints

The dual primary efficacy endpoints were PFS (i.e. time from randomization to the first documented disease progression per RECIST 1.1 based on BICR or death due to any cause, whichever occurs first), and OS (i.e. time from randomization to death due to any cause).

As secondary endpoints, ORR per RECIST 1.1 and mRECIST by BICR, duration response per RECIST 1.1 by BICR and PFS per mRECIST were evaluated.

ORR was defined as the proportion of the subjects in the analysis population who have a confirmed complete response (CR) or partial response (PR), based upon blinded independent central radiologists' review per RECIST 1.1.

Response duration was defined as the time from first documented evidence of confirmed CR or PR until disease progression or death. For subjects who had not progressed or died at the time of analysis, response duration was censored at the date of their last tumor assessment.

PFS and ORR per mRECIST were defined as for endpoints using RECIST 1.1, with the exception that a confirmation of progressive disease (PD) at least 4 weeks after the initial assessment was required for subjects who remained on treatment following a documented PD per RECIST 1.1. Subjects who discontinued treatment following a documented PD assessment per RECIST 1.1 were counted as having disease progression on the date of the documented PD assessment.

The assessment of response was performed initially at Week 9 (±7days), then every 6 weeks (±7 days) for the first year and every 12 weeks (±7 days) thereafter. Images obtained on study were submitted for BICR and were assessed based on the RECIST 1.1 for determination of ORR and PFS. Investigator/local site assessment of measurable disease, based on RECIST 1.1, was used to determine subject eligibility. Investigator assessment based on modified RECIST and site radiology reading(s) was used for treatment decisions and subject management.

Among the planned exploratory endpoints, results have been submitted for EORTC QLQ-C30 and EUROQoL EQ-5D. No formal hypotheses were formulated for PRO.

The global health status/quality of life scale from EORTC QLQ-C30, containing 5 functioning scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, nausea, pain), and six single item measures (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties), was the key PRO endpoint, in particular in terms of mean score changes from baseline to week 15 and Time to deterioration (TTD), measured as the time point when the score decreases by ≥10 (out of 100), with or without subsequent confirmation. Supportive analyses included all QLQ-C30 sub-scales/items and alternative approaches such as estimating the effect of disease progression on HRQoL.

<div style=\"page-break-after: always\"></div>

## Sample size

The trial planned to randomize 470 subjects in a 1:1 ratio between pembrolizumab and the standard treatment arm. The sample size calculation was driven by survival events. Assuming the prevalence rates of PD-L1 CPS ≥1% and PD-L1 CPS ≥10% subjects among the overall population of 55% and 33%, respectively, a sample size of 470 all subjects would provide approximately 260 PD-L1 CPS ≥1% subjects and 156 PD-L1 CPS ≥10% subjects.

The assumptions for the sample size and power calculation of PFS were that PFS follows an exponential distribution with a median of 4 months in the standard treatment arm; the true HR between pembrolizumab and standard therapy are 0.45, 0.5, and 0.5 for PD-L1 CPS ≥10%, PD-L1 CPS ≥1%, and all subjects, respectively; an enrollment period of 12 months; and a yearly drop-out rate of 5%.

Based on information from study KEYNOTE-052, indicating that the PD-L1 CPS ≥ 10% cutpoint is more meaningful than CPS ≥ 1% used in KEYNOTE-012, the study protocol was amended after IA1, and only the primary hypotheses for all comers and subjects with PD-L1 CPS &gt;10% were retained.

The numbers of PFS events in PD-L1 CPS ≥ 10% and all subjects at the final PFS evaluation were estimated to be 137 and 420, respectively, with 97% power for the PFS hypothesis in PD-L1 CPS ≥ 10% subjects and &gt;99% power for the PFS hypothesis in all subjects.

The sample size and power calculation of OS are based on the assumptions that OS follows an exponential distribution with a median of 8 months in the standard treatment arm; the hazard ratio for OS between pembrolizumab and standard treatment is 0.5, 0.6, and 0.7 for PD-L1 CPS ≥ 10%, PD-L1 CPS ≥ 1%, and all subjects, respectively (deemed to be clinically meaningful in this population); an enrollment period of 12 months and a minimum of 18 months follow-up after enrollment completion; and a yearly drop-out rate of 2%.

The final OS analysis was to be carried out after approximately 370 deaths in all subjects and 110 deaths in PD-L1 CPS ≥10% subjects had occurred between the pembrolizumab arm and the standard treatment arm for all subjects, barring early stopping for futility or efficacy. With the above numbers of events and before any alpha roll-over, the trial provides 88% and 86% power to demonstrate OS superiority of pembrolizumab compared to standard therapy at the pre-specified initial alpha (one-sided) levels in PDL1 CPS ≥10% and all subjects, respectively.

The family-wise type I error rate is controlled at 2.5% (one-sided) with 0.5% allocated to the PFS hypotheses and 2.0% allocated to the OS hypotheses.

## Randomisation

Randomization (1:1) to pembrolizumab or the Investigator's choice (paclitaxel, docetaxel, or vinflunine) occurred centrally with block size of 2 within each of strata, using an interactive voice response system/integrated web response system (IVRS/IWRS). Investigators had to select 1 treatment among the control arm options before randomization occurred to use in the event that the subject was randomized to the control arm.

Randomized patients were stratified according to ECOG-PS (0/1 versus 2), presence or absence of liver metastases, Hemoglobin (≥10 g/dL versus &lt;10 g/dL), and time from completion of most recent chemotherapy (&lt;3 months or ≥3 months).

<div style=\"page-break-after: always\"></div>

## Blinding (masking)

Not applicable. This was an open label trial.

However, in order to ensure the unbiased use/ integrity of the PD-L1 analysis, the Medical Monitoring Team, consisting of clinical, statistical, statistical programming, and data management personnel, was blinded to treatment assignments and PD-L1 biomarker results (including CPS ≥1%), until the Cut-off value of PD-L1 expression level for CPS ≥10% was established and formally documented exclusively based on data outside of this trial.

## Statistical methods

Efficacy analyses were performed in the ITT population for all subjects, for subjects with CPS ≥ 10%, and for subjects with CPS ≥ 1% (only at the first interim analysis).

The treatment difference in PFS and OS was assessed by the stratified log-rank test. A stratified Cox proportional hazard model with Efron's method of tie handling was used to assess the magnitude of the treatment difference (i.e. hazard ratio) between the treatment arms.

In the PFS primary analysis, for the subjects who have PD, the true date of disease progression was approximated by the date of the first assessment at which PD is objectively documented per RECIST 1.1, regardless of discontinuation of study drug. Sensitivity analyses were performed for comparison of PFS based on investigator's assessment. In order to evaluate the robustness of the PFS endpoint, two sensitivity analyses with a different set of censoring rules were performed. The first sensitivity analysis censors at the last disease assessment without PD when PD or death is documented after more than one missed disease assessment. The second sensitivity analysis considers discontinuation of treatment or initiation of new anticancer treatment, whichever occurs later, to be a PD event for subjects without documented PD or death.

For the objective response rates (ORR) the Stratified Miettinen and Nurminen's method was used for comparison between the treatment groups. Sensitivity analyses were performed for comparison of ORR based on investigator's assessment and multiple imputation methods was considered to address the issue of informative missing data.

Response duration was summarised descriptively using Kaplan-Meier medians and quartiles. Only the subset of subjects who show a complete response or partial response was included in this analysis.

Longitudinal and descriptive data analyses were used to evaluate patient-reported outcomes (PRO). Several approaches were considered to address the issue of informative missing data: (1) truncating the analysis observation period at the visit closest to median duration of treatment in the comparator arm, (2) hierarchical pattern mixture models incorporating reasons for missingness, and (3) multiple imputation methods.

## Interim Analyses

There were two planned PFS analyses and three planned OS analyses. Results of the first PFS analysis and the interim analysis of OS were to be reviewed by an external data monitoring committee (DMC). Timing, sample size and boundaries for decision guidance are displayed in the Table below.

The second interim analyses of OS was planned to be performed about 8 months after the first PFS analysis. The final OS analysis will be conducted after ~356 OS events are observed at the alpha level determined by the spending function boundaries and actual number of OS events.

<div style=\"page-break-after: always\"></div>

## Summary of Timing, Sample Size and Decision Guidance at the Planned PFS and OS Analyses

<!-- image -->

## Multiplicity Adjustment

The family-wise type I error rate is controlled at 2.5% (one-sided) with 0.5% allocated to the PFS hypothesis and 2.0% allocated to the OS hypothesis. A strategy for the control of the family-wise type I error rate (FWER) was done to take into account the six primary hypotheses (two primary endpoints and three population) and the two planned interim analyses.

The alpha initially allocated among the six hypotheses, and the reallocation strategy according to the method of Maurer and Bretz, are displayed in the Figure below.

<div style=\"page-break-after: always\"></div>

TypeIErrorReallocationStrategyFollowingClosedTestingPrinciple

<!-- image -->

For each analysis (IA1, IA2 and final), alpha allocation was determined by applying a Hwang-Shih-DeCani alpha-spending function with the gamma parameter (-4).

As the biomarker strategy was changed (Amendment 13) and the hypotheses on PD-L1 positive (CPS ≥1%) were not be formally tested at the second interim analysis and the final analysis, the alpha allocation was revised accordingly to reflect the change in biomarker strategy. The reallocation of alpha occurred after the conduct of IA1. The type I error actually spent at IA1 was to be kept intact and the reallocation was to be applied only to the remaining unspent alpha, by first applying the same HSD gamma (-4) spending function and then updated based on the actual numbers of events (information fraction) and alpha roll-over.

The secondary hypotheses on PFS (modified RECIST 1.1), ORR (RECIST 1.1) and ORR (modified RECIST 1.1), were tested sequentially with alpha level depending on the alpha roll-over. The updated efficacy boundaries after taking into consideration of all alpha rollovers are summarized in the Table (see below).

<div style=\"page-break-after: always\"></div>

UpdatedEfficacyBoundaryAfterAlphaRollover

| Hypothesis                       | Alpha Allocationfor each Hypothesis after alpha roll- over   | Updated Cumulative Alpha Spending (%of Overall Alpha)   | Updated Cumulative Alpha Spending (%of Overall Alpha)   | Updated Efficacy Boundary in p-Value (and Z-Statistic)at IA2   |
|----------------------------------|--------------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|----------------------------------------------------------------|
|                                  | Alpha Allocationfor each Hypothesis after alpha roll- over   | IA1                                                     | IA2                                                     |                                                                |
| Hl:PFS in All Subjects           | 0.019212*                                                    | 0.012891 (67.1%)                                        | 0.019212 (100%)                                         | 0.0151 (2.168)                                                 |
| H2: OS in All Subjects           | 0.018212#                                                    | 0.000674 (3.7%)                                         | 0.012457 (68.4%)                                        | 0.0123 (2.246)                                                 |
| H5:PFS in PD-L1 StronglyPositive | 0.003709                                                     | 0.000867 (23.4%)                                        | 0.003241 (87.4%)                                        | 0.0029 (2.7590)                                                |
| H6:OS in PD-L1 Strongly Positive | 0.008212                                                     | 0.000584 (7.1%)                                         | 0.006677 (81.3%)                                        | 0.0065 (2.4836)                                                |
| ORR in All Subjects              | 0.018212$                                                    | 0.003188 (17.5%)                                        | 0.018212 (100%)                                         | 0.0170 (2.1207)                                                |

Updated based on alpha rollover from H6, H2 and ORR in All Subjects;

The overall alpha allocated to the hypothesis, not the single analysis;

# Updated based on alpha rollover from H6;

$ Updated based on alpha rollover from H6 and H2.

## Results

## Participant flow

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Recruitment

Overall, 542 patients were enrolled in 120 out of the 140 activated sites. The recruitment period lasted 1 year, with the first patient entered on 23 October 2014 and the last one randomized on 13 November 2015. The highest enrolling country was the US with a total of 105 subjects.

## Conduct of the study

A total of 14 amendments to the original protocol (dated 23 Jun 2014), including global and countryspecific changes, were implemented during the study.

The key changes introduced by the protocol amendments are summarized below:

| Protocol Amendment    | Most relevant changes                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| #01 (1 August 2014)   | Country specific (Germany): the timing for follow-up radiographic imaging was changed to every 12 weeks ( ± 7 days) following the initial radiographic assessment at 9 weeks or sooner if clinically indicated.                                                                                                                                                                                                                                             |
| #2 (26 August 2014)   | To include docetaxel as a comparator in the control arm.                                                                                                                                                                                                                                                                                                                                                                                                    |
| # 3 (28 August 2014)  | Country specific (Germany): to incorporate modifications as for Amendment #2.                                                                                                                                                                                                                                                                                                                                                                               |
| #4 (not released)     | To incorporate the agency feedback and to update the statistical analysis plan, including elevating PFS and OS in subjects with PD- L1 positive and PD-L1 strongly positive tumors to co-primary objectives. Due to a change in the biomarker strategy, this amendment was not released to the Health Authorities.                                                                                                                                          |
| #5 (not released)     | Country specific (Germany): to incorporate modifications as for Amendment #4.                                                                                                                                                                                                                                                                                                                                                                               |
| #6 (15 January 2015)  | Country specific (UK): to exclude subjects who required ongoing therapy with medications that are strong inducers of the CYP3A4 enzymes.                                                                                                                                                                                                                                                                                                                    |
| #7 (20 February 2015) | Country specific (France): to incorporate as Appendix the current Event of Clinical Interest (ECI) Guidance Document (18-Dec-2014                                                                                                                                                                                                                                                                                                                           |
| #8 (not released)     | Country specific (France): to incorporate modifications as for Amendment #4.                                                                                                                                                                                                                                                                                                                                                                                |
| #9 (27 February 2016) | To include the planned changes for Amendment 04: incorporated agency feedback, and PFS and OS in subjects with PD-L1 positive (CPS ≥ 1%) and PD-L1 strongly positive tumors as co-primary objectives due to emerging evidence suggesting that PD-L1 status may correlate to outcomes. In addition, the statistical analysis plan was updated throughout to reflect the incorporation of the analyses of the primary hypotheses on PD-L1 positive (CPS ≥ 1%) |

<div style=\"page-break-after: always\"></div>

|                         | and PD-L1 strongly positive subjects.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| #10 (10 March 2016)     | Country specific (Germany): to incorporate modifications as for Amendment #9.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| #11 (26 May 2016)       | To update the statistical analysis plan to account for the number of events in the PD-L1 positive (CPS ≥ 1%) subjects in timing and conduct of the interim and final analysis, because most of the alpha for testing OS was allocated to the PD-L1 positive(CPS ≥ 1%) biomarker subgroup. The statistical analysis plan was also updated to account for the possible postponement of the second interim analysis and/or the final analysis for up to 4 additional months to accrue enough OS events in the PD-L1 positive (CPS ≥ 1%) subjects after the planned number of OS events in all subjects is achieved.                                                                                                                                            |
| #12 (21 June 2016)      | Country specific (Germany): to incorporate modifications as for Amendment #11.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| #13 (19 September 2016) | To clarify that the basis for PD-L1 positive and strongly positive categories using CPS cutpoints was determined from external data (ie, KEYNOTE-012, KEYNOTE-052, and epidemiologic studies). The biomarker strategy was changed based on these emerging data. Primary hypotheses on PD-L1 positive (CPS ≥ 1%) subjects would not be formally tested at the second interim analysis and the final analysis. Alpha allocation among the primary hypotheses for interim and final analyses was revised accordingly to reflect the change in biomarker strategy. The reallocation of alpha occurs after the conduct of IA1, and proper adjustment was made to maintain the control of family-wise type I error rate (FWER) with implementation of this change |
| #14 (19 September 2016) | Country specific (Germany): to incorporate modifications as for Amendment #13.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

Clinically relevant protocol deviations were reported in a total of 28 patients, and concerned entry criteria (16 patients), discontinuation criteria (1 patient), and prohibited medication (11 patients). No subject was excluded from the analysis due to protocol deviation.

<div style=\"page-break-after: always\"></div>

## Baseline data

Baseline characteristics of the ITT population are presented in the following Table:

Table 1: Subjects Characteristics

## All Subjects (ITT Population)- KEYNOTE-045

|                              | Control   | Control   | Pembrolizuwab   | Pembrolizuwab   | Total    | Total   |
|------------------------------|-----------|-----------|-----------------|-----------------|----------|---------|
| Subjects in population       | n 272     | (.)       | n 270           | (.)             | n 542    | ()      |
| Gender                       |           |           |                 |                 |          |         |
| Male                         | 202       | (74.3)    | 200             | (74.1)          | 402      | (74.2)  |
| Female                       | 70        | (25.7)    | 70              | (25.9)          | 140      | (25.8)  |
| Age (Years)                  |           |           |                 |                 |          |         |
| 65                           | 125       | (46.0)    | 105             | (38.9)          | 230      | (42.4)  |
| = 65                         | 147       | (54.0)    | 165             | (61.1)          | 312      | (57.6)  |
| Mean                         | 65.1      |           | 66.0            |                 | 65.5     |         |
| SD                           | 9.2       |           | 10.2            |                 | 9.7      |         |
| Median                       | 65.0      |           | 67.0            |                 | 66.0     |         |
| Range                        | 26 to 84  |           | 29 to 88        |                 | 26 to 88 |         |
| Race                         |           |           |                 |                 |          |         |
| Asian                        | 58        | (21.3)    | 19              | (23.7)          | 122      | (22.5)  |
| Black Or African American    | 4         | (1.5)     | 5               | (1.9)           | 9        | (1.7)   |
| Multiple                     | 1         | (0.4)     | 1               | (0.4)           | 2        | (0.4)   |
| White                        | 201       | (73.9)    | 188             | (69.6)          | 389      | (71.8)  |
| Missing                      | 8         | (2.9)     | 12              | (4.4)           | 20       | (3.7)   |
| Ethnicity                    |           |           |                 |                 |          |         |
| Hispanic Or Latino           | 15        | (5.5)     | 17              | (6.3)           | 32       | (5.9)   |
| Not Hispanic Or Latino       | 235       | (86.4)    | 221             | (81.9)          | 456      | (84.1)  |
| Not Reported                 | 16        | (5.9)     | 28              | (10.4)          | 44       | (8.1)   |
| Unknown                      | 6         | (2.2)     | 4               | (1.5)           | 10       | (1.8)   |
| ECOG'                        |           |           |                 |                 |          |         |
| [0] Nomal Activity           | 106       | (39.0)    | 119             | (44.1)          | 225      | (41.5)  |
| [1] Symptoms, but ambulatory | 158       | (58.1)    | 143             | (53.0)          | 301      | (55.5)  |
| [2] Ambulatory but unable to | 4         | (1.5)     | 2               | (0.7)           | 6        | (1.1)   |
| Missing                      | 4         | (1.5)     | 6               | (2.2)           | 10       | (1.8)   |
| Metastatic Staging           |           |           |                 |                 |          |         |
| MX                           | 0         | (0.0)     | 2               | (0.7)           | 2        | (0.4)   |
| M0                           | 10        | (3.7)     | 10              | (3.7)           | 20       | (3.7)   |
| M1                           | 261       | (96.0)    | 258             | (95.6)          | 519      | (95.8)  |
| Missing                      | 1         | (0.4)     | 0               | (0.0)           | 1        | (0.2)   |
| Cancer Staging               |           |           |                 |                 |          |         |
| n                            | 0         | (0.0)     | 1               | (0.4)           | 1        | (0.2)   |
| V                            | 271       | (966)     | 269             | (99.6)          | 540      | (99.6)  |
| Missing                      | 1         | (0.4)     | 0               | (0.0)           | 1        | (0.2)   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                                                                | Control                                                                        | Control                                                                        | Pembrolizumab                                                                  | Pembrolizumab                                                                  | Total                                                                          | Total                                                                          |
|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
|                                                                                |                                                                                | (.)                                                                            | n                                                                              | (.)                                                                            | n                                                                              | ()                                                                             |
| Prior Platinum Therapy                                                         |                                                                                |                                                                                |                                                                                |                                                                                |                                                                                |                                                                                |
| Cisplatin                                                                      | 213                                                                            | (78.3)                                                                         | 198                                                                            | (73.3)                                                                         | 411                                                                            | (75.8)                                                                         |
| Carboplatin                                                                    | 56                                                                             | (20.6)                                                                         | 70                                                                             | (25.9)                                                                         | 126                                                                            | (23.2)                                                                         |
| Other (oxaliplatin,nedaplatin)                                                 | 2                                                                              | (0.7)                                                                          | 1                                                                              | (0.4)                                                                          | 3                                                                              | (0.6)                                                                          |
| Missing                                                                        | 1                                                                              | (0.4)                                                                          | 1                                                                              | (0.4)                                                                          | 2                                                                              | (0.4)                                                                          |
| Setting of Most Recent Prior Therapy                                           | Setting of Most Recent Prior Therapy                                           |                                                                                |                                                                                |                                                                                |                                                                                |                                                                                |
| Neo Adjuvant                                                                   | 22                                                                             | (8.1)                                                                          | 19                                                                             | (7.0)                                                                          | 41                                                                             | (7.6)                                                                          |
| Adjuvant                                                                       | 31                                                                             | (11.4)                                                                         | 12                                                                             | (4.4)                                                                          | 43                                                                             | (62)                                                                           |
| Fist Line                                                                      | 157                                                                            | (57.7)                                                                         | 183                                                                            | (67.8)                                                                         | 340                                                                            | (62.7)                                                                         |
| Second Line                                                                    | 60                                                                             | (22.1)                                                                         | 55                                                                             | (20.4)                                                                         | 115                                                                            | (21.2)                                                                         |
| Third Line                                                                     | 1                                                                              | (0.4)                                                                          | 0                                                                              | (0.0)                                                                          | 1                                                                              | (0.2)                                                                          |
| Missing                                                                        | 1                                                                              | (0.4)                                                                          | 1                                                                              | (0.4)                                                                          | 2                                                                              | (0.4)                                                                          |
| Liver Metastases                                                               |                                                                                |                                                                                |                                                                                |                                                                                |                                                                                |                                                                                |
| Absent                                                                         | 176                                                                            | (64.7)                                                                         | 179                                                                            | (66.3)                                                                         | 355                                                                            | (65.5)                                                                         |
| Present                                                                        | 95                                                                             | (34.9)                                                                         | 91                                                                             | (33.7)                                                                         | 186                                                                            | (34.3)                                                                         |
| Missing                                                                        | 1                                                                              | (0.4)                                                                          | 0                                                                              | (0.0)                                                                          | 1                                                                              | (0.2)                                                                          |
| Baseline hemoglobin                                                            |                                                                                |                                                                                |                                                                                |                                                                                |                                                                                |                                                                                |
| >=10 g/dL                                                                      | 223                                                                            | (82.0)                                                                         | 219                                                                            | (81.1)                                                                         | 442                                                                            | (81.5)                                                                         |
| <10 g/aL                                                                       | 44                                                                             | (16.2)                                                                         | 43                                                                             | (15.9)                                                                         | 87                                                                             | (16.1)                                                                         |
| Missing                                                                        | 5                                                                              | (1.8)                                                                          | 8                                                                              | (3.0)                                                                          | 13                                                                             | (2.4)                                                                          |
| Time from Completion/Discontinuation of Mfost recent Prior Therapy to Baseline | Time from Completion/Discontinuation of Mfost recent Prior Therapy to Baseline | Time from Completion/Discontinuation of Mfost recent Prior Therapy to Baseline | Time from Completion/Discontinuation of Mfost recent Prior Therapy to Baseline | Time from Completion/Discontinuation of Mfost recent Prior Therapy to Baseline | Time from Completion/Discontinuation of Mfost recent Prior Therapy to Baseline | Time from Completion/Discontinuation of Mfost recent Prior Therapy to Baseline |
| =3 Months                                                                      | 167                                                                            | (61.4)                                                                         | 166                                                                            | (61.5)                                                                         | 333                                                                            | (61.4)                                                                         |
| 3 Months                                                                       | 104                                                                            | (38.2)                                                                         | 103                                                                            | (38.1)                                                                         | 207                                                                            | (38.2)                                                                         |
| Missing                                                                        | 1                                                                              | (0.4)                                                                          | 1                                                                              | (0.4)                                                                          | 2                                                                              | (0.4)                                                                          |
| Prior Brain Metastasis Status                                                  | Prior Brain Metastasis Status                                                  |                                                                                |                                                                                |                                                                                |                                                                                |                                                                                |
| Absent                                                                         | 267                                                                            | (98.2)                                                                         | 268                                                                            | (99.3)                                                                         | 535                                                                            | (98.7)                                                                         |
| Present                                                                        | 5                                                                              | (1.0)                                                                          | 2                                                                              | (0.7)                                                                          | 7                                                                              | (1.3)                                                                          |
| Geographic Region EU                                                           | Geographic Region EU                                                           |                                                                                |                                                                                |                                                                                |                                                                                |                                                                                |
| EU                                                                             | 117                                                                            | (43.0)                                                                         | 106                                                                            | (39.3)                                                                         | 223                                                                            | (41.1)                                                                         |
| Non-EU                                                                         | 155                                                                            | (57.0)                                                                         | 164                                                                            | (60.7)                                                                         | 319                                                                            | (58.9)                                                                         |
| Geographic Region US                                                           | Geographic Region US                                                           |                                                                                |                                                                                |                                                                                |                                                                                |                                                                                |
| US                                                                             | 59                                                                             | (21.7)                                                                         | 47                                                                             | (17.4)                                                                         | 106                                                                            | (19.6)                                                                         |
| Non-US                                                                         | 213                                                                            | (78.3)                                                                         | 223                                                                            | (82.6)                                                                         | 436                                                                            | (80.4)                                                                         |
| Geographic Region Asian                                                        | Geographic Region Asian                                                        |                                                                                |                                                                                |                                                                                |                                                                                |                                                                                |
| East-Asian                                                                     | 48                                                                             | (17.6)                                                                         | 58                                                                             | (21.5)                                                                         | 106                                                                            | (19.6)                                                                         |
| Non-East Asian                                                                 | ttt                                                                            | (82.4)                                                                         | 212                                                                            | (78.5)                                                                         | 436                                                                            | (80.4)                                                                         |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                  | Control   | Control   | Pembrolizmab   | Pembrolizmab   | Total   | Total   |
|----------------------------------|-----------|-----------|----------------|----------------|---------|---------|
|                                  |           | (6)       |                | (6)            |         | ()      |
| Study Medication Breakdown       |           |           |                |                |         |         |
| Paclitawel                       | 84        | (30.9)    | 0              | (0.0)          | 84      | (15.5)  |
| Docetawel                        | 84        | (30.9)    | 0              | (0.0)          | 84      | (15.5)  |
| Vinflunine                       | 87        | (32.0)    | 0              | (0.0)          | 87      | (16.1)  |
| Pembrolizumab                    | 0         | (0.0)     | 266            | (98.5)         | 266     | (49.1)  |
| Missing                          | 17        | (6.3)     | 4              | (1.5)          | 21      | (3.9)   |
| Smoling Status                   |           |           |                |                |         |         |
| Never Smoker                     | 83        | (30.5)    | 104            | (38.5)         | 187     | (34.5)  |
| Ex Smoker                        | 148       | (54.4)    | 136            | (50.4)         | 284     | (52.4)  |
| Curent Smoker                    | 38        | (14.0)    | 29             | (10.7)         | 67      | (12.4)  |
| Missing                          | 3         | (1.1)     | 1              | (0.4)          | 4       | (0.7)   |
| Histology                        |           |           |                |                |         |         |
| Pure Transitional Cell           | 197       | (72.4)    | 186            | (68.9)         | 383     | (70.7)  |
| Predominantly Transitional Cell  | 73        | (26.8)    | 82             | (30.4)         | 155     | (28.6)  |
| Other                            | 0         | (0.0)     | 2              | (0.7)          | 2       | (0.4)   |
| Missing                          | 2         | (0.7)     | 0              | (0.0)          | 2       | (0.4)   |
| PD-L1 CPS 1 Cutoff               |           |           |                |                |         |         |
| PD-L1 CPS ≤1%                    | 147       | (54.0)    | 151            | (55.9)         | 298     | (55.0)  |
| PD-L1 CPS >= 1%                  | 120       | (44.1)    | 110            | (40.7)         | 230     | (42.4)  |
| Missing                          | 5         | (1.8)     | 9              | (3.3)          | 14      | (2.6)   |
| PD-L1 CPS 1046 Cutoff            |           |           |                |                |         |         |
| PD-L1 CPS≤10%                    | 176       | (64.7)    | 186            | (68.9)         | 362     | (66.8)  |
| PD-L1 CPS >= 10%                 | 90        | (33.1)    | 74             | (27.4)         | 164     | (30.3)  |
| Missing                          | 6         | (2.2)     | 10             | (3.7)          | 16      | (3.0)   |
| Sum of Target Lesion at Baseline |           |           |                |                |         |         |
| cMedian                          | 117       | (43.0)    | 132            | (48.9)         | 249     | (45.9)  |
| =Median                          | 135       | (49.6)    | 115            | (42.6)         | 250     | (46.1)  |
| Missing                          | 20        | (7.4)     | 23             | (8.5)          | 43      | (7.9)   |
| Risk Scores                      |           |           |                |                |         |         |
| 0                                | 44        | (16.2)    | 54             | (20.0)         | 98      | (18.1)  |
| 1                                | 97        | (35.7)    | 96             | (35.6)         | 193     | (35.6)  |
| 2                                | 80        | (29.4)    | 66             | (24.4)         | 146     | (26.9)  |
| 3-4                              | 45        | (16.5)    | 45             | (16.7)         | 90      | (16.6)  |
| Missing                          | 6         | (2.2)     | 9              | (3.3)          | 15      | (2.8)   |
| Prior Cystectomy/Nephrectom      |           |           |                |                |         |         |
| No                               | 221       | (81.3)    | 607            | (77.4)         | 430     | (79.3)  |
| sa1                              | 51        | (18.8)    | 61             | (22.6)         | 112     | (20.7)  |

## Numbers analysed

The ITT population, including all randomized subjects in the treatment group to which they were assigned (270 in the pembrolizumab arm and 272 in the control arm), served as the primary efficacy analysis population.

For the analysis of pre-specified key exploratory PRO endpoints, a specific Full Analysis Set (FAS) population, that consisted of all randomized subjects who received at least one dose of study medication and completed at least one PRO instrument (266 subjects in the pembrolizumab arm and 254 subjects in the control arm), was considered.

The All Subject as Treated (ASaT) population, defined as all randomized subjects who received at least one dose of study treatment (266 in the pembrolizumab arm and 255 in the control arm) was used for the analysis of safety data.

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

Results from the second interim analysis (cut-off date 07-Sep-2016) were provided for primary (PFS and OS) and secondary (ORR, DOR, and PFS/ORR per mRECIST) endpoints.  Even if, based on external biomarker data only primary hypotheses of all comers and PD-L1 CPS ≥ 10% were included in the multiplicity-controlled statistical testing for the IA2, results in subjects with CPS ≥ 1% are also reported although p-value was not multiplicity-adjusted.

The median follow up duration was 10.3 (range 0.2 to 20.8) months in the pembrolizumab arm and 7.9 (range 0.3 to 20.3) months in the control arm.

## Primary endpoints

## Overall Survival

- All Subjects (ITT Population)

Table 2: OS-All Subjects (ITT Population)

Data Cut-off date: 07 Sep 2016

|               |     |                  |                | Event Rate/            | Median Os t       | OS Rate at                         | OS Rate at              | Pembrolizumab vs. Control   | Pembrolizumab vs. Control   |
|---------------|-----|------------------|----------------|------------------------|-------------------|------------------------------------|-------------------------|-----------------------------|-----------------------------|
| Treatment     | N   | Number of Events | Person Month 5 | 100 Person- Months (%) | (Months) (95% CI) | Months 6 in % t (95% CI)           | Months 12 in % (95% CI) | Hazard Ratio(95% CI)        | p-Value?                    |
| Control       | 272 | (%) 179 (65.8)   | 1935.1         | 9.3                    | 7.4 (6.1, 8.3)    | 56.7 (50.3, 62.6)                  | 30.7 (25.0, 36.7)       |                             |                             |
| Pembrolizumab | 270 | 155 (57.4)       | 2364.7         | 6.6                    | 10.3 (8.0, 11.8)  | 63.9 (57.9, 69.4)43.9 (37.8, 49.9) |                         | 0.73 (0.59, 0.91)           | 0.00224                     |

From product-limit (Kaplan-Meier) method for censored data.

Based on stratified Cox regression model with treatment as a covaniate shratified by Eastem Cooperative Oncology Group (ECOG) Performance Scale (O/l vs. 2), presence or absence of liver metastases, hemoglobin (≥ 10 g/dL vs. ≤10 g/dL), and time from completion of most recent chemotherapy (&lt;3 months or ≥3 months)

One-sided p-value based on shratified log-rank test.

Control arm is investigator's choice of paclitaxel, docetaxel or vinflunine.

Database CutoffDate:07SEP2016

Source:[P045V0l: analysis-adsl; adtte]

Figure: Kaplan-Meier estimates of OS

All Subjects (ITT Population)

Data Cut-off date: 07 Sep 2016

<div style=\"page-break-after: always\"></div>

<!-- image -->

Control arm is investigator's choice of paclitaxel, docetaxel or vinflunine

(Database Cut-off date: 07SEP2016)

An updated analysis (cut-off date:18JAN2017) was conducted with a total of 366 OS events that are very close to the approximately 370 OS events defined in the protocol as the final analysis. The final study report is planned to be submitted in July 2018.

Table 3: OS-All Subjects (ITT Population)

Data cut-off date: 18 Jan 2017

|               |     |                       |                | Event Rate/              | Median OS          | OS Rateat             | OS Rateat              | Pembrolizumabvs.Control   | Pembrolizumabvs.Control   |
|---------------|-----|-----------------------|----------------|--------------------------|--------------------|-----------------------|------------------------|---------------------------|---------------------------|
| Treatment     | N   | Nunber of Events (%6) | Person- Months | 100 Personl- Months (96) | (Months) (959% CI) | Months6in%6+ (95% C1) | Months12in96+ (95% C1) | HazardRatio(95%6C1)       | p-Values                  |
| Control       | 272 | 196 (72.1)            | 2197.9         | 8.9                      | 7.4 (6.3, 8.1)     | 56.9 (50.6, 62.8)     | 30.2 (24.6, 36.0)      |                           |                           |
| Pembrolizumab | 270 | 170 (63.0)            | 2795.5         | 6.1                      | 10.3 (8.0,12.3)    | 63.9 (57.9, 69.4)     | 44.4 (38.4, 50.3)      | 0.70 (0.57, 0.86)         | 0.00040                   |

<!-- image -->

Source:[P045V01: analysis-adsl; adtte]

<div style=\"page-break-after: always\"></div>

## Figure: Kaplan-Meier estimates of OS

All Subjects (ITT Population)

## Data Cut-off date: 18 Jan 2017

<!-- image -->

## Number of subject at risk

Control

272

Pembrolizumab

270

231

226

171

194

139

169

109

147

91

132

73

116

61

106

Control anm is investigator's choice of paclitaxel, docetaxel or vinflumine.

(Database cutoff date:18IAN2017)

Sowrce: [P045V0l: analysis-adsl; adtte]

## Analysis of OS before Month 4

Due to the slope of KM curves, with an initial favourable treatment effect for the control arm followed by a convergence at approximately 2 months and a subsequent cross between Month 3 and Month 4, a review of OS events in the period from randomization to Month 4 was performed.

In order to understand in more detail the risk of death within the first 4 months, the instantaneous hazard rate over time was evaluated (see Figure below).

<!-- image -->

While the hazard rate for the pembrolizumab arm between 0 and approximately 2 months is above that of the control arm, thereafter the hazard rate in the pembrolizumab arm stays below the control arm. Subsequent analyses thus focused on the interval up to 2 months as well as up to 4 months.

In the interval from randomization to 2 months, there were more deaths but far fewer subjects censored in the pembrolizumab arm than the control arm (43 vs. 24 deaths, respectively; 3 vs. 17 censored,

46

79

26

52

15

27

6

12

1

4

0

0

<div style=\"page-break-after: always\"></div>

respectively). Reasons for censoring were Withdrawal by Subject (2) and Lost to Follow-up (1) for the 3 patients on pembrolizumab arm, and Withdrawal by Subject for all 17 subjects on the control arm.

In the interval from 2 months to Month 4, twice as many subjects died in the control arm as in the pembrolizumab arm (56 vs. 28, respectively) with 4 subjects and 2 subjects censored, respectively.

Overall in the pembrolizumab arm there were 9 fewer deaths up to 4 months (71 deaths) compared to the control arm (80 deaths) and there were far fewer censored subjects (5 compared to 21).

For subjects that died or were censored in the first 2.1 months, there are modest imbalances in baseline risk factors between the treatment groups, including a higher prevalence of the presence of liver metastases and reduced treatment free interval (&lt; 3 months) in subjects treated with pembrolizumab compared with control subjects.

To further assess potential factors that may influence the outcome in patients that might be treated with pembrolizumab compared to those on chemotherapy, a comparison of baseline characteristics between pembrolizumab and control arms of subjects who experienced early OS events (within 2.1 months) and of subjects who were censored for OS were each evaluated. It should be noted that the total number of subjects censored in the pembrolizumab arm within the first 2.1 months is small, 3 subjects, compared with 17 subjects in control arm, in part limiting the analysis.

The percentages of subjects at baseline with each individual Bellmunt risk factor of poor prognosis (ECOG PS &gt; 0, presence of liver metastasis, hemoglobin &lt; 10g/dL, time from prior chemotherapy &lt; 3 months), Bellmunt risk scores ≥ 2, and additional characteristics of aggressive disease (baseline tumor burden ≥ median, and presence of visceral metastasis) among early deaths (within 2.1 months) and among early censoring events (within 2.1 months) are shown in the following Tables.

## Table 4: KN045 Percentage of Subjects with Risk Factors and Additional Characteristics of Aggressive Disease Among Early Overall Survival Events (&lt; 2.1 months) -

## All Subjects Randomized (ITT Population)

<!-- image -->

|                                             | Control   | Pembrolizumab   |
|---------------------------------------------|-----------|-----------------|
| Risk Factor                                 |           |                 |
| EC0G>0                                      | 79.1%     | 69.7%           |
| Liver metastasis                            | 66.7%     | 74.4%           |
| Hemoglobin<10g/dL                           | 33.3%     | 32.6%           |
| Time fromprior chemotherapy<3months         | 37.5%     | 51.2%           |
| Bellhmunt Risk Score≥2                      | 79.1%     | 81.4%           |
| Additional Characteristics of PoorPrognosis |           |                 |
| Baselinetumorburden2median                  | 75%       | 74.4%           |
| Visceralmetastasis                          | 95.89%    | 100%            |

<div style=\"page-break-after: always\"></div>

Table 5: KN045 Percentage of Subjects with Risk Factors and Additional Characteristics of Aggressive Disease Among Early Overall Survival Censorings (&lt;2.1 months) -All Subjects Randomized (ITT Population)

<!-- image -->

|                                           | Control   | Pembrolizumab   |
|-------------------------------------------|-----------|-----------------|
| Risk Factor                               |           |                 |
| ECOG>0                                    | 58.8%     | 33.3%           |
| Liver metastasis                          | 35.3%     | 33.3%           |
| Hemoglobin<10g/dL                         | 17.6%     | 0%              |
| Timefrompriorchemotherapy3months          | 41.2%     | 66.7%           |
| Bellmunt≥2                                | 47.1%     | 33.3%           |
| Additional CharacteristicsofPoorPrognosis |           |                 |
| Baselinetumorburden≥median                | 58.8%     | 33.3%           |
| Visceralmetastasis                        | 82.4%     | 66.7%           |

Among the deaths occurring within the first 2.1 months, a greater proportion of subjects in the pembrolizumab arm had liver metastasis and time from prior chemo &lt;3 months. A higher proportion of subjects in the control arm had ECOG PS &gt;0 and a similar proportion of subjects in both arms had haemoglobin &lt;10 g/dL, Bellmunt Risk Score &gt;2, baseline tumor burden &gt; median and visceral metastasis. Among the early censored OS events, a greater proportion of subjects in the control arm had ECOG PS &gt;0, Hb&lt;10g/dL, Bellmunt risk scores &gt;2, visceral metastasis and baseline tumor burden &gt; median. A higher proportion of subjects in the pembrolizumab arm had time from prior chemotherapy &lt; 3 months and a similar proportion of subjects in both arms had liver metastasis.

- OS results based on PD-L1 expression

Table 6: OS - Subjects with PD-L1 CPS≥10%

Cut-off Date:07Sep2016

|               |    |                  |              | Event Rate/            | Median Os t       | OS Rate at                       | OS Rateat            | Pembrolizumabvs.Control   | Pembrolizumabvs.Control   |
|---------------|----|------------------|--------------|------------------------|-------------------|----------------------------------|----------------------|---------------------------|---------------------------|
| Treatment     | N  | Number of Events | Person Month | 100 Person- Months (%) | (Months) (95% CI) | Months6in%t (95% CI)             | Months12in% (95% CI) | HazardRatio(95%C1)t       | p-Value?                  |
| Control       | 90 | (%) 60 (66.7)    | 570.3        | 10.5                   | 5.2 (4.0, 7.4)    | 47.2 (36.0, 57.6)                | 26.9(17.5,37.2)      |                           |                           |
| Pembrolizumab | 74 | 44 (59.5)        | 589.1        | 7.5                    | 8.0 (5.0, 12.3)   | 58.5 (46.3,68.9)39.8 (28.0,51.3) |                      | 0.57 (0.37,0.88)          | 0.00483                   |

<!-- image -->

Source:[P045V01:analysis-adsl;adtte]

<div style=\"page-break-after: always\"></div>

Table 7: OS - Subjects with PD-L1 CPS≥1%

Cut-off Date:07Sep2016

|               |     |                      |                | Event Rate/            | Median OS t       | OS Rate at           | OS Rate at              | Pembrolizumabvs.Control   | Pembrolizumabvs.Control   |
|---------------|-----|----------------------|----------------|------------------------|-------------------|----------------------|-------------------------|---------------------------|---------------------------|
| Treatment     | N   | Number of Events (%) | Person Month 5 | 100 Person- Months (%) | (Months) (95% CI) | Months6in%t (95% CI) | Months 12 in % (95% CI) | Hazard Ratio+(95% C1)t    | p-Value?                  |
| Control       | 120 | 81 (67.5)            | 823.0          | 9.8                    | 6.9 (4.7,8.8)     | 51.6 (41.9, 60.4)    | 28.8 (20.4, 37.7)       |                           |                           |
| Pembrolizumab | 110 | 61 (55.5)            | 971.1          | 6.3                    | 11.3 (7.7, 16.0)  | 65.9 (56.1, 73.9)    | 46.5 (36.4, 55.8)       | 0.61 (0.43, 0.86)         | 0.00239                   |

tBased on stratified Cox regression model with treatment as a covariate stratified by Eastem Cooperative Oncology Group (ECOG) Performance Scale (O/l vs. 2),presence or absenceof liver metastases,hemoglobin(10g/dLvs.&lt;10g/dL),andtime from completion ofmostrecent chemotherapy（&lt;3months or≥3 months)

From product-limit (Kaplan-Meier) method for censored data.

$ One-sided p-value based on stratified log-rank test.

Control arm is investigator's choice of paclitaxel, docetaxel or vinflunine.

DatabaseCutoffDate:07SEP2016

Source:[P045V01: analysis-adsl; adtte]

Kaplan-Meier EstimatesofOverall Survival

Kaplan-MeierEstimatesof Overall Survival

SubjectswithPD-L1 CPS&gt;=1%(ITT Population)

SubjectswithPD-L1CPS&gt;=10%(ITTPopulation)

Table 8: Summary of OS results

<!-- image -->

Cut- off date: 18Jan2017

| Treatment group   | N=272                   | Pembrolizumnb N= 270    | Pembrolizumab vs.Control   | Pembrolizumab vs.Control   |
|-------------------|-------------------------|-------------------------|----------------------------|----------------------------|
|                   | Median, months (95% CD) | Median, months (95% CD) | HR.(95% CI)                | p-value                    |
| OS                |                         |                         |                            |                            |
| ITT               | N=272                   | N= 270                  |                            |                            |
|                   | 7.4 (6.3.8.1)           | 10.3 (8.0, 12.3)        | 0.70 (0.57. 0.86)          | 0.00040                    |
| CPS210%           | N= 74                   | 06=N                    |                            |                            |
|                   | 5.2 (4.0.7.4)           | 8.0 (5.0,12.3)          | 0.57 (0.38,0.86)           | 0.00335                    |
| CPS2 116          | N=120                   | N= 110                  |                            |                            |
|                   | 6.9 (4.7.8.8)           | 11.3 (7.7, 16.0)        | 0.59 (0.42.0.83)           | 0.00092                    |
| CPS<10%           | N = 176                 | N=186                   |                            |                            |
|                   | 7.7 (6.8.9.7)           | 10.8 (8.0, 13.9)        | 0.76(0.58,0.98)            |                            |
| CPS<146           | N= 147                  | N= 151                  |                            |                            |
|                   | 7.5 (6.6, 9.7)          | 9.6 (6.9, 11.6)         | 0.89 (0.66.1.20)           |                            |

<div style=\"page-break-after: always\"></div>

## Progression Free Survival per RECIST 1.1 by Central Radiology Assessment

- All Subjects (ITT Population)

Table 9: PFS based on RECIST 1.1 per central radiology assessment

## All Subjects (ITT Population)

Data cut-off: 07 Sep 2016

|               |     |                      |                 | Event Rate/ 100    | MedianPFSt (Months)   | PFS Rate at         | PFS Rate at                       | Pembrolizumabvs.Control   | Pembrolizumabvs.Control   |
|---------------|-----|----------------------|-----------------|--------------------|-----------------------|---------------------|-----------------------------------|---------------------------|---------------------------|
| Treatment     | N   | Number of Events (%) | rPerson Month 5 | Person- Months (%) | (95% CI)              | Months6in% (95% CI) | Months 12 in% (95% CI)            | Hazard Ratio(95% CI)*     | p-Value?                  |
| Control       | 272 | 219 (80.5)           | 1014.1          | 21.6               | 3.3 (2.3,3.5)         | 26.8 (21.2,32.6)    | 6.2 (3.3, 10.2)                   |                           |                           |
| Pembrolizumab | 270 | 218 (80.7)           | 1206.7          | 18.1               | 2.1 (2.0, 2.2)        |                     | 28.8 (23.5,34.3)16.8 (12.3, 22.0) | 0.98 (0.81, 1.19)         | 0.41648                   |

Progression-free survival is defined as time from randomization to disease progression, or death, whichever occurs first.

From product-limit (Kaplan-Meier) method for censored data.

Based on shratified Cox regression model with treatment as a covaniate stratified by Eastem Cooperative Oncology Group (ECOG) Performance Scale (O/1 vs. 2), presence or absence of liver metastases, hemoglobin ( 10 g/dL vs. ≤10 g/dL), and time from completion of mostrecent chemotherapy (&lt;3 months or ≥3 months)

One-sided p-valuebased on shratified log-rank test.

Control arm is investigator's choice of paclitaxel, docetaxel or vinflunine.

DatabaseCutoff Date:07SEP2016

Source:[P045V0l:analysis-adsl; adtte]

## Figure: Kaplan-Meier estimates of PFS based on RECIST 1.1 per central radiology assessment (Primary Censoring Rule)

All Subjects (ITT Population)

Data cut- off: 07 Sep 2016

<!-- image -->

## Number of subject at risk

| Control       |   272 |   188 |   85 |   56 |   27 |   17 |   10 |   5 1 | 0 0   |   0 | 0   |
|---------------|-------|-------|------|------|------|------|------|-------|-------|-----|-----|
| Pembrolizumab |   270 |   165 |   85 |   73 |   56 |   51 |   23 |    16 | 7 0   |   0 | 0 0 |

<div style=\"page-break-after: always\"></div>

Table 10: PFS based on RECIST 1.1 per central radiology assessment

## All Subjects (ITT Population)

Data cut-off:  18 Jan 2017

<!-- image -->

|               |     |                      |               | Event Rate/             | MedianPFS↑        | PFSRate at          | PFSRate at            | Pembrolizumabvs.Control   | Pembrolizumabvs.Control   |
|---------------|-----|----------------------|---------------|-------------------------|-------------------|---------------------|-----------------------|---------------------------|---------------------------|
| Treatment     | N   | NumberPerson- of (%) | Events Months | 100 Personl- Months (%) | (Months) (95% CI) | Months6in% (95% C1) | Mfonths12in% (95% CI) | Hazard Ratio(95%C1)       | p-Values                  |
| Control       | 272 | 227 (83.5)           | 1110.7        | 20.4                    | 3.3 (2.4,3.5)     | 28.4(22.8,34.2)     | 7.9 (4.8,12.0)        |                           |                           |
| Pembrolizumab | 270 | 219 (81.1)           | 1371.2        | 16.0                    | 2.1 (2.0, 2.2)    | 28.8(23.5,34.3)     | 17.6 (13.2,22.6)      | 0.96 (0.79, 1.16)         | 0.32274                   |

Progression-free survivalis defined astime from randomization to disease progression,or death,whichever occurs first.

Fromproduct-limit(Kaplan-Mfeier)methodforcensoreddata.

Basedonstratified Coxregression model with treatmentasacovariate stratified byEasternCooperative OncologyGroup(ECOG) Performance Scale (0/1 rs. 2),presence or absence of liver metastases,hemoglobin(≥10 g/dLvs.&lt;10 g/dL),and time from completion of most recent chemotherapy （&lt;3monthsor≥3months)

SOne-sidedp-valuebased on stratifiedlog-ranktest.

Control armisinvestigator'schoiceofpaclitaxel,docetaxelorvinflunine.

DatabaseCutoff Date:18JAN2017

Source:[P045V0l: analysis-adsl;adtte]

Figure: Kaplan-Meier estimates of PFS based on RECIST 1.1 per central radiology assessment (Primary Censoring Rule)

## All Subjects (ITT Population)

Data cut- off: 18 Jan 2017

<!-- image -->

## Numberofsubjectatrisk

| Control       | 272 192 98 70 40 28 17 II 8 5 2 1 0 0     |
|---------------|-------------------------------------------|
| Pembrolizumab | 270 173 101 86 68 f9 54 51 32 17 11 5 0 0 |

Control anmis investigator's choice ofpaclitaxel,docetaxel or vinflumine.

(Database cutoff date: 18JAN2017)

Sowrce:[P045V01: analysis-adsl; adtte]

<div style=\"page-break-after: always\"></div>

## · PFS results based on PD-L1 expression

## Table 11: PFS based on RECIST 1.1 per Central Radiology Assessment  Subjects with PD-L1 CPS≥10%

Cut- off Date: 07Sep2016

|              |    |                             |         | Event Rate/            | MedianPFSI        | PFS Rate at                      | PFS Rate at             | Pembrolizmabvs.Control   | Pembrolizmabvs.Control   |
|--------------|----|-----------------------------|---------|------------------------|-------------------|----------------------------------|-------------------------|--------------------------|--------------------------|
| Treatment    | N  | Number Person of Events (%) | Month S | 100 Person- Months (%) | (Months) (95% CI) | Months 6in % t (95% CI)          | Months 12 in % (95% CI) | Hazard Ratio (95% CI)    | p-Values                 |
| Control      | 90 | 72 (80.0)                   | 283.8   | 25.4                   | 3.1 (2.2, 3.4)    | 18.5 (10.6,28.1)                 | 3.7 (0.7, 10.9)         |                          |                          |
| Pembrolizmab | 74 | 59 (79.7)                   | 316.4   | 18.6                   | 2.1 (1.9,2.1)     | 24.7 (15.5, 34.9)17.7 (9.5,27.9) |                         | 0.89 (0.61,1.28)         | 0.23958                  |

Progression-free survivalis defined as time from randomizationto disease progression,or death,whichever occuursfirst.

From product-limit (Kaplan-Meier)method for censored data.

+Based on stratified Cox regression model with treatment as a covariate stratified by Eastem Cooperative Oncology Group (ECOG) Performance Scale (O/1 ys. 2),presence or absence oflivermetastases,hemoglobin(10g/dLvs.10g/dL),and time from completionof most recent chemotherapy（3months or≥3 months)

One-sided p-value based on stratified log-rank test.

Control anm isinvestigator's choice ofpaclitaxel,docetaxel orvinflunine.

DatabaseCutoffDate:07SEP2016

Source:[P045V01: analysis-adsl; adtte]

## Table 12: PFS based on RECIST 1.1 per Central Radiology Assessment Subjects with PD-L1 CPS≥1%

Cut-off Date: 07Sep2016

|               |     |                             |         | Event Rate/            | Median PFSt       | PFS Rate at              | PFS Rate at             | Pembrolizumab vs.Control   | Pembrolizumab vs.Control   |
|---------------|-----|-----------------------------|---------|------------------------|-------------------|--------------------------|-------------------------|----------------------------|----------------------------|
| Treatment     | N   | Number Person of Events (%) | Month 5 | 100 Person- Months (%) | (Months) (95% CI) | Months 6 in % t (95% CI) | Months 12 in % (95% CI) | Hazard Ratio (95% CI)*     | p-Value?                   |
|               | 120 | 98 (81.7)                   | 421.3   | 23.3                   | 3.2 (2.2, 3.4)    | 20.5 (13.3, 28.8)        | 4.4 (1.4, 10.4)         |                            |                            |
| Pembrolizumab | 110 | 85 (77.3)                   | 509.8   | 16.7                   | 2.1 (2.0, 2.4)    | 28.4 (20.3, 37.1)        | 20.9 (13.6,29.3)        | 0.91 (0.68, 1.24)          | 0.26443                    |

Progression-free survival is defined as time from randomization to disease progression, or death, whichever occurs first.

From product-limit (Kaplan-Meier)method for censored data.

Based on stratified Cox regression model with treatment as a covariate stratified by Eastem Cooperative Oncology Group (ECOG) Performance Scale (O/l vs. 2), presence or absence of liver metastases, hemoglobin (&gt; 10 g/dL vs. &lt;10 g/dL), and time from completion of most recent chemotherapy (&lt;3 months or &gt;3 months)

One-sided p-value based on stratified log-rank test.

Conhrol arm is investigator's choice of paclitaxel,docetaxel or vinflumine.

Database Cutoff Date:07SEP2016

Source:[P045V0l: analysis-adsl; adtte]

<div style=\"page-break-after: always\"></div>

KapanMeier Esmates ofPogen-Free Suvial Based on RECIST 1lpr CetalKaplanMeer Estatesof Progessi-Free Surval Based en RECIST L.l per Cental BadiologyAssessumentPrimaryCensoringRule) Radiology Assessmest (Primary CensoaingRale) SubjecswithPD-L1CPS&gt;=1O%(ITTPopabtoo) SubjecwPD-L1CPS&gt;I%(ITTPoputioe)

<!-- image -->

Table 13: Summary of PFS results

Cut- off date: 18Jan2017

| Treatmentgroup                         | Control N=272                                                                                  | Pembrolizumab N=270                                                                              | Pembrolizimabvs.Control                                                          | Pembrolizimabvs.Control   |
|----------------------------------------|------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|---------------------------|
|                                        | Median, months (95% CI)                                                                        | Median, months (95% CI)                                                                          | HR (95% C1)                                                                      | p-value                   |
| PFS LII CPS≥10% CPS≥1% CPS<10% CPS<106 | N=272 3.3 (2.4.3.5) 06=N 3.2(22.3.5) N=120 3.2(2.2.3.4) N=176 3.3(2.2.4.2) N=147 3.3 (2.2,4.7) | N=270 2.1 (2.0.2.2) N=74 2.1(1.9.2.1) N=110 2.1 (2.0.2.4) N=186 2.1 (2.0.23) N=151 2.1 (2.0.2.3) | 0.96 (0.79.1.16) 0.94(0.65.135) 0.92(0.68.1.24) 1.00 (0.79.1.26) 1.07(0.82.1.39) | 0.32274 0.33449 0.26416*  |

## Secondary endpoints

## Objective Response Rate per confirmed RECIST 1.1 by Central Radiology Assessment

- All Subjects (ITT Population)

The ORR was 21.1% (95% CI: 16.4, 26.5) in the pembrolizumab arm compared to 11.4% (95% CI: 7.9, 15.8) in the control arm, with an estimated difference of 9.6% (95% CI: 3.5, 15.9; p=0.001).

<div style=\"page-break-after: always\"></div>

Table 14: Summary of Best Overall Response based on RECIST 1.1  by Central Radiology Assessment; Cut- off Date: 07Sep2016

<!-- image -->

| Response Evaluation                          | Control (N=272)   | Control (N=272)   | Control (N=272)       | Pembrolizumab (N=270)   | Pembrolizumab (N=270)   | Pembrolizumab (N=270)   |
|----------------------------------------------|-------------------|-------------------|-----------------------|-------------------------|-------------------------|-------------------------|
|                                              | n                 | %                 | 95% CIt               | n                       | %                       | 95% CI                  |
| Complete Response (CR) Partial Response (PR) | 6 22              | 3.3 8.1           | (1.5,6.2) (5.1, 12.0) | 19 38                   | 7.0 14.1                | (4.3,10.8) (10.2, 18.8) |
| Objective Response (CR+PR)                   | 31                | 11.4              | (7.9, 15.8)           | 57                      | 21.1                    | (16.4, 26.5)            |
| Stable Disease (SD)                          | 91                | 33.5              | (27.9,39.4)           | 47                      | 17.4                    | (13.1, 22.5)            |
| Disease Control (CR+PR+SD)                   | 122               | 44.9              | (38.8, 51.0)          | 104                     | 38.5                    | (32.7,44.6)             |
| Progressive Disease (PD)                     | 06                | 33.1              | (27.5,39.0)           | 131                     | 48.5                    | (42.4, 54.7)            |
| Non-evaluable (NE)                           | 9                 | 3.3               | (1.5, 6.2)            | 4                       | 1.5                     | (0.4, 3.7)              |
| No Assessment                                | 51                | 18.8              | (14.3, 23.9)          | 31                      | 11.5                    | (7.9, 15.9)             |

Source: [P045V01: analysis-adsl; adopa]

The median follow-up in patients with confirmed CR and PR was 13.4 (7.3-19.1) months in the control arm and 14.1 (10.2-20.8) months in the pembrolizumab group.

Across arms, the reduction of tumour burden in patients with at least 1 baseline imaging assessment was 53.9% (118 of 219 subjects) in the pembrolizumab arm, and 54.5% (109 of 200 subjects) in the control arm, as shown in the following figures:

WaterfallPlot ofBestTumorChangefromBaselineinPembrolizumabArm Based on RECIST 1.1per Central Radiology Assessment All SubjectswithMeasureableDisease atBaseline(ITTPopulation)

110

100

90

80

70

848200

-10

-20

30

40

-50

-60

-70

-80

90

-100

<!-- image -->

<!-- image -->

Subject ID

Percentagechanges&gt;100%weretruncatedat100%.

Control arm is investigator's choice of paclitaxel, docetaxel or vinflunine.

DatabaseCutoffDate:07SEP2016

+20%Tuor Inerease

-30%Tumor Reduction

<div style=\"page-break-after: always\"></div>

Table 15: Summary of Best Overall Response based on RECIST 1.1

by Central Radiology Assessment

Cutoff Date:18Jan2017

| Response Evaluation      | Control (N=272)   | Control (N=272)   | Control (N=272)   | Pembrolizumab (N=270)   | Pembrolizumab (N=270)   | Pembrolizumab (N=270)   |
|--------------------------|-------------------|-------------------|-------------------|-------------------------|-------------------------|-------------------------|
|                          | n                 | %                 | 95% C1            | n                       | %                       | 95% CT                  |
| Complete Response (CR)   | 8                 | 2.9               | (1.3.5.7)         | 21                      | 7.8                     | (4.9. 11.6)             |
| Partial Response (PR)    | 22                | 8.1               | (5.1, 12.0)       | 36                      | 13.3                    | (9.5, 18.0)             |
| ObjectiveResponse(CR+PR) | 30                | 11.0              | (7.6, 15.4)       | 57                      | 21.1                    | (16.4, 26.5)            |
| Stable Disease (SD)      | 92                | 33.8              | (28.2.39.8)       | 47                      | 17.4                    | (13.1,22.5)             |
| DiseaseControl(CR+PR+SD) | 122               | 44.9              | (38.8,51.0)       | 104                     | 38.5                    | (32.7,44.0)             |
| Progressive Disease (PD) | 90                | 33.1              | (27.5,39.0)       | 131                     | 48.5                    | (42.4, 54.7)            |
| Non-evaluable (NE)       | 9                 | 3.3               | (1.5,6.2)         | 4                       | 1.5                     | (0.4,3.7)               |
| No Assessment            | 51                | 18.8              | (14.3,23.9)       | 31                      | 11.5                    | (7.9, 15.9)             |

Source:[P045V01:analysis-adsl; adopa]

<!-- image -->

- ORR Results based on PD-L1 expression

## Table 16: Summary of Best Overall Response based on RECIST 1.1 by Central Radiology

Assessment; (ITT Population) Cut-off Date: 07Sep2016

|                            | PD-L1 CPS≥10%         | PD-L1 CPS≥10%         | PD-L1 CPS≥1%          | PD-L1 CPS≥1%          |
|----------------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| Response evaluation        | Control (N=90)        | Pembrolizumab (N=74)  | Control (N=120)       | Pembrolizumab (N=110) |
|                            | n (%) 95% CI°         | n(%) 95% CI°          | n(%) 95% CI°          | n(%) 95% CI°          |
| Complete response (CR)     | 2 (2.2) (0.3,7.8)     | 5 (6.8) (2.2,15.1)    | 5 (4.2) (1.4,9.5)     | 10 (9.1) (4.4,16.1)   |
| Partial response (PR)      | 4 (4.4) (1.2,11.0)    | 11 (14.9) (7.7,25.0)  | 5 (4.2) (1.4,9.5)     | 16 (14.5) (8.5,22.5)  |
| Objective response (CR+PR) | 6 (6.7) (2.5,13.9)    | 16 (21.6) (12.9,32.7) | 10 (8.3) (4.1,14.8)   | 26 (23.6) (16.1,32.7) |
| Stable disease (SD)        | 32 (35.6) (25.7,46.3) | 9 (12.2) (5.7,21.8)   | 42 (35.0) (26.5,44.2) | 17 (15.5) (9.3,23.6)  |
| Disease control (CR+PR+SD) | 38 (42.2) (31.9,53.1) | 25 (33.8) (23.2,45.7) | 52 (43.3) (34.3,52.7) | 43 (39.1) (29.9,48.9) |
| Progressive disease (PD)   | 28 (31.1) (21.8,41.7) | 37 (50.0) (38.1,61.9) | 38 (31.7) (23.5,40.8) | 53 (48.2) (38.6,57.9) |

<div style=\"page-break-after: always\"></div>

| Non-evaluable (NE)   | 4 (4.4)     | 0 (0.0)    | 4 (3.3)     | 0 (0.0)    |
|----------------------|-------------|------------|-------------|------------|
|                      | (1.2,11.0)  | (0.0,4.9)  | (0.9,8.3)   | (0.0,3.3)  |
| No Assessment        | 20 (22.2)   | 12(16.2)   | 26 (21.7)   | 14 (12.7)  |
|                      | (14.1,32.2) | (8.7,26.6) | (14.7,30.1) | (7.1,20.4) |

°Based on binomial exact confidence interval method.

Non-evaluable: subject had post-baseline imaging and the BOR was determined to be NE per RECIST 1.1 No Assessment: subjects had no post-baseline imaging.

Table 17: Summary of ORR results - Cut-off date: 18Jan2017

| Treamentgroup   | Control N = 272            | Pembrolizumab N= 270       | Pembrolizimabvs.Control   | Pembrolizimabvs.Control   |
|-----------------|----------------------------|----------------------------|---------------------------|---------------------------|
|                 | Median,months (95% C1)     | Median,months (95% C1)     | HR (95% C1)               | p-value                   |
| ORRanalysis     | (BICR-RECIST1.1) % (95%C1) | (BICR-RECIST1.1) % (95%C1) | Difference(95%C1)         | p-value                   |
| ITT             | N= 272                     | N= 270                     |                           |                           |
|                 | 11.0 (7.6,15.4)            | 21.1 (16.4,26.5)           | 10.0(3.9,16.2)            | 89000'0                   |
| CPS>10%         | N=90                       | N=74                       |                           |                           |
| CPS≥19          | 6.7(2.5.13.9) N=120        | 20.3(11.8.31.2) N=110      | 172(6.8.29.4)             | 0.00061                   |
|                 | 8.3 (4.1,14.8)             | 22.7 (15.3, 31.7)          | 15.6(6.5.25.7)            | 000000                    |
| CPS<10%         | N=176                      | N=186                      |                           |                           |
|                 | 13.6 (8.9,19.6)            | 19.4(13.9.25.8)            | 5.1(-2.6.12.8)            |                           |
| CPS<196         | N=Y47 13.6(8.5.20.2)       | N=YSI 17.9 (12.1.24.9)     | 3.9(4.5.123)              |                           |

## Time to Response (TTR) and Response Duration (DOR) by Central Radiology Assessment

- All Subjects (ITT Population)

Table 18: Summary of TTR and DOR based on RECIST 1.1 per BICR in subjects with confirmed response

## All Subjects (ITT Population)

|                                                   | Control (N=272)    | Pembrolizumab (N=270)      |
|---------------------------------------------------|--------------------|----------------------------|
| Number of Subjects with Response                  | 31                 | 57                         |
| Time to Response (months)                         |                    |                            |
| Mean (SD)                                         | 2.4 (0.8)          | 2.7 (1.2)                  |
| Median (Range)                                    | 2.1 (1.7-4.9)      | 2.1 (1.4-6.3)              |
| Response Duration (months)                        |                    |                            |
| Median (Range)                                    | 4.3 (1.4+ - 15.4+) | Not reached (1.6+ - 15.6+) |
| Number of Subjects with Response ≥ 6 Months (%)t  | 7 (40)             | 41 (78)                    |
| Number of Subjects with Response ≥ 12 Months (%)t | 3 (35)             | 14 (68)                    |

Analysis on time to response and response duration are based on patients with a best overall response as confirmed complete response or partial response only.

I\"+\" indicates the response duration is censored.

+Median and percentage are calculated from product-limit (Kaplan-Meier) method for censored data.

Control arm is investigator's choice of paclitaxel,docetaxel or vinflunine.

DatabaseCutoffDate:07SEP2016

Source: [P045V0l: analysis-adsl; adtte]

<div style=\"page-break-after: always\"></div>

## · PD-L1 CPS≥10% and PD-L1 CPS≥1% Populations

## Table 19: Summary of TTR and DOR based on RECIST 1.1 per BICR in subjects with confirmed response

## Subjects with PD-L1 CPS≥10% and Subjects with PD-L1 CPS≥1%

## (ITT Population)

|                                                     | PD-L1 CPS≥10%           | PD-L1 CPS≥10%           | PD-L1 CPS≥1%            | PD-L1 CPS≥1%            |
|-----------------------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
|                                                     | Control (N=90)          | Pembrolizuma b (N=74)   | Control (N=120)         | Pembrolizuma b (N=110)  |
| Number of subjects with response°                   | 6                       | 16                      | 10                      | 26                      |
| Time to Response° (months) Mean (SD) Median (Range) | 2.0 (0.1) 2.1 (1.9-2.2) | 2.5 (1.0) 2.1 (1.4-5.3) | 2.0 (0.1) 2.1 (1.9-2.2) | 2.6 (1.0) 2.2 (1.4-5.3) |
| Response Duration* (months) Median (Range)          | 4.4 (1.5+-10.8+)        | NR (1.6+-15.4+)         | NR (1.5+- 15.4+)        | NR (1.6+-15.6+)         |
| N. of subjects with response ≥6 months (%)*         | 1 (40)                  | 14 (93)                 | 3 (56)                  | 21 (88)                 |
| N. of subjects with response ≥12 months (%)*        | 0                       | 3 (76)                  | 2 (56)                  | 7 (78)                  |

Table made by the Assessor from Table 11-9 and Table 14.2-51 in KEYNOTE-045 CSR v.01

NR: Not reached

°Analysis on time to response and response duration are based on patients with a best overall response as confirmed complete response or partial response only.

*Median and percentage are calculated from product-limit (Kaplan-Meier) method for censored data.

Control arm is investigator's choice of paclitaxel, docetaxel or vinflunine.

Database Cut-off Date: 07SEP2016

Results of PFS and ORR analysis per mRECIST by BICR were consistent with those per RECIST 1.1.

<div style=\"page-break-after: always\"></div>

## Summary of updated efficacy results (Data Cut-off: 18 Jan 2017)

Table 20: KN045 Summary of Efficacy Results -All Subjects Randomized (ITT Population) 18-Jan-2017

<!-- image -->

|                   | Control N= 272                     | Pembrolizuwnb N=270                       | Pembrolizimab Ts.Conirol         | Pembrolizimab Ts.Conirol   |
|-------------------|------------------------------------|-------------------------------------------|----------------------------------|----------------------------|
|                   | Median, months (95% CI)            | Median, months (95% CI)                   | HR (95%, C1)                     | p-value                    |
| OS ITT            | N=272 7.4 (6.3.8.1)                | N=270 10.3 (8.0.12.3) N=90 8.0 (5.0. 123) | 0.70 (0.57.0.86) 0.57(0.38.0.86) | 0.00040                    |
| CPS≥ 10%          | N= 74 5.2 (4.0.7.4)                | N=110                                     |                                  | 0.00335                    |
| CPS≥ 16 CPSc10%6  | N=120 6.9 (4.7.8.8) 9LI=N          | 11.3 (7.7. 16.0) N=186                    | 0.59 (0.42.0.83)                 | 0.00092*                   |
| CPS<1             | 7.7(6.8.9.7) N= 147                | 10.8 (8.0.13.9) N=15T                     | 0.76 (0.58. 0198)                |                            |
|                   | 7.5 (6.6, 9.7)                     | 9.6 (6.9,11.6)                            | 0.89 (0.66, 1.20)                |                            |
| PES TIT CPS: 10%6 | N=272 3.3 (24.3.5) N=90            | N=270 21(2.0.22) N=74                     | 0.96 (0.79.1.16)                 | 0.32274                    |
| CPS≥116           | 3.2.(0.2.3.5) N=120                | 2.1 (1.9.2.1) N=110                       | 0.94 (0.65.1.35)                 | 0.33449                    |
| CPS c1096         | 3.2 (2.2.3.4) 9LI=N                | 2.1 (2.0,2.4) 981=N                       | 0.92 (0.68, 1.24)                | 0.26416*                   |
|                   | 3.3 (2.2.4.2)                      | 2.1(2.0.23)                               | 1.00 (0.79, 1.26)                |                            |
| CPSc1%            | N=147 3.3 (2.2.4.7)                | N- 151 2.1 (2.0.2.3)                      | 1.07 (0.82.139)                  |                            |
| ORR analysis      | (BICR-RECIST 1.1) 9% (95% CD)      | (BICR-RECIST 1.1) 9% (95% CD)             | Difference (95% C1)              | p-value                    |
| ITT               | N= 272 11.0 (7.6, 15.4)            | N= 270 21.1 (16.4, 26.5)                  | 10.0 (3.9,16.2)                  | 8900010                    |
| CPS≥10% CPS2 116  | N=90 6.70.5.13.9) N = 120          | N=74 ICTE'SIOEOL N= 110                   | 172(6.8.29.4)                    | 0.00061                    |
| CPS<1096          | 8.3 (4.1. 14.8) N= 176             | 22.7 (15.3. 31.7) N=186 19.4 (13.9.25.8)  | 15.6(65,25.7)                    | 010000                     |
| CPS<1             | 13.6 (8.9.19.6) =N 13.6 (8.5.20.2) | ISIaN 17.9 (12.1.24.9)                    | 3.1 (-2.6,12.8) 3.9 (4.5.12.3)   |                            |

+Not muliplicity controlled.

Abbreviations: BICR=blinded independent cental review: CI=confidence interval; CPS=combined proportion score: ITT=intent-to-treat; OS=overall suwrvival; PFS=progression-free suvival; ORR=objective response rate.

## Exploratory endpoints- Patient-reported Outcome Analyses

## EORTC QLQ-C30

- EORTC QLQ-C30 score change from baseline to week 9 and week 15

At Week 9, the global health status/QoL score was stable from baseline in the pembrolizumab arm (LS mean = -1.37 points; 95% CI: -4.10, 1.35), and a greater worsening of -5.75 points (95% CI: -8.62,2.87) was observed in the control, with a difference between arms at Week 9 of 4.38 points (95% CI: 0.59, 8.16; two-sided p =0.02, not controlled for multiplicity).

An even greater difference in LS means was reported at Week 15 between pembrolizumab and control (9.05 points; 95% CI: 4.61, 13.48; two-sided p &lt;0.001, not controlled for multiplicity).

<div style=\"page-break-after: always\"></div>

## · EORTC QLQ-C30 Global Health Status Score at each visit to week 27

Table 21: Summary of QLQ-C30 Global Health Status/QoL at Study Visit (FAS Population)

|             | Treatment        | Treatment        | Treatment              | Treatment              |
|-------------|------------------|------------------|------------------------|------------------------|
| Study Visit | Control (Nf=254) | Control (Nf=254) | Pembrolizumab (Nf=266) | Pembrolizumab (Nf=266) |
|             | n                | Mean (SE)        | 11                     | Mean (SE)              |
| BASELINE    | 243              | 59.1 (1.4)       | 260                    | 61.5 (1.4)             |
| WEEK3       | 220              | 57.7 (1.5)       | 238                    | 63.2 (1.4)             |
| WEEK6       | 199              | 58.9 (1.6)       | 215                    | 64.3 (1.6)             |
| WEEK9       | 176              | 58.5 (1.6)       | 200                    | 63.0 (1.6)             |
| WEEK 15     | 118              | 57.9 (1.8)       | 157                    | 67.6 (1.8)             |
| WEEK21      | 73               | 60.5 (2.2)       | 126                    | 67.4 (1.8)             |
| WEEK27      | 46               | 59.4 (3.4)       | 105                    | 67.3 (2.3)             |

t: Number of subjects in Full Analysis Set population Database Cutoff: 07SEP2016

Souurce: [P045V01: analysis-adsl; adpro]

- Time to Deterioration analysis of EORTC QLQ-C30 Global Health Status/QoL score A longer time to deterioration was registered with pembrolizumab compared to the control arm (HR =

0.70; 95% CI:0.55, 0.90; two-sided p =0.002, not controlled for multiplicity).

Figure: Kaplan-Meier of Time to Traditional Deterioration for EORTC QLQ-C30 Global Health Status/QOL (FAS Population with baseline)

<!-- image -->

<div style=\"page-break-after: always\"></div>

- Additional EORTC QLQ-C30 analyses

Table 22: Analysis of Change from Baseline of EORTC QLQ-C30 Global health status/QoL at Week 9 by Progressive Disease (PD) Status (FAS Population)

| Treatment                                                                                                                                                                                                                                                                                                                                         | WithoutPD LS Mean (95% CI)                                                                                                                                                                                                                                                                                                                        | WithPD LS Mean (95%CI                                                                                                                                                                                                                                                                                                                             | DifferencebyPDStatus LS Mean (95%CI)                                                                                                                                                                                                                                                                                                              |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pembrolizmab                                                                                                                                                                                                                                                                                                                                      | 3.13 (-0.03, 6.30)                                                                                                                                                                                                                                                                                                                                | -6.87 (-10.34,-3.41)                                                                                                                                                                                                                                                                                                                              | -10.01(-13.94,-6.07)                                                                                                                                                                                                                                                                                                                              |
| Control                                                                                                                                                                                                                                                                                                                                           | -2.23 (-5.43,0.97)                                                                                                                                                                                                                                                                                                                                | -12.30 (-15.80,-8.79)                                                                                                                                                                                                                                                                                                                             | -10.06 (-13.08,-7.05)                                                                                                                                                                                                                                                                                                                             |
| Oncology Group (EC0G) Performance Scale (0/1 vs. 2), presence or absence of liver metastases, hemoglobin ( =10 g/dL vs. ≤10 g/dL), and time from completion of mostrecent chemotherapy(<3 months or=3months),PDstatus and PD status by treatment arm as covariates. LS Mean: Least square mean; CI: Confidence interval. DatabaseCutoff:07SEP2016 | Oncology Group (EC0G) Performance Scale (0/1 vs. 2), presence or absence of liver metastases, hemoglobin ( =10 g/dL vs. ≤10 g/dL), and time from completion of mostrecent chemotherapy(<3 months or=3months),PDstatus and PD status by treatment arm as covariates. LS Mean: Least square mean; CI: Confidence interval. DatabaseCutoff:07SEP2016 | Oncology Group (EC0G) Performance Scale (0/1 vs. 2), presence or absence of liver metastases, hemoglobin ( =10 g/dL vs. ≤10 g/dL), and time from completion of mostrecent chemotherapy(<3 months or=3months),PDstatus and PD status by treatment arm as covariates. LS Mean: Least square mean; CI: Confidence interval. DatabaseCutoff:07SEP2016 | Oncology Group (EC0G) Performance Scale (0/1 vs. 2), presence or absence of liver metastases, hemoglobin ( =10 g/dL vs. ≤10 g/dL), and time from completion of mostrecent chemotherapy(<3 months or=3months),PDstatus and PD status by treatment arm as covariates. LS Mean: Least square mean; CI: Confidence interval. DatabaseCutoff:07SEP2016 |

Source: [P045V01: analysis-adsl; adpro]

Table 23: Analysis of Change from Baseline of EORTC QLQ-C30 Global health status/QoL at Week 15 by Progressive Disease (PD) Status (FAS Population)

| Treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | WithoutPD LS Mean (95% CI)f                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | With PD LS Mean (95%CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | DifferencebyPDStatus LS Mean (95%CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pembrolizmab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 5.97 (2.48,9.46)                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | -3.54 (-6.95, -0.13)                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | -9.52（-12.88,-6.15)                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Control                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | -4.31 (-8.02, -0.60)                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | -13.95 (-17.75,-10.15)                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | -9.64 (-12.21,-7.07)                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Based on cLDA model with the PRO scores as the response variable, treatment by study visit interaction, and stratification factors: Eastem Cooperative Oncology Group (ECOG) Perfonmance Scale (0/1 vs. 2), presence or absence of liver metastases, hemoglobin (=10 g/dL vs. ≤10 g/dL), and time from completionofmostrecentchemotherapy（<3monthsor=3months),PDstatus andPDstatusbytreatment armascovariates. LS Mean: Least square mean; CI: Confidence interval. DatabaseCutoff:07SEP2016 | Based on cLDA model with the PRO scores as the response variable, treatment by study visit interaction, and stratification factors: Eastem Cooperative Oncology Group (ECOG) Perfonmance Scale (0/1 vs. 2), presence or absence of liver metastases, hemoglobin (=10 g/dL vs. ≤10 g/dL), and time from completionofmostrecentchemotherapy（<3monthsor=3months),PDstatus andPDstatusbytreatment armascovariates. LS Mean: Least square mean; CI: Confidence interval. DatabaseCutoff:07SEP2016 | Based on cLDA model with the PRO scores as the response variable, treatment by study visit interaction, and stratification factors: Eastem Cooperative Oncology Group (ECOG) Perfonmance Scale (0/1 vs. 2), presence or absence of liver metastases, hemoglobin (=10 g/dL vs. ≤10 g/dL), and time from completionofmostrecentchemotherapy（<3monthsor=3months),PDstatus andPDstatusbytreatment armascovariates. LS Mean: Least square mean; CI: Confidence interval. DatabaseCutoff:07SEP2016 | Based on cLDA model with the PRO scores as the response variable, treatment by study visit interaction, and stratification factors: Eastem Cooperative Oncology Group (ECOG) Perfonmance Scale (0/1 vs. 2), presence or absence of liver metastases, hemoglobin (=10 g/dL vs. ≤10 g/dL), and time from completionofmostrecentchemotherapy（<3monthsor=3months),PDstatus andPDstatusbytreatment armascovariates. LS Mean: Least square mean; CI: Confidence interval. DatabaseCutoff:07SEP2016 |

Souuce:[P045V01: analysis-adsl; adpro]

<div style=\"page-break-after: always\"></div>

## Ancillary analyses

OS

## Subgroup analysis

## Figure: Overall Survival by Subgroup Factors, Point Estimate and Nominal 95% Confidence Interval, All Subjects (ITT Population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Priee Flatinn Therapy

Cahoplarin

Cisplatin

Mast Rexen Prior Therapr

Aval

Keo Aljiwam

IL Meastatic

2L Meastatic

Liver Hetastases at Baseline

Absenee

EresHKe

Baelne Hemgiebin cgE

&gt;=10 g/fL

Time from Mest Eecest Chemo Teapy c3 Moefts

Hisalagy

Mised Trsifioal/nor-transitieeal histology

2=3 Monrts

Trarsitioral Cell

Besks Metastaals Stats

Frixr Brain Matastasis

No Erier Brain Metatsis

MK-3475 vs. Paditasel

ME-3475 vs. Farlirmo]

MK-3475 vs. Dacetael

ME-3475 vs. Doretzoel

MK-3475 vs, Finfbuui*

MK-3475 vs. Vinflenine

248/411

82/136

22/41

203/340

27/43

8/115

145/186

189/355

257/442

71/87

193/333

140/207

240/383

93/155

6/7

328/535

208/350

203/350

216/353

0.74

.53

0.72

53

0.83

.85

0.67

.71

.75

9.66

.82

.80

.58

KA

9.73

9.76

9.76

9.69

(0.56, 0.94)

(0.47, 1.18)

(0.20, 1.41)

(0.54, 0.95)

(0.18, 1.57)

(0.52, 1.33)

(0.61, 1.20)

(0.50, 0.89)

(0.55, 0.91)

(0.46, 1.22)

(0.49, 0.89)

(0.58, 1.15)

(0.62, 104)

(0.37,0.89)

(MA, NA)

(0.58, 0.91)

(0.55, 1.04)

(0.55, 1.05)

(0.51, 0.94)

0

Estimated Hansrd Ratio (HR)

<!-- image -->

4

<div style=\"page-break-after: always\"></div>

Based on Cox regression model with treatment as covariates and stratified by ECOG Performance Scale (0/1 vs. 2), presence or absence of liver metastases, hemoglobin (&gt;=10 g/dL vs. &lt;10 g/dL), and time from completion of most recent chemotherapy (&lt;3 months or &gt;=3 months).

Control arm is investigator's choice of paclitaxel, docetaxel or vinflunine.

Database Cut-off Date: 07SEP2016

PFS

## Subgroup analysis

## Figure: PFS based on RECIST 1.1 per central radiology assessment by Subgroup Factors Point Estimate and Nominal 95% Confidence Interval All Subjects (ITT Population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Based  on  Cox  regression  model  with  treatment  as  covariates  and  stratified  by  ECOG  Performance  Scale  (0/1  vs.  2),  presence  or absence  of  liver  metastases,  hemoglobin  (&gt;=10  g/dL  vs.  &lt;10  g/dL),  and  time  from  completion  of  most  recent  chemotherapy  (&lt;3 months or &gt;=3 months).

Control arm is investigator's choice of paclitaxel, docetaxel or vinflunine.

Database Cut-off Date: 07SEP2016

<div style=\"page-break-after: always\"></div>

## Sensitivity analyses

The results of the PFS analyses per RECIST 1.1 by Central Radiology Assessment according to Sensitivity Censoring Rules are reported in the following Table:

## Table 24: Analysis of PFS based on RECIST 1.1 per Central Radiology Assessment Sensitivity Censoring Rules 1,2 and 3 All Subjects (ITT Population)

|                              | N                            | N. events                    | Person- Months               | Event Rate/ 100 Person-      | Median PFS* (months)         | PFS Rate 6 months (%)*       | PFS Rate 12 months (95% CI)   | Pem vs control               | Pem vs control               |
|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|-------------------------------|------------------------------|------------------------------|
|                              |                              | (%)                          |                              | Months (%)                   | (95% CI)                     | (95% CI)                     | (%)*                          | HR (95%CI)°                  | p- value                     |
| Sensitivity Censoring Rule 1 | Sensitivity Censoring Rule 1 | Sensitivity Censoring Rule 1 | Sensitivity Censoring Rule 1 | Sensitivity Censoring Rule 1 | Sensitivity Censoring Rule 1 | Sensitivity Censoring Rule 1 | Sensitivity Censoring Rule 1  | Sensitivity Censoring Rule 1 | Sensitivity Censoring Rule 1 |
| control                      | 272                          | 199 (73.2)                   | 885.7                        | 22.5                         | 3.0 (2.2, 3.4)               | 24.3 (18.7, 30.3)            | 6.1 (3.0, 10.7)               | 0.99 (0.81, 1.21)            | 0.462                        |
| pembro                       | 270                          | 214 (79.3)                   | 1161.6                       | 18.4                         | 2.1 (2.0, 2.2)               | 28.5 (23.1, 34.0)            | 16.4 (11.8, 21.6)             | 0.99 (0.81, 1.21)            | 0.462                        |
|                              | Sensitivity Censoring Rule 2 | Sensitivity Censoring Rule 2 | Sensitivity Censoring Rule 2 | Sensitivity Censoring Rule 2 | Sensitivity Censoring Rule 2 | Sensitivity Censoring Rule 2 | Sensitivity Censoring Rule 2  | Sensitivity Censoring Rule 2 | Sensitivity Censoring Rule 2 |
| control                      | 272                          | 264 (97.1)                   | 994.5                        | 26.5                         | 2.7 (2.2, 3.3)               | 20.8 (16.2, 25.9)            | 2.3 (0.9, 4.6)                | 0.86 (0.71, 1.03)            | 0.042                        |
| pembro                       | 270                          | 239 (88.5)                   | 1172.3                       | 20.4                         | 2.1 (2.0, 2.2)               | 26.8 (21.6, 32.2)            | 11.5 (7.9, 15.9)              | 0.86 (0.71, 1.03)            | 0.042                        |
|                              | Sensitivity Censoring Rule 3 | Sensitivity Censoring Rule 3 | Sensitivity Censoring Rule 3 | Sensitivity Censoring Rule 3 | Sensitivity Censoring Rule 3 | Sensitivity Censoring Rule 3 | Sensitivity Censoring Rule 3  | Sensitivity Censoring Rule 3 | Sensitivity Censoring Rule 3 |
| control                      | 272                          | 212 (77.9)                   | 985.7                        | 21.5                         | 3.3 (2.3, 3.5)               | 26.4 (20.8, 32.3)            | 6.6 (3.6, 10.9)               | 0.98 (0.80, 1.19)            | 0.392                        |
| pembro                       | 270                          | 212 (78.5)                   | 1179.0                       | 18.0                         | 2.1 (2.0, 2.2)               | 29.2 (23.8, 34.8)            | 16.6 (12.0, 21.9)             | 0.98 (0.80, 1.19)            | 0.392                        |

Table made by Assessor from Table 14.2-1, Table 14.2-2 and Table 14.2-3.

Sensitivity  Censoring  Rule  1:  data  for  any  subject  who  misses  two  or  more  consecutive  disease  assessments  (with  or without a subsequent death or progression) are censored at the last disease assessment prior to missing visits.

Sensitivity  Censoring  Rule  2:  discontinuation  of  treatment  or  initiation  of  new  anticancer  treatment  subsequent  to discontinuation of study specified treatments, whichever occurs later, is a PD event for subjects without documented PD or death.

Sensitivity Censoring Rule 3: censoring of subjects with any of the following two clinical scenarios before PD or death at the time  of  last  disease  assessment  prior  to  the  clinical  scenarios:  (1)  use  of  radiotherapy  before  study  treatment discontinuation; (2) occurrence of a skeletal-related event (e.g., fracture) in patients with bone metastases at study entry.

*From product-limit (Kaplan-Meier) method for censored data.

°Based on stratified Cox regression model with treatment as a covariate stratified by ECOG) Performance Scale (0/1 vs. 2), presence or absence of liver metastases, hemoglobin ( ≥ 10 g/dL vs. &lt;10 g/dL), and time from completion of most recent chemotherapy (&lt;3 months or ≥ 3 months)

One-sided p-value based on stratified log-rank test.

Control arm is investigator ' s choice of paclitaxel, docetaxel or vinflunine.

Database Cut-off Date: 07SEP2016

<div style=\"page-break-after: always\"></div>

The results of the PFS analyses per RECIST 1.1 by Site Radiology Assessment for all subjects in the ITT population were similar compared to those by Central Radiology assessment.

## Analyses of OS/PFS and ORR by age group

|                                               | control           | control           | control           | control   | pembrolizumab           | pembrolizumab           | pembrolizumab           | pembrolizumab         |
|-----------------------------------------------|-------------------|-------------------|-------------------|-----------|-------------------------|-------------------------|-------------------------|-----------------------|
|                                               | <65               | 65-74             | 75-84             | 85+       | 65                      | 65-74                   | 75-84                   | 85+                   |
| N. Subject                                    | 125               | 104               | 43                | 0         | 105                     | 113                     | 46                      | 6                     |
| OS                                            |                   |                   |                   |           |                         |                         |                         |                       |
| n. of events                                  | 85                | 70                | 24                | 0         | 64                      | 61                      | 28                      | 2                     |
| Median OS (months) (95%CI)                    | 7.5 (6.3, 9.7)    | 6.8 (4.7, 8.0)    | 8.9 (3.6, .)      | NA        | 8.0 (6.0, 11.8)         | 10.5 (8.0, 16.0)        | 10.3 (4.7, 15.2)        | Not reached (11.6...) |
| OS at 6 months (%) (95%C1)                    | 60.5 (51.0, 68.7) | 52.6 (42.1, 62.1) | 55.7 (39.2, 69.4) | NA        | 60.7 (50.7, 69.3)       | 65.7 (56.0, 73.7)       | 62.3 (46.5, 74.6)       | 100.0 (..)            |
| OSat12months (%) (95%CI)                      | 29.7 (21.5, 38.4) | 29.0 (20.0, 38.6) | 38.3 (22.9, 53.5) | NA        | 40.1 (30.4, 49.6)       | 46.2 (36.5, 55.4)       | 42.2 (27.8, 56.0)       | 2'88 (27.3, 97.5)     |
| pem vs. control Hazard Ratio (95% CI) p-Value |                   |                   |                   |           | 0.75 (0.53, 1.05) 0.045 | 0.64 (0.45, 0.92) 0.007 | 1.52 (0.79, 2.89) 0.897 |                       |
| PFS                                           |                   |                   |                   |           |                         |                         |                         |                       |
| n. of events                                  | 105               | 81                | 33                | 0         | 88                      | 87                      | 38                      | 5                     |
| Median PFS (months) (95%CI)                   | 2.3 (2.1, 3.4)    | 3.3 (2.6, 4.2)    | 3.7 (2.1, 5.2)    | NA        | 2.0 (1.9, 2.1)          | 2.2 (2.1, 3.4)          | 2.1 (2.0, 4.8)          | 2.7 (1.9, ..)         |
| PFS at6 months (%) (95%CI)                    | 21.8 (14.5, 30.1) | 32.0 (22.5, 41.9) | 28.6 (15.3, 43.5) | NA        | 23.6 (15.9, 32.1)       | 30.7 (22.4, 39.4)       | 35.6 (22.0, 49.3)       | 33.3 (4.6, 67.6)      |
| PFS at 12months (%) (95%CI)                   | 2.3 (0.5, 7.2)    | 9.4 (4.1, 17.4)   | 9.1 (1.8, 23.7)   | NA        | 16.0 (9.3, 24.3)        | 19.7 (12.5, 28.2)       | 11.2 (3.0, 25.7)        | 16.7 (0.8, 51.7)      |
| pem vs. control Hazard Ratio (95% CI) p-Value |                   |                   |                   |           | 0.98 (0.73, 1.33) 0.457 | 1.00 (0.73, 1.38) 0.504 | 1.52 (0.88, 2.64) 0.931 |                       |
| ORR                                           |                   |                   |                   |           |                         |                         |                         |                       |
| ORR (%)                                       | 6.4               | 11.5              | 25.6              | NA        | 18.1                    | 23.0                    | 21.7                    | 33.3                  |
| (95%CI)                                       | (2.8, 12.2)       | (6.1, 19.3)       | (13.5, 41.2)      |           | (11.3, 26.8)            | (15.6, 31.9)            | (10.9, 36.4)            | (4.3, 77.7)           |
| pem vs. control Estimate (95% CI)             |                   |                   |                   |           | 12.7 (4.3, 22.2) 0.001  | 10.6 (0.5, 21.1) 0.019  | -8.0 (-27.7,11.3) 0.790 |                       |
| p-Value                                       |                   |                   |                   |           |                         |                         |                         |                       |

Table made by the Assessor from Tables 14.2-12 to 14.2-15 (0s), from Tables 14.2-7 to 14.2-10 (PFS) and from Tables 14.2-35 to 14.2-38 (0RR) inKEYNOTE-045 CSRv01

<div style=\"page-break-after: always\"></div>

## Summary of main study(ies)

The  following  table  summarises  the  efficacy  results  from  the  main  studies  supporting  the  present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 25: Summary of Efficacy for trial KEYNOTE-045

| Title: A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic   | Title: A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic                                                                                                               | Title: A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic                                                                                                               | Title: A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic                                                                                                               |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                          | EudraCT number: 2014-002009-40                                                                                                                                                                                                                                                        | EudraCT number: 2014-002009-40                                                                                                                                                                                                                                                        | EudraCT number: 2014-002009-40                                                                                                                                                                                                                                                        |
| Design                                                                                                                                                                    | Randomized, active-controlled, multicenter, open-label trial of IV pembrolizumab monotherapy vs the investigator's choice of paclitaxel, docetaxel or vinflunine in locally advanced or metastatic urothelial carcinoma patients who have received prior platinum-containing therapy. | Randomized, active-controlled, multicenter, open-label trial of IV pembrolizumab monotherapy vs the investigator's choice of paclitaxel, docetaxel or vinflunine in locally advanced or metastatic urothelial carcinoma patients who have received prior platinum-containing therapy. | Randomized, active-controlled, multicenter, open-label trial of IV pembrolizumab monotherapy vs the investigator's choice of paclitaxel, docetaxel or vinflunine in locally advanced or metastatic urothelial carcinoma patients who have received prior platinum-containing therapy. |
| Design                                                                                                                                                                    | Duration of main phase: Duration of Run-in phase:                                                                                                                                                                                                                                     | Duration of main phase: Duration of Run-in phase:                                                                                                                                                                                                                                     | not applicable not applicable not applicable                                                                                                                                                                                                                                          |
| Hypothesis                                                                                                                                                                | Duration of Extension phase: Superiority                                                                                                                                                                                                                                              | Duration of Extension phase: Superiority                                                                                                                                                                                                                                              | Duration of Extension phase: Superiority                                                                                                                                                                                                                                              |
| Treatments groups                                                                                                                                                         | pembrolizumab                                                                                                                                                                                                                                                                         | pembrolizumab                                                                                                                                                                                                                                                                         | 200 mg IV Q3W 270 enrolled patients                                                                                                                                                                                                                                                   |
| Treatments groups                                                                                                                                                         | Investigator's choice                                                                                                                                                                                                                                                                 | Investigator's choice                                                                                                                                                                                                                                                                 | paclitaxel 175 mg/m 2 Q3W OR docetaxel 75 mg/m 2 Q3W OR vinflunine 320 mg/m 2 Q3W 272 enrolled patients                                                                                                                                                                               |
| Endpoints and definitions                                                                                                                                                 | Co-Primary endpoint                                                                                                                                                                                                                                                                   | OS                                                                                                                                                                                                                                                                                    | time from randomization to death due to any cause                                                                                                                                                                                                                                     |
| Endpoints and definitions                                                                                                                                                 | Co-primary endpoint                                                                                                                                                                                                                                                                   | PFS                                                                                                                                                                                                                                                                                   | time from randomization to documented progressive disease per RECIST 1.1 based on BICR or death due to any cause, whichever occurred first                                                                                                                                            |
| Endpoints and definitions                                                                                                                                                 | Secondary endpoint                                                                                                                                                                                                                                                                    | ORR                                                                                                                                                                                                                                                                                   | Proportion of patients in the analysis population with a CR or PR, based on BICR review per RECIST 1.1                                                                                                                                                                                |
| Endpoints and definitions                                                                                                                                                 | Secondary endpoint                                                                                                                                                                                                                                                                    | Time to response                                                                                                                                                                                                                                                                      | Time from randomization to the first assessment of CR or PR. Only confirmed CR/PR were included in the analysis.                                                                                                                                                                      |
| Endpoints and definitions                                                                                                                                                 | Secondary endpoint                                                                                                                                                                                                                                                                    | Response duration                                                                                                                                                                                                                                                                     | Time from the first CR/PR to documented PD. Only confirmed CR/PR were included in the analysis.                                                                                                                                                                                       |
| Cut-off date Database lock                                                                                                                                                | 07-SEP-2016 07-OCT- 2016                                                                                                                                                                                                                                                              | 07-SEP-2016 07-OCT- 2016                                                                                                                                                                                                                                                              | 07-SEP-2016 07-OCT- 2016                                                                                                                                                                                                                                                              |
| Results and Analysis                                                                                                                                                      | Results and Analysis                                                                                                                                                                                                                                                                  | Results and Analysis                                                                                                                                                                                                                                                                  | Results and Analysis                                                                                                                                                                                                                                                                  |
| Analysis description                                                                                                                                                      | Primary Analysis                                                                                                                                                                                                                                                                      | Primary Analysis                                                                                                                                                                                                                                                                      | Primary Analysis                                                                                                                                                                                                                                                                      |
| Analysis population and time point description                                                                                                                            | Intent to treat                                                                                                                                                                                                                                                                       | Intent to treat                                                                                                                                                                                                                                                                       | Intent to treat                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| Descriptive statistics and effect estimate per comparison   | Treatment group                                | Pembrolizumab 200 mg      | Control                |
|-------------------------------------------------------------|------------------------------------------------|---------------------------|------------------------|
| Descriptive statistics and effect estimate per comparison   | All subject (N)                                | 270                       | 272                    |
| Descriptive statistics and effect estimate per comparison   | Dual Primary endpoints                         | Dual Primary endpoints    | Dual Primary endpoints |
| Descriptive statistics and effect estimate per comparison   | OS N. with events n (%)                        | 155 (57.4)                | 179 (65.8)             |
| Descriptive statistics and effect estimate per comparison   | Median OS months (95% CI)                      | 10.3 (8.0,11.8)           | 7.4 (6.1, 8.3)         |
| Descriptive statistics and effect estimate per comparison   | Hazard Ratio Pembrolizumab vs control (95% CI) | 0.73 (0.59, 0.91)         | 0.73 (0.59, 0.91)      |
| Descriptive statistics and effect estimate per comparison   | p-value (one sided log-rank test)              | 0.002                     | 0.002                  |
| Descriptive statistics and effect estimate per comparison   | PFS (BICR RECIST 1.1) N. with events (%)       | 218 (80.7)                | 219 (80.5)             |
| Descriptive statistics and effect estimate per comparison   | Median PFS months (95% CI)                     | 2.1 (2.0,2.2)             | 3.3 (2.3,3.5)          |
| Descriptive statistics and effect estimate per comparison   | Hazard Ratio Pembrolizumab vs control (95% CI) | 0.98 (0.81, 1.19)         | 0.98 (0.81, 1.19)      |
| Descriptive statistics and effect estimate per comparison   | p-value (one sided log-rank test)              | 0.416                     | 0.416                  |
| Descriptive statistics and effect estimate per comparison   | Secondary endpoints                            | Secondary endpoints       | Secondary endpoints    |
| Descriptive statistics and effect estimate per comparison   | ORR (BICR-RECIST 1.1) (95% CI)                 | 21.1 (16.4, 26.5)         | 11.4 (7.9, 15.8)       |
| Descriptive statistics and effect estimate per comparison   | Difference %vs control (95% CI)                | 9.6 (3.5, 15.9)           | 9.6 (3.5, 15.9)        |
| Descriptive statistics and effect estimate per comparison   | p-value (one sided)                            | 0.001                     | 0.001                  |
| Descriptive statistics and effect estimate per comparison   | Number of subjects with response               | 57                        | 31                     |
| Descriptive statistics and effect estimate per comparison   | Time to response Median (months) range         | 2.1 (1.4, 6.3)            | 2.1 (1.7, 4.9)         |
| Descriptive statistics and effect estimate per comparison   | Response duration Median (months) range        | Not reached (1.6+, 15.6+) | 4.3 (1.4+, 15.4+)      |

<div style=\"page-break-after: always\"></div>

-  Main study (Urothelial carcinoma ineligible for cisplatin-based chemotherapy)

Study KEYNOTE-052: A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Advanced/Unresectable or Metastatic Urothelial Cancer

Figure: Trial design

<!-- image -->

## Methods

## Study participants

## Main inclusion criteria

- Histologically or cytologically confirmed diagnosis of advanced/unresectable (inoperable) or metastatic urothelial cancer of the renal pelvis, ureter, bladder, or urethra. Both transitional cell and mixed transitional/non-transitional cell histologies were allowed.
- Age ≥18 years.
- Cisplatin-ineligibility to receive cisplatin-based combination therapy, based on at least one of the following criteria:

<div style=\"page-break-after: always\"></div>

- o ECOG  Performance  Status  of  2  (the  proportion  of  these  subjects  will  be  limited  to approximately 50% of the total population
- o Creatinine clearance (calculated or measured) &lt;60 mL/min but ≥30 mL/min Note: Subjects with a creatinine clearance (calculated or measured) &lt;30 mL/min or on dialysis are excluded from the trial
- o CTCAE v.4, Grade ≥2 audiometric hearing loss (25dB in two consecutive wave ranges)
- o CTCAE v.4, Grade ≥2 peripheral neuropathy
- o New York Heart Association (NYHA) Class III heart failure

Note: In the event that subjects are enrolled for the purposes of determining the biomarker cut-point prior to the start of the main body of this study, these subjects are not required to be cisplatin-ineligible and the above criteria does not apply.

- No  prior  systemic  chemotherapy  for  advanced/unresectable  (inoperable)  or  metastatic  urothelial cancer.
- o Adjuvant platinum based chemotherapy, following radial cystectomy, with recurrence &gt;12 months from completion of therapy is permitted
- o Neoadjuvant platinum based chemotherapy, with recurrence &gt;12 months since completion of therapy is permitted

Note: Low-dose chemotherapy (eg, low dose cisplatin, cisplatin+5FU, mytomycin+5FU, or cisplatin+paclitaxel) given concurrent with radiation to the primary tumor site is not considered as systemic therapy.

- Provided tissue for biomarker analysis from a newly obtained core or excisional biopsy of a tumor lesion not previously irradiated (mandatory). Adequacy of the biopsy specimen for PD-L1 biomarker analysis must be confirmed by the central laboratory.
- Measureable disease based on RECIST 1.1 as assessed by central review. Tumor lesions situated in a previously irradiated area were considered measureable if progression had been demonstrated in such lesions.
- ECOG Performance Status of 0, 1, or 2, as assessed within 10 days prior to treatment initiation.

## Main exclusion criteria

- Disease suitable for local therapy administered with curative intent.
- Current or previous participation in a study of an investigational agent, with study therapy received or investigation device used within 4 weeks of the first dose of treatment.
- Prior  anticancer  monoclonal antibody for direct anti-neoplastic treatment within 4 weeks prior to study Day 1 or not recovered (ie, ≤ Grade 1 or at baseline) from AEs due to agents administered more than 4 weeks earlier.
- Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to

<div style=\"page-break-after: always\"></div>

study Day 1 or who had not recovered (ie, ≤ Grade 1 or at baseline) from AEs due to a previously administered agent.

Notes:  Subjects  with  neuropathy  or ≤ Grade  2  alopecia  were  an  exception  to  this  criterion  and  may qualify for the study.  If a subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.

- Known additional malignancy progressing or requiring active treatment. Exceptions included basal cell  carcinoma  of  the  skin,  squamous  cell  carcinoma  of  the  skin  that  had  undergone  potentially curative  therapy,  or  in  situ  cervical  cancer.  A  history  of  prostate  cancer  identified  incidentally following cysto-prostatectomy for bladder cancer was acceptable, provided that Stage was T2N0M0 or lower, Gleason score ≤ 6, and prostate-specific antigen undetectable.
- Known active central nervous system metastases and/or carcinomatous meningitis. Subjects with previously-treated brain metastases may participate provided they were stable (without evidence of progression by imaging, confirmed by CT scan or MRI if used as prior imaging, for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and were not using steroids for at least 7 days prior to trial treatment. This exception did not include carcinomatous meningitis, which was excluded regardless of clinical stability.
- Active  autoimmune  disease  requiring  systemic  treatment  in  the  past  2  years  (i.e.  with  use  of disease  modifying  agents,  corticosteroids  or  immunosuppressive  drugs).  Replacement  therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considere d a form of systemic treatment.
- History  or  current  evidence  of  any  condition,  therapy,  or  laboratory  abnormality  that  could confound the results of the trial, interfere with the subject ' s participation for the full duration of the  trial,  or  not  in  the  best  interest  of  the  subject  to  participate,  in  the  opinion  of  the  treating Investigator.
- Prior therapy with an anti-PD-1, anti-PD-L1 agent, or with anagent directed to another co-inhibitory T-cell receptor (eg, CTLA-4,OX-40, CD137).
- Known history of Human Immunodeficiency Virus (HIV) (HIV-1/2 antibodies).
- Administration of live vaccine within 30 days prior to the first administration of study medication.

## Treatments

Pembrolizumab was administered at the fixed dosing regimen of 200 mg as a 30 minute (-5 min/+10 min) IV infusion Q3W.

Treatment could be continued until confirmed radiographic disease progression by RECIST 1.1, unacceptable adverse experiences, intercurrent illness that prevented further administration of treatment, Investigator's decision to withdraw the subject, confirmed positive pregnancy test, non-compliance with trial treatment or procedure requirements, completed 24 months of pembrolizumab treatment or administrative reasons.

Despite RECIST 1.1 defined progression, pembrolizumab could have been continued while awaiting radiologic confirmation of PD. If repeat imaging still meets the threshold for PD ( ≥ 20% increase in tumor

<div style=\"page-break-after: always\"></div>

burden compared to nadir) but shows a reduction in tumor burden compared to the previous time point, treatment may be continued as per treatment calendar after consultation with Sponsor. pembrolizumab and at least 2 treatments beyond the date of initial CR declared, may have been eligible

Patients who stopped pembrolizumab after receiving 24 months of treatment for reasons other than disease progression or intolerability, or after a complete response having received at least 24 weeks of for up to one additional year of retreatment upon experiencing disease progression.

## Objectives

The study primary objective was to evaluate the anti-tumor activity of pembrolizumab in terms of Objective Response Rate (ORR) per RECIST 1.1 by independent radiology review in all subjects with advanced/unresectable or metastatic urothelial carcinoma who are ineligible to receive cisplatin-based therapy, as well as in those with PD-L1 positive (CPS≥1%) and PD-L1 strongly positive (CPS cut point determined from biomarker discovery population) tumors.

As secondary objectives, the pembrolizumab activity was evaluated in terms of duration of response (DOR) per RECIST 1.1 by independent radiology review, PFS  per RECIST 1.1 by independent radiology review (including PFS rate at 6 and 12 months), and OS (including OS rate at 6 and 12 months). In addition, the anti-tumor activity in terms of ORR, DOR and PFS based on modified RECIST 1.1 by independent radiology review, the relationship between candidate efficacy/resistance biomarkers and pembrolizumab anti-tumor activity based on pre- and post-treatment tumor biopsies and blood sampling, the PK profile of pembrolizumab 200 mg Q3W, the changes in health-related quality-of-life assessments from baseline using the EORTC QLQ-C30, and the characterization of utilities using the EQ-5D  were evaluated as exploratory objectives in PD-L1 strongly positive, PD-L1 positive, and all subjects.

## Outcomes/endpoints

The primary efficacy endpoint was objective response rate (ORR) based on RECIST 1.1 criteria assessed by independent radiology review of imaging studies performed at both planned and unplanned time points during the study. ORR was estimated for all subjects, for subjects with PD-L1 expression (CPS) ≥ 1%, and for subjects with strongly positive CPS expression (CPS) ≥ 10%, that was determined as a secondary study objective of the trial, based on assessment of activity in the biomarker discovery cohort (the first 100 subjects enrolled). All other efficacy analyses involving subsets of the population defined in terms of the strongly positive CPS cutpoint were conducted among the PD-L1 ≥10% from the validation cohort, with the exclusion of patients in the discovery cohort.

Additional secondary efficacy endpoints were DOR (RECIST 1.1 by independent radiology review); PFS (RECIST 1.1 by independent radiology review); overall survival (OS); PFS (RECIST 1.1 by independent radiology review) rate and OS rate at 6 months and 12 months.

Additional exploratory endpoints were to investigate the relationship between biomarkers and anti-tumor activity, to evaluate the pembrolizumab anti-tumor activity by ORR, DOR and PFS based on modified RECIST 1.1 by independent radiology review, and to evaluate changes in health-related quality-of-life assessments from baseline using the EORTC QLQ-C30.

The definition of primary and secondary endpoints is reported in the below Table ' Summary of Efficacy for trial KEYNOTE-052 '.

<div style=\"page-break-after: always\"></div>

Response to treatment was assessed with radiographic imaging at 9 weeks (63 ± 7 days) after the first dose of pembrolizumab and every 6 weeks thereafter (42 days ± 7 days). Subjects who remained on treatment beyond 1 year had imaging assessments performed every 12 weeks (84 ± 7 days). All on-trial imaging was submitted to the central vendor for BICR review per RECIST 1.1 for determination of ORR and PFS. The Investigator may have chosen to treat beyond RECIST 1.1 defined progression if subjects continued deriving clinical benefit and were clinically stable.

The APT population, including all enrolled subjects who received at least 1 dose of pembrolizumab, pembrolizumab and had measureable disease at baseline. In this case, the APT and FAS  populations overlapped,  and therefore supportive analyses were not performed.

served as the primary population for the efficacy analyses. Supportive analyses were to be conducted in the Full Analysis Set (FAS) population, consisting of all enrolled subjects who received at least 1 dose of Additional not protocol-specified analyses were conducted to further characterize pembrolizumab efficacy and safety profile in the target population. In order to determine the influence on the primary endpoint estimation of the duration of follow up and of radiology reader variability ORR was determined among subjects with longer follow-up than the total APT population and by investigator per RECIST v1.1. Although the primary analysis for CPS ≥ 10% was conducted on the validation cohort, a supportive analysis combining the biomarker discovery and validation cohorts was performed in order to assess the ORR in strongly positive across the entire study population.

## Sample size

The sample size calculation was driven by the primary efficacy estimation for PD -L1 CPS ≥ 10% subjects. Up to 350 subjects were to be enrolled. Assuming a 33% prevalence rate of PD-L1 CPS ≥ 10% subjects and 100 subjects in the biomarker discovery population, there was an 88% chance to have at least 75 PD-L1 CPS ≥ 10% subjects and 99.9% chance to have at least 60 PD-L1 CPS ≥ 10% subjects in the validation cohort (N ≈ 250).

## Randomisation

Treatment allocation was performed centrally using an interactive voice response system/integrated web response system (IVRS/IWRS) by non-random assignment.

## Blinding (masking)

Not applicable. This is an open label trial.

## Statistical methods

A preliminary assessment of clinical activity within the discovery cohort to determine the strongly positive cut-off as a function of ORR was performed in the first 100 subjects.  The APT population, consisting of all enrolled subjects who received at least one dose of study treatment, served as the primary population for the analyses of efficacy data in this trial. The biomarker discovery population, subjects in this trial used for the determination of the PD-L1 strongly positive cut-point, was to be excluded from efficacy analyses for the PD-L1 strongly positive population. These subjects were still to be included in the efficacy analyses for all and PD-L1 positive subjects. Efficacy analyses were conducted according to the methods reported in the table below.

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Endpoint/Variable+ (Description, Time Point)                                                                                                          | Statistical Method                                                                              | Analysis Population                                                                             | Missing Data Approach                                                                           |
|-------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| Primary Objectives:                                                                                                                                   |                                                                                                 |                                                                                                 |                                                                                                 |
| RECIST1.1 ORR by independent radiology review for PD-L1 strongly positive subjects, PD-L1 positive subjects, and all subjects                         | Exactmethod based on binomial distribution                                                      | APT/FAS                                                                                         | Subjects with missing data are considered non-responders                                        |
| Secondary Objectives:                                                                                                                                 |                                                                                                 |                                                                                                 |                                                                                                 |
| Duration of Response,RECIST1.1 byindependentradiologyreview, for PD-L1 strongly positive subjects, PD-L1 positive subjects, and all subjects          | Summary statistics /Kaplan-Meier method                                                         | APT/FAS                                                                                         | Non-responders are excludedin analysis                                                          |
| Progression-free survival, RECIST1.1 by independent radiology review, for PD-L1 strongly positive subjects, PD-L1 positive subjects, and all subjects | Summary statistics /Kaplan-Meier method                                                         | APT/FAS                                                                                         | Censored at last assessiment                                                                    |
| Overall survival, for PD-L1 strongly positive subjects, PD-L1 positive subjects, and all subjects                                                     | Summarystatistics /Kaplan-Meier method                                                          | APT/FAS                                                                                         | Censored at last assessment                                                                     |
| 95% confidence interval is determined by the upper and lower 97.5% one-sided confidence bounds.                                                       | 95% confidence interval is determined by the upper and lower 97.5% one-sided confidence bounds. | 95% confidence interval is determined by the upper and lower 97.5% one-sided confidence bounds. | 95% confidence interval is determined by the upper and lower 97.5% one-sided confidence bounds. |

An interim efficacy evaluation was performed in which enrollment of PD-L1 negative (CPS &lt;1%) subjects could have been stopped if the ORR was low and substantial enrollment remained. This futility analysis was based on the evaluable PD-L1 negative subjects in the biomarker discovery population (up to the first 25 subjects). If the number of PD-L1 negative subjects in the biomarker subgroup was less than 20, additional PD-L1 negative subjects could be included until the number reached at least 20. The nonbinding rule for futility required that the upper limit of the 95% confidence interval (CI) (2-sided) for the ORR be less than 20% (needed at least 1 response in N &lt; 26 subjects and at least 2 responses in N = 26 to 40 subjects).

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

APT: All Patients Treated; APaT: All Palients as Treated; PRO FAS: Patient Reported Outcomes Full Analysis Set.

<!-- image -->

## Recruitment

Overall, 370 patients were enrolled and treated in 77 activated centers from 20 April 2015 to 21 June 2016. The highest enrolling country was the US with a total of 159 subjects.

## Conduct of the study

The original protocol (dated 29 August 2014) was amended twice during the study conduction. The key changes introduced by the protocol amendments are summarized below:

| Protocol Amendment   | Most relevant changes                                                                                                                                                                                                                                         |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| #01 (8 October 2014) | Clarification that subjects must be refractory to available or standard therapy for treatment of their bladder cancer in order to participate in the biomarker cut-point determination part of the Study, if they do not meet cisplatin- ineligible criteria. |

<div style=\"page-break-after: always\"></div>

|                    | Safety and tolerability were to be evaluated in all subjects regardless of PD-L1 status. The screening window for the new core or excisional biopsy for biomarker analysis was increased to 56 days (8 weeks).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| #2 (11 March 2016) | Addition to indicate that PD-L1 positive was prospectively defined as subjects with Combined Positive Score (CPS) ≥ 1%. Removal of hypotheses testing since the objective of the trial was to estimate efficacy, and the success of the trial was determined by clinically meaningful ORRs and durability of the response. The number of subjects to be used for the biomarker cut-point analysis was updated from ~150 subjects to ~100 subjects. Clarification that bone scans must have been submitted for review at baseline to the central imaging vendor even though bone scans were not part of determining RECIST measurability. The 56 day screening window requirement for the new core or excisional biopsy was removed from the protocol to offer more operational flexibility, as long as the subject has not received any intervening systemic therapy from the time the tissue was collected until the time the subject enters the study. The All-Patients-Treated (APT) population was identified as the primary efficacy and safety analysis population, based on FDA requirement for single arm trials. |

There were 9 major protocol deviations deemed clinically relevant from 6 different sites, 3 in Spain, 1 in the US, and 2 in Italy. Two clinically relevant major protocol deviations were categorized as entry criteria deviations and pertained to allocation/treatment despite creatinine and bilirubin being above allowable limits. A third subject was allocated/treated despite having a history of Gleason 8 prostate cancer. Two major protocol deviations occurred when 2 subjects each were treated with corticosteroids for non-ECI AEs during the trial which was prohibited except to treat pre-defined immune-related AEs. For 4 subjects, clinically relevant major protocol deviations occurred in relation to bone scan efficacy assessments, as they did not have follow-up scans despite the presence of osseous metastatic disease at study entry. No subjects were excluded from the analysis due to a protocol deviation.

For 2 additional subjects, the blinded central independent radiology vendor notified sites that the subjects had RECIST-measurable disease. However, when the imaging data for these subjects was formally analyzed for outcome, no target lesions were identified. Being treated, subjects were included in the analysis in the denominator of the ORR calculations as per the protocol statistical analysis plan, but they were not counted as complete or partial responders.

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 26: Subjects Characteristics

## All Subjects (ITT Population)- KEYNOTE-052

|                                   | Pembrolizmab   | Pembrolizmab   |
|-----------------------------------|----------------|----------------|
| Subjects in population            | n 370          | (6)            |
| Male                              | 286            | (77.3)         |
| Female                            | 84             | (22.7)         |
| Age (Years)                       |                |                |
| < 65 Years                        | 68             | (18.4)         |
| 2= 65 Years                       | 302            | (81.6)         |
| Mean                              | 73.0           |                |
| SD                                | 9.9            |                |
| Median                            | 74.0           |                |
| Range                             | 34 to 94       |                |
| Race                              |                |                |
| American Indian Or Alaska Native  | 2              | (0.5)          |
| Asian                             | 26             | (7.0)          |
| Black Or Afican American          | 8              | (2.2)          |
| Multiple                          | 2              | (0.5)          |
| White                             | 328            | (88.6)         |
| Missing                           | 4              | (1.1)          |
| Ethnicity                         |                |                |
| Hispanic Or Latino                | 22             | (5.9)          |
| Not Hispanic Or Latino            | 319            | (86.2)         |
| Not Reported                      | 21             | (5.7)          |
| Unknown                           | 8              | (2.2)          |
| Age Group ?                       |                |                |
| 65 Years                          | 89             | (+8D)          |
| 2= 65 to c 75 Years               | 123            | (33.2)         |
| >= 75 to < 85 Years               | 139            | (37.6)         |
| = 85 Years                        | 40             | (10.8)         |
| PD-L1 Status                      |                |                |
| PD-L1 CPS < 1%                    | 79             | (21.4)         |
| PD-L1 CPS ≥= 1% to ≤10%           | 172            | (46.5)         |
| PD-L1 CPS >=10%                   | 110            | (29.7)         |
| Unknown                           | 9              | (2.4)          |
| ECOG'                             |                |                |
| [0] Normal Activity               | 80             | (21.6)         |
| [1] Symptoms, but ambulatory      | 133            | (35.9)         |
| [2] Ambulatory but umable to work | 156            | (42.2)         |
| [3] Limited selfcare              | 1              | (0.3)          |

<div style=\"page-break-after: always\"></div>

|                                                           | Pembrolizimab ()   | Pembrolizimab ()   |
|-----------------------------------------------------------|--------------------|--------------------|
| Metastatic Staging                                        |                    |                    |
| MO                                                        | 47                 | (12.7)             |
| M1                                                        | 323                | (87.3)             |
| Chemotherapy Naive (Y/N)                                  |                    |                    |
| No                                                        | 67                 | (18.1)             |
|                                                           | 303                | (81.9)             |
| Baseline Hemoglobin                                       |                    |                    |
| >=10g/dL                                                  | 329                | (88.9)             |
| c10 giL                                                   | 41                 | (11.1)             |
| Liver Metastasis (Y/N)                                    |                    |                    |
| No                                                        | 292                | (78.9)             |
| 1                                                         | 78                 | (21.1)             |
| Prior Adjuvant or Neoadjuvant Platinum-based Chemotherapy |                    |                    |
| No                                                        | 334                | (90.3)             |
| 91                                                        | 36                 | (9.7)              |
| Prior BCG Therapy                                         |                    |                    |
| No                                                        | 316                | (85.4)             |
| 5a1.                                                      | 54                 | (14.6)             |
| Metastases Location                                       |                    |                    |
| Lymph Node Only                                           | 51                 | (13.8)             |
| Viscenl Disease                                           | 315                | (85.1)             |
| Not Reported                                              | 4                  | (1.1)              |
| Primary Tumor Location                                    |                    |                    |
| Upper Tract                                               | 69                 | (18.6)             |
| Lower Trnact                                              | 300                | (81.1)             |
| Unknown                                                   | 1                  | (0.3)              |
| Reason for Cisplatin Ineligibility                        |                    |                    |
| ECOG2                                                     | 120                | (32.4)             |
| Renal Dysfunction                                         | 182                | (49.2)             |
| ECOG 2 and Remal Dysfimciion                              | 35                 | (9.5)              |

Other Reasonst

ECOG performance sthatus assessed during screening.

Missing: not reported or unkmowm

33

Inchuding Class I Heart Failure, Grade ≥ 2 Pernipheral Neuropathy. and Grade ≥ 2 Hearing Loss.

Renal dysfiunction is defined as a baseline creatinine clearance &lt; 60 mL/min.

M stage Database Cutoff Date: 14FEB2017

Databave Cutoff Date: 01SEP2016

Source: [P052V01MK3475: amalysis-ads1]

## Numbers analysed

The same patient population, consisting of the 370 subjects who were enrolled and treated in the trial, served as the primary population for the efficacy analyses (APT: All-Patients-Treated population) and was used for the analysis of safety data (APaT: All Patients as Treated population).

A biomarker discovery population cohort including the first 100 subjects enrolled and treated served for determination of the PD-L1 strongly positive cut-point.

Analyses of the pre-specified patient reported outcomes (PRO) from the EORTC QLC-C30 and EQ-5D questionnaires were conducted in the PRO-specific full analysis set (FAS) population, including 367 patients who received at least 1 dose of study medication and completed at least 1 PRO instrument.

## Outcomes and estimation

The activity reported in the biomarker discovery cohort, including the first 100 subjects enrolled and treated, served for determination of the PD-L1 strongly positive cut-point.

The biomarker discovery cohort was excluded from the primary efficacy analyses for subjects in the

(8.9)

<div style=\"page-break-after: always\"></div>

validation cohort whose tumors were PD-L1 strongly positive.

In the initial submission (cut-off data:01-Sep-2016), the median duration of follow-up for all subjects in the APT population was 5 months (range 0.1-16.5 months). An updated analysis (Cut-off data: 09Mar2017) was conducted at a median follow-up of 9.5 months (0.1-22.7). For the tables below, first the 01-Sep-2016 cut-off is presented, followed by a presentation of the same data with the 09-Mar-2017 cut-off.

## Primary endpoint

## Objective Response Rate

- All Subjects (APT Population)

Table 27: Summary of Best Overall Response with Confirmation Based on RECIST 1.1 per

## Central Radiology Assessment

All Subjects (APT Population)

(Cut-off date: 01-Sep-2016)

| Response Evaluation        | Pembrolizumab (N=370)   | Pembrolizumab (N=370)   | Pembrolizumab (N=370)   |
|----------------------------|-------------------------|-------------------------|-------------------------|
|                            | n                       | %                       | 95% CIt                 |
| Complete Response (CR)     | 17                      | 4.6                     | (2.7, 7.3)              |
| Partial Response (PR)      | 72                      | 19.5                    | (15.5, 23.9)            |
| Objectire Response (CR+PR) | 89                      | 24.1                    | (19.8, 28.7)            |
| Stable Disease (SD)        | 84                      | 22.7                    | (18.5, 27.3)            |
| Disease Control (CR+PR+SD) | 173                     | 46.8                    | (41.6, 52.0)            |
| Progressive Disease (PD)   | 156                     | 42.2                    | (37.1, 47.4)            |
| Non-evaluable (NE)         | 10                      | 2.7                     | (1.3,4.9)               |
| No Assessment              | 31                      | 8.4                     | (5.8, 11.7)             |

Confirmed responses are included.

Based on binomial exact confidence interval method.

Non-evaluable: subject had post-baseline imaging and the BOR was determined to be NE per RECIST

1.1.

No Assessment: subject had no post-baseline imaging

Database Cutoff Date:0lSEP2016

Source: [P052V01MK3475: analysis-adsl; adopa]

<div style=\"page-break-after: always\"></div>

Table 28: Summary of Best Overall Response with Confirmation Based on RECIST 1.1 per Central Radiology Assessment

All Subjects (APT Population)

(Cut-off date: 09-Mar-2017)

| Response Evaluation        | Pembrolizumab (N=370)   | Pembrolizumab (N=370)   | Pembrolizumab (N=370)   |
|----------------------------|-------------------------|-------------------------|-------------------------|
|                            | n                       | %                       | 95%CIt                  |
| Complete Response (CR)     | 27                      | 7.3                     | (4.9, 10.4)             |
| Partial Response (PR)      | 81                      | 21.9                    | (17.8, 26.5)            |
| Objective Response (CR+PR) | 108                     | 29.2                    | (24.6, 34.1)            |
| Stable Disease (SD)        | 67                      | 18.1                    | (14.3, 22.4)            |
| Disease Control (CR+PR+SD) | 175                     | 47.3                    | (42.1, 52.5)            |
| Progressive Disease (PD)   | 155                     | 41.9                    | (36.8, 47.1)            |
| Non-evaluable (NE)         | 9                       | 2.4                     | (1.1, 4.6)              |
| No Assessment              | 31                      | 8.4                     | (5.8, 11.7)             |

Confirmed responses are included.

↑Based onbinomialexact confidence interval method.

Non-evaluable: subject had post-baseline imaging and the BOR was determined to be NE per RECIST 1.1.

No Assessment: subject had no post-baseline imaging

DatabaseCutoffDate:09MAR2017

Source: [P052V01MK3475: analysis-adsl; adopa]

## · Subjects with PD-L1 CPS≥1%

Table 29: Summary of Best Overall Response with Confirmation Based on RECIST 1.1 per Central Radiology Assessment Subjects with PD-L1 CPS≥1% (APT Population)

Cut-off date: 01-Sep-2016

| ResponseEvaluation                                                                                                                                                                                                              | Pembrolizumab (N=282)                                                                                                                                                                                                           | Pembrolizumab (N=282)                                                                                                                                                                                                           | Pembrolizumab (N=282)                                                                                                                                                                                                           |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                 | n                                                                                                                                                                                                                               | %                                                                                                                                                                                                                               | 95%CI                                                                                                                                                                                                                           |
| Complete Response (CR)                                                                                                                                                                                                          | 14                                                                                                                                                                                                                              | 5.0                                                                                                                                                                                                                             | (2.7,8.2)                                                                                                                                                                                                                       |
| Partial Response (PR)                                                                                                                                                                                                           | 61                                                                                                                                                                                                                              | 21.6                                                                                                                                                                                                                            | (17.0, 26.9)                                                                                                                                                                                                                    |
| ObjectiveResponse(CR+PR)                                                                                                                                                                                                        | 75                                                                                                                                                                                                                              | 26.6                                                                                                                                                                                                                            | (21.5,32.2)                                                                                                                                                                                                                     |
| Stable Disease (SD)                                                                                                                                                                                                             | 72                                                                                                                                                                                                                              | 25.5                                                                                                                                                                                                                            | (20.5,31.0)                                                                                                                                                                                                                     |
| DiseaseControl(CR+PR+SD)                                                                                                                                                                                                        | 147                                                                                                                                                                                                                             | 52.1                                                                                                                                                                                                                            | (46.1,58.1)                                                                                                                                                                                                                     |
| Progressive Disease (PD)                                                                                                                                                                                                        | 109                                                                                                                                                                                                                             | 38.7                                                                                                                                                                                                                            | (32.9,44.6)                                                                                                                                                                                                                     |
| Non-evaluable (NE)                                                                                                                                                                                                              | 6                                                                                                                                                                                                                               | 2.1                                                                                                                                                                                                                             | (0.8, 4.6)                                                                                                                                                                                                                      |
| NoAssessment                                                                                                                                                                                                                    | 20                                                                                                                                                                                                                              | 7.1                                                                                                                                                                                                                             | (4.4, 10.7)                                                                                                                                                                                                                     |
| Confirmedresponses are included. tBasedonbinomialexactconfidenceintervalmethod. Non-evaluable:subject had post-baseline imaging and theBORwas determined tobeNEper RECIST 1.1. NoAssessment:subject had nopost-baseline imaging | Confirmedresponses are included. tBasedonbinomialexactconfidenceintervalmethod. Non-evaluable:subject had post-baseline imaging and theBORwas determined tobeNEper RECIST 1.1. NoAssessment:subject had nopost-baseline imaging | Confirmedresponses are included. tBasedonbinomialexactconfidenceintervalmethod. Non-evaluable:subject had post-baseline imaging and theBORwas determined tobeNEper RECIST 1.1. NoAssessment:subject had nopost-baseline imaging | Confirmedresponses are included. tBasedonbinomialexactconfidenceintervalmethod. Non-evaluable:subject had post-baseline imaging and theBORwas determined tobeNEper RECIST 1.1. NoAssessment:subject had nopost-baseline imaging |

Source:[P052V01MK3475:analysis-adsl;adopa]

<div style=\"page-break-after: always\"></div>

Table 30: Summary of Best Overall Response with Confirmation Based on RECIST 1.1 per Central Radiology Assessment Subjects with PD-L1 CPS≥1% (APT Population)

Cut-off date: 09-Mar-2017

| Response Evaluation                          | Pembrolizumab (N=282)   | Pembrolizumab (N=282)   | Pembrolizumab (N=282)    |
|----------------------------------------------|-------------------------|-------------------------|--------------------------|
|                                              |                         | %                       | 95% CI                   |
| Complete Response (CR) Partial Response (PR) | 24 68                   | 8.5 24.1                | (5.5, 12.4) (19.2, 29.5) |
| ObjectiveResponse(CR+PR)                     | 92                      | 32.6                    | (27.2,38.4)              |
| Stable Disease (SD)                          | 57                      | 20.2                    | (15.7, 25.4)             |
| DiseaseControl(CR+PR+SD)                     | 149                     | 52.8                    | (46.8,58.8)              |
| Progtessive Disease (PD)                     | 108                     | 38.3                    | (32.6, 44.2)             |
| Non-evaluable (NE)                           | 5                       | 1.8                     | (0.6, 4.1)               |
| No Assessment                                | 20                      | 7.1                     | (4.4, 10.7)              |

Source:[P052V01MK3475:analysis-adsl; adopa]

## · Subjects with PD-L1 CPS≥10%

The PD-L1 CPS strongly positive cut point for efficacy was determined among subjects in the discovery cohort to be CPS ≥10% through a systematic assessment that included analysis of the positive and negative predictive values and receiver operating characteristics (ROC) across a wide range of potential CPS cut points. Table 31, depicts the results for the Biomarker Discovery population and Table 32 depicts the results for the Biomarker validation population. Tables 33 and 34 present the summary of best overall response for the total population with PD-L1 CPS≥10%, first according to the 01-Sep-2016 cut-off, followed by the data from the 08-Mar-2017 cut-off. Tables 35 and 36 represent the data for the &lt;1% CPS and &lt;10% CPS populations, respectively, for the most recent data cut-off point.

Table 31: Summary of Best Overall Response with Confirmation Based on RECIST 1.1 per Central Radiology Assessment Subjects with PD-L1 CPS≥10% (APT Population) Biomarker Discovery Population

Cut-off date: 01-Sep-2016

| Response Evaluation                                                                                                                                                                   | Pembrolizumab (N=30)                                                                                                                                                                  | Pembrolizumab (N=30)                                                                                                                                                                  | Pembrolizumab (N=30)                                                                                                                                                                  |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                       | n                                                                                                                                                                                     | %                                                                                                                                                                                     | 95% CIt                                                                                                                                                                               |
| Complete Response (CR)                                                                                                                                                                | 5                                                                                                                                                                                     | 16.7                                                                                                                                                                                  | (5.6, 34.7)                                                                                                                                                                           |
| Partial Response (PR)                                                                                                                                                                 | 6                                                                                                                                                                                     | 20.0                                                                                                                                                                                  | (7.7, 38.6)                                                                                                                                                                           |
| Objective Response (CR+PR)                                                                                                                                                            | 11                                                                                                                                                                                    | 36.7                                                                                                                                                                                  | (19.9, 56.1)                                                                                                                                                                          |
| Stable Disease (SD)                                                                                                                                                                   | 7                                                                                                                                                                                     | 23.3                                                                                                                                                                                  | (9.9, 42.3)                                                                                                                                                                           |
| Disease Control (CR+PR+SD)                                                                                                                                                            | 18                                                                                                                                                                                    | 60.0                                                                                                                                                                                  | (40.6, 77.3)                                                                                                                                                                          |
| Progressive Disease (PD)                                                                                                                                                              | 11                                                                                                                                                                                    | 36.7                                                                                                                                                                                  | (19.9, 56.1)                                                                                                                                                                          |
| Non-evaluable (NE)                                                                                                                                                                    | 0                                                                                                                                                                                     | 0.0                                                                                                                                                                                   | (0.0, 11.6)                                                                                                                                                                           |
| No Assessment                                                                                                                                                                         | 1                                                                                                                                                                                     | 3.3                                                                                                                                                                                   | (0.1, 17.2)                                                                                                                                                                           |
| Confiumed responses are included. Based on binomial exact confidence interval method. Non-evaluable: subject had post-baseline imaging and the BOR was determined to be NE per RECIST | Confiumed responses are included. Based on binomial exact confidence interval method. Non-evaluable: subject had post-baseline imaging and the BOR was determined to be NE per RECIST | Confiumed responses are included. Based on binomial exact confidence interval method. Non-evaluable: subject had post-baseline imaging and the BOR was determined to be NE per RECIST | Confiumed responses are included. Based on binomial exact confidence interval method. Non-evaluable: subject had post-baseline imaging and the BOR was determined to be NE per RECIST |

Source:[P052V01MK3475: analysis-adsl; adopa]

<div style=\"page-break-after: always\"></div>

Table 32: Summary of Best Overall Response with Confirmation Based on RECIST 1.1 per Central Radiology Assessment Subjects with PD-L1 CPS≥10% (APT Population) Efficacy Validation Population

Cut-off date: 01-Sep-2016

| Response Evaluation        | Pembrolizumab (N=80)   | Pembrolizumab (N=80)   | Pembrolizumab (N=80)   |
|----------------------------|------------------------|------------------------|------------------------|
|                            | n                      | %                      | 95% CI                 |
| Complete Response (CR)     | 8                      | 10.0                   | (4.4, 18.8)            |
| Partial Response (PR)      | 23                     | 28.8                   | (19.2,40.0)            |
| Objective Response (CR+PR) | 31                     | 38.8                   | (28.1, 50.3)           |
| Stable Disease (SD)        | 24                     | 30.0                   | (20.3, 41.3)           |
| Disease Control (CR+PR+SD) | 55                     | 68.8                   | (57.4, 78.7)           |
| Progressive Disease (PD)   | 20                     | 25.0                   | (16.0, 35.9)           |
| Non-evaluable (NE)         | 0                      | 0.0                    | (0.0,4.5)              |
| No Assessment              | 5                      | 6.3                    | (2.1, 14.0)            |

Confimed responses are included.

Based on binomial exact confidence interval method.

Non-evaluable: subject had post-baseline imaging and the BOR was determined to be NE per RECIST 1.1.

No Assessment: subject had no post-baseline imaging Database CutoffDate:01SEP2016

Source: [P052V01MK3475: analysis-adsl; adopa]

Table 33: Summary of Best Overall Response with Confirmation Based on RECIST 1.1 per Central Radiology Assessment

## Subjects with PD-L1 CPS ≥ 10% (APT Population)

Cut-off date: 01-Sep-2016

| Response Evaluation        | Pembrolizumab (N=110)   | Pembrolizumab (N=110)   | Pembrolizumab (N=110)   |
|----------------------------|-------------------------|-------------------------|-------------------------|
|                            | n                       | %                       | 95% CIt                 |
| Complete Response (CR)     | 13                      | 11.8                    | (6.4, 19.4)             |
| Partial Response (PR)      | 29                      | 26.4                    | (18.4, 35.6)            |
| Objective Response (CR+PR) | 42                      | 38.2                    | (29.1, 47.9)            |
| Stable Disease (SD)        | 31                      | 28.2                    | (20.0, 37.6)            |
| Disease Control (CR+PR+SD) | 73                      | 66.4                    | (56.7, 76.1)            |
| Progressive Disease (PD)   | 31                      | 28.2                    | (20.0,37.6)             |
| Non-evaluable (NE)         | 0                       | 0.0                     | (0.0, 3.3)              |
| No Assessment              | 6                       | 5.5                     | (2.0, 11.5)             |

Confinmed responses are included

Based on binomial exact confidence interval method.

Non-evaluable: subject had post-baseline imaging and the BOR was determined to be NE per RECIST 1.1.

No Assessment: subject had no post-baseline imaging

Database Cutoff Date:01SEP2016

Sowrce:[P052V01MK3475: analysis-adsl; adopa]

<div style=\"page-break-after: always\"></div>

Table 34: Summary of Best Overall Response with Confirmation Based on RECIST 1.1 per Central Radiology Assessment Subjects with PD-L1 CPS≥10% (APT Population)

Cut-off date: 09-Mar-2017

<!-- image -->

| Response Evaluation                                                                                                                                                                                                                      | Pembrolizumab (N=110)                                                                                                                                                                                                                    | Pembrolizumab (N=110)                                                                                                                                                                                                                    | Pembrolizumab (N=110)                                                                                                                                                                                                                    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                          | %                                                                                                                                                                                                                                        | 95%CI                                                                                                                                                                                                                                    |
| Complete Response (CR) Partial Response (PR)                                                                                                                                                                                             | 18                                                                                                                                                                                                                                       | 16.4 30.9                                                                                                                                                                                                                                | (10.0, 24.6) (22.4, 40.4)                                                                                                                                                                                                                |
| ObjectiveResponse(CR+PR)                                                                                                                                                                                                                 | 52                                                                                                                                                                                                                                       | 47.3                                                                                                                                                                                                                                     | (37.7,57.0)                                                                                                                                                                                                                              |
| Stable Disease (SD)                                                                                                                                                                                                                      | 22                                                                                                                                                                                                                                       | 20.0                                                                                                                                                                                                                                     | (13.0, 28.7)                                                                                                                                                                                                                             |
| Disease Control(CR+PR+SD)                                                                                                                                                                                                                | 74                                                                                                                                                                                                                                       | 67.3                                                                                                                                                                                                                                     | (57.7, 75.9)                                                                                                                                                                                                                             |
| Progtessive Disease (PD)                                                                                                                                                                                                                 | 30                                                                                                                                                                                                                                       | 27.3                                                                                                                                                                                                                                     | (19.2, 36.6)                                                                                                                                                                                                                             |
| Non-evaluable (NE)                                                                                                                                                                                                                       | 0                                                                                                                                                                                                                                        | 0.0                                                                                                                                                                                                                                      | (0.0, 3.3)                                                                                                                                                                                                                               |
| No Assessment                                                                                                                                                                                                                            | 6                                                                                                                                                                                                                                        | 5.5                                                                                                                                                                                                                                      | (2.0, 11.5)                                                                                                                                                                                                                              |
| Confinmed responses are included. Based onbinomialexactconfidence interval method. Non-evaluable: subject had post-baseline imaging and the BOR was detemmined to be NE per RECIST 1.1. NoAssessment:subject had nopost-baseline imaging | Confinmed responses are included. Based onbinomialexactconfidence interval method. Non-evaluable: subject had post-baseline imaging and the BOR was detemmined to be NE per RECIST 1.1. NoAssessment:subject had nopost-baseline imaging | Confinmed responses are included. Based onbinomialexactconfidence interval method. Non-evaluable: subject had post-baseline imaging and the BOR was detemmined to be NE per RECIST 1.1. NoAssessment:subject had nopost-baseline imaging | Confinmed responses are included. Based onbinomialexactconfidence interval method. Non-evaluable: subject had post-baseline imaging and the BOR was detemmined to be NE per RECIST 1.1. NoAssessment:subject had nopost-baseline imaging |

Source:[P052V01MK3475:analysis-adsl;adopa]

## · Subjects with PD-L1 CPS&lt;1% and subjects with PD-L1 CPS&lt;10%

Table 35: Summary of Best Overall Response with Confirmation Based on RECIST 1.1 per Central Radiology Assessment Subjects with PD-L1 CPS &lt;1% (APT Population)

Cut-off date: 09-Mar-2017

<!-- image -->

| Response Evaluation                                                                                                                                                                                                                     | Pembrolizumab (N=79)                                                                                                                                                                                                                    | Pembrolizumab (N=79)                                                                                                                                                                                                                    | Pembrolizumab (N=79)                                                                                                                                                                                                                    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                         | %                                                                                                                                                                                                                                       | 95% CI                                                                                                                                                                                                                                  |
| Complete Response(CR) Partial Response (PR)                                                                                                                                                                                             | 2                                                                                                                                                                                                                                       | 2.5 13.9                                                                                                                                                                                                                                | (0.3, 8.8) (7.2, 23.5)                                                                                                                                                                                                                  |
|                                                                                                                                                                                                                                         | 11                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                         |
| ObjectiveResponse(CR+PR)                                                                                                                                                                                                                | 13                                                                                                                                                                                                                                      | 16.5                                                                                                                                                                                                                                    | (9.1, 26.5)                                                                                                                                                                                                                             |
| Stable Disease (SD)                                                                                                                                                                                                                     | 9                                                                                                                                                                                                                                       | 11.4                                                                                                                                                                                                                                    | (5.3, 20.5)                                                                                                                                                                                                                             |
| DiseaseControl(CR+PR+SD)                                                                                                                                                                                                                | 22                                                                                                                                                                                                                                      | 27.8                                                                                                                                                                                                                                    | (18.3,39.1)                                                                                                                                                                                                                             |
| Progressive Disease (PD)                                                                                                                                                                                                                | 43                                                                                                                                                                                                                                      | 54.4                                                                                                                                                                                                                                    | (42.8, 65.7)                                                                                                                                                                                                                            |
| Non-evaluable (NE)                                                                                                                                                                                                                      | 4                                                                                                                                                                                                                                       | 5.1                                                                                                                                                                                                                                     | (1.4, 12.5)                                                                                                                                                                                                                             |
| No Assessment                                                                                                                                                                                                                           | 10                                                                                                                                                                                                                                      | 12.7                                                                                                                                                                                                                                    | (6.2, 22.0)                                                                                                                                                                                                                             |
| Confimed responses are included Basedonbinomialexactconfidenceinterval method. Non-evaluable: subject had post-baseline imaging and the BOR was detemmined to be NE per RECIST 1.1. No Assessment: subject had no post-baseline imaging | Confimed responses are included Basedonbinomialexactconfidenceinterval method. Non-evaluable: subject had post-baseline imaging and the BOR was detemmined to be NE per RECIST 1.1. No Assessment: subject had no post-baseline imaging | Confimed responses are included Basedonbinomialexactconfidenceinterval method. Non-evaluable: subject had post-baseline imaging and the BOR was detemmined to be NE per RECIST 1.1. No Assessment: subject had no post-baseline imaging | Confimed responses are included Basedonbinomialexactconfidenceinterval method. Non-evaluable: subject had post-baseline imaging and the BOR was detemmined to be NE per RECIST 1.1. No Assessment: subject had no post-baseline imaging |

Source:[P052V01MK3475:analysis-adsl; adopa]

Table 36: Summary of Best Overall Response with Confirmation Based on RECIST 1.1 per Central Radiology Assessment Subjects with PD-L1 CPS &lt;10% (APT Population)

Cut-off date: 09-Mar-2017

<!-- image -->

| ResponseEvaluation                                                                                                                                                                                                                      | Pembrolizumab (N=251)                                                                                                                                                                                                                   | Pembrolizumab (N=251)                                                                                                                                                                                                                   | Pembrolizumab (N=251)                                                                                                                                                                                                                   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                         | n                                                                                                                                                                                                                                       | %                                                                                                                                                                                                                                       | 95% CI                                                                                                                                                                                                                                  |
| CompleteResponse(CR) Partial Response (PR)                                                                                                                                                                                              | 8 45                                                                                                                                                                                                                                    | 3.2 17.9                                                                                                                                                                                                                                | (1.4, 6.2)                                                                                                                                                                                                                              |
|                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                         | (13.4, 23.2)                                                                                                                                                                                                                            |
| ObjectiveResponse(CR+PR)                                                                                                                                                                                                                | 53                                                                                                                                                                                                                                      | 21.1                                                                                                                                                                                                                                    | (16.2, 26.7)                                                                                                                                                                                                                            |
| Stable Disease (SD)                                                                                                                                                                                                                     | 44                                                                                                                                                                                                                                      | 17.5                                                                                                                                                                                                                                    | (13.0, 22.8)                                                                                                                                                                                                                            |
| DiseaseControl(CR+PR+SD)                                                                                                                                                                                                                | 97                                                                                                                                                                                                                                      | 38.6                                                                                                                                                                                                                                    | (32.6, 45.0)                                                                                                                                                                                                                            |
| Progressive Disease (PD)                                                                                                                                                                                                                | 121                                                                                                                                                                                                                                     | 48.2                                                                                                                                                                                                                                    | (41.9, 54.6)                                                                                                                                                                                                                            |
| Non-evaluable (NE)                                                                                                                                                                                                                      | 9                                                                                                                                                                                                                                       | 3.6                                                                                                                                                                                                                                     | (1.7, 6.7)                                                                                                                                                                                                                              |
| No Assessment                                                                                                                                                                                                                           | 24                                                                                                                                                                                                                                      | 9.6                                                                                                                                                                                                                                     | (6.2, 13.9)                                                                                                                                                                                                                             |
| Confimmed responses are included Basedonbinomialexactconfidenceinterval method. Non-evaluable: subject had post-baseline imaging and the BOR was detemmined to be NE per RECIST 1.1. No Assessment: subject had nopost-baseline imaging | Confimmed responses are included Basedonbinomialexactconfidenceinterval method. Non-evaluable: subject had post-baseline imaging and the BOR was detemmined to be NE per RECIST 1.1. No Assessment: subject had nopost-baseline imaging | Confimmed responses are included Basedonbinomialexactconfidenceinterval method. Non-evaluable: subject had post-baseline imaging and the BOR was detemmined to be NE per RECIST 1.1. No Assessment: subject had nopost-baseline imaging | Confimmed responses are included Basedonbinomialexactconfidenceinterval method. Non-evaluable: subject had post-baseline imaging and the BOR was detemmined to be NE per RECIST 1.1. No Assessment: subject had nopost-baseline imaging |

Source:[P052V01MK3475:analysis-adsl;adopa]

<div style=\"page-break-after: always\"></div>

- Subjects with PD-L1 CPS≥1% to&lt;10%

Table 37: Summary of Best Overall Response with Confirmation Based on RECIST 1.1 per Central Radiology Assessment Subjects with PD-L1 CPS ≥ 1% to &lt; 10% (APT Population)

Cut-off date: 09-Mar-2017

| ResponseEvaluation       | Pembrolizumab (N=172)   | Pembrolizumab (N=172)   | Pembrolizumab (N=172)   |
|--------------------------|-------------------------|-------------------------|-------------------------|
|                          |                         | %                       | 95% CI                  |
| CompleteResponse(CR)     | 6                       | 3.5                     | (1.3, 7.4)              |
| Partial Response (PR)    |                         | 19.8                    | (14.1, 26.5)            |
| ObjectiveResponse(CR+PR) | 40                      | 23.3                    | (17.2,30.3)             |
| Stable Disease (SD)      | 35                      | 20.3                    | (14.6, 27.1)            |
| DiseaseControl(CR+PR+SD) | 75                      | 43.6                    | (36.1, 51.4)            |
| Progressive Disease (PD) | 78                      | 45.3                    | (37.8, 53.1)            |
| Non-evaluable (NE)       | 5                       | 2.9                     | (1.0, 6.7)              |
| No Assessment            | 14                      | 8.1                     | (4.5, 13.3)             |

Confimed responses are included

Basedonbinomial exactconfidenceinterval method

Non-evaluable: subject had post-baseline imaging and the BOR was detemmined to be NE per RECIST 1.1.

No Assessment: subject had nopost-baseline imaging DatabaseCutoffDate:09MAR2017

Source:[P052V01MK3475: analysis-adsl;adopa]

## Secondary endpoints

Duration of Response

Table 38: Time to Response and Response Duration Based on RECIST 1.1 per Central Radiology Assessment in Subjects with Confirmed Response

Cut-off date: 09-Mar-2017

| All subjects (APT Population)                           | Pembrolizumab (N=370)      |
|---------------------------------------------------------|----------------------------|
| N. subjects with response*                              | 108                        |
| Time to Response* (months) • Mean (SD) • Median (Range) | 2.5 (1.1) 2.1 (1.3-9.0)    |
| Response Duration° (months) • Median (Range)            | Not reached (1.4+ - 19.6+) |
| N. subjects with response≥6 months° (%)                 | 77 (82)                    |
| PD-L1 CPS≥1%                                            | Pembrolizumab (N=282)      |
| N. subjects with response*                              | 92                         |
| Time to Response* (months) • Mean (SD) • Median (Range) | 2.5 (1.1) 2.1 (1.3-9.0)    |
| Response Duration° (months) • Median (Range)            | Not reached (1.4+ - 19.2+) |
| N. subjects with response≥6 months° (%)                 | 64 (81)                    |
| PD-L1 CPS≥10%                                           | Pembrolizumab (N=110)      |
| N. subjects with response*                              | 52                         |
| Time to Response* (months) • Mean (SD)                  | 2.4 (0.9)                  |

<div style=\"page-break-after: always\"></div>

| • Median (Range)                                        | 2.1 (1.3-6.1)              |
|---------------------------------------------------------|----------------------------|
| Response Duration° (months) • Median (Range)            | 12.6 (1.4+ - 18.3+)        |
| N. subjects with response≥6 months° (%)                 | 35 (79)                    |
| PD-L1 CPS<1%                                            | Pembrolizumab (N=79)       |
| N. subjects with response*                              | 13                         |
| Time to Response* (months) • Mean (SD) • Median (Range) | 2.5 (1.2) 2.1 (1.9-5.9)    |
| Response Duration° (months) Median (Range)              | 11.3 (1.4+ - 15.8+)        |
| N. subjects with response≥6 months° (%)                 | 10 (83)                    |
| PD-L1 CPS<10%                                           | Pembrolizumab (N=251)      |
| N. subjects with response*                              | 53                         |
| Time to Response* (months) • Mean (SD) • Median (Range) | 2.6 (1.3) 2.1 (1.6-9.0)    |
| Response Duration° (months) Median (Range)              | Not reached (1.4+ - 19.2+) |
| N. subjects with response≥6 months° (%)                 | 39 (84)                    |
| PD-L1 CPS≥1% to <10%                                    | Pembrolizumab (N=172)      |
| N. subjects with response*                              | 40                         |
| Time to Response* (months) • Mean (SD) • Median (Range) | 2.6 (1.3) 2.1 (1.6-9.0)    |
| Response Duration° (months) Median (Range)              | Not reached (3.2 - 19.2+)  |
| N. subjects with response≥6 months° (%)                 | 29 (84)                    |

Table made by Assessor.

- *Analysis on time to response and response duration are based on patients with a best overall response as confirmed complete response or partial response only.
- °Median and percentage are calculated from product-limit (Kaplan-Meier) method for censored data.
- \"+\" indicates there is no progressive disease by the time of last disease assessment.

Database Cut-off Date: 09 MAR2017

## Progression Free Survival

Table 39: Progression Free Survival Based on RECIST 1.1 per Central Radiology Assessment

Cut-off Date: 01Sep2016

<div style=\"page-break-after: always\"></div>

| N                             | N. events (%)                 | Person- Months                | Event Rate/ 100 Person- Months (%)   | Median PFS* (months) (95% CI)   | PFS Rate 6 months (%)* (95% CI)   | PFS Rate 12 months (%)* (95% CI)   |
|-------------------------------|-------------------------------|-------------------------------|--------------------------------------|---------------------------------|-----------------------------------|------------------------------------|
| All subjects (APT Population) | All subjects (APT Population) | All subjects (APT Population) | All subjects (APT Population)        | All subjects (APT Population)   | All subjects (APT Population)     | All subjects (APT Population)      |
| 370                           | 248 (67.0)                    | 1259.9                        | 19.7                                 | 2.1 (2.1, 3.0)                  | 30.0 (24.8, 35.3)                 | 18.6 (12.8, 25.2)                  |
| PD-L1 CPS≥1%                  | PD-L1 CPS≥1%                  | PD-L1 CPS≥1%                  | PD-L1 CPS≥1%                         | PD-L1 CPS≥1%                    | PD-L1 CPS≥1%                      | PD-L1 CPS≥1%                       |
| 282                           | 177 (62.8)                    | 982.1                         | 18.0                                 | 3.0 (2.1, 3.5)                  | 32.7 (26.5, 39.0)                 | 21.3 (14.0, 29.7)                  |
| PD-L1 CPS≥10%                 | PD-L1 CPS≥10%                 | PD-L1 CPS≥10%                 | PD-L1 CPS≥10%                        | PD-L1 CPS≥10%                   | PD-L1 CPS≥10%                     | PD-L1 CPS≥10%                      |
| 80                            | 37 (46.3)                     | 300.8                         | 12.3                                 | 4.9 (3.5,..)                    | 45.6 (31.9, 58.3)                 | Not reached                        |

Table made by Assessor from Table 11-17, Table 11-18 and Table 11-19.

*From product-limit (Kaplan-Meier) method for censored data.

Database Cut-off Date: 01SEP2016

## Kaplan-Meier of Progression Free Survival based on RECIST 1.1 per Central Radiology Assessment All subjects (APT Population)

<!-- image -->

Number of subject at risk

Pembrolizumab

Table 40: Progression Free Survival Based on RECIST 1.1 per Central Radiology Assessment All Subjects (APT Population)

Cut-off Date: 09-Mar-2017

<div style=\"page-break-after: always\"></div>

| Treatment     |   N | Numberof Events (%)   |   Person- Months |   Event Rate/ 100Person- Months (%) | MedianPFS (Months) (95% CI)   | PFSRate at Months6in%t (95% CI)   | PFSRate at Months12in%t (95% CI)   |
|---------------|-----|-----------------------|------------------|-------------------------------------|-------------------------------|-----------------------------------|------------------------------------|
| Pembrolizumab | 370 | 284 (76.8)            |           1878.3 |                                15.1 | 2.3 (2.1,3.4)                 | 33.8 (29.0,38.7)                  | 21.8 (17.4, 26.6)                  |

<!-- image -->

Source:[P052V01MK3475:analysis-adsl;adlte]

## Kaplan-Meier of Progression Free Survival based on RECIST 1.1 per Central Radiology Assessment

## All subjects (APT Population)

<!-- image -->

(Databasecutoff date:09MAR2017)

Source:[P052V01MK3475:analysis-adsl; adtte]

## Overall Survival

## Table 41: Overall Survival

Cut- off date: 01-Sep-2016

| N   | N                             | N. events (%)                 | Person- Months                | Event Rate/ 100 Person- Months (%)   | Median OS* (months) (95% CI)   | OS Rate 6 months (%)* (95% CI)   | OS Rate 12 months (%)* (95% CI)   |
|-----|-------------------------------|-------------------------------|-------------------------------|--------------------------------------|--------------------------------|----------------------------------|-----------------------------------|
|     | All subjects (APT Population) | All subjects (APT Population) | All subjects (APT Population) | All subjects (APT Population)        | All subjects (APT Population)  | All subjects (APT Population)    |                                   |
| 370 |                               | 130 (35.1)                    | 2056.6                        | 6.3                                  | 10.9 (9.7, …)                  | 67.4 (61.7, 72.5)                | 41.2 (31.4, 50.7)                 |
|     | PD-L1 CPS≥1%                  | PD-L1 CPS≥1%                  | PD-L1 CPS≥1%                  | PD-L1 CPS≥1%                         | PD-L1 CPS≥1%                   | PD-L1 CPS≥1%                     |                                   |
| 282 |                               | 85 (30.1)                     | 1584.9                        | 5.4                                  | 11.6 (10.1,...)                | 70.5 (64.0, 76.1)                | 49.3 (37.6, 60.0)                 |
|     | PD-L1 CPS≥10%                 | PD-L1 CPS≥10%                 | PD-L1 CPS≥10%                 | PD-L1 CPS≥10%                        | PD-L1 CPS≥10%                  | PD-L1 CPS≥10%                    |                                   |
| 80  |                               | 18 (22.5)                     | 409.0                         | 4.4                                  | Not reached (8.4,..)           | 76.5 (63.4, 85.5)                | Not reached                       |

Database cut-off date: 01-Sep-2017

Tables 7, 45 and 46 Response to RSI

*From product-limit (Kaplan-Meier) method for censored data.

<div style=\"page-break-after: always\"></div>

## Exploratory endpoints

Table 42: Summary of Best Overall Response with Confirmation Based on Modified RECIST 1.1 per Central Radiology Assessment

All Subjects (APT Population)

Cut-off Date: 09Mar2017

| Response Evaluation       | Pembrolizmab (N=370)   | Pembrolizmab (N=370)   | Pembrolizmab (N=370)   |
|---------------------------|------------------------|------------------------|------------------------|
|                           | n                      | %                      | ID %56                 |
| Complete Response (CR)    | 27                     | 7.3                    | (4.9,10.4)             |
| Patial Response (PR)      | 86                     | 23.2                   | (19.0, 27.9)           |
| ObjectiveResponse(CR+PR)  | 113                    | 30.5                   | (25.9,35.5)            |
| Stable Disease (SD)       | 76                     | 20.5                   | (16.5, 25.0)           |
| Disease Control(CR+PR+SD) | 189                    | 51.1                   | (45.9,56.3)            |
| Progressive Disease (PD)  | 142                    | 38.4                   | (33.4,43.5)            |
| Non-evaluable (NE)        | 9                      | 2.4                    | (1.1, 4.6)             |
| No Assessment             | 30                     | 8.1                    | (5.5, 11.4)            |

Sowrce: [P052V01MK3475: analysis-adsl; adopa]

Table 43: Summary of PFS

<!-- image -->

## Based on Modified RECIST 1.1 per Central Radiology Assessment All Subjects (APT Population)

Cut-off Date: 09Mar2017

<!-- image -->

Source:[P052V01MK3475:analysis-adsl;adtte]

## Patient Reported Outcomes

## EORTC QLQ-C30 and EQ-5D Compliance Rate and Completion Rate

Compliance rates for both the EORTC QLQ-C30 and EQ-5D were 90% or above at baseline, and over 86% at Week 9. Completion rates, calculated for each visit from baseline to Week 57, remained above 70% at each time point after baseline, until Week 9, when they dropped as patients discontinued the study due to disease progression, physician decision, AEs, or death.

## EORTC QLQ-C30 analysis

At week 9, the majority of the subjects experienced improvement of 10 or more points (31%) or stable global health status/QoL (42%). This was observed for all EORTC functioning and symptom domains. An improved quality of life was registered for patients who remained on treatment, although scores after Week 9 should be interpreted with caution due to the small sample size.

## Figure: Summary of EORTC QLQ-C30 Global health status/QoL at Study Visit

Mean +/- SE

(FAS Population)

<div style=\"page-break-after: always\"></div>

Ancillary analyses

<!-- image -->

Objective Response Rate in protocol-specified subgroups

Figure: ORR with Confirmation Based on RECIST 1.1 per Central Radiology Assessment by Subgroup Factors All Subjects (APT Population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Hearing Loss.

Renal dysfunction is defined as a baseline creatinine clearance &lt; 60 mL/min.

Database Cut-off Date: 09 March 2017

Source: [P052V01MK3475: analysis-adsl; adopa]

## Summary of main study(ies)

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 44: Summary of Efficacy for trial KEYNOTE-052

| Study identifier          | Advanced/Unresectable or Metastatic Urothelial Cancer EudraCT number: 2014-002206-20                                                                                                                                                                       | Advanced/Unresectable or Metastatic Urothelial Cancer EudraCT number: 2014-002206-20                                                                                                                                                                       | Advanced/Unresectable or Metastatic Urothelial Cancer EudraCT number: 2014-002206-20                                                                                                                                                                       |
|---------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Design                    | Non-randomized, multicenter, open-label, trial of IV pembrolizumab monotherapy in subjects with advanced/unresectable or metastatic urothelial carcinoma, who have not received prior systemic chemotherapy and who are not eligible to receive cisplatin. | Non-randomized, multicenter, open-label, trial of IV pembrolizumab monotherapy in subjects with advanced/unresectable or metastatic urothelial carcinoma, who have not received prior systemic chemotherapy and who are not eligible to receive cisplatin. | Non-randomized, multicenter, open-label, trial of IV pembrolizumab monotherapy in subjects with advanced/unresectable or metastatic urothelial carcinoma, who have not received prior systemic chemotherapy and who are not eligible to receive cisplatin. |
| Design                    | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                             | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                             | not applicable not applicable not applicable                                                                                                                                                                                                               |
| Hypothesis                | Not applicable                                                                                                                                                                                                                                             | Not applicable                                                                                                                                                                                                                                             | Not applicable                                                                                                                                                                                                                                             |
| Treatments groups         | pembrolizumab                                                                                                                                                                                                                                              | pembrolizumab                                                                                                                                                                                                                                              | 200 mg IV Q3W 370 subjects treated                                                                                                                                                                                                                         |
| Endpoints and definitions | Primary endpoint                                                                                                                                                                                                                                           | ORR                                                                                                                                                                                                                                                        | Percentage of patients having a CR or PR during the trial, based on BICR review per RECIST 1.1.                                                                                                                                                            |
| Endpoints and definitions | Secondary endpoint                                                                                                                                                                                                                                         | Response duration                                                                                                                                                                                                                                          | Time from first RECIST 1.1 response to disease progression assessed by BICR in subjects who achieve a PR or CR.                                                                                                                                            |
| Endpoints and definitions | Secondary endpoint                                                                                                                                                                                                                                         | OS                                                                                                                                                                                                                                                         | Time from allocation to death due to any cause                                                                                                                                                                                                             |
| Endpoints and definitions | Secondary endpoint                                                                                                                                                                                                                                         | PFS                                                                                                                                                                                                                                                        | Time from allocation to the first documented disease progression according to RECIST 1.1 based on BICR or death due to any cause, whichever occurred first.                                                                                                |
| Data Cut-off              | 01-SEP-2016/ 09-MAR-2017                                                                                                                                                                                                                                   | 01-SEP-2016/ 09-MAR-2017                                                                                                                                                                                                                                   | 01-SEP-2016/ 09-MAR-2017                                                                                                                                                                                                                                   |
| Results and Analysis      | Results and Analysis                                                                                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                                                       |
| Analysis description      | Primary Analysis                                                                                                                                                                                                                                           | Primary Analysis                                                                                                                                                                                                                                           | Primary Analysis                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| Analysis population and time point description            | All-Patients-Treated (APT) All Subjects   | All-Patients-Treated (APT) All Subjects   | All-Patients-Treated (APT) All Subjects   |
|-----------------------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
| Descriptive statistics and effect estimate per comparison | Treatment group                           | Pembrolizumab 200 mg                      | Pembrolizumab 200 mg                      |
|                                                           | Number of subject                         | 370                                       | 370                                       |
|                                                           | Primary endpoint                          |                                           |                                           |
|                                                           |                                           | Data Cut-off: 1 st September 2016         | Data cut-off: 9 th March 2017             |
|                                                           | ORR (BICR-RECIST 1.1) n (%) (95% CI)      | 89 (24.1) (19.8, 28.7)                    | 108 (29.2) (24.6, 34.1)                   |
|                                                           | Secondary endpoints                       |                                           |                                           |
|                                                           | Time to response Median (months) (range)  | 2.0 (0.2-4.8)                             | 2.1 (1.3-9.0)                             |
|                                                           | Response duration Median (months) (range) | Not reached (1.0+ - 13.6+)                | Not reached (1.4+ -19.6)                  |
|                                                           | PFS N. with events n (%)                  | 248 (67.0)                                | 284 (76.8)                                |
|                                                           | Median PFS months (95% CI)                | 2.1 (2.1, 3.0)                            | 2.3 (2.1, 3.4)                            |
|                                                           | PFS rate at 6 months (%) (95% CI)         | 30.0 (24.8, 35.3)                         | 33.8 (29.0, 38.7)                         |
|                                                           | PFS rate at 12 months (%) (95% CI)        | 18.6 (12.8, 25.2)                         | 21.8 (17.4, 26.6)                         |
|                                                           | OS N. with events n (%)                   | 130 (35.1)                                | 188 (50.8)                                |
|                                                           | Median OS months (95% CI)                 | 10.9 (9.7, …)                             | 11.0 (10.0, 13.6)                         |
|                                                           | OS rate at 6 months (%) (95% CI)          | 67.4 (61.7, 72.5)                         | 67.4 (62.3, 72.0)                         |
|                                                           | OS rate at 12 months (%) (95% CI)         | 41.2 (31.4, 50.7)                         | 46.8 (41.1, 52.3)                         |

## Analysis performed across trials (pooled analyses and meta-analysis)

A systematic literature review and meta-analysis to compile ORR, DOR and OS to historical first line therapies for advanced/metastatic urothelial cancer was submitted.

PUBMED (Medline), Cochrane, and EMBASE databases were searched to identify clinical trials published in English language since 1 January 1991. Randomized controlled trials, single arm trials, retrospective studies and observational studies were included in the initial step of the review. Any agent given in the

<div style=\"page-break-after: always\"></div>

first line setting for subjects with advanced or metastatic urothelial cancer who are cisplatin-ineligible (i.e. single agent or combination therapy, including, but not limited to, carboplatin, gemcitabine, paclitaxel, methotrexate, vinflunine, vinblastine, epirubicin, docetaxel, oxaliplatin and doxorubicin) were defined as comparator therapies.

## Systematic Review

The combined literature searches (PUBMED, Cochrane, Embase), identified a total of 3297 references. A comprehensive search strategy was used to identify references that addressed the 1L therapy of cisplatinineligible subjects with advanced/metastatic urothelial cancer, thus resulting in 97 references. However, the majority of these 97 references included subjects with good performance status and adequate renal function. In order to generate the most appropriate reference data for KN052, only references with similar inclusion criteria in terms of performance status and renal function were included in the metaanalysis. At the end of the filtering process, 18 publications, representing 21 treatment arms (12 carboplatin based; 13 gemcitabine based; 8 carboplatin/gemcitabine), that unambiguously reported responses in cisplatin-ineligible subjects being treated in the first line setting for advanced/metastatic urothelial cancer, were included. Only one Phase III study was reported for the scenario of interest, while the other identified studies were mostly Phase II studies or retrospective studies. For many combinations, multiple studies were unavailable, and hence meta-analysis was not feasible.

The pooled analysis yielded an ORR of 36% (95% CI: 30%, 42%). Median duration of response (DOR) was 6.52 months (95% CI: 5.47-7.76), and median overall survival (OS) was 9.84 months (95% CI: 8.37-11.57). Heterogeneity among studies was performed through the I 2  statistic and resulted to be substantial for ORR and OS data (60.4% and 81.5% respectively).

## 2.4.3. Discussion on clinical efficacy

The  Keytruda  extension  of  indication  in  the  treatment  of  locally  advanced  or  metastatic  urothelial carcinoma is sought concomitantly in two specific settings, each one based on one single pivotal trial:

1. Study KEYNOTE-045, in advanced or metastatic urothelial carcinoma progressing after platinumbased chemotherapy
2. Study  KEYNOTE-052,  in  patients  previously  untreated  and  not  eligible  to  cisplatin-containing chemotherapy.

In both studies, patients were enrolled independently from PD-L1 expression, with the provision of tissue for  biomarker  analysis  as  a  requirement  for  eligibility,  and  the  PD-L1  status  was  defined  based  on  a Combined Positive Score (CPS), including the PD-L1 expression on both tumor and infiltrating immune cells. This scoring system was selected based on the results from an earlier study KEYNOTE-012, in which two different scoring systems, one based on tumour cell staining alone and the other based on staining in both  tumour  cells  and  inflammatory  cells,  were  evaluated  to  analyse  the  relationship  between  PD-L1 expression  and  clinical  response.  Results  from  this  post-hoc  analysis  showed  the  importance  to incorporate inflammatory cells into the determination of PD-L1 status for the selection of patients more likely  to  respond  to  pembrolizumab.  In  both  urothelial  carcinoma  studies,  two  PD-L1  CPS  cut-off  were evaluated: PD-L1 CPS ≥ 1% determined exclusively using KN012 data, and the CPS ≥ 10% defined based on the first 100 subjects in KN052 which served as the training data set.

<div style=\"page-break-after: always\"></div>

## Study KEYNOTE-045 in advanced or metastatic urothelial carcinoma patients progressing after platinum-based chemotherapy

## Design and conduct of clinical study

This is a phase III randomized trial of pembrolizumab versus Investigator's choice (paclitaxel, docetaxel or vinflunine) in subjects with recurrent or metastatic urothelial carcinoma who experienced progression after a platinum-based regimen.

Overall, 542 patients were randomized in the trial and allocated with a 1:1 ratio in the pembrolizumab arm (270 patients) and in the chemotherapy group (272 patients). Inclusion criteria allowed the enrolment in the trial of a quite heterogeneous population in terms of prior treatments and ECOG PS. Indeed, differently from studies with other checkpoint inhibitors in patients progressing after platinumbased chemotherapy, ECOG PS2 patients were considered eligible, but only in selected conditions (i.e, haemoglobin ≥ 10 g/dL, no liver metastases, treatment interval before enrollment ≥ 3 months). In the absence of a well globally established standard of care, the proposed comparators are deemed acceptable. Indeed, taxanes are commonly used off-label in clinical practice, and vinflunine is approved only in EU for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen. On this basis, an imbalance in the number of patients allocated to each regimen in the control arm could have been expected. However, the number of patients allocated to each chemotherapy regimen was quite well balanced (i.e. 84 patients with paclitaxel; 84 patients with docetaxel; 85 patients with vinflunine).

PFS per RECIST 1.1 based on BICR and OS were selected as dual primary endpoints, meaning that the study could be considered to have met its primary objective if superiority was demonstrated for PFS or OS in the overall population or in any of the subgroups analysed based on PD-L1 expression. As secondary endpoints, confirmed ORR per RECIST 1.1 and mRECIST by BICR, duration response per RECIST 1.1 by BICR and PFS per mRECIST were also evaluated. The statistical assumptions for the definition of sample size can be considered reasonable, providing enough power for the comparison also in PD-L1 CPS ≥ 10% subjects. There are two planned PFS analyses (IA1 and final), and three planned OS analyses (IA1, IA2 and final). The statistical plan includes a set of comprehensive subgroup analyses, taking into account the most relevant prognostic factors, which is considered appropriate. Overall, the statistical methods are acceptable. The control for multiplicity is considered appropriate.

The choice to include patients regardless of PD-L1 status is acceptable based on the lack of sufficient data to justify enrichment at the time the study started. For the same reason PD-L1 status was not even considered as a stratification factor. However, based on emerging evidence on the correlation between PD-L1 status and outcomes, the statistical analysis plan was updated while the study was ongoing to incorporate new primary hypotheses for PD-L1 positive (CPS≥1%) and strongly positive (CPS≥10%) subjects (Amendment#9). Further changes to the biomarker strategy were then introduced based on external results coming KN052, and the formal test for hypotheses on PD-L1 CPS ≥ 1% was deleted through Amendment# 13, released after IA1 and data cut-off date. A reallocation of alpha with proper adjustment to maintain the control of family-wise type I error rate (FWER) was made. Even if the adopted strategy of alpha re-allocation seems to be in principle reasonable, the lack of a rigorous approach in the specification of the statistical methods in the protocol, before any interim analysis was conducted, is noted.

Stratification has been performed according to well recognised prognostic factors in second line setting (ECOG PS 0/1 vs 2; presence or absence of liver metastases; Haemoglobin ≥10 g/dL vs &lt;10 g/dL; time from completion of most recent chemotherapy &lt;3 months vs ≥3 months).

<div style=\"page-break-after: always\"></div>

Baseline characteristics were overall well balanced in the two treatment arms. The median age of patients was slightly higher in the pembrolizumab arm (67 vs 65 years), with 61.1% of patients ≥65 years compared to 54% in the control arm. Fifty-five percent of patients were PD-L1 &lt;1% (56% in the pembrolizumab arm and 54% in the control group), while respectively 33% in the control arm and 27.4% in the pembrolizumab group were PD-L1≥10%.

In general eligibility criteria are considered adequate to define a 2L+ UC patient population (including subjects with failure of neoadjuvant/adjuvant treatment within 12 months). However subjects with poor prognostic /baseline characteristics are not fully represented (e.g. ECOG PS 2 subjects could not have additional unfavourable prognostic factors, subjects with more than 2 prior lines of systemic chemotherapy for metastatic disease, active brain metastases or inadequate organ function were excluded). Lastly, only 6 patients with ECOG PS of 2 (1.1% of study population) were included, which is seen as critical considering the general high proportion of patients with reduced performance status in patients with advanced / metastatic UC. Only 7 patients (1.3%) were included with brain metastases and only 21% had two prior treatments. Most patients (76%) had been eligible to receive Cisplatin as prior platinum therapy. In this context it is notable that 27% of screened subjects were non-randomized, because they did not meet eligibility criteria. Most of these (nearly 80%) were not included in the study due to unfavourable prognostic factors or comorbidities.

15 subjects in the control arm withdrew consent after randomisation before start of treatment (none in the pembrolizumab treatment arm). Moreover a higher proportion of subjects discontinued studied medication due to withdrawal by subjects or physician decision in the control arm (n=56) compared to the pembrolizumab arm (n=9). It may be assumed that this at least partly reflects that assignment to the chemotherapy arm did not meet expectations of patients and physicians in this open-label trial. This high rate of (premature) withdrawals raises concerns with regards to a possible underperformance of the control arm in an ITT analysis. However a consistent benefit in OS favouring pembrolizumab versus chemotherapy has been reported by sensitivity analyses, even when patients not treated or discontinued due to withdrawal by subject or physician decision were excluded.

## Efficacy data and additional analyses

The MAH submitted OS results from IA2, with 334 OS events in all comer patients and 104 in PD-L1 CPS≥10% patients. Even if, with 36 additional OS events, results are not expected to significantly change, the final analysis data should be provided and this is requested as a post-authorisation efficacy study.

Overall, a statistically significant gain of 3 months in OS is reported in the overall population (HR:0.73, 95% CI 0.59, 0.91, p=0.002). The median OS in the chemotherapy arm (7.4 months, 95% CI 6.1, 8.3) is consistent with historical data from single-agent second line treatment.

Consistently, a significant OS increase was observed in PD-L1 strongly positive patients (CPS≥10%) treated with pembrolizumab compared to chemotherapy (HR:0.57, 95% CI 0.37, 0.88, p=0.004). In addition, even though p-value was not multiplicity-adjusted, results in PD-L1 positive patients (CPS≥1%) showed a similar magnitude of OS benefit (HR:0.61, 95% CI 0.43, 0.86, p=0.002) compared to PD-L1 strongly positive.

The visual inspection of the KM curves of OS shows an initial favourable effect in the control arm followed by a cross between month 3 and month 4 from the start of treatment. A review of early events in order to clarify potential factors influencing such outcome was provided: apart from the number of censoring in the first 2 months that was much higher in the control arm compared to the pembrolizumab arm (17 vs 3), an excess of deaths in the pembrolizumab arm was observed in the first two months (43 in pembrolizumab vs 24 in control arm). Liver metastases and time from most recent prior therapy of &lt; 3

<div style=\"page-break-after: always\"></div>

months were identified as possible factors associated to the higher risk of early death. No benefit (instead a detrimental effect) was observed for pembrolizumab in terms of median PFS per RECIST 1.1 based on BICR in the ITT population. This is not an unexpected finding, considering the different mechanism of action of chemotherapy and immune checkpoint inhibitors, and taking into account the possibility of a delayed response not captured by RECIST 1.1. As observed for OS curves, the slope of the KM curves shows an initial unfavourable treatment effect for pembrolizumab followed by a cross at Month 5 and a trend to diverge after 6 months, with a PFS rate at 12 months of 6.2% in the control arm and 16.8% with pembrolizumab.

A similar trend of PFS KM-curves was observed in patients with PD-L1 positive tumour (CPS ≥10% and ≥1%), with consistent median PFS value across subpopulations and a sustained effect in a subset of patients. PFS based on modified RECIST in these subgroups also showed similar results.

Since patients could stay on treatment beyond progression to account for the possibility of pseudoprogression and delayed response, PFS based on modified RECIST was also analysed, showing however similar findings.

A higher ORR has been consistently reported in the pembrolizumab arm compared to chemotherapy in the total population (21.1% vs 11.4%), in PD-L1 CPS≥10% (21.6% vs 6.7%) and in PD-L1 CPS≥1% (23.6% vs 8.3%). On the other hand, chemotherapy produced disease stabilisation in a larger number of patients (33.5% vs 17.4% in the total population; 35.6% vs 12.2% in PD-L1 CPS≥10%; 35% vs 15.5% in PD-L1 CPS≥1%). Waterfall Plots of Best Tumour Change from Baseline were provided showing a higher frequency of deep responses with pembrolizumab compared to chemotherapy. ORR differences for pembrolizumab vs. control in subjects with PD-L1 CPS &lt;1% and PD-L1 &lt;10% were lower compared to those of the higher PD-L1 subgroups, but ORR results for pembrolizumab still remained favourable compared to the chemotherapy control group.

No differences in the median time to tumour response were observed among arms in all populations, but responses were considerably longer with pembrolizumab (median time not reached with the current data cut-off for pembrolizumab and 4.3 months in the control arm).

Efficacy results for all endpoints were confirmed by the performed sensitivity analyses.

More than half of included patients were PD-L1 negative (CPS &lt;1%) in both arms (54% in the control arm and 56% in the pembrolizumab arm). Efficacy results, in subgroups with PD-L1 CPS &lt;1% and PD-L1 &lt;10%, show that OS, PFS, ORR and best change from tumor baseline were overall consistent with the results in the overall population.

Indeed, contrasting evidences on the role of PD-L1 expression as biomarker for response are provided by other immune checkpoint inhibitors. In the phase II, single arm study CheckMate 275, responses to nivolumab were seen irrespective of PD-L1 expression (Sharma P, Lancet 2017). On the other hand, a higher immune-cell PD-L1 expression was associated with higher atezolizumab response in the phase II, single arm IMvigor 210 study (Rosemberg JE, Lancet 2016). However the randomized phase III study (IMvigor 211) of atezolizumab vs. chemotherapy control demonstrated a negative prognostic value of PDL1 expression in immune cells (i.e. higher PD-L1 expression was associated with worse outcome in both, the atezolizumab treatment group and the control arm), but PD-L1 expression was not predictive.

An updated efficacy analysis for KN045 was performed with a cut-off date of 18JAN2017 and a total of 366 OS events. A robust OS improvement favoring pembrolizumab as compared with chemotherapy control continues to be noted in the overall population [OS HR: 0.70 (0.57, 0.86), p-value:0.0004]. No improvement in PFS for pembrolizumab compared with chemotherapy control is observed [PFS HR: 0.96 (0.79, 1.16), p-value:0.322] albeit a plateau in the tail of the Kaplan-Meier curves suggest durable clinical benefit for a subset of patients. The improvement in response rates compared with the

<div style=\"page-break-after: always\"></div>

chemotherapy control was confirmed at the longer follow-up in the overall population (21.1% vs 11%), as well as in PD-L1 CPS≥10% (20.3% vs 6.7%) and in PD-L1 CPS≥1% (22.7% vs 8.3%).

Results of analyses on exploratory biomarkers (proteomic signatures, genetic variation, and gene expression signatures) will be part of the final KN045 CSR that is planned to be submitted as a PostAuthorisation Efficacy Study (PAES) in July 2018.

Patient-reported outcomes (PROs) were assessed using EORTC QLQ-C30. A prolonged time to deterioration in EORTC QLQ-C30 global health status/QoL was observed for patients treated with pembrolizumab compared to investigator's choice chemotherapy (HR 0.70; 95% CI 0.55-0.90). Over 15 weeks of follow-up, patients treated with pembrolizumab had stable global health status/QoL, while those treated with investigator's choice chemotherapy had a decline in global health status/QoL, however these results should be interpreted in the context of the open-label study design and therefore taken cautiously.

## Study  KEYNOTE-052:  patients  previously  untreated  and  not  eligible  to  cisplatin-containing chemotherapy

## Design and conduct of clinical study

This is a Phase II single arm trial of pembrolizumab in first-line cisplatin-ineligible advanced/unresectable or metastatic urothelial carcinoma. Overall, the eligibility criteria are acceptable. In particular, the criteria for cisplatin-ineligibility are deemed acceptable and reflect the standard criteria used in clinical practice.

Patients were enrolled irrespective of PD-L1 status. In comparison to study KN-045, only freshly-obtained biopsy specimen was required for PD-L1 biomarker analysis. A total of 370 patients were enrolled. A biomarker discovery cohort, including the first 100 subjects enrolled and treated, served for determination of the PD-L1 strongly positive cut-point. This population was excluded from efficacy analyses for the PD-L1 strongly positive population, which were conducted on the biomarker validation cohort (n = 270 overall). The primary efficacy endpoint was ORR based on RECIST 1.1 criteria assessed by independent radiology review that was estimated for all subjects, for subjects with PD-L1 expression (CPS) ≥ 1%, and for subjects with strongly positive CPS expression (CPS) ≥ 10%. DOR (RECIST 1.1 by independent radiology review); PFS (RECIST 1.1 by independent radiology review); OS; PFS (RECIST 1.1 by independent radiology review) rate and OS rate at 6 months and 12 months were among secondary endpoints.

The sample size was initially driven by the primary efficacy hypothesis of a true ORR &gt; 30% and 2.5% (one-sided) type 1 error in PD -L1 positive subjects. Based on amendment#2 the efficacy hypothesis on ORR was removed with the justification that the success of the study was to be determined by clinically meaningful ORRs and durability of the response.

As expected based on eligibility criteria, the enrolled population was mostly ≥ 65 years (81.6%), with a median age of 74 years. The most common reasons for cisplatin ineligibility were renal dysfunction (50%), ECOG PS 2 (32.4) or both renal dysfunction and ECOG PS 2 (9%). In addition, the majority of patients (85.1%) had visceral metastases. As concern PD-L1 expression, 21.4% were PD-L1&lt;1%, while most of patients (46.5%) of had a PD-L1 CPS in the range of 1% to 10%. A discrepancy is noted between the prevalence of PD-L1&lt; 1% patients in Study KN052 and Study KN045 that could not be explained by the MAH, but will be further evaluated in future clinical trials in UC.

Pembrolizumab was administered at the fixed dosing regimen of 200 mg Q3W, which is acceptable.

<div style=\"page-break-after: always\"></div>

## Efficacy data and additional analyses

An ORR of 24.1% (95% CI 19.8, 28.7) was reported in the overall population. In 282 PD-L1 positive patients ORR was 26.6% (95% CI 21.5, 32.2). When considering the subgroup of PD-L1 strongly positive patients from the validation cohort, a higher ORR was reported 38.8% (95% CI 28.1, 50.3).

In the first-line therapy of urothelial carcinoma, an ORR up to 30%-40% with a median OS of 9 months has been reported with carboplatin-containing (De Santis M, J Clin Oncol 2012).

Updated results with a median follow-up of 9.5 months showed an improvement in ORR in the overall population [29.2% (95% CI 24.6, 34.1)]. Median DOR has not been reached yet, thus responses with pembrolizumab last longer compared to those achieved by chemotherapy in the submitted meta-analysis (median DOR 6.52, upper 95% CI 7.76 months). Although the ORR was higher in PD-L1 CPS ≥ 10% patients [47.3% (95% CI: 37.7, 57.0)], responses were also registered in PD-L1 CPS &lt; 10% and CPS &lt;1% patients [21.1% (95% CI: 16.2, 26.7) and 16.5% (95% CI: 9.1, 26.5), respectively]. The disease control rate, which includes subjects with CR, PR, and stable disease was 47.3% (95% CI: 42.1, 52.5), suggesting that there is a larger pool of subjects who may benefit from pembrolizumab beyond those who experience a confirmed response as measured by RECIST 1.1.

With 67 additional PFS events at longer follow up, a slight improvement compared to the original analysis has been reported in terms of median PFS [2.3 months (95% CI: 2.1, 3.4) versus 2.1 months (95% CI: 2.1,  3.3)],  PFS  rate  at  6  months  [33.8%  (95%  CI:  29.0%,  38.7%)  versus  30.6%  (95%  CI:  25.2%, 36.2%)] and PFS rate at 12 months [21.8% (95% CI: 17.4%, 26.6%) versus 19.0% (95% CI: 13.0%, 25.8%)].

Compared to the original submission, a consistent median OS (11 months) was reported, with a slight increase in the OS rate at 12 months [46.8 (41.1, 52.3) versus 41.2 (31.4, 50.7)].

Median PFS data remained unfavourable in comparison to chemotherapy despite a small improvement with  longer  duration  of  follow-up;  however  benefits  of  pembrolizumab  might  not  been  captured  by median PFS values. Durable responses appear to be reflected in a plateau in the tail of the KM curve beginning at approximately 8 months.

In order to provide information for contextualisation of the results in cisplatin ineligible patients, the MAH conducted and provided a systematic literature review and meta-analysis. The pooled analysis yielded an ORR of 36% (95% CI: 30%, 42%). Median duration of response (DOR) was 6.52 months (95% CI: 5.477.76), and median overall survival (OS) was 9.84 months (95% CI: 8.37-11.57). Heterogeneity among studies was performed through the I 2  statistic and resulted to be substantial for ORR and OS data (60.4% and 81.5% respectively). The quality of trials included in the meta-analysis was assessed by the MAH to evaluate  the  risk  of  bias  (including  selection  bias,  performance  bias,  detection  bias,  attrition  bias  or reporting bias) that resulted to be high in most of the trials. This can be explained considering that only one of them was a phase III study, while the others were phase II trials with a small sample size. Overall, the quality of the included trials is not fully reassuring on the validity of the results of the meta-analysis.

In the context of scientific advice (EMEA/H/SA/2437/14/2016/II) it was recommended to capture in Study KN052  post-progression  treatments  and  responses  to  treatments  to  assess  the  impact  of  2nd-line chemotherapies.  Overall,  post-progression  systemic  therapy  was  reported  in  88  subjects  (24%),  and most  of  them  (56  patients)  received  carboplatin/gemcitabine  combination.  However,  post-progression treatment responses were not captured for KN052 subjects.

Patient reported outcomes were assessed using EORTC QLQ-C30. At week 9, the majority of the subjects experienced improvement or stable global health status/QoL across all EORTC functioning and symptom domains, although scores after Week 9 should be interpreted with caution due to the small sample size. Both the EQ-5D VAS score and the EQ-5D Utility scores were stable over time.

<div style=\"page-break-after: always\"></div>

Additional efficacy data will be provided with the following Post-Authorisation Efficacy Study (PAES):

- Study KN361 comparing pembrolizumab with or without platinum-based combination chemotherapy and chemotherapy alone in both cisplatin-eligible and ineligible patients.

- Study P045 comparing pembrolizumab versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer.

- Study P052, evaluating pembrolizumab in patients with Advanced/Unresectable or Metastatic Urothelial Cancer.

## 2.4.4. Conclusions on the clinical efficacy

Based on efficacy results from study KN045, a broad indication, including patients with locally advanced or metastatic urothelial  carcinoma  who  have  received  prior  chemotherapy,  regardless  of  PD-L1 expression, has been requested by the MAH. Statistically significant and clinically meaningful gains in OS were reported across population (all-comers, PD-L1 CPS ≥1% and PD-L1 CPS ≥10%).

Even if the efficacy of pembrolizumab in the 1L cisplatin-ineligible UC population is only based on a single non-randomized study, with still an insufficient duration of follow-up and observed response rates slightly lower compared to historical data for chemotherapy, results compare rather favourable with chemotherapy in terms of duration of responses and OS.

Additional efficacy data from the ongoing Studies should be provided in order to obtain further efficacy data as Post-Authorisation Efficacy Studies (PAES):

- Study P361 comparing pembrolizumab with or without platinum-based combination chemotherapy and chemotherapy alone in both cisplatin-eligible and ineligible patients.

-  Study  P045  comparing  pembrolizumab  versus  Paclitaxel,  Docetaxel  or  Vinflunine  in  Subjects  with Recurrent or Progressive Metastatic Urothelial Cancer.

-  Study  P052,  evaluating  pembrolizumab  (MK-3475)  in  Subjects  with  Advanced/Unresectable  or Metastatic Urothelial Cancer.

## 2.5. Clinical safety

## Introduction

The known pembrolizumab safety profile, evaluated across clinical studies in advanced melanoma (1567 patients from studies KEYNOTE-001, KEYNOTE-002 and KEYNOTE-006), advanced NSCLC (1386 patients from  studies  KEYNOTE-001,  KEYNOTE-010  and  KEYNOTE-024),  and  classical  Hodgkin  Lymphoma  (241 patients  from  studies  KEYNOTE-087  and  KEYNOTE-013)  is  mainly  associated  with  immune-related adverse  reactions  and  characterized  by  general  (fatigue),  gastrointestinal  (diarrhoea  and  nausea)  and skin  (rash  and  pruritus)  disorders.  The  majority  of  adverse  reactions  reported  were  of  Grade  1  or  2 severity  and  the  most  serious  were  immune-related  adverse  reactions  and  severe  infusion-related reactions.

Within this application safety results have been presented by:

- Study KEYNOTE-045, including 266 locally advanced or metastatic urothelial carcinoma patients previously  treated  with  platinum-containing  chemotherapy,  who  received  at  least  1  dose  of

<div style=\"page-break-after: always\"></div>

- pembrolizumab  (data  Cut-off  date:  07  September  2016;  updated  data  Cut-off  date:  18  Jan 2017).
- Study KEYNOTE-052, including 370 locally advanced or metastatic urothelial carcinoma patients previously untreated and cisplatin-ineligible, who received at least 1 dose of pembrolizumab (data Cut-off date: 01 September 2016; updated data Cut-off date: 09 Mar 2017).
- Reference Safety Dataset, a pooled population of 3,194 subjects, including  patients with NSCLC (studies  KN-001,  KN-010  and  KN-024),  melanoma  (studies  KN-001,  KEYNOTE-002,  KEYNOTE006), Hodgkin's Lymphoma (studies KN-013 and KN-087) and urothelial carcinoma ( studies KN045 and KN-052), which is used to compare with studies KEYNOTE-045 and -052.
- Cumulative  Running  Safety  Dataset,  including  cumulative  pembrolizumab  safety  data  from  all studies  reported  to  the  regulatory  authority,  provided  to  demonstrate  no  meaningful  safety related difference between the cumulative dataset and the reference safety dataset.

## Patient exposure

Overall, the median exposure to pembrolizumab was shorter in urothelial carcinoma patients compared to the Reference dataset (see Table below):

## Studies KN045, KN052, and Reference Safety Dataset

Table 45: Summary of Drug Exposure (APaT Population)

|                           | KN045 and KN052 for MK-3475 N=636   | Refrence Safety Dataset for MK-34751t N=3194   | CumulativeSafety Dataset for MK-3475# N=3830   |
|---------------------------|-------------------------------------|------------------------------------------------|------------------------------------------------|
| Time on Therapy (months)  |                                     |                                                |                                                |
| Mean                      | 5.68                                | 6.65                                           | 6.49                                           |
| Median                    | 3.42                                | 4.86                                           | 4.71                                           |
| SD                        | 5.66                                | 5.79                                           | 5.78                                           |
| Range                     | 0.03 to 22.80                       | 0.03 to 30.39                                  | 0.03 to 30.39                                  |
| Number of Administrations |                                     |                                                |                                                |
| Mean                      | 8.81                                | 11.23                                          | 10.83                                          |
| Median                    | 5.50                                | 8.00                                           | 8.00                                           |
| SD                        | 7.87                                | 9.45                                           | 9.25                                           |
| Range                     | 1.00 to 34.00                       | 1.00 to 59.00                                  | 1.00 to 59.00                                  |

Duration of Exposure is calculated as last dose date -first dose date +1.

I Includes all subjects who received at least one dose ofMK-3475 in KN001 Part B1, B2, B3, D, C, F1, F2, F3; KN002 (original phase), KN006, KN010, KN013 Cohort 3 (Hodgkin's Lymphoma), KN024, and KN087.

Includes all subjects who received at least one dose ofMK-3475 in KN001 Part B1, B2, B3, D, C, F1, F2, F3; KN002 (original phase), KN006, KN010, KN013 Cohort 3 (Hodgkin's Lymphoma), KN024, KN045, KN052, and KN087.

(KN001 Database Cutoff Date for Melanoma: 18APR2014).

(KN001 Database Cutoff Date for Lung Cancer: 23JAN2015).

(KN002 Database Cutoff Date: 28FEB2015).

(KN006 Database Cutoff Date: 03MAR2015).

(KN010 Database Cutoff Date: 30SEP2015).

(KN013 Database Cutoff Date for Hodgkin's Lymphoma: 27SEP2016).

(KN024 Database Cutoff Date: 09MA Y2016).

(KN045 Database Cutoff Date: 18JAN2017).

(KN052 Database Cutoff Date: 09MAR2017).

(KN087 Database Cutoff Date: 25SEP2016).

In study KEYNOTE-045 the duration of exposure was 3.45 months for the pembrolizumab arm at the last updated data Cut-off, with a median number of 6 administrations. At the initial data Cut-off, a total of 139 (52.2%) and 95 (35.7%) subjects received pembrolizumab for ≥3 months and for ≥6 months,

<div style=\"page-break-after: always\"></div>

respectively. The exposure to pembrolizumab was 1 year or longer for 43 (16 %) patients. In contrast, of the 255 subjects in the control arm, only 29 (11.4%) received treatment for ≥ 6 months and 3 (1.2%) received treatment for ≥ 12 months.

The duration of exposure was similar in study KEYNOTE-052, with a median time on therapy of 3.40 months and a median number of 5 administrations.At the initial data Cut-off, a total of 157 (42.4%) patients were treated for at least 3 months, 72 (19.5%) for at least 6 months and 9 (2.4%) patients exposed ≥ 1 year to pembrolizumab.

In comparison to the reference safety dataset, patients in both KN-045 and KN-052 were mostly male (74.4% and 77.3%, respectively, versus 59.3%), older, as demonstrated by the higher percentage of subjects ≥65 years (61.3% and 81.6%, respectively, versus 43.3%), and had ECOG PS of 2 (1.5% and 42.2%, respectively versus 0).

## Adverse events

In both studies KN-045 and KN-052 pembrolizumab safety and tolerability has been evaluated during the treatment period up to two different cut-off dates, 7-Sep-2016 (Table 46) and 18-Jan-2017 (Table 47). Adverse events, which occurred from the first dose up to 30 days after the last dose, were reported and coded using Medical Dictionary for Regulatory Activities (MedDRA) Version 19.0 and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0.

## Table 46: AEs Summary Study KN045

## (APaT Population)

|                                                                                                                                                                                                                                                                                                                                                                | KN045                                                                                                  | KN045                                                                                                           |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                | control n (%)                                                                                          | pembrolizumab n (%)                                                                                             |
| Subjects in population with one or more adverse events with no adverse event with drug-related † adverse events with toxicity grade ≥3 AEs with toxicity grade ≥3 drug-related AEs with serious adverse events with serious drug-related AEs who died who died due to a drug-related AE discontinued ‡ due to an adverse discontinued due to a drug-related AE | 255 250 (98.0) 5 (2.0) 230 (90.2) 160 (62.7) 126 (49.4) 104 (40.8) 57 (22.4) 8 (3.1) 4 (1.6) 32 (12.5) | 266 248 (93.2) 18 (6.8) 162 (60.9) 139 (52.3) 40 (15.0) 104 (39.1) 27 (10.2) 13 (4.9) 4 (1.6) 22 (8.3) 15 (5.6) |
| event                                                                                                                                                                                                                                                                                                                                                          |                                                                                                        |                                                                                                                 |
|                                                                                                                                                                                                                                                                                                                                                                | 28 (11.0)                                                                                              |                                                                                                                 |
| discontinued due to a serious AE                                                                                                                                                                                                                                                                                                                               | 12 (4.7)                                                                                               | 15 (5.6)                                                                                                        |
| discontinued due to a serious drug- related AE                                                                                                                                                                                                                                                                                                                 | 10 (3.9)                                                                                               | 9 (3.4)                                                                                                         |

Data cut-off 7-Sept-2016

<div style=\"page-break-after: always\"></div>

The overall pembrolizumab safety profile favorably compares with chemotherapy in study KN045, with a lower rate of drug-related AEs (60.9% vs 90.2%), drug-related Grade≥3 AEs (15% vs 49.4%), serious drug-related AEs (10.2 vs 22.4%) and discontinuations due to drug-related AEs (11% vs 5.6%).

Table 47: Adverse Event Summary Studies KN045, KN052, KN001, KN002, KN006, KN010, KN013, KN024, and KN087

## (APaT Population)

|                                                          | KN045 for MK-3475   | KN045 for MK-3475   | Refrence Safety Dataset for MK-3475tt   | Refrence Safety Dataset for MK-3475tt   | Cumulative Safety Dataset for MK-3475   | Cumulative Safety Dataset for MK-3475   |
|----------------------------------------------------------|---------------------|---------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|
|                                                          | n                   | (%)                 | n                                       | (%)                                     |                                         | (%)                                     |
| Subjects in population                                   | 266                 |                     | 3,194                                   |                                         | 3,460                                   |                                         |
| with one or more adverse events                          | 249                 | (93.6)              | 3,107                                   | (97.3)                                  | 3,356                                   | (97.0)                                  |
| with no adverse event                                    | 17                  | (6.4)               | 87                                      | (2.7)                                   | 104                                     | (3.0)                                   |
| with drug-related adverse events                         | 163                 | (61.3)              | 2,340                                   | (73.3)                                  | 2,503                                   | (72.3)                                  |
| with toxicity grade 3-5 adverse events                   | 145                 | (54.5)              | 1,421                                   | (44.5)                                  | 1,566                                   | (45.3)                                  |
| with toxicity grade 3-5 drug-related adverse events      | 44                  | (16.5)              | 456                                     | (14.3)                                  | 500                                     | (14.5)                                  |
| with non-serious adverse events                          | 244                 | (91.7)              | 3,046                                   | (95.4)                                  | 3,290                                   | (95.1)                                  |
| with serious adverse events                              | 108                 | (40.6)              | 1,154                                   | (36.1)                                  | 1,262                                   | (36.5)                                  |
| with serious drug-related adverse events                 | 31                  | (11.7)              | 329                                     | (10.3)                                  | 360                                     | (10.4)                                  |
| with dose modification due to an adverse event           | 80                  | (30.1)              | 1,021                                   | (32.0)                                  | 1,101                                   | (31.8)                                  |
| who died                                                 | 13                  | (4.9)               | 121                                     | (3.8)                                   | 134                                     | (3.9)                                   |
| who died due to a drug-related adverse event             | 4                   | (1.5)               | 11                                      | (0.3)                                   | 15                                      | (0.4)                                   |
| discontinued due to an adverse event                     | 26                  | (9.8)               | 362                                     | (11.3)                                  | 388                                     | (11.2)                                  |
| discontinued due to a drug-related adverse event         | 18                  | (6.8)               | 169                                     | (5.3)                                   | 187                                     | (5.4)                                   |
| discontinued due to a serious adverse event              | 19                  | (7.1)               | 274                                     | (8.6)                                   | 293                                     | (8.5)                                   |
| discontinued due to a serious drug-related adverse event | 12                  | (4.5)               | 117                                     | (3.7)                                   | 129                                     | (3.7)                                   |

I Study medication withdrawn.

Determined by the investigator to be related to the drug.

Defined as overall action taken of dose reduced, drug interrupted or drug withdrawn.

MedDRA version used is 19.1.

- MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

I Includes all subjects who received at least one dose of MK-3475 in KN001 Part B1, B2, B3, D, C, F1, F2, F3; KN002 (original phase), KN006, KN010, KN013 Cohort 3 (Hodgkin's Lymphoma), KN024, and KN087.

- )  1  1     1 1   o  o p      s phase), KN006, KN010, KN013 Cohort 3 (Hodgkin's Lymphoma), KN024, KN045, and KN087.

(KN001 Database Cutoff Date for Melanoma: 18APR2014).

- (KN001 Database Cutoff Date for Lung Cancer: 23JAN2015).
- (KN002 Database Cutoff Date: 28FEB2015).
- (KN006 Database Cutoff Date: 03MAR2015).
- (KN010 Database Cutoff Date: 30SEP2015).
- (KN013 Database Cutoff Date for Hodgkin's Lymphoma: 27SEP2016).
- (KN024 Database Cutoff Date: 09MAY2016).

(KN045 Database Cutoff Date: 18JAN2017).

(KN087 Database Cutoff Date:25SEP2016).

Source: [ISS: analysis-adsl; adaeosi; aeplus]

Data cut-off 18-Jan-2017

In study KN-045, the most frequent AEs in the pembrolizumab arm were fatigue (25.6%), pruritus (23.7%), decreased appetite (21.4%) and nausea (20.7%). In the control arm, AEs observed in ≥ 20% of the subjects were alopecia (38.8%), anemia (35.7%), fatigue (33.7%), constipation (31.8%), nausea (28.6%), decreased appetite (20.8 %) and asthenia (20.8%).

<div style=\"page-break-after: always\"></div>

Table 48: Adverse Event Summary (incidence ≥10% in One or More Groups) All Subjects in Study KN045

## (APaT Population)

|                                                        | Control   | Control   | Pembrolizimab   | Pembrolizimab   |
|--------------------------------------------------------|-----------|-----------|-----------------|-----------------|
|                                                        |           | (%:0)     | n               | (6)             |
| Subjects in population with one or more adverse events | 255 250   | (98.0)    | 266 248         | (93.2)          |
| with no adverse events                                 | 5         | (2.0)     | 18              | (6.8)           |
| Blood and lymphatic system disorders                   | 130       | (51.0)    | 53              | (19.9)          |
| Anaemia                                                | 16        | (35.7)    | 46              | (17.3)          |
| Neutropenia                                            | 43        | (16.9)    | 0               | (0.0)           |
| Endocrine disorders                                    | 4         | (1.6)     | 28              | (10.5)          |
| Gastrointestinal disorders                             | 174       | (68.2)    | 150             | (56.4)          |
| Abdominal pain                                         | 34        | (13.3)    | 34              | (12.8)          |
| Constipation                                           | 81        | (31.8)    | 50              | (18.8)          |
| Dianhoea                                               | 48        | (18.8)    | 43              | (16.2)          |
| Nausea                                                 | 73        | (28.6)    | 55              | (20.7)          |
| Vomiting                                               | 34        | (13.3)    | 39              | (14.7)          |
| General disorders and administration site conditions   | 184       | (72.2)    | 153             | (61.5)          |
| Asthenia                                               | 53        | (20.8)    | 30              | (11.3)          |
| Fatigue                                                | 86        | (33.7)    | 69              | (25.9)          |
| Oedema peripheral                                      | 40        | (15.7)    | 26              | (9.8)           |
| Pyrexia                                                | 33        | (12.9)    | 36              | (13.5)          |
| Iufections and infestations                            | 94        | (36.9)    | 105             | (39.5)          |
| Urinary tract infection                                | 34        | (13.3)    | 39              | (14.7)          |
| Investigations                                         | 89        | (34.9)    | 77              | (28.9)          |
| Neutrophil count decreased                             | 38        | (14.9)    | 1               | (0.4)           |
| Metabolism and nutrition disorders                     | 97        | (38.0)    | 101             | (38.0)          |
| Decreased appetite                                     | 53        | (20.8)    | 56              | (21.1)          |
| Musculoskeletaland connective tissue                   | 95        | (37.3)    | 113             | (42.5)          |
| Arthralgia                                             | 30        | (11.8)    | 24              | (9.0)           |
| Back pain                                              | 21        | (8.2)     | 37              | (13.9)          |
| Pain in extremity                                      | 28        | (11.0)    | 21              | (62)            |
| Nervous system disorders                               | 105       | (41.2)    | 58              | (21.8)          |
| Neuropathy peripheral                                  | 31        | (12.2)    | 1               | (0.4)           |
| Pariphernl sensory neuropathy                          | 28        | (11.0)    | 2               | (0.8)           |
| Psychiatric disorders                                  | 43        | (16.9)    | 38              | (14.3)          |
| Renal and urinary disorders                            | 45        | (17.6)    | 72              | (27.1)          |
| Haemaruria                                             | 20        | (7.8)     | 30              | (11.3)          |
| Respiratory, thoracic and mediastinal disorders        | 15        | (29.4)    | 91              | (34.2)          |
| Cough                                                  | 18        | (7.1)     | 38              | (14.3)          |
| Dyspnoea                                               | 23        | (9.0)     | 33              | (12.4)          |
| Slin and subcutaneous tissue disorders                 | 127       | (49.8)    | 114             | (42.9)          |
| Alopecia                                               | 66        | (38.8)    | 2               | (0.8)           |
|                                                        | 14        | (5.5)     | 62              | (23.3)          |
| Rash                                                   | 16        | (6.3)     | 29              | (10.9)          |
| Vascular disorders                                     | 32        | (12.5)    | 39              | (14.7)          |

Every subject is coumted a single time for each applicable row and columm.

A system organ class or speciic adverse event appears on this report only ifits incidence in one or more of the columns meets the incidence criterion in the report title, afier rounding.

MedDRA V19.0 prefered teruis \"Neoplasm progression\", *Malignant neoplasm progression and \"Disease progression\" not related to the drug are excluded.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. Control aurm is investigator's choice of paclitaxel, docetaxel or vinflunine.

Database Cutoff Date: 07SEP2016

Source: [P045V01: analysis-adsl] [P045V01: tabulations-aeplus]

In study KN052, the most common reported AEs were fatigue (31.1%), decreased appetite (21.6%), and constipation (21.1%).

<div style=\"page-break-after: always\"></div>

The frequency of AEs was generally comparable between both populations in studies KN045 and KN052, and the Reference Safety Dataset.

Table 49: Adverse Event Summary (incidence ≥5% in One or More Groups)  Studies KN045, KN052 and Reference Safety Dataset by Body System or Organ Class and PT

## (APaT Population)

|                                                                              | KN045 n (%)                              | KN052 n (%)                    | Reference Safety Dataset * n (%)   |
|------------------------------------------------------------------------------|------------------------------------------|--------------------------------|------------------------------------|
| Subjects in population with one or more adverse events with no adverse event | 266 248 (93.2) 18 (6.8)                  | 370 354 (95.7) 16 (4.3)        | 2,799 2,727 (97.4) 72 (2.6)        |
| Blood and lymphatic system disorders                                         | 53 (19.9) 46 (17.3)                      | 73 (19.7) 61 (16.5)            | 487 (17.4) 347 (12.4)              |
| Cardiac disorders Endocrine disorders                                        | 15 (5.6)                                 | 28 (7.6)                       | 253 (9.0)                          |
| Hypothyroidism                                                               | 28 (10.5) 17 (6.4)                       | 38 (10.3) 24 (6.5)             | 335 (12.0) 236 (8.4)               |
| Gastrointestinal disorders Abdominal pain Constipation Diarrhoea             | 150 (56.4) 34 (12.8) 50 (18.8) 43 (16.2) | 202 (54.6) 40 (10.8) 78 (21.1) | 1,705 (60.9) 274 (9.8) 497 (17.8)  |
| Dry mouth Nausea                                                             | 7 (2.6) 55 (20.7)                        | 69 (18.6) 18 (4.9) 68 (18.4)   | 625 (22.3) 142 (5.1)               |
| Vomiting General disorders and administration site conditions                | 39 (14.7) 153                            | 46 (12.4) 211 (57.0)           | 685 (24.5) 387 (13.8)              |
|                                                                              | (57.5)                                   |                                | 1,856 (66.3)                       |
| Asthenia Chest pain                                                          | 30 (11.3)                                | 38 (10.3) 13 (3.5)             | 362 (12.9) 165 (5.9)               |
|                                                                              | 5 (1.9)                                  |                                |                                    |
|                                                                              |                                          | 21 (5.7)                       |                                    |
| Chills                                                                       | 5 (1.9)                                  |                                | 153 (5.5)                          |
| Fatigue                                                                      | 69 (25.9)                                | 115 (31.1)                     | 1,044 (37.3)                       |

<div style=\"page-break-after: always\"></div>

| Pyrexia                                                             | 36 (13.5)   | 41 (11.1)   | 357 (12.8)   |
|---------------------------------------------------------------------|-------------|-------------|--------------|
| Infections and infestations                                         | 105 (39.5)  | 146 (39.5)  | 1,180 (42.2) |
| Nasopharyngitis                                                     | 14 (5.3)    | 1 (0.3)     | 182 (6.5)    |
| Pneumonia                                                           | 12 (4.5)    | 15 (4.1)    | 140 (5.0)    |
| Upper respiratory tract infection                                   | 7 (2.6)     | 12 (3.2)    | 182 (6.5)    |
| Urinary tract infection                                             | 39 (14.7)   | 70 (18.9)   | 162 (5.8)    |
| Injury, poisoning and procedural complications                      | 25 (9.4)    | 42 (11.4)   | 362 (12.9)   |
| Investigations                                                      | 77 (28.9)   | 128 (34.6)  | 865 (30.9)   |
| Alanine aminotransferase increased                                  | 14 (5.3)    | 23 (6.2)    | 172 (6.1)    |
| Aspartate aminotransferase increased                                | 14 (5.3)    | 25 (6.8)    | 168 (6.0)    |
| Blood alkaline phosphatase increased                                | 9 (3.4)     | 21 (5.7)    | 112 (4.0)    |
| Blood creatinine increased                                          | 13 (4.9)    | 41 (11.1)   | 108 (3.9)    |
| Weight decreased                                                    | 24 (9.0)    | 37 (10.0)   | 219 (7.8)    |
| Metabolism and nutrition disorders                                  | 101 (38.0)  | 157 (42.4)  | 1,109 (39.6) |
| Hyperglycaemia                                                      | /           | 33 (8.9)    | 130 (4.6)    |
| Hyperkalaemia                                                       | /           | 24 (6.5)    | 61 (2.2)     |
| Hyponatraemia                                                       | 15 (5.6)    | 36 (9.7)    | 146 (5.2)    |
| Musculoskeletal and connective                                      | 113 (42.5)  | 145 (39.2)  | 1,411 (50.4) |
| Arthralgia                                                          | 24 (9.0)    | 37 (10.0)   | 504 (18.0)   |
| Back pain                                                           | 37 (13.9)   | 42 (11.4)   | 349 (12.5)   |
| Musculoskeletal pain                                                | 13 (4.9)    | 16 (4.3)    | 226 (8.1)    |
| Myalgia                                                             | 14 (5.3)    | 15 (4.1)    | 253 (9.0)    |
| Pain in extremity                                                   | 21 (7.9)    | 22 (5.9)    | 237 (8.5)    |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 18 (6.8)    | 16 (4.3)    | 256 (9.1)    |
| Nervous system disorders                                            | 58 (21.8)   | 97 (26.2)   | 1,037 (37.0) |
| Dizziness                                                           | 15 (5.6)    | 24 (6.5)    | 244 (8.7)    |
| Headache                                                            | 13 (4.9)    | 13 (3.5)    | 400 (14.3)   |

<div style=\"page-break-after: always\"></div>

| Psychiatric disorders Anxiety Insomnia                                                                  | 38 (14.3) 8 (3.0) 16 (6.0)                     | 55 (14.9) 9 (2.4) 23 (6.2)       | 523 (18.7) 141 (5.0) 218 (7.8)   |
|---------------------------------------------------------------------------------------------------------|------------------------------------------------|----------------------------------|----------------------------------|
| Renal and urinary disorders Acute kidney injury Haematuria                                              | 72 (27.1) 15 (5.6) 30 (11.3)                   | 111 (30.0) 21 (5.7) 48 (13.0)    | 271 (9.7) 40 (1.4) 39 (1.4)      |
| Reproductive system and breast disorders Respiratory, thoracic and mediastinal disorders Cough Dyspnoea | 18 (6.8) 91 (34.2) 38 (14.3) 33 (12.4) 6 (2.3) | 24 (6.5) 118 51 (13.8) 39 (10.5) | 129 (4.6) 1,391 615 (22.0)       |
| Productive cough                                                                                        |                                                | (31.9) 14 (3.8)                  | (49.7) 534 (19.1) 142 (5.1)      |
| Skin and subcutaneous tissue disorders Dry skin Pruritus                                                | 114                                            | 139 (37.6) 11 (3.0) 70 (18.9)    | 1,360                            |
|                                                                                                         | (42.9)                                         | 42 (11.4)                        | (48.6) 165 (5.9)                 |
| Rash                                                                                                    | 39 (14.7)                                      |                                  | 562 (20.1) 499 (17.8) 171 (6.1)  |
|                                                                                                         | 14 (5.3) 62 (23.3) 29 (10.9)                   | 46 (12.4) 0 (0.0)                |                                  |
| Vitiligo                                                                                                |                                                |                                  |                                  |
|                                                                                                         | 1 (0.4)                                        |                                  |                                  |
| Vascular disorders                                                                                      |                                                |                                  | 410 (14.6)                       |

Every subject is counted a single time for each applicable row and column.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

* Includes all subjects who received at least one dose of MK-3475 in KN001 Part B1, B2, B3, D, C, F1, F2, F3; KN002 (original phase), KN006, KN010.

(KN001 Database Cut-off Date for Melanoma: 18APR2014).

(KN001 Database Cut-off Date for Lung Cancer: 23JAN2015).

(KN002 Database Cut-off Date: 28FEB2015).

(KN006 Database Cut-off Date: 03MAR2015).

(KN010 Database Cut-off Date: 30SEP2015).

<div style=\"page-break-after: always\"></div>

Across both studies in Urothelial cancer, Urinary tract infection and Haematuria , as well as increase of Blood alkaline phosphatase and Blood creatinine in study KN052, occurred more frequently than in the reference safety dataset. Upon medical review, these events were deemed unlikely related to pembrolizumab and more likely associated with the underlying disease condition, medical history, or medical procedures (eg, cystoscopy). None of these AEs represents a new safety signal for pembrolizumab.

## Grade 3-5 Adverse Events

A lower rate of subjects in the pembrolizumab arm of Study KN045 experienced Grade ≥3 AEs (52.3%) compared to the control arm (62.7%).

Table 50: Grade ≥3 Adverse Events (incidence ≥5% in One or More Groups) All Subjects in Study KN045 (APaT Population)

|                                  | Control   | Control   | Pembrolizumab   | Pembrolizumab   |
|----------------------------------|-----------|-----------|-----------------|-----------------|
|                                  |           | (%)       | n               | (%)             |
| Subjects in population           | 255       |           | 266             |                 |
| with one or more adverse events  | 160       | (62.7)    | 139             | (52.3)          |
| withno adverse events            | 95        | (37.3)    | 127             | (47.7)          |
| Anaemia                          | 31        | (12.2)    | 22              | (8.3)           |
| Neutropenia                      | 37        | (14.5)    | 0               | (0.0)           |
| Neutrophil count decreased       | 32        | (12.5)    | 1               | (0.4)           |
| Fatigue                          | 15        | (5.9)     | 10              | (3.8)           |
| Febrile neutropenia              | 19        | (7.5)     | 0               | (0.0)           |
| Asthenia                         | 13        | (5.1)     | 2               | (0.8)           |
| White blood cell count decreased | 14        | (5.5)     | 1               | (0.4)           |

Every subject is counted a single time for each applicable specific adverse event.

A specific adverse event appears on this report only ifits incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

MedDRA V19.0 preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and \"Disease progression\" not related to the drug are excluded.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

Control arm is investigator's choice of paclitaxel, docetaxel or vinflunine.

DatabaseCutoffDate:07SEP2016

Source:[P045V01: analysis-adsl] [P045V01:tabulations-aeplus]

In  study  KN052, 53.8%  of  subjects  experienced  at  least  1  Grade  ≥3  AEs,  and  the  most  commonly reported were urinary tract infection (9.5%) and anemia (7.0%), see Table 51.

Table 51: Grade ≥3 Adverse Events (incidence ≥5% in One or More Groups) All Subjects in Study KN052 (APaT Population)

|                            | Pembrolizumab   | Pembrolizumab   |
|----------------------------|-----------------|-----------------|
|                            | n               | (%)             |
| Subjects in population     | 370             |                 |
| withoneormoreadverseevents | 199             | (53.8)          |
| withnoadverseevents        | 171             | (46.2)          |
| Urinary tract infection    | 35              | (9.5)           |
| Anaemia                    | 26              | (7.0)           |

Every subjectis counted a singletimeforeach applicable specific adverseevent.

A specific adverse event appears on this report only if its incidence meets the incidence criterion in the report title, after rounding. MedDRA V19 preferred terms \"Neoplasm progression\",\"Malignant neoplasm progression\" and \"Disease progression\" not related to the drug are excluded.

Non-serious adverse events up to30days of last dose andserious adverseevents up to90days of last dose are included. DatabaseCutoffDate:01SEP2016

Source:[P052V01MK3475: analysis-adsl] [P052V01MK3475: tabulations-aeplus]

<div style=\"page-break-after: always\"></div>

## Drug-related Adverse Events

In  Study KN045, fewer subjects in the pembrolizumab arm than in the control arm experienced drugrelated AEs (60.9% vs 90.2%, respectively). In the pembrolizumab arm, the most frequently observed drug-related AEs were Pruritus (19.5%), Fatigue (13.9%) and Nausea (10.9%). In the control arm, drugrelated AEs observed in ≥10% of the subjects were Alopecia (37.6%), Fatigue (27.8%), Anemia (24.7%), Nausea (24.3%), Constipation (20.4%), Decreased  appetite (16.1%), Neutropenia (15.3%), Asthenia (14.1%), Neutrophil  count  decreased (14.1%), Diarrhea (12.9%), Peripheral  sensory  neuropathy (11.0%), and Neuropathy peripheral (10.6%).

With the exception of Pruritus , all most common drug-related AEs observed in the pembrolizumab group were reported in a lower or similar frequency compared to control, while all most common drug-related AEs observed in the control arm were reported in higher or similar frequency in comparison to patients receiving pembrolizumab.

In Study KN052, The most commonly reported drug-related AEs were Fatigue (16.8%), Pruritus (14.6%) and Rash (9.7%).

Overall, the pattern of drug-related adverse events in KN045 and KN052 is comparable to the reference safety dataset as shown in Table 52, which was compiled from the most recent data-cut-off for KN045 and KN052 (18-Jan-2017 and 8-Mar-2017, respectively).

Table 52: Drug-related Adverse Events (incidence &gt;2 in KN045 and KN052) Studies KN045, KN052, KN001, KN002, KN006, KN010, KN013, KN024 and KN087 by Body System or Organ Class and PT

(APaT Population)

|                                                                              | KN045 and KN052 n (%)     | Reference Safety Dataset ° n (%)   | Cumulative Safety Dataset * n (%)   |
|------------------------------------------------------------------------------|---------------------------|------------------------------------|-------------------------------------|
| Subjects in population with one or more adverse events with no adverse event | 636 406 (63.8) 230 (36.2) | 3,194 2,340 (73.3) 854 (26.7)      | 3,830 2,746 (71.7) 1,084 (28.3)     |
| Blood and lymphatic system disorders                                         | 24 (3.8)                  | 185 (5.8)                          | 209 (5.5)                           |
| Cardiac disorders Myocarditis                                                | 3 (0.5) 2 (0.3)           | 30 (0.9) 1 (0.0)                   | 33 (0.9) 3 (0.1)                    |
| Thrombocytopenia                                                             | 3 (0.5)                   | 26 (0.8)                           | 29 (0.8)                            |
| Ear and labyrinth disorders                                                  | 2 (0.3)                   | 20 (0.6)                           | 22 (0.6)                            |
| Endocrine disorders                                                          | 72 (11.3)                 | 348 (10.9)                         | 420 (11.0)                          |
| Adrenal insufficiency                                                        | 5 (0.8)                   | 15 (0.5)                           | 20 (0.5)                            |
| Hyperthyroidism                                                              | 18 (2.8) 2 (0.3)          | 99 (3.1) 8 (0.3)                   | 117 (3.1) 10 (0.3)                  |
| Hypophysitis Hypothyroidism                                                  | 53 (8.3)                  | 255 (8.0)                          |                                     |
|                                                                              |                           |                                    | 308 (8.0)                           |
| Thyroiditis                                                                  | 3 (0.5)                   | 16 (0.5)                           | 19 (0.5)                            |
|                                                                              | 11 (1.7)                  | 134 (4.2)                          | 145 (3.8)                           |
| Eye disorders Dry eye                                                        | 2 (0.3)                   | 32 (1.0)                           | 34 (0.9)                            |

<div style=\"page-break-after: always\"></div>

| Lacrimation increased                                                                                                                                                             | 2 (0.3)                                                                                                                                                                                       | 11 (0.3)                                                                                                                                                                                                    |                                                                                                                                                                |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Gastrointestinal disorders Abdominal discomfort Abdominal distension Abdominal pain Abdominal pain upper Colitis Constipation                                                     | 149 (23.4) 2 (0.3) 2 (0.3)                                                                                                                                                                    | 897 (28.1) 15 (0.5) 23 (0.7)                                                                                                                                                                                | 1,046                                                                                                                                                          |
| Nausea Oral pain Stomatitis Vomiting General disorders and administration site Asthenia Chest pain Chills Face oedema Fatigue Influenza like illness Malaise Mucosal inflammation | 4 (0.6) 13 (2.0) 18 (2.8) 56 (8.8) 15 (2.4) 5 (0.8) 3 (0.5) 60 (9.4) 2 (0.3) 8 (1.3) 25 (3.9) 32 (5.0) 2 (0.3) 13 (2.0) 2 (0.3) 104 (16.4) 14 (2.2) 5 (0.8) 5 (0.8) 12 (1.9) 31 (4.9) 2 (0.3) | 103 (3.2) 386 (12.1) 81 (2.5) 13 (0.4) 4 (0.1) 335 (10.5) 4 (0.1) 40 (1.3) 121 (3.8) 228 (7.1) 20 (0.6) 88 (2.8) 8 (0.3) 716 (22.4) 49 (1.5) 26 (0.8) 23 (0.7) 60 (1.9) 164 (5.1) 13 (0.4) 34 (1.1) 4 (0.1) | 13 (0.3) (28.5) 17 (0.4) 25 (0.7) 83 (2.2) 31 (0.8) 55 (1.4) 121 (3.2) 442 (11.5) 96 (2.5) 18 (0.5) 7 (0.2) 395 (10.3) 6 (0.2) 48 (1.3) 146 (3.8) 1,360 (35.5) |
| Immune system disorders                                                                                                                                                           | 2 (0.3)                                                                                                                                                                                       | 36 (1.1) 160 (5.0)                                                                                                                                                                                          | 38 (1.0)                                                                                                                                                       |
| Cellulitis Conjunctivitis                                                                                                                                                         | 2 (0.3) 2 (0.3)                                                                                                                                                                               | 74 (2.3)                                                                                                                                                                                                    |                                                                                                                                                                |
|                                                                                                                                                                                   | 9 (1.4)                                                                                                                                                                                       | 27 (0.8)                                                                                                                                                                                                    |                                                                                                                                                                |
|                                                                                                                                                                                   |                                                                                                                                                                                               | 42 (1.3)                                                                                                                                                                                                    |                                                                                                                                                                |
| Diarrhoea                                                                                                                                                                         |                                                                                                                                                                                               |                                                                                                                                                                                                             |                                                                                                                                                                |
| Dry mouth                                                                                                                                                                         |                                                                                                                                                                                               |                                                                                                                                                                                                             |                                                                                                                                                                |
| Dyspepsia                                                                                                                                                                         |                                                                                                                                                                                               |                                                                                                                                                                                                             |                                                                                                                                                                |
| Flatulence                                                                                                                                                                        |                                                                                                                                                                                               |                                                                                                                                                                                                             |                                                                                                                                                                |
|                                                                                                                                                                                   | 182 (28.6)                                                                                                                                                                                    | 1,178 (36.9)                                                                                                                                                                                                |                                                                                                                                                                |
| conditions                                                                                                                                                                        |                                                                                                                                                                                               |                                                                                                                                                                                                             | 260 (6.8) 22 (0.6)                                                                                                                                             |
|                                                                                                                                                                                   |                                                                                                                                                                                               |                                                                                                                                                                                                             | 101 (2.6)                                                                                                                                                      |
|                                                                                                                                                                                   |                                                                                                                                                                                               |                                                                                                                                                                                                             | 10 (0.3)                                                                                                                                                       |
|                                                                                                                                                                                   |                                                                                                                                                                                               |                                                                                                                                                                                                             | 820 (21.4) 63 (1.6)                                                                                                                                            |
|                                                                                                                                                                                   |                                                                                                                                                                                               |                                                                                                                                                                                                             | 31 (0.8)                                                                                                                                                       |
|                                                                                                                                                                                   |                                                                                                                                                                                               |                                                                                                                                                                                                             | 28 (0.7)                                                                                                                                                       |
| Oedema peripheral                                                                                                                                                                 |                                                                                                                                                                                               |                                                                                                                                                                                                             | 72 (1.9)                                                                                                                                                       |
| Pyrexia                                                                                                                                                                           |                                                                                                                                                                                               |                                                                                                                                                                                                             | 195 (5.1)                                                                                                                                                      |
| Xerosis                                                                                                                                                                           |                                                                                                                                                                                               |                                                                                                                                                                                                             | 15 (0.4)                                                                                                                                                       |
| Hepatobiliary disorders Hepatitis                                                                                                                                                 | 7 (1.1) 3 (0.5)                                                                                                                                                                               |                                                                                                                                                                                                             | 41 (1.1) 7 (0.2)                                                                                                                                               |
| infestations                                                                                                                                                                      |                                                                                                                                                                                               |                                                                                                                                                                                                             |                                                                                                                                                                |
| Infections and                                                                                                                                                                    | 33 (5.2)                                                                                                                                                                                      | 1 (0.0)                                                                                                                                                                                                     | 193 (5.0) 3 (0.1) 18 (0.5)                                                                                                                                     |
|                                                                                                                                                                                   |                                                                                                                                                                                               | 16 (0.5)                                                                                                                                                                                                    |                                                                                                                                                                |
| Fungal skin infection Herpes zoster                                                                                                                                               | 2 (0.3) 2 (0.3)                                                                                                                                                                               | 2 (0.1)                                                                                                                                                                                                     | 4 (0.1) 8 (0.2)                                                                                                                                                |
| Oral fungal                                                                                                                                                                       | 2 (0.3)                                                                                                                                                                                       | 6 (0.2)                                                                                                                                                                                                     | 9 (0.2)                                                                                                                                                        |
| infection                                                                                                                                                                         |                                                                                                                                                                                               | 7 (0.2)                                                                                                                                                                                                     |                                                                                                                                                                |
| Rash pustular                                                                                                                                                                     | 3 (0.5)                                                                                                                                                                                       | 2 (0.1)                                                                                                                                                                                                     | 5 (0.1)                                                                                                                                                        |
| Rhinitis                                                                                                                                                                          | 3 (0.5)                                                                                                                                                                                       | 5 (0.2)                                                                                                                                                                                                     | 8 (0.2)                                                                                                                                                        |
| Urinary tract infection                                                                                                                                                           | 5                                                                                                                                                                                             | 5                                                                                                                                                                                                           | 10                                                                                                                                                             |
|                                                                                                                                                                                   | (0.8)                                                                                                                                                                                         | (0.2)                                                                                                                                                                                                       |                                                                                                                                                                |
| Injury, poisoning                                                                                                                                                                 | 4                                                                                                                                                                                             |                                                                                                                                                                                                             | (0.3)                                                                                                                                                          |
| and procedural complications                                                                                                                                                      | (0.6)                                                                                                                                                                                         | 53 (1.7)                                                                                                                                                                                                    | 57 (1.5)                                                                                                                                                       |
| Investigations Alanine aminotransferase increased                                                                                                                                 | 84 (13.2) 20 (3.1) 21 (3.3) 11 (1.7)                                                                                                                                                          | 446 (14.0) 111 (3.5) 106 (3.3)                                                                                                                                                                              | 530 (13.8) 131 (3.4) 127 (3.3) 51 (1.3)                                                                                                                        |
| Aspartate aminotransferase increased Blood alkaline phosphatase increased Blood bilirubin increased                                                                               | 7 (1.1) 9 (1.4)                                                                                                                                                                               | 40 (1.3) 27 (0.8)                                                                                                                                                                                           | 34 (0.9) 49 (1.3)                                                                                                                                              |
| Blood creatinine increased Blood thyroid stimulating hormone                                                                                                                      | 5 (0.8)                                                                                                                                                                                       | 40 (1.3) 36(1.1)                                                                                                                                                                                            | 41 (1.1)                                                                                                                                                       |
|                                                                                                                                                                                   | 3 (0.5)                                                                                                                                                                                       | 24 (0.8)                                                                                                                                                                                                    |                                                                                                                                                                |
| increased Lymphocyte count decreased                                                                                                                                              |                                                                                                                                                                                               |                                                                                                                                                                                                             | 27 (0.7)                                                                                                                                                       |
| Platelet count decreased                                                                                                                                                          | 6 (0.9)                                                                                                                                                                                       | 17 (0.5)                                                                                                                                                                                                    | 23                                                                                                                                                             |
|                                                                                                                                                                                   | 14                                                                                                                                                                                            | 70 (2.2)                                                                                                                                                                                                    | 84                                                                                                                                                             |
| Weight decreased                                                                                                                                                                  |                                                                                                                                                                                               |                                                                                                                                                                                                             |                                                                                                                                                                |
|                                                                                                                                                                                   | (2.2)                                                                                                                                                                                         |                                                                                                                                                                                                             | (0.6) (2.2)                                                                                                                                                    |
| Metabolism and nutrition disorders Decreased appetite                                                                                                                             | 94 (14.8) 61 (9.6)                                                                                                                                                                            | 428 (13.4) 275 (8.6)                                                                                                                                                                                        | 522 (13.6) 336 (8.8) 24 (0.6)                                                                                                                                  |
| Dehydration Hyperglycaemia Hyperuricaemia                                                                                                                                         | 6 (0.9) 8 (1.3) 4 (0.6)                                                                                                                                                                       | 18 (0.6) 17 (0.5) 10 (0.3)                                                                                                                                                                                  | 25 (0.7) 14 (0.4)                                                                                                                                              |
|                                                                                                                                                                                   | 9 (1.4)                                                                                                                                                                                       | 23 (0.7)                                                                                                                                                                                                    |                                                                                                                                                                |
| Hyponatraemia                                                                                                                                                                     | 5 (0.8)                                                                                                                                                                                       | 22 (0.7)                                                                                                                                                                                                    | 32 (0.8)                                                                                                                                                       |
|                                                                                                                                                                                   |                                                                                                                                                                                               |                                                                                                                                                                                                             | 27 (0.7)                                                                                                                                                       |
| Hypophosphataemia                                                                                                                                                                 |                                                                                                                                                                                               |                                                                                                                                                                                                             |                                                                                                                                                                |
| Musculoskeletal and                                                                                                                                                               |                                                                                                                                                                                               |                                                                                                                                                                                                             |                                                                                                                                                                |
| connective tissue disorders                                                                                                                                                       | 64 (10.1)                                                                                                                                                                                     | 594 (18.6)                                                                                                                                                                                                  | 658 (17.2)                                                                                                                                                     |
| Arthralgia Arthritis                                                                                                                                                              | 18 (2.8) 5 (0.8)                                                                                                                                                                              | 305 (9.5) 28 (0.9) 54 (1.7)                                                                                                                                                                                 | 323 (8.4) 33 (0.9) 59 (1.5)                                                                                                                                    |
| Back pain Muscle Muscular                                                                                                                                                         | 5 (0.8) 6 (0.9) 7 (1.1) 3 (0.5)                                                                                                                                                               | 46 (1.4) 24 (0.8) 33 (1.0)                                                                                                                                                                                  | 52 31                                                                                                                                                          |
| spasms Musculoskeletal                                                                                                                                                            |                                                                                                                                                                                               |                                                                                                                                                                                                             | 36                                                                                                                                                             |
| weakness                                                                                                                                                                          |                                                                                                                                                                                               | 155                                                                                                                                                                                                         | (1.4) (0.8) (0.9)                                                                                                                                              |
| pain Myalgia                                                                                                                                                                      | (2.4)                                                                                                                                                                                         |                                                                                                                                                                                                             | 170                                                                                                                                                            |
| Pain in extremity                                                                                                                                                                 | 15 5 (0.8)                                                                                                                                                                                    | (4.9) 45 (1.4)                                                                                                                                                                                              | (4.4) 50 (1.3)                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                 | 2 (0.3)                                                          | 25 (0.8)                                                                       | 27 (0.7)                                                                         |
|-----------------------------------------------------------------------------------------------------|------------------------------------------------------------------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| Nervous system disorders Dizziness Dysgeusia Headache Lethargy Peripheral sensory neuropathy Tremor | 51 (8.0) 12 (1.9) 15 (2.4) 7 (1.1) 6 (0.9) 2 (0.3) 3 (0.5)       | 353 (11.1) 49 (1.5) 47 (1.5) 126 (3.9) 9 (0.3) 14 (0.4) 6 (0.2)                | 404 (10.5) 61 (1.6) 62 (1.6) 133 (3.5) 15 (0.4) 16 (0.4) 9 (0.2)                 |
| Psychiatric disorders Confusional state Insomnia                                                    | 8 (1.3) 2 (0.3) 5 (0.8)                                          | 73 (2.3) 7 (0.2) 29 (0.9)                                                      | 81 (2.1) 9 (0.2) 34 (0.9)                                                        |
| Renal and urinary disorders Acute kidney injury                                                     | 13 (2.0) 3 (0.5)                                                 | 48 (1.5) 8 (0.3)                                                               | 61 (1.6) 11 (0.3)                                                                |
| Reproductive system and breast disorders                                                            | 6 (0.9)                                                          | 30 (0.9)                                                                       | 36 (0.9)                                                                         |
| Respiratory, thoracic and mediastinal disorders Cough Dyspnoea Pneumonitis                          | 59 (9.3) 17 (2.7) 16 (2.5) 20 (3.1)                              | 402 (12.6) 130 (4.1) 123 (3.9) 98 (3.1)                                        | 461 (12.0) 147 (3.8) 139 (3.6) 118 (3.1)                                         |
| Skin and subcutaneous tissue disorders Alopecia Dermatitis Dry skin Erythema Pruritus Rash          | 195 (30.7) 2 (0.3) 14 (2.2) 11 (1.7) 8 (1.3) 100 (15.7) 22 (8.3) | 1,107 (34.7) 28 (0.9) 54 (1.6) 105 (3.3) 51 (1.6) 584 (18.2) 36 (9.7) 13 (0.4) | 1,302 (34.0) 30 (0.8) 68 (1.7) 116 (3.0) 59 (1.5) 684 (17.8) 386 (13.8) 19 (0.5) |
| Vascular Hypertension                                                                               | 11 (1.7) 2 (0.3)                                                 | 86 (2.7) 14 (0.4)                                                              | 97 16 (0.4)                                                                      |
|                                                                                                     | 6 (0.9)                                                          |                                                                                |                                                                                  |
| Urticaria                                                                                           |                                                                  |                                                                                |                                                                                  |
|                                                                                                     |                                                                  |                                                                                | (2.5)                                                                            |
|                                                                                                     | disorders                                                        |                                                                                |                                                                                  |

Every subject is counted a single time for each applicable row and column.

MedDRA version used is 19.1.

° Includes all subjects who received at least one dose of MK-3475 in KN001 Part B1, B2, B3, D, C, F1, F2, F3; KN002 (original phase), KN006, KN010, KN013 Cohort 3 (Hodgkin's Lymphoma), KN024 an KN087.

* Includes all subjects who received at least one dose of MK-3475 in KN001 Part B1, B2, B3, D, C, F1, F2, F3; KN002 (original phase), KN006, KN010, KN013 Cohort 3 (Hodgkin's Lymphoma), KN024, KN045, KN052 and KN087.

(KN001 Database Cut-off Date for Melanoma: 18APR2014).

(KN001 Database Cut-off Date for Lung Cancer: 23JAN2015).

(KN002 Database Cut-off Date: 28FEB2015).

(KN006 Database Cut-off Date: 03MAR2015).

(KN010 Database Cut-off Date: 30SEP2015).

(KN013 Database Cut-off Date for Hodgkin's Lymphoma: 27SEP2016).

(KN024 Database Cut-off Date: 09MAY2016).

(KN087 Database Cut-off Date: 27SEP2016).

Database Cut-off KN045 Date: 18 JAN 2017.

Database Cut-off KN052 Date: 09 MAR 2017.

Overall,  a  total  of  28  (10.5%)  patients  treated  with  pembrolizumab  in  Study  KN045  and  43  (11.6%) patients in Study KN052 had a drug-related AE resulting in treatment interruption. The most common events leading to treatment interruption were Colitis and Diarrhea (1.1% each) in KN045, and Alanine aminotransferase increased (1.6%), Aspartate aminotransferase increased and Diarrhea (1.1% each) in Study KN052.

<div style=\"page-break-after: always\"></div>

In the control arm of Study KN045, treatment was interrupted due to drug-related AE in a total of 40 (15.7%)  patients,  and  the  most  frequent  events  were Anemia (4.7%), Neutropenia (2.0%), Asthenia (1.6%), Neutrophil count decrease (1.6%), and Infusion-related reaction (1.2%).

## Drug-related Grade 3-5 Adverse Events

In  Study  KN045,  a  lower  frequency  of  subjects  in  the  pembrolizumab  arm  experienced  drug-related Grade ≥3 AEs compared to the control (15% vs 49.4%). In the pembrolizumab arm, the most commonly reported events were pneumonitis (1.5%), AST increased (1.1%), diarrhea (1.1%), and fatigue (1.1%) in the pembrolizumab arm, and neutropenia (13.3%), neutrophil count decreased (12.2%), anemia (7.8%), febrile  neutropenia  (7.1%),  and  white  blood  cell  decreased  (5.1%)  in  the  control  arm.  Two  Grade≥3 Anemia events were considered drug-related by the Investigator. However, based on evaluation of the available information for these events, they were finally deemed unlikely related to pembrolizumab, and more likely related to the underlying medical condition.

All the drug-related Grade ≥3 AEs observed in ≥5% of subjects in the control arm were reported with a frequency &lt; 1% in the pembrolizumab arm.

In  Study  KN052,  15.7%  of  subjects  experienced  at  least  1  Grade  ≥3  AEs,  and  the  most  commonly reported were Fatigue (2.2%), Blood alkaline phosphatase increased (1.4%), Colitis (1.1%) and Muscular weakness (1.1%). There were no drug-related Grade≥ 3 AEs reported with incidence ≥3%. One Grade≥ 3 Anemia and  1  Grade≥  3 Urinary  tract  infection were  considered  drug-related  by  the  Investigator. However,  upon  medical  review  of  the  available  information,  both Anemia and Urinary  tract  infections cases were deemed more likely related to the underlying medical condition.

## Serious adverse event/deaths/other significant events

## Serious Adverse Events (SAEs)

Overall,  in  Study  KN045,  39.1%  of  patients  in  the  pembrolizumab  arm  and  40.8%  in  the  control  arm experienced at least 1 SAEs up to 90 days after the last dose of study treatment. In the pembrolizumab arm,  the  SAEs  observed  at  frequency  ≥1%  were Urinary  tract  infection (4.5%), Pneumonia (3.4%), Anemia (2.6%), Pneumonitis (2.3%), Hematuria (1.9%), Pyrexia (1.9%), Acute  kidney  injury (1.5%), Cancer pain (1.5%), Urosepsis (1.5%), Colitis (1.5%), Dehydration (1.1% vs 0.8%), Diarrhea (1.1%), Dyspnea (1.1%), Urinary  tract  obstruction (1.1%), Device  dislocation (1.1%),  and General  physical health deterioration (1.1%). With the exception of pneumonitis and colitis, all these events were reported in a lower or similar frequency in the pembrolizumab group compared to control.

In the control arm, the SAE reported in ≥5% of subjects was febrile neutropenia (5.9%).

Table 53 shows the subject incidence and frequencies of drug-related SAEs observed in Study KN045. Most of the events were reported once on both groups but pembrolizumab was associated with a higher frequency of immune-mediated pneumonitis compared to the control arm (Table 55)

## Table 53: Drug-related Serious Adverse Events Up to 90 Days After Last Dose (Incidence &gt;0% in One or More Treatment Groups) Study KN045 All Subjects (APaT Population)

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                                                        | Control ()   | Control ()                         | Pembrolizumab (-)   | Pembrolizumab (-)          |
|------------------------------------------------------------------------|--------------|------------------------------------|---------------------|----------------------------|
| Subjects in population                                                 | n 255        |                                    | n 266               |                            |
| with one or more adverse events with no adverse events                 | 57 198       | (22.4) (77.6)                      | 27 239              | (10.2) (89.8)              |
| Blood and lymphaticsystem disorders                                    | 28           | (11.0)                             | 0                   | (0.0)                      |
| Anaemia                                                                | 5            | (2.0)                              | 0                   | (0.0)                      |
| Febrile neutropenia                                                    | 15 1         | (5.9)                              | 0 0                 | (0.0)                      |
| Leukopenia Neutopenia                                                  | 5            | (0.4) (2.0)                        | 0                   | (0.0) (0.0)                |
| Normochromic normocytic anaemia                                        | 1            | (0.4)                              | 0                   | (0.0)                      |
| Pancytopenia Thrombocytopenia                                          | 2 1          | (0.8) (0.4)                        | 0 0                 | (0.0) (0.0)                |
| Eudocrine disorders                                                    | 0            | (0.0)                              | 1                   | (0.4)                      |
| Adrenal insufficiency                                                  | 0            | (0.0)                              | 1                   | (0.4)                      |
| Gastrointestiual disorders                                             | 20           | (7.8)                              | 5                   | (61)                       |
|                                                                        | 0            | (0.0)                              | 4                   | (1.5)                      |
| Colitis Constipation                                                   | 7            | (2.7)                              | 0                   | (0.0)                      |
| Dianhoea                                                               | 1            | (0.4)                              | 2                   | (0.8)                      |
| Ileus                                                                  | 2            | (0.8)                              | 0                   | (0.0)                      |
| leus paralytic                                                         | 2            | (0.8)                              | 0                   | (0.0)                      |
| Intestinal obstruction                                                 | 5 1          | (2.0) (0.4)                        | 0                   | (0.0)                      |
| Large intestinal obstruction Nausea                                    | 1            | (0.4)                              | 0                   | (0.0) (0.0)                |
| Neutropenic colitis                                                    | 1            | (0.4)                              | 0                   | (0.0)                      |
| Subileus                                                               | 1            | (0.4)                              | 0                   | (0.0)                      |
| Vomiting                                                               | 1            | (0.4)                              | 0                   | (0.0)                      |
| General disorders and administration site                              | 5            | (2.0)                              | 3                   | (1.1)                      |
| conditions                                                             |              |                                    |                     |                            |
| Death Fatigue                                                          | 1 1          | (0.4) (0.4)                        | 1 1 1               | (0.4) (0.4) (0.4)          |
| Influenza like illness Malaise                                         | 0 1 1        | (0.0) (0.4)                        | 0 0                 | (0.0) (0.0)                |
| Mucosal inflammation Pyrexia                                           | 1            | (0.4) (0.4)                        | 0                   | (0.0)                      |
| Hepatobiliary disorders                                                | 1            | (0.4)                              | 0                   | (0.0) (0.0)                |
| Jaundice                                                               | 1            | (0.4)                              | 0                   |                            |
| Infectious and infestations                                            | 10           | (3.9)                              | 2 1                 | (0.8)                      |
| Lung infection                                                         |              | (0.0)                              |                     | (0.4)                      |
|                                                                        | 0            |                                    |                     |                            |
|                                                                        |              |                                    |                     | Pembrolizumab              |
| Infectious and iufestations Pneumocystis jirovecii infection Pneumonia | 10 1 1 2     | (%.) (3.9) (0.4) (0.4) (0.8) (0.4) | n 2 0 1 0 0         | () (0.8) (0.0) (0.4) (0.0) |
| Sepsis Septic shock                                                    | 1            |                                    | 0                   | (0.0)                      |
| Upper respiratory tract infection Urinary tract infection              | 1            | (0.4)                              | 0                   | (0.0)                      |
|                                                                        | 4            | (1.6) (1.0)                        | 2                   | (0.0)                      |
| Investigations                                                         | 4            |                                    |                     | (0.8)                      |
| Alanine aminotansfense increased                                       | 0            | (0.0)                              | 1 1                 | (0.4)                      |
| Aspartate aminotransferase increased Neutrophil count decreased        | 0            | (0.0)                              | 0                   | (0.4) (0.0)                |
| Platelet count decreased                                               | 3            | (1.2) (0.4)                        | 0                   | (0.0)                      |
| Transaminases increased                                                | 1 0          | (0.0) (1.2)                        | 1 1                 | (0.4)                      |
| Metabolism andnutrilion disorders                                      |              |                                    |                     |                            |
| Decreased appetite                                                     | 3            |                                    |                     | (0.4) (0.0)                |
| Dehydration                                                            | 1            | (0.4) (0.4)                        |                     | (0.0)                      |
| Fluid retention                                                        | 1            | (0.4)                              | 0 1                 | (0.0)                      |
| Hyponatraemia                                                          | 1 0          | (0.0)                              |                     | (0.4)                      |
| Neoplasms benigu, maliguant and unspecified (incl cysts and polyps)    |              | (0.0)                              |                     | (0.4)                      |
|                                                                        | 0            |                                    | 1                   |                            |
| Malignant neoplasm progression                                         | 0 1          | (0.0)                              | 1                   | (0.4) (0.4)                |
| Nervous system disorders Encephalopathy                                | 0            | (0.4) (0.0)                        | 1                   | (0.4)                      |
| Posterior reversible encephalopathy syndrome                           | 1            | (0.4)                              | 0                   | (0.0)                      |
| Renal and urinary disorders                                            | 3            | (1.2)                              |                     | (sD)                       |
| Acute kidney injuy                                                     |              | (0.8)                              |                     | (0.0)                      |
| Autoimmune nephritis                                                   | 2 0          | (0.0)                              | 0 1                 | (0.4)                      |
| Nephritis Renal failure                                                | 0            | (0.0)                              | 1 0                 | (0.4) (0.0)                |
| Renal injury                                                           | 1            | (0.4) (0.0)                        | 1                   | (0.4)                      |
| Urimary tract obsiruction                                              | 0 0          |                                    | 1                   | (0.4)                      |
|                                                                        |              | (0.0)                              |                     |                            |
| Reproductive system and breast disorders                               | 0            | (0.0)                              |                     |                            |
| Female genital tract fishula                                           | 0            | (0.0)                              | 1 1                 | (0.4) (0.4)                |

<div style=\"page-break-after: always\"></div>

| Respiratory, thoracic and mediastinal   | 2   | (0.8)   | 7 (2.0)   |
|-----------------------------------------|-----|---------|-----------|
| Chronic obstructive pulmonary disease   | 0   | (0.0)   | 1 (0.4)   |
| paoudsfg                                | 1   | (0.4)   | 0 (0.0) 1 |
| Interstitial lung disease               | 0   | (0.0)   | (0.4)     |
| Pheumonitis                             | 0   | (0.0)   | 5 (1.9)   |
| Pulmonary bypertension                  | 1   | (0.4)   | 0 (0.0)   |
| Skin and subcutaneous tissue disorders  | 0   | (0.0)   | 1 (0.4)   |
| Rash maculo-papular                     | 0   | (0.0)   | 1 (0.4)   |
| Vascular disorders                      | 1   | (0.4)   | 0 (00)    |
| Deep vein thrombosis                    |     | (0.4)   | 0 (0.0)   |

Source: [P045V01: annlysis-adsl] [P045 V01: tabuations-aephus]

<!-- image -->

In  Study  KN052,  the  frequency  of  subjects  with  1  or  more  SAEs  up  to  90  days  after  the  last pembrolizumab dose was 41.4%, and the most commonly reported events were Urinary tract infection (6.2%), Acute kidney injury , Hematuria , Pneumonia , and Urosepsis (2.7% each).

The drug-related SAEs observed in ≥1% of pembrolizumab treated patients across the urothelial cancer population  (Study  KN045  and  Study  KN052)  and  the  Reference  Safety  Dataset  are  reported  in  the following Table (Table 54).

Table 54: Drug-related Serious Adverse Events Up to 90 Days After Last Dose (Incidence &gt;1% in One or More Treatment Groups) Pembrolizumab treated patients in Studies KN045, KN052 and Reference Safety Dataset by Body System or Organ Class and PT (APaT Population)

|                                                                              | KN045 n (%)              | KN052 n (%)             | Reference Safety Dataset * n (%)   |
|------------------------------------------------------------------------------|--------------------------|-------------------------|------------------------------------|
| Subjects in population with one or more adverse events with no adverse event | 266 27 (10.2) 239 (89.8) | 370 36 (9.7) 334 (90.3) | 2,799 281 (10.0) 2,518 (90.0)      |
| Endocrine disorders                                                          | 1 (0.4)                  | 6 (1.6)                 | 27 (1.0)                           |
| Gastrointestinal disorders Colitis                                           | 5 (1.9) 4 (1.5)          | 5 (1.4) 2 (0.5)         | 60 (2.1) 25 (0.9)                  |
| General disorders and administration site conditions Pyrexia                 | 3 (1.1) 0 (0.0)          | 5 (1.4) 4 (1.1)         | 24 (0.9) 10 (0.4)                  |
| Hepatobiliary disorders                                                      | 0 (0.0)                  | 4 (1.1)                 | 15 (0.5)                           |
| Infections and infestations                                                  | 2 (0.8)                  | 5 (1.4)                 | 20(0.7)                            |
| Metabolism and nutrition disorders                                           | 1 (0.4)                  | 5 (1.4)                 | 25 (0.9)                           |
| Musculoskeletal and connective tissue disorders                              | 0 (0.0)                  | 5 (1.4)                 | 13 (0.5)                           |
| Renal and urinary disorders                                                  | 4 (1.5)                  | 3 (0.8)                 | 13 (0.5)                           |
| Respiratory, thoracic and mediastinal disorders Pneumonitis                  | 7 (2.6) 5 (1.9)          | 2 (0.5) 2 (0.5)         | 66 (2.4) 44 (1.6)                  |

Table 5.3.5.3.3-urothelial:28 (ISS KN045) and Table 5.3.5.3.3-urothelial:29 (ISS KN052). Every subject is counted a single time for each applicable row and column.

<div style=\"page-break-after: always\"></div>

```
MedDRA version used is 19.0. * Includes all subjects who received at least one dose of MK-3475 in KN001 Part B1, B2, B3, D, C, F1, F2, F3; KN002 (original phase), KN006, KN010. (KN001 Database Cut-off Date for Melanoma: 18APR2014). (KN001 Database Cut-off Date for Lung Cancer: 23JAN2015). (KN002 Database Cut-off Date: 28FEB2015). (KN006 Database Cut-off Date: 03MAR2015). (KN010 Database Cut-off Date: 30SEP2015).
```

## Deaths

In Study KN045, a total of 13 patients (4.9%) in the pembrolizumab arm and 8 patients (3.1%) in the control group had AEs resulting in death within 90 days of the last dose (Table 55).

Table 55: Subjects With Adverse Events Resulting in Death Up to 90 Days After Last Dose (Incidence &gt;0% in One or More Treatment Groups) Study KN045 All Subjects (APaT Population)

<!-- image -->

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Control                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Control                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Pembrolizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Pembrolizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | (3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | n.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | ()                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Subjects in population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 255                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 266                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| with one or more adverse events                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (3.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 13                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | (4.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| with no adverse events                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 247                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | (96.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 253                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | (95.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Gastrointestinal disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Gastrointestinalperforation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Geueral disordersand administration site conditions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (1.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Death                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (1.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| General physical health deterioration                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Infections and infestations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (1.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (6D)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Atypical pneumonia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Pneumonia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (1.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Sepsis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Septic shock                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Urosepsis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Metabolism and nutrition disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Cachexia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Neoplasms benign, maliguant and unspecified (incl cysts and polyps)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Malignant neoplasm progression                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Renal and urinary disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Urinary tact obstruction.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Respiratory, thoracic and mediastinal disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Pneumonitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | (0.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Every subject is counted a single time for each applicable row and columm. A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columms meets the incidence criterion in the report title, after rounding. MedDRA V19.0 preferred terms \"Neoplasm progression\". *Malignant neoplasm progression' and \"Disease progression not related to the drug are excluded. Non-serious adverse events up to 30 days of lhst dose and serious adverse events up to 90 days of lhst dose are included. Control arm is investigator's choice of paclitaxel, docetaxel or vinflhumine. | Every subject is counted a single time for each applicable row and columm. A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columms meets the incidence criterion in the report title, after rounding. MedDRA V19.0 preferred terms \"Neoplasm progression\". *Malignant neoplasm progression' and \"Disease progression not related to the drug are excluded. Non-serious adverse events up to 30 days of lhst dose and serious adverse events up to 90 days of lhst dose are included. Control arm is investigator's choice of paclitaxel, docetaxel or vinflhumine. | Every subject is counted a single time for each applicable row and columm. A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columms meets the incidence criterion in the report title, after rounding. MedDRA V19.0 preferred terms \"Neoplasm progression\". *Malignant neoplasm progression' and \"Disease progression not related to the drug are excluded. Non-serious adverse events up to 30 days of lhst dose and serious adverse events up to 90 days of lhst dose are included. Control arm is investigator's choice of paclitaxel, docetaxel or vinflhumine. | Every subject is counted a single time for each applicable row and columm. A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columms meets the incidence criterion in the report title, after rounding. MedDRA V19.0 preferred terms \"Neoplasm progression\". *Malignant neoplasm progression' and \"Disease progression not related to the drug are excluded. Non-serious adverse events up to 30 days of lhst dose and serious adverse events up to 90 days of lhst dose are included. Control arm is investigator's choice of paclitaxel, docetaxel or vinflhumine. | Every subject is counted a single time for each applicable row and columm. A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columms meets the incidence criterion in the report title, after rounding. MedDRA V19.0 preferred terms \"Neoplasm progression\". *Malignant neoplasm progression' and \"Disease progression not related to the drug are excluded. Non-serious adverse events up to 30 days of lhst dose and serious adverse events up to 90 days of lhst dose are included. Control arm is investigator's choice of paclitaxel, docetaxel or vinflhumine. |

Source: [P045V01: analysis-adsl] [P045V01: tabulations-aeplus]

Upon medical review, the fatal pneumonitis event was consistent with the previously described immunemediated events related to  pembrolizumab.  Based  on  available  information,  the  remaining  AEs  with  a fatal outcome in subjects receiving pembrolizumab were deemed more likely related to either malignant neoplasm progression,  infections  (common  among  subjects  with  cancer),  or  related  to  complication  of surgery for gastrointestinal perforation. No new safety signal was identified upon review of these fatal events.

In Study KN052, 18 (4.9%) patients died due to an AE during the trial. A summary of all AEs resulting in death is provided in the following Table (Table 56).

<div style=\"page-break-after: always\"></div>

Table 56: Subjects With Adverse Events Resulting in Death Up to 90 Days After Last Dose (Incidence &gt;0%) Study KN052 All Subjects (APaT Population)

<!-- image -->

|                                                        | Pembrolizmab   | Pembrolizmab   |
|--------------------------------------------------------|----------------|----------------|
|                                                        | n              | (6)            |
| Subjects in population with one or more adverse events | 370 18         | (4.9)          |
| with no adverse events                                 | 352            | (95.1)         |
| Cardiac disorders                                      | 1              | (0.3)          |
| Ischaemic cardiomyopathy                               | 1              | (0.3)          |
| Gastrointestinal disorders                             | 2              | (s0)           |
| Duodenal obstuction                                    | 1              | (0.3)          |
| Large intestine perforation                            | 1              | (0.3)          |
| General disorders and administrationsiteconditions     | 1              | (0.3)          |
| Death                                                  | 1              | (0.3)          |
| Infections and infestations                            | 8              | (2.2)          |
| Pneumonia                                              | 3              | (0.8)          |
| Sepsis                                                 | 2              | (0.5)          |
| Urosepsis                                              | 3              | (0.8)          |
| Metabolism and nutrition disorders                     | 1              | (0.3)          |
| Type 2 diabetes mellitus                               | 1              | (0.3)          |
| Musculoskeletal and connective tissue disorders        | 1              | (0.3)          |
| Myosiis                                                | 1              | (0.3)          |
| Nervous system disorders                               | 1              | (0.3)          |
| Cerebrovascular accident                               | 1              | (0.3)          |
| Reual and uriuary disorders                            | 3              | (0.8)          |
| Acute kidney injuy                                     | 1              | (0.3)          |
| Chronic kidney disease                                 | 1              | (0.3)          |
| Renal fnilure                                          | 1              | (0.3)          |
| Respiratory, thoracic and mediastinal disorders        | 2              | (0.5)          |
| Aspiration                                             | 1              | (0.3)          |
| Respiratory, thoracic and mediastinal disorders        | 2              | (0.5)          |
| Respiatory fsilre                                      | 1              | (0.3)          |

Source:[P052V01MK3475: amalysis-adsl] [P052V01MK3475: tabulations-aephus]

All  fatal  events,  including  those  reported  only  once,  were  medically  reviewed.  The  only  fatal  event reported as drug-related by the Investigator refers to a patient  who developed Thyroiditis (Grade 3 with hyperthyroidism followed by hypothyroidism), immune-mediated Myositis (Grade 5), Myocarditis (Grade 4), Hepatitis (Grade 3) and Pneumonia (Grade 3), approximately 20 days after initiation of pembrolizumab. Despite treatment, including steroid therapy, IV immunoglobulin and thyroid hormone replacement, the subject experienced respiratory insufficiency and pneumonia with a fatal outcome. In total, the patient received 2 doses prior to drug discontinuation. The Investigator considered the SAEs of thyroiditis, myositis, myocarditis, hepatitis, and pneumonia to be immune related, related to the study therapy,  and  events  of  clinical  interest.  According  to  the  MAH,  the  available  information  permit  to conclude the correlation of the reported SAEs Thyroiditis and Myositis with pembrolizumab administration, while SAEs of Hepatitis and Myocarditis were not related to pembrolizumab considering that there was no biopsy confirming the immune mediated nature of these events. This is the first reported fatal case of Myositis with pembrolizumab.

For the remaining cases, based on available information, the fatal outcomes of Pneumonia (3 subjects), Urosepsis (3  subjects),  and Sepsis (2  subjects)  were  more  likely  related  to  the  underlying  medical condition or confounded by a medical procedure.

<div style=\"page-break-after: always\"></div>

Two additional fatal cases (PTs septic shock and malignant neoplasm progression; PT Clostridium difficile i nfection ) were reported at the updated safety analysis.

No new safety signal was identified upon review of the fatal events reported in both Study KN045 and Study KN052.

## Adverse Events of Special Interest (AEOSI)

The AEOSI, including immune-mediated AEs and infusion-related reactions considered to be identified or potential risk for pembrolizumab, are characterized in an ongoing manner as part of the pembrolizumab development program. A pre-specified list of PTs was developed for assessing AEOSI.

Table 57: Subjects with AEOSI (Incidence&gt;0% in One or More Treatment Group) Study KN045 All Subjects (APaT Population)

<!-- image -->

Source: [P045V01: analysis-adsl; adae] [P045V01: tabulations-aeplus]

<div style=\"page-break-after: always\"></div>

Table 58: Subjects with AEOSI (Incidence&gt;0% in One or More Treatment Group) Study KN052 All Subjects (APaT Population)

<!-- image -->

|                                                | Pembrolizimab   | Pembrolizimab   |
|------------------------------------------------|-----------------|-----------------|
|                                                | n               | (6)             |
| Subjects in population                         | 370             |                 |
| with one or more adverse events                | 63              | (17.0)          |
| with no adverse events                         | 307             | (83.0)          |
| Adrenal Insufficiency                          | 5               | (1.4)           |
| Adrenal insufficiency                          | 5               | (1.4)           |
| Colitis                                        | 9               | (2.4)           |
| Colitis                                        | 8               | (2.2)           |
| Enterocolitis                                  | 1               | (0.3)           |
| Hepatitis                                      | 4               | (1.1)           |
| Autoimmume hepatitis                           | 1               | (0.3)           |
| Hepatitis                                      | 3               | (0.8)           |
| Hyperthyroidism                                | 9               | (2.4)           |
| Hyperthyroidism                                | 9               | (2.4)           |
| Hypophysilfis                                  | 2               | (0.5)           |
| Hypophysitis                                   | 1               | (0.3)           |
| Hypopititarism                                 | 1               | (0.3)           |
| Hypothyroidism                                 | 24              | (6.5)           |
| Hypothyroidism                                 |                 | (6.5)           |
| Infusion Related Reactions                     | 1               | (0.3)           |
| Hypersensitivity                               | 1               | (0.3)           |
| Myositis                                       | 1               | (0.3)           |
| Myositis                                       | 1               | (0.3)           |
| Nephritis                                      | 1               | (0.3)           |
| Tubulointerstitial nephritis                   | 1               | (0.3)           |
| Pneumonitis                                    | 7               | (1.9)           |
| Pnewwonitis                                    | 7               | (6D)            |
| Severe Slin Reactions                          | 4               | (1.1)           |
| Dematifis bullous                              | 1               | (0.3)           |
| Lichen planus                                  | 1               | (0.3)           |
|                                                | 1               | (0.3)           |
| Rash                                           | 1               | (0.3)           |
| Rash maculo-papular                            | 1               | (0.3)           |
| Thyroiditis                                    | 3               | (s'0)           |
| Thyroid disorder Thyroiditis                   | 1               | (0.3)           |
|                                                | 2               | (0.5)           |
| Type l Diabetes Melitus                        | 4               | (1.1)           |
| Diabetic ketoacidosis Type I diabetes mellitus | 2 3             | (0.5) (0.8)     |

Source: [P052V01MK3475: analysis-adsl: adae] [P052V01MK3475: tabulations-aeplus]

In general, the frequency and severity of each AEOSI observed in Study KN045 and KN052 were in line with  the  previously  described  characterization  of  the  pembrolizumab  safety  profile.  No  new  immunemediated event causally associated with pembrolizumab and indication-specific was identified.

One fatal case each was reported in Study KN045 ( Pneumonitis ) and in Study KN052 ( Myositis ).

## Laboratory findings

Laboratory abnormalities were analysed based on the highest CTCAE grade reported for each subject, in order to assess the clinically meaningful changes from baseline, defined as a shift from less than Grade 3 to Grade≥ 3 or a shift from Grade 0 to Grade 2.

<div style=\"page-break-after: always\"></div>

In  the  pembrolizumab  arm  of  Study  KN045,  the  most  frequently  reported  laboratory  values  with  a clinically  meaningful  worsening  in  CTCAE  grade  from  baseline  were Lymphocytes  decreased (25.6%), Phosphate decreased (23.7%). The rate of these laboratory abnormalities was higher in the control arm (34.9% and 27.5%, respectively). Additional laboratory findings with a clinically meaningful worsening most  commonly  observed  in  the  control  group  were Neutrophils  decreased (52.2%)  and Leukocytes decreased (47.8%).

In Study KN052, the most common clinically meaningful worsened laboratory values were Lymphocytes decreased (21.9%)  and Albumin decreased (13.8%). The most frequent liver function finding observed was Alkaline phosphatase ≥1.5 ULN (24.5%).

As  concern  the  liver  functioning  test,  in  both  studies  the  most  frequent  finding  observed  was Alkaline phosphatase ≥1.5 ULN (31.6% with pembrolizumab and 28.5% in the control group in KN045; 24.5% in KN052). Overall, no liver function abnormalities consistent with severe drug injury (Hy's Law: AST or ALT ≥3 ULN, total bilirubin ≥2 ULN and an alkaline phosphatase &lt;2 X ULN) were reported. However, 4 (1.6%) subjects  in  the  control  arm  and  8  (3.2%)  subjects  in  the  pembrolizumab  arm  of  Study  KN045,  and  4 (1.1%) patients in Study KN052 had either an AST or ALT value ≥3 ULN with a total bilirubin value ≥2 ULN.

The  frequency  of  subjects  with  clinically  meaningful  worsening  in  laboratory  CTCAE  grades  in  Study KN045, Study KN052 and in the reference safety data set is reported in the below Table (Table 59)

Table 59: Summary of clinically meaningful worsening in laboratory CTCAE Grades from baseline Pembrolizumab treated patients in Studies KN045, KN052, and Reference Safety Dataset  (APaT Population)

| Laboratory test                      | KN045 (n=266)   | KN052 (n=370)   | Reference Safety Dataset (n=2,799)   |
|--------------------------------------|-----------------|-----------------|--------------------------------------|
| APTT increased                       | 1 (0.4)         | 7 (1.9)         | 16 (0.6)                             |
| Alanine Aminotransferase Increased   | 9 (3.4)         | 21 (5.7)        | 114 (4.1)                            |
| Albumin decreased                    | 40 (15.0)       | 51 (13.8)       | 252 (9.0)                            |
| Alkaline phosphatase increased       | 25 (9.4)        | 30 (8.1)        | 122 (4.4)                            |
| Amylase increased                    | 0 (0.0)         | 2 (0.5)         | 7 (0.3)                              |
| Aspartate Aminotransferase Increased | 15 (5.6)        | 22 (5.9)        | 122 (4.4)                            |
| Bilirubin increased                  | 17 (6.4)        | 12 (3.2)        | 91(3.3)                              |
| Calcium decreased                    | 21 (7.9)        | 18 (4.9)        | 108 (3.9)                            |
| Calcium increased                    | 5 (1.9)         | 7 (1.9)         | 36 (1.3)                             |
| Creatinine increased                 | 21 (7.9)        | 30 (8.1)        | 57 (2.0)                             |
| Gamma glutamyl transferase increased | 10 (3.8)        | 5 (1.4)         | 23 (0.8)                             |
| Glucose decreased                    | 1 (0.4)         | 5 (1.4)         | 40 (1.4)                             |
| Glucose increased                    | 42 (15.8)       | 48 (13.0)       | 296 (10.6)                           |
| Haemoglobin decreased                | 46 (17.3)       | 45 (12.2)       | 122 (4.4)                            |
| Leukocytes decreased                 | 1 (0.4)         | 7 (1.9)         | 69 (2.5)                             |
| Lymphocytes decreased                | 68 (25.6)       | 81 (21.9)       | 438 (15.6)                           |
| Lymphocytes increased                | 1 (0.4)         | 2 (0.5)         | 2 (0.1)                              |
| Neutophils decreased                 | 9 (3.4)         | 18 (4.9)        | 67 (2.4)                             |
| Phosphate decreased                  | 63 (23.7)       | 48 (13.0)       | 470 (16.8)                           |
| Platelet decreased                   | 8 (3.0)         | 5 (1.4)         | 46 (1.6)                             |
| Potassium decreased                  | 4 (1.5)         | 3 (0.8)         | 50 (1.8)                             |
| Potassium increased                  | 19 (7.1)        | 28 (7.6)        | 114 (4.1)                            |
| Prothrombin INR increased            | 3 (1.1)         | 8 (2.2)         | 29 (1.0)                             |
| Sodium decreased                     | 21 (7.9)        | 43 (11.6)       | 185 (6.6)                            |
| Sodium increased                     | 1 (0.4)         | 0 (0.0)         | 4 (0.1)                              |
| Triacylglycerol lipase increased     | 2 (0.8)         | 2 (0.5)         | 5 (0.2)                              |

<div style=\"page-break-after: always\"></div>

## Safety in special populations

## Age

In  Study  KN045,  the  percentage  of  AEs  was  generally  comparable  between  age  categories  in  both treatment arms (Table 60).

|                                      | Age (Years)   | Age (Years)   | Age (Years)             | Age (Years)             | Age (Years)   | Age (Years)   | Age (Years)                | Age (Years)                | Age (Years)   |
|--------------------------------------|---------------|---------------|-------------------------|-------------------------|---------------|---------------|----------------------------|----------------------------|---------------|
|                                      | Contol        | Contol        | Contol                  | Contol                  | Contol        | Pembrolizumab | Pembrolizumab              | Pembrolizumab              | Pembrolizumab |
|                                      | ≤ 65          | ≤ 65          | = 65 to ≤ 75 =75 to <85 | = 65 to ≤ 75 =75 to <85 | >=85          | ≤ 65          | = 65 to ≤ 75 >= 75 to < 85 | = 65 to ≤ 75 >= 75 to < 85 | =85           |
|                                      |               | (96)          | (96)                    | (96)                    | (%)           | (96)          | (%)                        | (96)                       | (%)           |
| Subjects in Population               | 118           |               | 94                      | 43                      | 0             | 103           | 111                        | 46                         | 6             |
| with one or more adverse events      | 116           | (98.3)        | 91 (96.8)               | 43 (100.0)              | 0             | 96 (93.2)     | 104 (93.7)                 | 42 (91.3)                  | 6 (100.0)     |
| who died                             | 4             | (3.4)         | 1 (1.1)                 | E (7.0)                 | 0             | 5 (4.9)       | 5 (4.5)                    | 3 (6.5)                    | 0 (0.0)       |
| with serious adverse eveuts          | 44            | (37.3)        | 44 (46.8)               | 16 (37.2)               | 0             | 31 (30.1)     | 49 (44.1)                  | 20 (43.5)                  | + (66.7)      |
| discontinued due to an adverse event | 18            | (15.3)        | 8 (8.5)                 | 6 (14.0)                | 0             | 6 (5.8)       | 10 (9.0)                   | 6 (13.0)                   | 0 (0.0)       |
| CNS (confusion/extrapyra midal)      | 10            | (8.5)         | 6 (6.4)                 | 3 (7.0)                 | 0             | 6 (5.8)       | 7 (6.3)                    | 2 (4.3)                    | (16.7)        |
| AErelated to falling                 | 2             | (1.7)         | 6 (6.4)                 | 十 (9.3)                 | 0             | 5 (4.9)       | 7 (6.3)                    | 5 (10.9)                   | 2 (33.3)      |
| CVevents                             | 20            | (16.9)        | 15 (16.0)               | 7 (16.3)                | 0             | 15 (14.6)     | 28 (25.2)                  | 5 (10.9)                   | 1 (16.7)      |
| Cerebrovascular events               | 0             | (0.0)         | 1 (1.1)                 | 0 (0.0)                 | 0             | 1 (1.0)       | 0 (0.0)                    | 0 (0.0)                    | 0 (0.0)       |
| Infections                           | 41            | (34.7)        | 37 (39.4)               | 16 (37.2)               | 0             | 36 (35.0)     | 47 (42.3)                  | 18 (39.1)                  | 4 (66.7)      |

Table 60: Adverse Events Summary by Age Study KN045 All Subjects (APaT Population)

<!-- image -->

Source:[P045V01: analysis-adsl] [P045V01: tabulations-aeplus]

Overall, no impact of age was identified for pembrolizumab in both Study KN045 and KN052 populations in comparison to the Reference Safety Dataset (Table 61).

## Pembrolizumab treated patients in Studies KN045, KN052, and Reference Safety Dataset

Table 61: AEs Summary by Age (&lt;65, ≥65) (APaT Population)

|                                                                                                                                       | KN045                           | KN045                              | KN052                             | KN052                                | Reference Safety Dataset *              | Reference Safety Dataset *              |
|---------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|------------------------------------|-----------------------------------|--------------------------------------|-----------------------------------------|-----------------------------------------|
|                                                                                                                                       | <65 n (%)                       | ≥65 n (%)                          | <65 n (%)                         | ≥65 n (%)                            | <65 n (%)                               | ≥65 n (%)                               |
| Subjects in population with one or more AEs with no AE with drug-related° AEs                                                         | 103 96 (93.2) 7 (6.8) 62 (60.2) | 163 152 (93.3) 11 (6.7) 100 (61.3) | 68 65 (95.6) 3 (4.4) 37 (54.4)    | 302 289 (95.7) 13 (4.3) 192 (63.6)   | 1,587 1,547(97.5) 40 (2.5) 1,164 (73.3) | 1,212 1,180 (97.4) 32 (2.6) 898 (74.1)  |
| with toxicity Grade≥3 AEs with toxicity Grade≥3 drug-related AEs                                                                      | 47 (45.6) 13 (12.6)             | 92 (56.4) 27 (16.6)                | 34 (50.0) 10 (14.7)               | 165 (54.6) 48 (15.9)                 | 695 (43.8) 202 (12.7)                   | 578 (47.7) 184 (15.2)                   |
| with serious AEs with serious drug-related AEs                                                                                        | 31 (30.1) 7 (6.8)               | 73 (44.8) 20 (12.3)                | 26 (38.2) 8 (11.8)                | 127 (42.1) 28 (9.3)                  | 553 (34.8) 145 (9.1)                    | 488 (40.3) 136 (11.2)                   |
| who died who died due to drug-related AEs                                                                                             | 5 (4.9) 2 (1.9)                 | 8 (4.9) 2 (1.2)                    | 3 (4.4) 0 (0.0)                   | 15 (5.0) 1 (0.3)                     | 46 (2.9) 4 (0.3)                        | 64 (5.3) 6 (0.5)                        |
| discontinued due to AE discontinued due to drug-related AE discontinued due to serious AE discontinued due to serious drug-related AE | 6 (5.8) 3 (2.9) 6 (5.8) 3 (2.9) | 16 (9.8) 12 (7.4) 9 (5.5) 6 (3.7)  | 9 (13.2) 4 (5.9) 8 (11.8) 3 (4.4) | 32 (10.6) 15 (5.0) 26 (8.6) 11 (3.6) | 164 (10.3) 66 (4.2) 123 (7.8) 47 (3.0)  | 170 (14.0) 80 (6.6) 130 (10.7) 54 (4.5) |

Table made by the Assessor from Table 2.7.4:16 (CSR KN045) and Table 2.7.4:15 (CSR KN052).

°determined by the Investigator to be related to the drug

* Includes all subjects who received at least one dose of MK-3475 in KN001 Part B1, B2, B3, D, C, F1, F2, F3; KN002 (original phase), KN006, KN010.

(KN001 Database Cut-off Date for Melanoma: 18APR2014).

(KN001 Database Cut-off Date for Lung Cancer: 23JAN2015).

(KN002 Database Cut-off Date: 28FEB2015).

(KN006 Database Cut-off Date: 03MAR2015).

(KN010 Database Cut-off Date: 30SEP2015).

<div style=\"page-break-after: always\"></div>

## Gender

Pembrolizumab was similarly well tolerated in either male or female patients enrolled in Study KN045, on the basis of lower frequency of drug-related AEs, Grade≥ 3 AEs, Grade≥3 drug-related AEs, and drugrelated SAEs (Table 62).

Table 62: Adverse Events Summary by Gender Study KN045 -All Subjects (APaT Population)

<!-- image -->

|                                                                                                                                                                                                      | Control                                                                                                                                                                                              | Control                                                                                                                                                                                              | Control                                                                                                                                                                                              | Control                                                                                                                                                                                              | Pembrolizumab                                                                                                                                                                                        | Pembrolizumab                                                                                                                                                                                        | Pembrolizumab                                                                                                                                                                                        | Pembrolizumab                                                                                                                                                                                        |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                      | Mhle                                                                                                                                                                                                 | Mhle                                                                                                                                                                                                 | Female                                                                                                                                                                                               | Female                                                                                                                                                                                               | Male                                                                                                                                                                                                 | Male                                                                                                                                                                                                 | Female                                                                                                                                                                                               | Female                                                                                                                                                                                               |
|                                                                                                                                                                                                      |                                                                                                                                                                                                      | (36)                                                                                                                                                                                                 |                                                                                                                                                                                                      | (6)                                                                                                                                                                                                  |                                                                                                                                                                                                      | (36)                                                                                                                                                                                                 | n                                                                                                                                                                                                    | (6)                                                                                                                                                                                                  |
| Subjects in population                                                                                                                                                                               | 192                                                                                                                                                                                                  |                                                                                                                                                                                                      | 63                                                                                                                                                                                                   |                                                                                                                                                                                                      | 198                                                                                                                                                                                                  |                                                                                                                                                                                                      | 68                                                                                                                                                                                                   |                                                                                                                                                                                                      |
| with one or more adverse events                                                                                                                                                                      | 188                                                                                                                                                                                                  | (97.9)                                                                                                                                                                                               | 62                                                                                                                                                                                                   | (98.4)                                                                                                                                                                                               | 185                                                                                                                                                                                                  | (93.4)                                                                                                                                                                                               | 63                                                                                                                                                                                                   | (92.6)                                                                                                                                                                                               |
| with no adverse event                                                                                                                                                                                | 4                                                                                                                                                                                                    | (2.1)                                                                                                                                                                                                | 1                                                                                                                                                                                                    | (1.6)                                                                                                                                                                                                | 13                                                                                                                                                                                                   | (6.6)                                                                                                                                                                                                | 5                                                                                                                                                                                                    | (7.4)                                                                                                                                                                                                |
| with dnug-related' adverse events                                                                                                                                                                    | 173                                                                                                                                                                                                  | (90.1)                                                                                                                                                                                               | 57                                                                                                                                                                                                   | (90.5)                                                                                                                                                                                               | 125                                                                                                                                                                                                  | (63.1)                                                                                                                                                                                               | 37                                                                                                                                                                                                   | (54.4)                                                                                                                                                                                               |
| with toxicity gnde 3-5 adverse events                                                                                                                                                                | 117                                                                                                                                                                                                  | (60.9)                                                                                                                                                                                               | 43                                                                                                                                                                                                   | (68.3)                                                                                                                                                                                               | 107                                                                                                                                                                                                  | (54.0)                                                                                                                                                                                               | 32                                                                                                                                                                                                   | (47.1)                                                                                                                                                                                               |
| with toxicity grade 3-5 dnug-related adverse events                                                                                                                                                  | 92                                                                                                                                                                                                   | (47.9)                                                                                                                                                                                               | 34                                                                                                                                                                                                   | (54.0)                                                                                                                                                                                               | 31                                                                                                                                                                                                   | (15.7)                                                                                                                                                                                               | 9                                                                                                                                                                                                    | (13.2)                                                                                                                                                                                               |
| with senious adverse events                                                                                                                                                                          |                                                                                                                                                                                                      | (38.5)                                                                                                                                                                                               | 30                                                                                                                                                                                                   | (47.6)                                                                                                                                                                                               | 80                                                                                                                                                                                                   | (40.4)                                                                                                                                                                                               | 24                                                                                                                                                                                                   | (35.3)                                                                                                                                                                                               |
| with serious dnug-related adverse events                                                                                                                                                             | 41                                                                                                                                                                                                   | (21.4)                                                                                                                                                                                               | 16                                                                                                                                                                                                   | (25.4)                                                                                                                                                                                               | 22                                                                                                                                                                                                   | (11.1)                                                                                                                                                                                               | 5                                                                                                                                                                                                    | (7.4)                                                                                                                                                                                                |
| who died                                                                                                                                                                                             | 6                                                                                                                                                                                                    | (3.1)                                                                                                                                                                                                | 2                                                                                                                                                                                                    | (3.2)                                                                                                                                                                                                | 8                                                                                                                                                                                                    | (4.0)                                                                                                                                                                                                | 5                                                                                                                                                                                                    | (7.4)                                                                                                                                                                                                |
| who died due to a dnug-related adverse event                                                                                                                                                         | 3                                                                                                                                                                                                    | (1.6)                                                                                                                                                                                                | 1                                                                                                                                                                                                    | (1.6)                                                                                                                                                                                                | 3                                                                                                                                                                                                    | (1.5)                                                                                                                                                                                                | 1                                                                                                                                                                                                    | (1.5)                                                                                                                                                                                                |
| discontinued due to an adverse event                                                                                                                                                                 | 25                                                                                                                                                                                                   | (13.0)                                                                                                                                                                                               | 7                                                                                                                                                                                                    | (11.1)                                                                                                                                                                                               | 15                                                                                                                                                                                                   | (7.6)                                                                                                                                                                                                | 7                                                                                                                                                                                                    | (10.3)                                                                                                                                                                                               |
| discontinued due to a dnug-relhted adverse event                                                                                                                                                     | 22                                                                                                                                                                                                   | (11.5)                                                                                                                                                                                               | 6                                                                                                                                                                                                    | (9.5)                                                                                                                                                                                                | 11                                                                                                                                                                                                   | (5.60)                                                                                                                                                                                               | 4                                                                                                                                                                                                    | (6'5)                                                                                                                                                                                                |
| discontinued due to a serious adverse event                                                                                                                                                          | 9                                                                                                                                                                                                    | (4.7)                                                                                                                                                                                                | 3                                                                                                                                                                                                    | (4.8)                                                                                                                                                                                                | 10                                                                                                                                                                                                   | (5.1)                                                                                                                                                                                                | 5                                                                                                                                                                                                    | (7.4)                                                                                                                                                                                                |
| discontinued due to a serious dnug- related adverse event                                                                                                                                            | 7                                                                                                                                                                                                    | (3.6)                                                                                                                                                                                                | 3                                                                                                                                                                                                    | (4.8)                                                                                                                                                                                                | 7                                                                                                                                                                                                    | (3.5)                                                                                                                                                                                                | 2                                                                                                                                                                                                    | (2.9)                                                                                                                                                                                                |
| Enp ap oi patear aq oi roneapsanni ap fi paupmaied  I Study medication withdrawn. MedDRA Vig.0 prefenred terms Neoplasm progression\". “Malignant neoplasm progression\" and \"Disease progression\" not | Enp ap oi patear aq oi roneapsanni ap fi paupmaied  I Study medication withdrawn. MedDRA Vig.0 prefenred terms Neoplasm progression\". “Malignant neoplasm progression\" and \"Disease progression\" not | Enp ap oi patear aq oi roneapsanni ap fi paupmaied  I Study medication withdrawn. MedDRA Vig.0 prefenred terms Neoplasm progression\". “Malignant neoplasm progression\" and \"Disease progression\" not | Enp ap oi patear aq oi roneapsanni ap fi paupmaied  I Study medication withdrawn. MedDRA Vig.0 prefenred terms Neoplasm progression\". “Malignant neoplasm progression\" and \"Disease progression\" not | Enp ap oi patear aq oi roneapsanni ap fi paupmaied  I Study medication withdrawn. MedDRA Vig.0 prefenred terms Neoplasm progression\". “Malignant neoplasm progression\" and \"Disease progression\" not | Enp ap oi patear aq oi roneapsanni ap fi paupmaied  I Study medication withdrawn. MedDRA Vig.0 prefenred terms Neoplasm progression\". “Malignant neoplasm progression\" and \"Disease progression\" not | Enp ap oi patear aq oi roneapsanni ap fi paupmaied  I Study medication withdrawn. MedDRA Vig.0 prefenred terms Neoplasm progression\". “Malignant neoplasm progression\" and \"Disease progression\" not | Enp ap oi patear aq oi roneapsanni ap fi paupmaied  I Study medication withdrawn. MedDRA Vig.0 prefenred terms Neoplasm progression\". “Malignant neoplasm progression\" and \"Disease progression\" not | Enp ap oi patear aq oi roneapsanni ap fi paupmaied  I Study medication withdrawn. MedDRA Vig.0 prefenred terms Neoplasm progression\". “Malignant neoplasm progression\" and \"Disease progression\" not |

Sowce:[P045V01: analysis-adsl][P045V01: tabulations-aeplus]

The frequency of AEs by Gender in Study KN045 population was similar to that in the Reference Safety Dataset, while female patients in Study KN052 experienced a higher rate of SAEs and Grade ≥3 AEs in comparison to those in the reference safety dataset (50% vs 35.5% and 63.1% vs 45.1%, respectively. These  findings  should  be  evaluated  with  caution  given  the  low  number  of  females  (n=84)  in  Study KN052.

## ECOG Status

Pembrolizumab was consistently well  tolerated  in  ECOG  PS  0  or  ECOG  PS  1  patients  treated  in  Study KN045, with a better tolerability profile in both subgroups in terms of drug-related AEs, Grade ≥3 drugrelated AEs, and drug-related SAEs, compared to the control (Table 63).

<div style=\"page-break-after: always\"></div>

Table 63: Adverse Events Summary by ECOG Status Study KN045

All Subjects

## (APaT Population)

|                                                          | Control             | Control                      | Control                      | Control                          | Pembrolizumab               | Pembrolizumab                | Pembrolizumab                    | Pembrolizumab   |
|----------------------------------------------------------|---------------------|------------------------------|------------------------------|----------------------------------|-----------------------------|------------------------------|----------------------------------|-----------------|
|                                                          | [0] Normal Activity | [1] Symptoms, But Ambulatory | [1] Symptoms, But Ambulatory | [2] Ambulatory But Unable To pom | IIN [0] Normal Activity     | [1] Symptoms. But Ambulatory | [2] Ambuatory But Unable To Work | ImN             |
|                                                          | n ()                | n (%)                        | n (%)                        | (%)                              | ()                          | n ()                         | n (%)                            | n (%)           |
| Subjects in population with one or more adverse events   | 100 97 (97.0)       | 148 146                      | (98.6)                       | 3 4 3 (100.0) 4                  | n () 119 (100.0) 113 (95.0) | 140 129 (92.1)               | 2 2 (100.0)                      | 5 4 (80.0)      |
| with no adverse event                                    | 3 (3.0)             | 2                            | (1.4) (90.5)                 | (0.0) 0                          | 6 (5.0)                     | 11 (6'L)                     | 0 (0.0)                          | 1 (20.0)        |
| with drug-related adverse events                         | 90 (90.0)           | 134                          | 0 (66.7)                     | (0.0) 4 (100.0)                  | 81 (68.1)                   | 78 (55.7)                    | 0 (0.0)                          | 3 (60.0)        |
| with toxicity grade 3-5 adverse events                   | 59 (59.0)           | 96 (64.9)                    | 1 (33.3)                     | 4 (100.0)                        | 57 (47.9)                   | 80 (57.1)                    | 1 (50.0)                         | 1 (20.0)        |
| with toxicity gade 3-5 drug-related adverse evenis       | 51 (51.0)           | 71 (48.0)                    | 1 (33.3)                     | 3 (75.0)                         | 18 (15.1)                   | 22 (15.7)                    | 0 (0.0)                          | 0 (0.0)         |
| with serious adverse events                              | 32 (32.0)           | 67 (45.3)                    | 2 (66.7)                     | 3 (75.0)                         | 44 (37.0)                   | 57 (40.7)                    | 1 (50.0)                         | 2 (40.0)        |
| with serious drug- related adverse events                | 19 (19.0)           | 35 (23.6)                    | 1 (33.3)                     | 2 (50.0)                         | 13 (10.9)                   | 14 (10.0)                    | 0 (0.0)                          | 0 (0.0)         |
| who died                                                 | 2 (2.0)             | 6 (4.1)                      | 0 (0.0)                      | 0 (0.0)                          | 7 (5.9)                     | 6 (4.3)                      | 0 (0.0)                          | 0 (0.0)         |
| who died due to a drug- related adverse event            | 2 (2.0)             | 2 (1.4)                      | 0 (0.0)                      | 0 (0.0)                          | 2 (1.7)                     | 2 (1.4)                      | 0 (0.0)                          | 0 (0.0)         |
| discontinued’ due to an adverse event                    | 9 (9.0)             | 21 (14.2)                    | 2 (66.7)                     | 0 (0.0)                          | 10 (8.4)                    | 12 (8.6)                     | 0 (0.0)                          | 0 (0.0)         |
| discontinued due to a dnug-related adverse event         | 8 (8.0)             | 18 (12.2)                    | 2 (66.7)                     | 0 (0.0)                          | 6 (5.0)                     | 6 (6.4)                      | 0 (0.0)                          | 0 (0.0)         |
| discontinued due to a serious adverse event              | E (3.0)             | 8 (5.4)                      | 1 (33.3)                     | 0 (0.0)                          | 6 (5.0)                     | 9 (6.4)                      | 0 (0.0)                          | 0 (0.0)         |
| discontinued due to a serious drug-related adverse event | 3 (3.0)             | 6 (4.1)                      | 1 (33.3)                     | 0 (0.0)                          | 3 (2.5)                     | 6 (4.3)                      | 0 (0.0)                          | 0 (0.0)         |

Sowrce: [P045V01: analysis-adsl] [P045V01: tabulations-aeplus]

In general, the overall frequency of AEs in patients with ECOG-PS 0 or 1 reported in both Study KN045 and Study KN052 was similar to the Reference Safety Dataset for these respective groups.

Patients  with  ECOG  PS  2  were  only  included  in  Study  KN052,  and  therefore  the  comparison  of  AEs frequency versus the Reference Safety Dataset cannot be made (Table 64).

Table 64: Adverse Events Summary by ECOG Status Study KN052 All Subjects (APaT Population)

<!-- image -->

|                                                                                                                                                                             | Pembrolizumab                                                                                                                                                               | Pembrolizumab                                                                                                                                                               | Pembrolizumab                                                                                                                                                               | Pembrolizumab                                                                                                                                                               |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                             | [o]Nommal Activity                                                                                                                                                          | [1] Symptoms,But Ambulatory                                                                                                                                                 | [2]Ambulatory ButUnableTo Work                                                                                                                                              | [3]Limited Selfcare                                                                                                                                                         |
|                                                                                                                                                                             | n (%)                                                                                                                                                                       | n (%)                                                                                                                                                                       | n (6)                                                                                                                                                                       | n ()                                                                                                                                                                        |
| Subjectsinpopulation                                                                                                                                                        | 80                                                                                                                                                                          | 133                                                                                                                                                                         | 156                                                                                                                                                                         | 1 1 (100.0)                                                                                                                                                                 |
| with one or more adverse events                                                                                                                                             | 75 (93.8)                                                                                                                                                                   | 131 (98.5)                                                                                                                                                                  | 147 (94.2)                                                                                                                                                                  |                                                                                                                                                                             |
| with no adverse event                                                                                                                                                       | 5 (6.3)                                                                                                                                                                     | (SD                                                                                                                                                                         | 6 (5.8)                                                                                                                                                                     | 0 (0.0)                                                                                                                                                                     |
| with drug-related'adverse events                                                                                                                                            | 55 (68.8)                                                                                                                                                                   | 2 89 (66.9)                                                                                                                                                                 | 84 (53.8)                                                                                                                                                                   | 1 (100.0)                                                                                                                                                                   |
| with toxicitygrade 3-5adverse events                                                                                                                                        | 39 (48.8)                                                                                                                                                                   | 77 (57.9)                                                                                                                                                                   | 82 (52.0)                                                                                                                                                                   | 1 (100.0)                                                                                                                                                                   |
| with toxicity grade 3-5 drug-related adverse events                                                                                                                         | 11 (13.8)                                                                                                                                                                   | 24 (18.0)                                                                                                                                                                   | 22 (14.1)                                                                                                                                                                   | 1 (100.0)                                                                                                                                                                   |
| with senious adverse events                                                                                                                                                 | 26 (32.5)                                                                                                                                                                   | 61 (45.9)                                                                                                                                                                   | 65 (41.7)                                                                                                                                                                   | 1 (100.0)                                                                                                                                                                   |
| with serious drug-related adverse events                                                                                                                                    | 7 (8.8)                                                                                                                                                                     | 14 (10.5)                                                                                                                                                                   | 14 (9.0)                                                                                                                                                                    | 1 (100.0)                                                                                                                                                                   |
| who died                                                                                                                                                                    | 4 (5.0)                                                                                                                                                                     | 5 (3.8) 1                                                                                                                                                                   | 6 (5.8)                                                                                                                                                                     | 0 (0.0)                                                                                                                                                                     |
| who died due to a drug-related adverse event                                                                                                                                | 0 (0.0)                                                                                                                                                                     | (0.8)                                                                                                                                                                       | 0 (0.0)                                                                                                                                                                     | 0 (0.0)                                                                                                                                                                     |
| discontinued due to an adverse event                                                                                                                                        | 9 (11.3)                                                                                                                                                                    | 14 (10.5)                                                                                                                                                                   | 17 (6'01D)                                                                                                                                                                  | 1 (100.0)                                                                                                                                                                   |
| discontinued due to a drug-related adverseevent                                                                                                                             | 4 (5.0)                                                                                                                                                                     | 7 (5.3)                                                                                                                                                                     | 7 (4.5)                                                                                                                                                                     | 1 (100.0)                                                                                                                                                                   |
| discontinued due to a serious adverse event                                                                                                                                 | 8 (OOD)                                                                                                                                                                     | 12 (0'6)                                                                                                                                                                    | 13 (8.3)                                                                                                                                                                    | 1 (100.0)                                                                                                                                                                   |
| discontinued due to a serious drug- related adverse event                                                                                                                   | 3 (3.8)                                                                                                                                                                     | 5 (3.8)                                                                                                                                                                     | 5 (3.2)                                                                                                                                                                     | 1 (100.0)                                                                                                                                                                   |
| Study medication withdrawn. MedDRA V19 preferred terms \"Neoplasm progression\",\"Maligmant neoplasm progression and\"Disease progression not related to the drug are excluded. | Study medication withdrawn. MedDRA V19 preferred terms \"Neoplasm progression\",\"Maligmant neoplasm progression and\"Disease progression not related to the drug are excluded. | Study medication withdrawn. MedDRA V19 preferred terms \"Neoplasm progression\",\"Maligmant neoplasm progression and\"Disease progression not related to the drug are excluded. | Study medication withdrawn. MedDRA V19 preferred terms \"Neoplasm progression\",\"Maligmant neoplasm progression and\"Disease progression not related to the drug are excluded. | Study medication withdrawn. MedDRA V19 preferred terms \"Neoplasm progression\",\"Maligmant neoplasm progression and\"Disease progression not related to the drug are excluded. |

<div style=\"page-break-after: always\"></div>

## Region

The overall summary by region (EU versus non-EU) for KN045 showed similar results for the EU compared to non-EU (Table 65). Table 65: Adverse Events Summary by Region (EU vs Non-EU) Study KN045 - All Subjects

## (APaT Population)

|                                                                                                                                                                                                            | Control                                                                                                                                                                                                    | Control                                                                                                                                                                                                    | Control                                                                                                                                                                                                    | Control                                                                                                                                                                                                    | Pembrolizumab                                                                                                                                                                                              | Pembrolizumab                                                                                                                                                                                              | Pembrolizumab                                                                                                                                                                                              | Pembrolizumab                                                                                                                                                                                              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                            | EU                                                                                                                                                                                                         | EU                                                                                                                                                                                                         | Non-EU                                                                                                                                                                                                     | Non-EU                                                                                                                                                                                                     | EU                                                                                                                                                                                                         | EU                                                                                                                                                                                                         | Non-EU                                                                                                                                                                                                     | Non-EU                                                                                                                                                                                                     |
|                                                                                                                                                                                                            | n                                                                                                                                                                                                          | (%)                                                                                                                                                                                                        | n                                                                                                                                                                                                          | ()                                                                                                                                                                                                         | n                                                                                                                                                                                                          | (.0)                                                                                                                                                                                                       | n                                                                                                                                                                                                          | ()                                                                                                                                                                                                         |
| Subjects in population                                                                                                                                                                                     | 112                                                                                                                                                                                                        |                                                                                                                                                                                                            | 143                                                                                                                                                                                                        |                                                                                                                                                                                                            | 104                                                                                                                                                                                                        |                                                                                                                                                                                                            | 162                                                                                                                                                                                                        |                                                                                                                                                                                                            |
| with one or more adverse events                                                                                                                                                                            | 111                                                                                                                                                                                                        | (99.1)                                                                                                                                                                                                     | 139                                                                                                                                                                                                        | (97.2)                                                                                                                                                                                                     | 98                                                                                                                                                                                                         | (94.2)                                                                                                                                                                                                     | 150                                                                                                                                                                                                        | (92.6)                                                                                                                                                                                                     |
| with no adverse event                                                                                                                                                                                      | 1                                                                                                                                                                                                          | (0.9)                                                                                                                                                                                                      | 4                                                                                                                                                                                                          | (2.8)                                                                                                                                                                                                      | 6                                                                                                                                                                                                          | (5.8)                                                                                                                                                                                                      | 12                                                                                                                                                                                                         | (7.4)                                                                                                                                                                                                      |
| with dnug-related adverse events                                                                                                                                                                           | 101                                                                                                                                                                                                        | (90.2)                                                                                                                                                                                                     | 129                                                                                                                                                                                                        | (90.2)                                                                                                                                                                                                     | 66                                                                                                                                                                                                         | (63.5)                                                                                                                                                                                                     | 96                                                                                                                                                                                                         | (59.3)                                                                                                                                                                                                     |
| with toxicity grade 3-5 adverse events                                                                                                                                                                     | 60                                                                                                                                                                                                         | (53.6)                                                                                                                                                                                                     | 100                                                                                                                                                                                                        | (69.9)                                                                                                                                                                                                     | 53                                                                                                                                                                                                         | (51.0)                                                                                                                                                                                                     | 86                                                                                                                                                                                                         | (53.1)                                                                                                                                                                                                     |
| with toxicity grade 3-5 dnug-related adverse evenis                                                                                                                                                        | 45                                                                                                                                                                                                         | (40.2)                                                                                                                                                                                                     | 81                                                                                                                                                                                                         | (56.6)                                                                                                                                                                                                     | 18                                                                                                                                                                                                         | (17.3)                                                                                                                                                                                                     | 22                                                                                                                                                                                                         | (13.6)                                                                                                                                                                                                     |
| with serious adverse events                                                                                                                                                                                | 52                                                                                                                                                                                                         | (46.4)                                                                                                                                                                                                     | 52                                                                                                                                                                                                         | (36.4)                                                                                                                                                                                                     | 38                                                                                                                                                                                                         | (36.5)                                                                                                                                                                                                     | 66                                                                                                                                                                                                         | (40.7)                                                                                                                                                                                                     |
| with serious dnug-related adverse events                                                                                                                                                                   | 32                                                                                                                                                                                                         | (28.0)                                                                                                                                                                                                     | 25                                                                                                                                                                                                         | (17.5)                                                                                                                                                                                                     | 9                                                                                                                                                                                                          | (8.7)                                                                                                                                                                                                      | 18                                                                                                                                                                                                         | (11.1)                                                                                                                                                                                                     |
| who died                                                                                                                                                                                                   |                                                                                                                                                                                                            | (3.6)                                                                                                                                                                                                      | 4                                                                                                                                                                                                          | (2.8)                                                                                                                                                                                                      | 4                                                                                                                                                                                                          | (3.8)                                                                                                                                                                                                      | 9                                                                                                                                                                                                          | (5.6)                                                                                                                                                                                                      |
| who died due to a dnug-related adverse event                                                                                                                                                               | 3                                                                                                                                                                                                          | (2.7)                                                                                                                                                                                                      | 1                                                                                                                                                                                                          | (0.7)                                                                                                                                                                                                      | 0                                                                                                                                                                                                          | (0.0)                                                                                                                                                                                                      | 4                                                                                                                                                                                                          | (2.5)                                                                                                                                                                                                      |
| discontinued due to an adverse event                                                                                                                                                                       | 13                                                                                                                                                                                                         | (11.6)                                                                                                                                                                                                     | 19                                                                                                                                                                                                         | (13.3)                                                                                                                                                                                                     | 7                                                                                                                                                                                                          | (6.7)                                                                                                                                                                                                      | 15                                                                                                                                                                                                         | (9.3)                                                                                                                                                                                                      |
| discontinued due to a drug-related adverse event                                                                                                                                                           | 11                                                                                                                                                                                                         | (9.8)                                                                                                                                                                                                      | 17                                                                                                                                                                                                         | (11.9)                                                                                                                                                                                                     | 5                                                                                                                                                                                                          | (4.8)                                                                                                                                                                                                      | 10                                                                                                                                                                                                         | (6.2)                                                                                                                                                                                                      |
| discontinued due to a serious adverse event                                                                                                                                                                | 8                                                                                                                                                                                                          | (7.1)                                                                                                                                                                                                      | 4                                                                                                                                                                                                          | (2.8)                                                                                                                                                                                                      | 2                                                                                                                                                                                                          | (1.9)                                                                                                                                                                                                      | 13                                                                                                                                                                                                         | (8.0)                                                                                                                                                                                                      |
| discontinued due to a serious dnug- related adverse event                                                                                                                                                  | 7                                                                                                                                                                                                          | (6.3)                                                                                                                                                                                                      | 3                                                                                                                                                                                                          | (2.1)                                                                                                                                                                                                      | 0                                                                                                                                                                                                          | (0.0)                                                                                                                                                                                                      | 9                                                                                                                                                                                                          | (5.6)                                                                                                                                                                                                      |
| Determined by the investigator to be related to the drug. I Study medication withdrawm. MedDRA V19.0 prefered terms \"Neoplasm progression\". \"Malignant neoplasm progression\" and \"Disease progression\" not | Determined by the investigator to be related to the drug. I Study medication withdrawm. MedDRA V19.0 prefered terms \"Neoplasm progression\". \"Malignant neoplasm progression\" and \"Disease progression\" not | Determined by the investigator to be related to the drug. I Study medication withdrawm. MedDRA V19.0 prefered terms \"Neoplasm progression\". \"Malignant neoplasm progression\" and \"Disease progression\" not | Determined by the investigator to be related to the drug. I Study medication withdrawm. MedDRA V19.0 prefered terms \"Neoplasm progression\". \"Malignant neoplasm progression\" and \"Disease progression\" not | Determined by the investigator to be related to the drug. I Study medication withdrawm. MedDRA V19.0 prefered terms \"Neoplasm progression\". \"Malignant neoplasm progression\" and \"Disease progression\" not | Determined by the investigator to be related to the drug. I Study medication withdrawm. MedDRA V19.0 prefered terms \"Neoplasm progression\". \"Malignant neoplasm progression\" and \"Disease progression\" not | Determined by the investigator to be related to the drug. I Study medication withdrawm. MedDRA V19.0 prefered terms \"Neoplasm progression\". \"Malignant neoplasm progression\" and \"Disease progression\" not | Determined by the investigator to be related to the drug. I Study medication withdrawm. MedDRA V19.0 prefered terms \"Neoplasm progression\". \"Malignant neoplasm progression\" and \"Disease progression\" not | Determined by the investigator to be related to the drug. I Study medication withdrawm. MedDRA V19.0 prefered terms \"Neoplasm progression\". \"Malignant neoplasm progression\" and \"Disease progression\" not |

Sowrce: [P045V01: analysis-adsl] [P045V01: tabulations-aeplus]

## Discontinuation due to adverse events

In Study KN045, a total of 22 (8.3%) patients in the pembrolizumab arm and 32 (12.5%) patients in the control group had an AE resulting in treatment discontinuation. The most common AEs leading to discontinuation were Pneumonitis (1.9%) in patients treated with pembrolizumab, and Peripheral sensory neuropathy (2.0%) and Neuropathy peripheral (1.6%) in patients who received chemotherapy.

In Study KN052, a total of 41 (11.1%) subjects discontinued treatment due to AEs. None of these events was reported in a frequency &gt;1%.

## Immunogenicity

A total of 3727 subjects were included in the immunogenicity assessment across indications (1,535 melanoma, 1,238 NSCLC, 101 HNSCC, 54 MSI-H, 220 HL, and 579 urothelial carcinoma subjects) and across doses (at 2 mg/kg Q3W, 10 mg/kg Q3W/ Q2W, and 200 mg Q3W).

The observed frequency of treatment-emergent anti-drug antibodies (ADA) in evaluable subjects from this pooled analysis across indications is 1.8% (36 out of 2034). Exposure to pembrolizumab was not compromised by the observed immune response. Indeed, in the 36 subjects with a treatment-emergent immunogenicity response pembrolizumab exposure was in the range of those observed for non-positive subjects treated with pembrolizumab in the same regimen. The treatment emergent positive subjects did not have any AEs associated with neutralizing antibodies, such as hypersensitivity events (e.g. anaphylaxis, urticaria, angioedema) or injection site reactions.

<div style=\"page-break-after: always\"></div>

In the subgroup of urothelial carcinoma subjects (pooled across KN012, KN045 and KN052), the incidence for treatment-emergent ADA in evaluable subjects is 1.4% (7 of 509; 497 negative, 5 non-treatment emergent positive and 7 treatment emergent positive), in line with the overall incidence.

## Post marketing experience

The Keytyruda Periodic Safety Update Report (PSUR), covering the reporting period 04 March 2016 to 03 September 2016, has been just reviewed by the PRAC. Assessment of the signal for sarcoidosis led to the conclusion that a causal association cannot be excluded and reflection in the SmPC and Package Leaflet was requested accordingly.

## 2.5.1. Discussion on clinical safety

The  pembrolizumab  safety  profile  in  locally  advanced  or  metastatic  urothelial  carcinoma  has  been presented in 266 subjected previously treated with platinum-containing chemotherapy (study KEYNOTE045), and in 370 patients previously untreated and cisplatin-ineligible (study KEYNOTE-052). In addition, safety data from a Reference Safety Dataset including overall 3,194 patients treated with pembrolizumab across  different  trials  (studies  KEYNOTE-001,  KEYNOTE-002  and  KEYNOTE-006  in  melanoma;  studies KEYNOTE-001,  KEYNOTE-010  and  KEYNOTE-024  in  NSCLC;  studies  KEYNOTE-013  Cohort  3  and KEYNOTE-087 in Hodgkin's Lymphoma) have been submitted, in order to allow a comparison with the already established pembrolizumab safety profile. At a median follow up of 12 months in study KN045 and of 11 months in study KN052, a shorter median time on therapy was reported in both KN045 and KN052 studies compared to the Reference Safety Dataset (3.45 months and 3.40 respectively, versus 4.86 months), resulting into a reduced number of administered doses ( 6 and 5 respectively, versus 8).

Consistently with the epidemiologic pattern of urothelial carcinoma, in comparison to the reference safety dataset, patients in both KN-045 and KN-052 were mostly male (74.4% and 77.3%, respectively, versus 59.3%), and ≥65 years (61.3% and 81.6%, respectively, versus 43.3%). ECOG PS2 patients were 42.2% in Study KN-052 and 1.5% in Study KN-045

In  study  KN045,  pembrolizumab  treatment  favorably  compares  with  chemotherapy  in  terms  of    drugrelated  AEs  (60.9% vs 90.2%), Grade≥3 AEs (52.3% vs 62.7%), drug-related Grade≥3 AEs (15% vs 49.4%),  serious  drug-related  AEs  (10.2  vs  22.4%),  treatment  interruption  due  to  drug-related  AEs (10.5% vs 15.7%) and treatment discontinuation due to drug-related AEs (11% vs 5.6%). As expected, pembrolizumab showed a well different safety profile compared to chemotherapy, with a higher rate in the control arm of AEs in SOCs General disorders and administration site conditions (72.2% vs 57.5%), Gastrointestinal  disorders (68.2% vs 56.4%), Blood and lymphatic system disorders (51% vs 19.9%), Nervous  system  disorders (41.2%  vs  21.8%)  and Investigations (34.9%  vs  28.9%),  and  a  higher frequency in pembrolizumab arm of AEs in SOCs Musculoskeletal and connective tissue disorders (42.5% vs  37.3%), Respiratory,  thoracic  and  mediastinal  disorders (34.2%  vs  29.4%), Renal  and  urinary disorders (27.1% vs 17.6%) and Endocrine disorders (10.5% vs 1.6%). Among the most common PTs, Pruritus and Decreased appetite were the only registered at higher frequency in the pembrolizumab arm (23.3% vs 5.5% and 21.1% vs 20.8%, respectively). In terms of drug-related AEs, the most frequently observed events in the pembrolizumab arm were Pruritus (19.5%), Fatigue (13.9%) and Nausea (10.9%) while  in  the  control  arm  patients  mostly  experienced Alopecia (37.6%), Fatigue (27.8%), Anemia (24.7%), Nausea (24.3%), Constipation (20.4%), Decreased  appetite (16.1%), Neutropenia (15.3%), Asthenia (14.1%), Neutrophil count decreased (14.1%), Diarrhea (12.9%), Peripheral sensory neuropathy (11.0%), and Neuropathy peripheral (10.6%).

Overall, in patients treated with pembrolizumab, no major differences in the safety profile were observed between  both  populations  in  studies  KN045  and  KN052  and  in  the  Reference  Safety  Dataset.  The

<div style=\"page-break-after: always\"></div>

frequency and severity of AEOSI in both UC populations were also in line with those previously described. However, a higher frequency of Urinary tract infection and Haematuria was registered across UC studies in comparison to the Reference Safety Dataset, together with an increase of Blood alkaline phosphatase and Blood  creatinine specifically  in  study  KN052. Urinary  tract  infection was  also  the  most  commonly reported Grade≥3 AE (9.5%) in study KN052.  Even though the underlying disease condition can possibly explain the higher than previously reported rate of these AEs, the contribution of pembrolizumab cannot be  ignored:  in  the  comparative  study  KN045,  patients  treated  with  pembrolizumab  experienced  more frequently  that  those  treated  with  chemotherapy Acute  kidney  injury (5.6%  vs  2.7%), Haematuria (11.3% vs 7.8%) and Urinary tract infection (14.7% vs 13.3%). In study KN052, consistently with the Reference  Safety  Dataset,  the  most  commonly  reported  drug-related  AEs  were  Fatigue  (16.8%  and 24.2%), Pruritus  (14.6%  and  16.7%)  and Rash (9.7%  and  13.8%). Pneumonitis and Colitis were the most common drug-related SAEs in KN045 (1.9% and 1.5%) and in the Reference Safety Dataset (1.6% and 0.9%).

Overall, a total of 31 fatal cases, 13 in study KN045 and 18 in study KN052, occurred within 90 days from the last pembrolizumab dose. The frequency of patients with AE leading to fatal outcome was comparable in  KN045  (4.9%),  KN052  (4.9%)  and  in  the  Reference  Safety  Dataset  (3.9%),  even  though  a  higher number of deaths was reported in cisplatin-ineligible patients compared to platinum-pretreated ones. This difference  can  be  explained  considering  the  baseline  characteristics  of  the  patient  population  in  study KN052. Indeed, 15 out of the 18 dead patients were ≥65 years old, including 10 patients aged ≥75 years and 4 patients older than 85 years. No new safety signal was identified from fatal cases. One AEOSI with fatal  outcome  was  reported  each  in  Study  KN045 ( Pneumonitis )  and  in  Study  KN052  ( Myositis );  while fatal Pneumonitis events were already reported, this is the first fatal case of Myositis and the information has been included in Section 4.4 of the SmPC.

The  frequency  of  clinically  meaningful  laboratory  abnormalities  was  overall  comparable  among  Study KN045,  Study  KN052  and    the  reference  safety  data  set,  with  the  exception  of Albumin  decreased , Creatinine  increased , Haemoglobin  decreased that  were  more  pronounced  in  the  urothelial  cancer population possibly due to the baseline medical condition.

No  major  and  unexpected  differences  in  the  tolerability  of  pembrolizumab  treatment  were  observed across the different classes of age (&lt;65 years, ≥65 to &lt;75 years,≥75 to &lt;85 years, ≥85 years), ECOG Performance  Status  categories  (PS  0/1),  and  gender  (Male/Female).  ECOG  PS≥2  patients  were  only included in Study KN052. Based on the overall 157 patients included, no impact on the pembrolizumab tolerability can be assumed.

In the application which was submitted also a change to section 4.4 of the SmPC was proposed, adding possible  hypersensitivity  and  anaphylaxis  as  part  of  infusion  reactions.  These  changes  have  been considered acceptable and were included in the SmPC.

## 2.5.2. Conclusions on clinical safety

Overall,  the  safety  profile  of  pembrolizumab  in  the  UC  population  does  not  seem  to  be  significantly influenced  by  prior  platinum-treatment  (KN045) or  baseline  patient  characteristics  leading  to  cisplatinineligibility (KN052). Available safety data are in general consistent with those previously reported in the SmPC.  New  warnings  were  added  under  section  4.4  regarding  the  delayed  onset  of  the  effect  of pembrolizumab to be considered when treating patients with poorer prognosis; the lack of data in frailer patients  (e.g  ECOG  ≥3)  ineligible  for  chemotherapy  and  the  first  reported  fatal  case  of  myositis.  The incidences of adverse reactions under section 4.8 of the SmPC were updated to reflect the totality of the data.

<div style=\"page-break-after: always\"></div>

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 7.2 is acceptable.

The CHMP endorsed the Risk Management Plan version 7.2 with the following content:

## Safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Immune-Related Adverse Reactions - Immune-related pneumonitis - Immune-related colitis - Immune-related hepatitis - Immune-related nephritis - Immune-related endocrinopathies • Hypophysitis (including hypopituitarism and secondary adrenal insufficiency) • Thyroid Disorder (hypothyroidism, hyperthyroidism, thyroiditis) • Type 1 diabetes mellitus - Other immune-related adverse reactions • Uveitis • Myositis • Pancreatitis • Severe Skin Reactions • Guillain-Barre Syndrome |
| Important potential risks    | Immune-Related Adverse Events • Gastrointestinal perforation secondary to colitis Immunogenicity                                                                                                                                                                                                                                                                                                                                                                                          |
| Missing information          | - Safety in patients with moderate or severe hepatic impairment - Safety in patients with severe renal impairment - Safety in patients with active systemic autoimmune disease - Safety in patients with HIV or Hepatitis B or Hepatitis C - Safety in pediatric patients - Reproductive and lactation data - Long term safety - Safety in various ethnic groups - Potential pharmacodynamic interaction with systemic                                                                    |

<div style=\"page-break-after: always\"></div>

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                          |
|------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                              | immunosuppressants - Safety in patients with previous hypersensitivity to another monoclonal antibody - Safety in patients with severe (grade 3) immune-related (ir)AEs on prior ipilimumab (ipi) requiring corticosteroids for > 12 weeks, or life-threatening irAEs on prior ipi, or with ongoing ipi-related AEs |

Having considered the updated data in the safety specification, no new safety concerns were included as part of this extension of indication. The list of safety concerns remains unchanged.

## Pharmacovigilance plan

Completed, ongoing and planned studies in the PhV development plan

| Activity/Study title (type of activity, study title, category 1-3)*                                                                                                                          | Objectives                                                                                                                                                                 | Safety concerns addressed                                                                                                                                                               | Status Planned, started,   | Date for submission of interim or final reports (planned or actual)   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|-----------------------------------------------------------------------|
| Validation report for anti-MK- 3475 neutralizing antibody assay (Category 3)                                                                                                                 | To validate the assay for the determination of neutralizing capacity of anti-MK-3475 antibodies and to report the results in an assay validation report.                   | Important potential risk (Immunogenicity)                                                                                                                                               | Started                    | Final assay validation report September 2016                          |
| Clinical trial Phase I Study of Single Agent MK-3475 in Patients with Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non- Small Cell Lung Carcinoma (P001) (Category 3) | To evaluate and characterize the tolerability and safety profile of single agent MK- 3475 in adult patients with unresectable advanced carcinoma (including NSCLC or MEL). | -Important identified risks (Immune-related adverse reactions, Infusion-related reactions) -Important potential risks (Immune-related adverse events, Immunogenicity) -Long term safety | Started                    | Final study report December 2016                                      |
| Clinical trial Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma (P002) (Category 3)                                                              | To evaluate the progression- free-survival (PFS) in patients with ipilimumab refractory advanced MEL receiving either MK-3475 or chemotherapy.                             | -Important identified risks (Immune-related adverse reactions, Infusion-related reactions) -Important potential risks                                                                   | Started                    | Final study report January 2017                                       |

<div style=\"page-break-after: always\"></div>

| Activity/Study title (type of activity, study title, category 1-3)*                                                                                                                                                             | Objectives                                                                                                                                                                                                                         | Safety concerns addressed                                                                                                                                                               | Status Planned, started,   | Date for submission of interim or final reports (planned or actual)   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|-----------------------------------------------------------------------|
|                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                    | (Immune-related adverse events, Immunogenicity) -Long term safety                                                                                                                       |                            |                                                                       |
| Clinical trial A Multicenter, Randomized, Controlled, Three- Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to IPI in Patients with Advanced Melanoma (P006) (Category 3) | To evaluate progression- free-survival (PFS) in patients with advanced MEL receiving either MK-3475 or IPI                                                                                                                         | -Important identified risks (Immune-related adverse reactions, Infusion-related reactions) -Important potential risks (Immune-related adverse events, Immunogenicity) -Long term safety | Started                    | Final study report January 2017                                       |
| Clinical trial A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer (P010) (Category 3)                                          | To compare the overall survival (OS) of previously- treated subjects with NSCLC in the strongly positive PD- L1 stratum treated with MK- 3475 compared to docetaxel                                                                | -Important identified risks (Immune-related adverse reactions, Infusion-related reactions -Important potential risks (Immune-related adverse events, Immunogenicity) -Long term safety  | Started                    | Final study report August 2019                                        |
| Clinical trial A Randomized Open-Label Phase III Trial of Pembrolizumab versus Platinum based Chemotherapy in 1L Subjects with PD-L1 Strong Metastatic Non-Small Cell Lung Cancer (P024) (Category 3)                           | To compare the Progression Free Survival (PFS) per RECIST 1.1 as assessed by blinded independent central radiologists' review in subjects with PDL1 strong, 1L metastatic NSCLC treated with pembrolizumab compared to standard of | -Important identified risks (Immune-related adverse reactions, Infusion-related reactions) -Important potential risks (Immune-related                                                   | Started                    | Final study report September 2018                                     |

<div style=\"page-break-after: always\"></div>

| Activity/Study title (type of activity, study title, category 1-3)*                                                                                                                                                                                                     | Objectives                                                                                                                                                                                                                                                                                                                                                             | Safety concerns addressed                                                                                                                                                               | Status Planned, started,   | Date for submission of interim or final reports (planned or actual)   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|-----------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                         | care (SOC) chemotherapies.                                                                                                                                                                                                                                                                                                                                             | adverse events, Immunogenicity) -Long term safety                                                                                                                                       |                            |                                                                       |
| Clinical trial A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (P042) (Category 3) | To compare the overall survival (OS) in subjects with PD-L1 strongly positive, 1L advanced/metastatic NSCLC treated with pembrolizumab compared to standard of care (SOC) chemotherapies.                                                                                                                                                                              | -Important identified risks (Immune-related adverse reactions, Infusion-related reactions) -Important potential risks (Immune-related adverse events, Immunogenicity) -Long term safety | Started                    | Final study report December 2019                                      |
| Clinical trial A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (P051) (Category 3)                                                                        | To define the rate of dose- limiting toxicities (DLTs) at the maximum tolerated dose (MTD) or maximum administered dose (MAD) of pembrolizumab when administered as monotherapy to children from 6 months to < 18 years of age pooled across all indications including advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma. | Important identified risks (Immune-related adverse reactions, Infusion-related reactions) -Important potential risks (Immune-related adverse events) -Safety in pediatric patients      | Started                    | Final Study Report July 2019                                          |

No changes to the PhV plan have been proposed as part of this extension of indication. The postauthorisation PhV development plan remains sufficient to identify and characterise the risks of the product.

<div style=\"page-break-after: always\"></div>

## Risk minimisation measures

| Safety concern                                                                                                                                                                                              | Routine risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                | Additional risk minimisation measures   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| Important Identified Risk                                                                                                                                                                                   | Important Identified Risk                                                                                                                                                                                                                                                                                                                                                                         | Important Identified Risk               |
| Immune-related Pneumonitis                                                                                                                                                                                  | The risk of the immune-related adverse reaction of pneumonitis associated with the use of pembrolizumab is described in the SmPC, Section 4.2, 4.4, 4.8 and appropriate advice is provided to the prescriber to minimize the risk.                                                                                                                                                                | Educational materials                   |
| Immune-related Colitis                                                                                                                                                                                      | The risk of the immune-related adverse reaction of colitis associated with the use of pembrolizumab is described in the SmPC, Section 4.2, 4.4, 4.8 and appropriate advice is provided to the prescriber to minimize the risk.                                                                                                                                                                    | Educational materials                   |
| Immune-related Hepatitis                                                                                                                                                                                    | The risk of the immune-related adverse reaction of hepatitis associated with the use of pembrolizumab is described in the SmPC, Section 4.2, 4.4, 4.8 and appropriate advice is provided to the prescriber to minimize the risk.                                                                                                                                                                  | Educational materials                   |
| Immune-related Nephritis                                                                                                                                                                                    | The risk of the immune-related adverse reaction of nephritis associated with the use of pembrolizumab is described in the SmPC, Section 4.2, 4.4, 4.8 and appropriate advice is provided to the prescriber to minimize the risk.                                                                                                                                                                  | Educational materials                   |
| Immune-related Endocrinopathies -Hypophysitis (including hypopituitarism and secondary adrenal insufficiency) - Thyroid Disorder ( Hypothyroidism, Hyperthyroidism, thyroiditis) - Type 1 Diabetes Mellitus | The risk of the immune-related endocrinopathies [Hypophysitis (including hypopituitarism and secondary adrenal insufficiency); Thyroid Disorder ( Hypothyroidism, Hyperthyroidism, thyroiditis); Type 1 Diabetes Mellitus] associated with the use of pembrolizumab is described in the SmPC, Section 4.2, 4.4 and 4.8 and appropriate advice is provided to the prescriber to minimize the risk. | Educational materials                   |
| Other Immune-related adverse reactions                                                                                                                                                                      | The risk of other immune-related adverse reactions (uveitis, myositis,                                                                                                                                                                                                                                                                                                                            | Educational materials                   |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                                                          | Routine risk minimisation measures                                                                                                                                                                                                                               | Additional risk minimisation measures   |
|---------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| -Uveitis, Myositis, Pancreatitis, Severe Skin Reactions, Guillain-Barre Syndrome                        | pancreatitis, severe skin reactions, Guillain-Barre syndrome) associated with the use of pembrolizumab is described in the SmPC, Section 4.4, 4.8 and appropriate advice is provided to the prescriber to minimize the risk.                                     |                                         |
| Infusion-Related Reactions                                                                              | The risk of infusion-related reactions associated with the use of pembrolizumab is described in the SmPC, Section 4.2, 4.4, 4.8 and appropriate advice is provided to the prescriber to minimize the risk.                                                       | Educational materials                   |
| Important Potential Risk                                                                                |                                                                                                                                                                                                                                                                  |                                         |
| Gastrointestinal perforation secondary to colitis                                                       | The risk of the immune-related adverse event of gastrointestinal perforation secondary to colitis associated with the use of pembrolizumab is described in the SmPC, Section 4.4, 4.8 and appropriate advice is provided to the prescriber to minimize the risk. | None                                    |
| Immunogenicity                                                                                          | The risk of immunogenicity associated with the use of pembrolizumab is described in the SmPC, Section 4.8.                                                                                                                                                       | None                                    |
| Missing Information                                                                                     |                                                                                                                                                                                                                                                                  |                                         |
| Safety in patients with moderate or severe hepatic impairment and patients with severe renal impairment | The missing information of safety in these patients is described in the SmPC, Section 4.2, 4.4.                                                                                                                                                                  | None                                    |
| Safety in patients with active systemic autoimmune disease                                              | The missing information of safety in patients with active systemic autoimmune disease is described in the SmPC, Section 4.4, 5.1                                                                                                                                 | None                                    |
| Safety in patients with HIV or Hepatitis B or Hepatitis C                                               | The missing information of safety in patients with patients with HIV or Hepatitis B or Hepatitis C is described in the SmPC, Section 4.4, 5.1.                                                                                                                   | None                                    |
| Safety in Pediatric patients                                                                            | The missing information of safety in pediatric patients is described in the SmPC, Section 4.2                                                                                                                                                                    | None                                    |
| Reproductive and lactation data                                                                         | Use during pregnancy and use in nursing mothers is described in the SmPC, Section 4.6, 5.3                                                                                                                                                                       | None                                    |
| Long term safety                                                                                        | None                                                                                                                                                                                                                                                             | None                                    |
| Safety in various ethnic groups                                                                         | None                                                                                                                                                                                                                                                             | None                                    |
| Potential pharmacodynamic interaction with systemic                                                     | The missing information of potential pharmacodynamic interaction with                                                                                                                                                                                            | None                                    |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                                                                                                                                                               | Routine risk minimisation measures                                                                                                                                                                                                                                                 | Additional risk minimisation measures   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| immunosuppressants                                                                                                                                                                                           | systemic immunosuppressants is described in the SmPC, Section 4.4, 4.5                                                                                                                                                                                                             |                                         |
| Safety in patients with previous hypersensitivity to another monoclonal antibody                                                                                                                             | The missing information of safety in patients with previous hypersensitivity to another monoclonal antibody is described in the SmPC, Section 4.4, 5.1                                                                                                                             | None                                    |
| Safety in patients with severe (grade 3) immune-related (ir)AEs on prior ipilimumab (ipi) requiring corticosteroids for > 12 weeks, or life- threatening irAEs on prior ipi, or with ongoing ipi-related AEs | The missing information of safety in patients with severe (grade 3) immune-related (ir)AEs on prior ipilimumab (ipi) requiring corticosteroids for > 12 weeks, or life- threatening irAEs on prior ipi, or with ongoing ipi-related AEs is described in the SmPC, Section 4.4, 5.1 | None                                    |

The risk minimisation measures have not changed. The existing risk minimisation measures remain sufficient to minimise the risks of the product in the proposed indication.

## 2.7. Update of the Product information

As a consequence of these new indications, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC have been updated and the Package Leaflet has been updated accordingly. Further,  a change to section 4.4 of the SmPC adding possible hypersensitivity and anaphylaxis as part of infusion reactions, have been included.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the applicant. Even though the justification can be considered in principle acceptable due to the limited changes to the package leaflet, since the readability test was performed several modification have been implemented based on variations.

The CHMP recommends an abridged testing of the current version of the package leaflet and Instruction for HPs should be performed with the next relevant submitted variation. This testing on package leaflet should be carried out with 5 participants (patients or caregivers) for each round (two); moreover, at least three HPs should be involved for an abridged test focused on the Instructions for preparation and administration and posology section. The relevant questions of the initial questionnaire should be used to reflect all amendments adequately.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

KEYTRUDA as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior chemotherapy.

The MAH agrees to revise the above indication taking into account that only patients previously treated with platinum-based chemotherapy were included in the pivotal trial (revised indication: 'KEYTRUDA as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who were previously treated with platinum-based chemotherapy'.)

KEYTRUDA as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy.

## 3.1.2. Available therapies and unmet medical need

Failing first-line platinum-based chemotherapy, the prognosis is compromised with a median OS reduced to 5 to 7 months (Bellmunt J, J Clin Oncol 2009). In this setting, there is no globally recognized standard of care. Vinflunine is the only drug approved in EU.

More than 50% of patients are unfit for cisplatin due to poor performance status, impaired renal function, or specific comorbidities. For these patients, NCCN Guidelines (version 2.2017) and ESMO Practice Guideline (Bellmunt J, Annals of Oncology 2014) recommend carboplatin-based regimens or single agent taxane or gemcitabine. A median OS of 9 months has been reported with the carboplatin/gemcitabine combination (De Santis M, J Clin Oncol 2012). In case of patients with PS ≥2 and poor renal function, the participation in clinical trials or BSC is recommended by ESMO guidelines.

## 3.1.3. Main clinical studies

Advanced or metastatic urothelial carcinoma progressing after prior chemotherapy

To support this indication, results of a phase III randomized (1:1) open-label clinical trial (KEYNOTE-045) of pembrolizumab versus Investigator's choice (paclitaxel, docetaxel or vinflunine) in 542 subjects with recurrent or metastatic urothelial carcinoma who experienced progression after a platinum-based regimen, enrolled regardless PD-L1 expression status were provided.

Previously untreated cisplatin-ineligible advanced/unresectable or metastatic urothelial carcinoma

To support this indication, results of a phase II single-arm clinical trial (KEYNOTE-052) of pembrolizumab in 370 cisplatin-ineligible subjects with locally advanced unresectable or metastatic urothelial carcinoma, enrolled regardless PD-L1 expression status were provided.

In order to provide information for contextualization of the results in cisplatin ineligible patients, the MAH conducted and provided a systematic literature review and meta-analysis.

## 3.2. Favourable effects

Advanced or metastatic urothelial carcinoma progressing after prior chemotherapy

<div style=\"page-break-after: always\"></div>

Overall, a statistically significant gain of 3 months in OS is reported in the overall population (HR:0.73, 95% CI 0.59, 0.91, p=0.002). The median OS in the chemotherapy arm (7.4 months, 95% CI 6.1, 8.3) is consistent with historical data from single-agent second line treatment. Consistently, a significant OS increase was observed in PD-L1 strongly positive patients treated with pembrolizumab compared to chemotherapy (HR:0.57, 95% CI 0.37, 0.88, p=0.004). In addition, even though p-value was not multiplicity-adjusted, results in PD-L1 positive patients showed a similar magnitude of OS benefit (HR:0.61, 95% CI 0.43, 0.86, p=0.002) compared to PD-L1 strongly positive. A prolonged time to deterioration in EORTC QLQ-C30 global health status/QoL was observed for patients treated with pembrolizumab compared to chemotherapy (HR 0.70; 95% CI 0.55-0.90) which remained at over 15 weeks of follow-up.

Previously untreated cisplatin-ineligible advanced/unresectable or metastatic urothelial carcinoma

An ORR of 24.1% (95% CI 19.8, 28.7) was reported in the overall population. In 282 PD-L1 positive patients ORR was 26.6% (95% CI 21.5, 32.2). When considering the subgroup of PD-L1 strongly positive patients from the validation cohort, a higher ORR of 38.8% (95% CI 28.1, 50.3) was reported.

Response rates improved with longer follow and responses remained durable (see efficacy results of updated analyses in effects tables below).

## 3.3. Uncertainties and limitations about favourable effects

Advanced or metastatic urothelial carcinoma progressing after prior chemotherapy

An excess of deaths in the pembrolizumab arm was observed in the first two months (43 in pembrolizumab vs. 24 in control arm) leading to an initial favourable effect for the control arm in OS K-M curves, followed by a crossing around 3-4 months from the start of treatment. In this regard, liver metastases and time from most recent prior therapy of &lt; 3 months were identified as possible factors associated to the higher risk of early death. Hence, a warning has been added in section 4.4 of the SmPC as follows: 'Physicians should consider the delayed onset of pembrolizumab effect before initiating treatment in patients with poorer prognostic features and/or aggressive disease. In urothelial cancer, a higher number of deaths within 2 months were observed in pembrolizumab compared to chemotherapy (see section 5.1).'

Improvement in patient-reported outcomes by EORTC QLQ-C30 such as prolonged time to deterioration in EORTC QLQ-C30 global health status/QoL was observed for patients treated with pembrolizumab compared to investigator's choice chemotherapy (HR 0.70; 95% CI 0.55-0.90) and its maintenance over 15 weeks of follow-up, was a significant result, however such results should be interpreted in the context of the open-label study design and therefore taken cautiously (See SmPC).

Previously untreated cisplatin-ineligible advanced/unresectable or metastatic urothelial carcinoma

Only data from an uncontrolled trial (KN052) were submitted to support this indication. A systematic review and meta-analysis of the literature was performed, however this systematic review presents some limitations. Taking into account the historical data in the target population, observed ORR data are not that compelling, even in the PD-L1 strongly positive cohort. Data on the median duration of response compare favourably, but are still immature. The same applies for time to event endpoints PFS and OS. Moreover the duration of follow-up is still insufficient. Efficacy updates will be provided with the final CSR (see RMP).

Unmet medical need is considered high in UC in general, but new therapies would be especially needed for cisplatin-ineligible and chemotherapy-ineligible patients; however these patients are not represented in the study population of KN-052, hence the following warning has been added in section 4.4 of the

<div style=\"page-break-after: always\"></div>

SmPC: ' The baseline and prognostic disease characteristics of the study population of KEYNOTE-052 included a proportion of patients eligible for a carboplatin-based combination or mono-chemotherapy. In the absence of comparative data, pembrolizumab should be used with caution in this population after careful consideration of the potential risk-benefit on an individual basis.'

Results from the on-going randomized studies P045, P052 and P361 and are requested as part of a PostAuthorisation Efficacy Study (PAES).

## 3.4. Unfavourable effects

In patients previously treated with platinum-containing chemotherapy (study KN045), pembrolizumab favorably compares with chemotherapy in terms of drug-related AEs (60.9% vs 90.2%), Grade≥3 AEs (52.3% vs 62.7%), drug-related Grade≥3 AEs (15% vs 49.4%), serious drug-related AEs (10.2 vs 22.4%), treatment interruption due to drug-related AEs (10.5% vs 15.7%) and treatment discontinuation due to drug-related AEs (11% vs 5.6%). In terms of drug-related AEs, the most frequently observed events in the pembrolizumab arm were Pruritus (19.5%), Fatigue (13.9%) and Nausea (10.9%) while in the control arm patients mostly experienced Alopecia (37.6%), Fatigue (27.8%), Anemia (24.7%), Nausea (24.3%), Constipation (20.4%), Decreased appetite (16.1%), Neutropenia (15.3%), Asthenia (14.1%), Neutrophil count decreased (14.1%), Diarrhea (12.9%), Peripheral sensory neuropathy (11.0%), and Neuropathy peripheral (10.6%).

In UC patients treated with pembrolizumab, no major differences in the safety profile were observed despite prior treatment and eligibility to cisplatin in studies KN045 and KN052 and in comparison to the Reference Safety Dataset. In study KN052, consistently with the Reference Safety Dataset, the most commonly reported drug-related AEs were Fatigue (16.8% and 24.2%), Pruritus (14.6% and 16.7%) and Rash (9.7% and 13.8%).

One fatal case of myositis was reported in KN052. This is the first registered with pembrolizumab.

## 3.5. Uncertainties and limitations about unfavourable effects

A higher number of deaths within 2 months was observed in pembrolizumab compared to chemotherapy which was attributed to the delayed onset of effect of pembrolizumab; this factor should be considered before initiating treatment in patients with poorer prognostic features and/or aggressive disease (see SmPC section 4.4).

No safety and efficacy data are available in frailer patients (e.g., ECOG performance status 3) considered not eligible for chemotherapy. In the SmPC section 4.4 it is stated that in the absence of these data, pembrolizumab should be used with caution in this population after careful consideration of the potential risk-benefit on an individual basis.

Longer safety follow up is needed and will be provided with the final reports from studies 045 and 052. Additional safety information for pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in advanced or metastatic Urothelial Carcinoma, will be provided with the results of study P361.

<div style=\"page-break-after: always\"></div>

## 3.6. Effects Table

Table 68 :  Effects Table for Keytruda in the treatment of recurrent or progressive metastatic urothelial carcinoma previously treated with platinum-based chemotherapy (Study KEYNOTE-045; Cut-off date: 7 SEP 2016)

| Effect               | Short Description                                                                                                                                      | Unit                                | Treatment                                           | Control                                             | Uncertainties/ Strength of evidence                                                                                                                                                                                                                                                                       | Ref                  |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| Favourable Effects   | Favourable Effects                                                                                                                                     | Favourable Effects                  | Favourable Effects                                  | Favourable Effects                                  | Favourable Effects                                                                                                                                                                                                                                                                                        | Favourable Effects   |
| All population       | All population                                                                                                                                         | All population                      | All population                                      | All population                                      | All population                                                                                                                                                                                                                                                                                            | All population       |
| OS                   | Time from randomization to death due to any cause                                                                                                      | months (95% CI) HR (95% CI) p-value | 10.3 (8.0,11.8) 0.73 (0.59,                         | 7.4 (6.1, 8.3) 0.91) 0.002                          | Significant gain in OS and a trend to PFS improvement after 6 months reported across population (all-comers, PD-L1 CPS ≥1% and PD- L1 CPS ≥10%). Updated results (data Cut-off: 18 Jan2017): Results based on PD-L1 expression (below and above the pre-specified cut-off of CPS 1% and 10%) did not show |                      |
| PFS                  | time from randomization to documented PD (RECIST 1.1 by BICR) or death due to any cause, whichever occurred first                                      | months (95% CI) HR (95% CI) p-value | 2.1 (2.0,2.2) (0.81, 0.416                          | 3.3 (2.3,3.5) 0.98 1.19)                            | important differences in favourable effects.                                                                                                                                                                                                                                                              |                      |
| Unfavourable Effects | Unfavourable Effects                                                                                                                                   | Unfavourable Effects                | Unfavourable Effects                                | Unfavourable Effects                                | Unfavourable Effects                                                                                                                                                                                                                                                                                      | Unfavourable Effects |
| Tolerability         | drug related AEs drug related Gr≥3 AE drug related SAEs death drug related discontinuation drug related AEs discontinuation drug related SAEs Pruritus | % % % % % % % %                     | 60.9 15.0 10.2 1.6 5.6 3.4 19.5 13.9 10.9 37.6 24.7 | 90.2 . 49.4 22.4 1.6 11.0 3.9 2.7 27.8 24.3 0.0 3.4 | The Pembrolizumab safety profile favourably compared to that of chemotherapy and importantly differed in the most frequent types of AEs. More frequent with pembrolizumab Acute kidney injury (5.6% vs 2.7%), Haematuria (11.3% vs 7.8%) and Urinary tract infection                                      | KN045 CSR            |
| Drug- related AEs    |                                                                                                                                                        |                                     |                                                     |                                                     | The Pembrolizumab safety profile favourably compared to that of chemotherapy and importantly differed in the most frequent types of AEs. More frequent with pembrolizumab Acute kidney injury (5.6% vs 2.7%), Haematuria (11.3% vs 7.8%) and Urinary tract infection                                      | KN045 CSR            |
| Drug- related AEs    | Fatigue                                                                                                                                                |                                     |                                                     |                                                     | The Pembrolizumab safety profile favourably compared to that of chemotherapy and importantly differed in the most frequent types of AEs. More frequent with pembrolizumab Acute kidney injury (5.6% vs 2.7%), Haematuria (11.3% vs 7.8%) and Urinary tract infection                                      | KN045 CSR            |
| Drug- related AEs    | Nausea Alopecia                                                                                                                                        | % %                                 |                                                     |                                                     | The Pembrolizumab safety profile favourably compared to that of chemotherapy and importantly differed in the most frequent types of AEs. More frequent with pembrolizumab Acute kidney injury (5.6% vs 2.7%), Haematuria (11.3% vs 7.8%) and Urinary tract infection                                      | KN045 CSR            |
| Drug- related AEs    | Anemia                                                                                                                                                 | %                                   |                                                     |                                                     | (14.7% vs 13.3%)                                                                                                                                                                                                                                                                                          | KN045 CSR            |
| Drug- related AEs    | Constipation                                                                                                                                           | %                                   | 2.3                                                 | 20.4                                                | The Pembrolizumab safety profile favourably compared to that of chemotherapy and importantly differed in the most frequent types of AEs. More frequent with pembrolizumab Acute kidney injury (5.6% vs 2.7%), Haematuria (11.3% vs 7.8%) and Urinary tract infection                                      | KN045 CSR            |
| Drug- related AEs    | Diarrhoea                                                                                                                                              | %                                   | 9.0                                                 | 12.9                                                | The Pembrolizumab safety profile favourably compared to that of chemotherapy and importantly differed in the most frequent types of AEs. More frequent with pembrolizumab Acute kidney injury (5.6% vs 2.7%), Haematuria (11.3% vs 7.8%) and Urinary tract infection                                      | KN045 CSR            |
| Drug- related AEs    |                                                                                                                                                        |                                     |                                                     |                                                     | The Pembrolizumab safety profile favourably compared to that of chemotherapy and importantly differed in the most frequent types of AEs. More frequent with pembrolizumab Acute kidney injury (5.6% vs 2.7%), Haematuria (11.3% vs 7.8%) and Urinary tract infection                                      | KN045 CSR            |
|                      |                                                                                                                                                        |                                     |                                                     |                                                     | The Pembrolizumab safety profile favourably compared to that of chemotherapy and importantly differed in the most frequent types of AEs. More frequent with pembrolizumab Acute kidney injury (5.6% vs 2.7%), Haematuria (11.3% vs 7.8%) and Urinary tract infection                                      | KN045 CSR            |
|                      |                                                                                                                                                        |                                     |                                                     |                                                     | The Pembrolizumab safety profile favourably compared to that of chemotherapy and importantly differed in the most frequent types of AEs. More frequent with pembrolizumab Acute kidney injury (5.6% vs 2.7%), Haematuria (11.3% vs 7.8%) and Urinary tract infection                                      | KN045 CSR            |
|                      |                                                                                                                                                        |                                     |                                                     |                                                     | The Pembrolizumab safety profile favourably compared to that of chemotherapy and importantly differed in the most frequent types of AEs. More frequent with pembrolizumab Acute kidney injury (5.6% vs 2.7%), Haematuria (11.3% vs 7.8%) and Urinary tract infection                                      | KN045 CSR            |
|                      |                                                                                                                                                        |                                     |                                                     |                                                     | The Pembrolizumab safety profile favourably compared to that of chemotherapy and importantly differed in the most frequent types of AEs. More frequent with pembrolizumab Acute kidney injury (5.6% vs 2.7%), Haematuria (11.3% vs 7.8%) and Urinary tract infection                                      | KN045 CSR            |

<div style=\"page-break-after: always\"></div>

Table  69 :  Effects  Table  for  Keytruda  in  the  treatment  of  advanced/unresectable  or  metastatic urothelial carcinoma previously untreated with systemic chemotherapy and not eligible to cisplatin. (Study KEYNOTE-052; Cut-off date: 1 SEP 2016)

| Effect               | Short Description                                       | Unit                 | Treatment                           | Uncertainties/ Strength of evidence                                                                                                                                                                                           | Ref.                 |
|----------------------|---------------------------------------------------------|----------------------|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| Favourable Effects   | Favourable Effects                                      | Favourable Effects   | Favourable Effects                  | Favourable Effects                                                                                                                                                                                                            | Favourable Effects   |
| All Population       | All Population                                          | All Population       | All Population                      | All Population                                                                                                                                                                                                                | All Population       |
| ORR                  | Proportion of patients with a CR or PR                  | % (95% CI)           | 24.1 (19.8, 28.7) CR 4.6 (2.7, 7.3) | Updated results (data Cut-off: 09Mar2017): ORR: 29.2% (24.6, 34.1) CR: 7.3% (4.9, 10.4) DOR: Not reached (1.4+,19.6+) ORR: 29.2% (24.6, 34.1) )                                                                               |                      |
| DOR                  | Time from the first CR/PR to documented PD %at 6 months | months (95% CI)      | Not reached (1.0+, 13.6+)           | Demonstration of efficacy based on a single non- randomized study. Duration of follow up still insufficient to fully evaluate clinical benefit. ORR not clearly outstanding. However, DOR superior to historical chemotherapy |                      |
| Unfavourable Effects | Unfavourable Effects                                    | Unfavourable Effects | Unfavourable Effects                | Unfavourable Effects                                                                                                                                                                                                          | Unfavourable Effects |
|                      | drug related AEs                                        | %                    | 61.9                                | Safety profile is in line                                                                                                                                                                                                     | KN052 CSR            |
| Tolerability         | drug related Gr≥3 AE                                    | %                    | 15.7                                | with that reported in                                                                                                                                                                                                         |                      |
| Tolerability         | drug related SAEs                                       | %                    | 9.7                                 | KN045 and in the                                                                                                                                                                                                              |                      |
| Tolerability         | death drug related                                      | %                    | 0.3                                 | reference melanoma and                                                                                                                                                                                                        |                      |
| Tolerability         | discontinuation drug related AEs                        | %                    | 5.1                                 | NSCLC population.                                                                                                                                                                                                             |                      |
| Tolerability         | discontinuation drug related SAEs                       | %                    | 3.8                                 | One Myositis fatal case was reported.                                                                                                                                                                                         |                      |
| Tolerability         | Fatigue                                                 | %                    | 16.8                                | One Myositis fatal case was reported.                                                                                                                                                                                         |                      |
| Drug-related         | Pruritus                                                | %                    | 14.6                                | One Myositis fatal case was reported.                                                                                                                                                                                         |                      |
| AEs                  | Rash                                                    | %                    | 9.7                                 | One Myositis fatal case was reported.                                                                                                                                                                                         |                      |

<div style=\"page-break-after: always\"></div>

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Advanced or metastatic urothelial carcinoma progressing after prior chemotherapy

Pembrolizumab favorably compares with chemotherapy in terms of drug-related AEs (60.9% vs 90.2%), Grade≥3 AEs (52.3% vs 62.7%), drug-related Grade≥3 AEs (15% vs 49.4%), serious drug-related AEs (10.2  vs  22.4%),  treatment  interruption  due  to  drug-related  AEs  (10.5%  vs  15.7%)  and  treatment discontinuation due to drug-related AEs (11% vs 5.6%). No major differences in the safety profile were observed in comparison to the Reference Safety Dataset.

## Previously untreated cisplatin-ineligible advanced/unresectable or metastatic urothelial carcinoma

The  effect  observed  in  terms  ORR  in  the  uncontrolled  trial  KN052  is  not  outstanding  compared  to historical data in the target population, even in the PD-L1 strongly positive cohort. Data on the median Duration of Response and other time to event endpoints PFS and OS are still immature to draw sound conclusions.

The safety profile observed in cisplatin  ineligible  UC  patients  was  consistent  to  that  observed in  study KN045, and no new safety signals emerged compared to the Reference Safety Dataset.

## 3.7.2. Balance of benefits and risks

Advanced or metastatic urothelial carcinoma progressing after prior chemotherapy

Based on OS results from study KN045, a benefit is claimed in the overall population. However, patients' characteristics influencing a higher risk of early death during treatment need to be further discussed, in order to include detailed information in the product SmPC.

The safety profile in the UC patient population does not significantly differ from the well-known limited risks associated with pembrolizumab therapy, far more manageable and less impacting on patients' quality of life than those associated with chemotherapy.

Previously untreated cisplatin-ineligible advanced/unresectable or metastatic urothelial carcinoma

However, duration of responses is clearly superior and OS compares rather favourable to those achieved by chemotherapy in the submitted meta-analysis.

The safety profile in the sought indication does not raise new concerns and seems to favorably compare to chemotherapy.

## 3.7.3. Additional considerations on the benefit-risk balance

Not applicable.

## 3.8. Conclusions

Based on the totality of the evidence, the benefit-risk balance of the use of pembrolizumab in 2nd line UC and in 1 st line cisplatin-ineligible UC is considered positive.

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following group of variations acceptable and therefore recommends by a majority of 24 out of 28 votes, the variations to the terms of the Marketing Authorisation, concerning the following changes:

| Variations accepted   | Variations accepted                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of Indication to add treatment as monotherapy of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy based on the results from study KEYNOTE-045; a phase 3, randomized, active-controlled, multi-site, open-label trial evaluating pembrolizumab administered at 200 mg Q3W versus investigators' choice of paclitaxel, docetaxel, or vinflunine in patients previously treated with chemotherapy.

Extension of Indication to add treatment as monotherapy of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy based on the results from study KEYNOTE-52; a phase 2, single-arm, multisite, open-label trial of pembrolizumab at 200 mg Q3W in the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.

As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC have been updated and the Package Leaflet has been updated accordingly.

Further, the MAH is taking the opportunity to implement a change to section 4.4 of the SmPC adding possible hypersensitivity and anaphylaxis as part of infusion reactions

In addition, Annex II has been updated to include new Post-authorisation efficacy studies (PAES) as obligations under 'conditions or restrictions with regard to the safe and effective use of the medicinal product'.

An updated RMP version 7.2 was agreed during the procedure.

This recommendation is subject to the following new conditions:

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Obligation to conduct post-authorisation measures

The MAH shall complete, within the stated timeframe, the below measures:

<div style=\"page-break-after: always\"></div>

|   5. | Post-authorisation efficacy study (PAES): In order to further evaluate the efficacy of Pembrolizumab versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer, the MAH should conduct and submit the results of study P045                        | 3Q 2018   |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
|    6 | Post-authorisation efficacy study (PAES): In order to further evaluate the efficacy of Pembrolizumab in patients with Advanced/Unresectable or Metastatic Urothelial Cancer, the MAH should conduct and submit the final results of study P052                                                             | 2Q 2019   |
|    7 | Post-authorisation efficacy study (PAES): In order to further evaluate the efficacy of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma, the MAH should conduct and submit the results of study P361 | 2Q 2019   |

The recommendation is also subject to the following modified condition:

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Obligation to conduct post-authorisation measures

The MAH shall complete, within the stated timeframe, the below measures:

| 4. The value of biomarkers to predict the efficacy of pembrolizumab should be further explored, specifically: Additional biomarkers other than PD-L1 expression status by Immunohistochemistry (IHC) (e.g. PD-L2, RNA signature, etc.) predictive of pembrolizumab efficacy should be investigated together with more information regarding the pattern of expression of PD-L1 obtained in the ongoing NSCLC studies (P001, P010, P024 and P042) and urothelial carcinoma studies (KN045, KN052): • Data on the Nanostring RNA gene signature • IHC staining for PD-L2 • Data on RNA and proteomic serum profiling   | 2Q 2020 2Q 2019   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|

Divergent positions to the majority recommendation are appended to this report.

<div style=\"page-break-after: always\"></div>

## APPENDIX 1

Divergent position dated 20.07.2017

<div style=\"page-break-after: always\"></div>

## DIVERGENT POSITION DATED 20 July 2017 Keytruda EMEA/H/C/003820/II/23/G

The undersigned members of the CHMP did not agree with the CHMP's positive opinion recommending the extension of the indication for Keytruda (pembrolizumab) in the 1st-line cisplatin-ineligible urothelial carcinoma (UC) for the following reasons:

- Current evidence on efficacy and safety in first-line cisplatin-ineligible patients only comprises a single-arm study, i.e. KEYNOTE-052. Upon indirect comparison of the Keytruda results obtained the first-line cisplatin-ineligible urothelial carcinoma population to control (i.e. gemcitabinecarboplatin) chemotherapy), the primary endpoint ORR results are not compelling and PFS compares unfavourably. Depending on the source of information, the OS of Keytruda compares either unfavourably or is suggested being similar. DoR is still immature.  Moreover, the lack of direct comparative efficacy data with first line agents precludes a determination of the extent of any potential 'loss of chance', in particular for the patients who do not respond to Keytruda.

It is acknowledged that safety seems to be more favourable when compared to chemotherapy.

- In conclusion, we consider that in the 1st-line cisplatin-ineligible UC population the results obtained with Keytruda are on itself not convincing and accompanied with large uncertainties associated with the single, non-comparative study design and a limited duration of follow-up. The current evidence is not compelling enough to support a positive B/R and, as a consequence, considered insufficient for approval.

<div style=\"page-break-after: always\"></div>

………………………………………….

## Alexandre Moreau (FR)

…………………………………………. Romaldas Maciulaitis  (LT)

…………………………………………. Johann Lodewijk Hillege (NL)

…………………………………………. Sinan B.Sarac (DK)

……………………………………. Svein Rune Anderson (NO)